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Abstract 
Diabetes Mellitus is a metabolic disease characterised by hyperglycaemia, resulting 
from an inability to secrete insulin, a resistance to insulin or both. The number of 
individuals suffering from Type-2 diabetes (T2D) is currently 336 million and this 
number is expected to surpass 552 million by the year 2030. Consequently, there exists 
a need for novel antidiabetic agents for the treatment of T2D.  
The retinol transporter, RBP4, is a possible target for the treatment of T2D as elevated 
levels of this protein are found in T2D sufferers. Compounds that reduce the levels of 
RBP4 in vivo have been found to improve the diabetic condition. Disruption of the 
RBP4-TTR complex is a known method for decreasing the levels of RBP4. Therefore, 
reducing the levels of RBP4 provides a mechanism to treat/manage T2D and allows for 
the identification and synthesis of novel antidiabetic agents. 
Computational studies were used to identify compounds (1, 2 and 3) that bind within 
RBP4 and have the potential to prevent the formation of the RBP4-TTR complex. 
Biological assays (SPR, fluorometric binding assay) were performed on these 
compounds to verify their ability to bind within the protein cavity of RBP4 and inhibit 
the formation of the RBP4-TTR complex.  
A SAR study of compound 1 uncovered compound 4 which was more active than its 
parent compound in the SPR assay. A subsequent SAR study performed on the new lead 
compound 4 to identify the functional groups necessary for its biological activity. The 
derivatives required for this study were synthesised using a variety of chemical 
processes and were tested in an assay to assess their ability to stimulate muscle cells to 
take up glucose. This study uncovered a number of compounds with increased activity 
(64, 79 and 82).  
While the glucose uptake assay allowed for the identification of a number of active 
compound 4 derivatives, it also indicated that a secondary protein target was involved 
as the glucose uptake assay was RBP4 independent. A method for identifying this 
unknown target was therefore needed. The method chosen involved immobilising active 
compounds on an affinity column, which is composed of sepharose beads. A solution of 
cellular proteins is then passed through the column and the subsequent bound proteins 
are lysed and analysed by mass spectrometry. Immobilisation of compounds onto this 
column first required the attachment of a PEG linker to each molecule. Compounds 4 
vii 
 
and 79 were successfully immobilised on the affinity column; at the time of writing, the 
results from their biological evulation remain outstanding. 
A SAR study was also performed on compounds 2 and 3. This uncovered compound 
115, which proved to be highly active in the glucose uptake assay. A number of 
derivatives of compound 2 and 3 have been designed, synthesised and characterised and 
are currently awaiting biological evaluation.  
Animal studies were carried out on compounds 1, 4 and 2. Compounds 1 and 4 proved 
to be more effective than compound 2 at improving the insulin and glucose tolerance of 
diabetic mice, while also causing a reduced weight gain. Compound 4 was administered 
to animals after 17 weeks, once insulin resistance had been established. Compound 4 
was found to restore both glucose and insulin sensitivity to normal levels. 
A number of additional animal studies were considered involving compound 4; however 
these required aqueous solutions of the compound. As compound 4 had proven to be 
insoluble in aqueous solutions, a method for preparing these solutions was needed. 
Cyclodextrins (CD) were chosen and the use of 20 eq of hydroxylpropyl-β-CD 
(HPBCD) gave a 0.02 M 5% DMSO/H2O solution of compound 4. The dissolution of 
compound 4 may have occurred due to the formation of an inclusion complex. A phase 
solubility diagram, SEM, DSC and NMR were used in the characterisation of the 
inclusion complex.  
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1.1 Introduction 
Diabetes Mellitus (diabetes) is a metabolic disease that is characterised by an increased 
level of plasma glucose (hyperglycaemia) resulting from an inability to secret insulin, a 
resistance to insulin or both.1,2 Over the past number of years the shift towards calorific 
diets and sedentary lifestyles has resulted in the prevalence of diabetes and its 
complications, with roughly 366 million people worldwide currently affected.3 If this 
trend is to continue the number of individuals affected is predicted to rise to a 
staggering 552 million by the year 2030, with a large number of sufferers remaining 
undiagnosed.3,4 The increase in obesity and reduction in physical activity has meant that 
in 2007 diabetes was the seventh leading cause of death in the U.S with the cost of 
treating this disease exceeding $110 billion annually.5 The rapid increase in the 
incidence of diabetes has meant that it is the only non-infectious disease classified as an 
epidemic by the World Health Organization (WHO).6 Of the 285 million current 
sufferers, it has been reported that 90% suffer from Type-2 Diabetes (T2D) with the 
remaining percentage of individuals suffering from Type-1 Diabetes (T1D).6 T1D can 
be described as a complete insulin deficiency due to the autoimmune destruction of the 
insulin producing β-cells of the pancreas.7 The more common T2D can be characterised 
by a reduction/lack of insulin secretion from pancreatic cells and/or the observed 
resistance of target tissues to insulin.8 
Hyperglycaemia associated with T1D and T2D causes microvascular and macrovascular 
issues leading to complications such as retinopathy, nephropathy, neuropathy, 
accelerated atherosclerosis, stroke and coronary heart disease.9,5  
 
1.2 Microvascular complications 
Diabetic microvascular complications arise due to the damage caused to the small blood 
vessels such as the capillaries, arterioles and venules. This occurs as a result of 
hyperglycaemia with the development of these complications being directly related to 
the duration and severity of the hyperglycaemic condition.10 The severity of these 
complications is obvious as diabetic nephropathy is the leading cause of kidney failure 
in the western world with 43% of patients requiring dialysis or transplantation, while 
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diabetic retinopathy is the most prevalent cause of acquired blindness in the developed 
world.2,7 
1.2.1 Diabetic Nephropathy 
The condition that occurs as a result of damage to the kidney cells is known as diabetic 
nephropathy or Kimmelstiel-Wilson syndrome.10 Diabetic nephropathy progresses 
through a series of characteristic stages. The first recognizable stage of nephropathy is 
microalbuminuria, which is the presence of the protein albumin in urine. Normally, 
albumin is too large to pass through the glomerulus but damage caused to these cells 
due to hyperglycaemia allows for this protein to pass from the blood stream into the 
urine.2 Microalbuminuria is followed by macroalbuminuria and is similar to the first 
stage only for the increased concentration of albumin found in the urine. The increase in 
concentration of albumin in urine is due to the increased damage caused to the renal 
glomerulus.2 The final stage of diabetic nephropathy is known as end-stage renal 
disease and results in the patient requiring either dialysis or a kidney transplant.2,10 
1.2.2 Diabetic Retinopathy 
Diabetic retinopathy is the most common microvascular complication associated with 
hyperglycaemia causing injury to the retina leading to blindness.10 This condition 
manifests in T1D sufferers twenty years after initial diagnosis while it is found in T2D 
patients as early as seven years after diagnosis.10  
The presence of glucose can cause damage to the retinal cells in a number of ways. 
Aldose reductase is an enzyme involved in the polyol pathway which is responsible for 
the conversion of glucose into sorbitol. When a hyperglycaemic state is in effect, this 
causes high levels of sorbitol to accumulate within cells. The osmotic stress that cells 
are exposed to due to the accumulation of sorbitol has been suggested as a possible 
mechanism for the development of microvascular conditions such as retinopathy.10,11 
The osmotic stress can cause damage in the form of microaneurysms and thickening of 
membranes.10 Other mechanisms have also been suggested to contribute to the injury of 
microvessels. These include the non-enzymatic formation of glycoproteins and 
oxidative stress.10 
Chapter 1                                                                                                          Introduction 
4 
 
1.2.3 Diabetic Neuropathy 
Diabetic neuropathy describes the damage caused to nerves as a result of excess glucose 
in the blood stream. Over time, excess glucose damages the walls of the blood vessels 
that supply the nerves with oxygen and nutrients resulting in injury.10 The mechanism 
responsible for this injury is similar to that of retinopathy.10 Peripheral neuropathy 
describes the injury caused to the nerves outside of the brain or spinal cord. The 
combination of peripheral neuropathies with vascular disease can lead to ulcer 
formation, gangrene and poor healing of the lower limbs and ultimately amputation.2 
Peripheral neuropathy can manifest in several forms with focal and generalized 
neuropathies most commonly encountered.2,10 
Focal neuropathy best describes the damage that occurs to one or a few nerves. One 
such example is carpal tunnel syndrome which results in a tingling sensation in limbs 
and periods of “nighttime” numbness. 12  Other types of conditions most frequently 
associated with focal neuropathies include; peroneal nerve and third cranial nerve 
palsies and diabetic amyotrophy to name but a few.2  
Generalized neuropathies are often termed polyneuropathies. The most common form of 
diabetic neuropathy is the generalized condition known as sensorimotor 
polyneuropathy.10 This is a systematic condition that affects, amongst other nerves, the 
autonomic nervous system (nerves associated with the internal organs and gut).2 
Individuals experience tingling, electric sensations or numbness.10 
 
1.3 Macrovascular complications 
The effects of persistent hyperglycaemia are not limited to complications associated 
with the microvascular system. Many conditions which cause damage to the 
macrovascular vessels resulting in cardiovascular disease (CVD) have been well 
documented. The prevalence of CVD is far greater in individuals with T2D than T1D, 
with CVD accounting for 70% of all deaths in T2D sufferers.2 Although the occurrence 
of CVD may be due in part to obesity, which is synonymous with diabetes and in 
particular T2D, other mechanisms such as atherosclerosis are suggested to play a pivotal 
role in diabetes associated CVD. 9,6,7,10, 13 Atherosclerosis is defined as the narrowing of 
the inner walls of the arteries due to the accumulation of lipids, macrophages and 
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fibrous elements.14,15 Diabetes is known to increase the incidence of conditions such as 
dyslipidaemia and hypertension which aid in the development of atherosclerosis.16  
1.3.1 Dyslipidaemia 
Dyslipidaemia is a condition in which the blood contains an abnormal amount of lipids. 
While many classes of dyslipidaemia exist, the phenotype that best characterises 
diabetic dyslipidaemia is high plasma triglyceride concentration and increased levels of 
low density lipoprotein (LDL) cholesterol, which can be converted to the more 
atherogenic small density LDL. Decreased levels of high density lipoprotein (HDL) 
cholesterol is also associated with diabetic dyslipidaemia.17,18,19 High levels of LDL 
cholesterol have been associated with cardiovascular complications while high levels of 
HDL cholesterol tends to be associated with individuals with fewer cardiovascular 
issues. 
Hyperinsulinaemia has been implicated in the mechanism of this altered lipid state.17,18 
The increased levels of insulin in circulation causes an increase in free fatty acid release 
from insulin resistant adipose tissue which in turn promotes the secretion of 
apolipoprotein B (apoB).18 ApoB is a major component of very low density lipoprotein 
(VLDL) cholesterol which can be metabolised to atherogenic remnant lipoproteins thus 
promoting atherosclerosis.13, 17,18 Hyperinsulinaemia has also been shown to decrease 
the activity of lipoprotein lipase which is the main enzyme involved in the clearance of 
VLDL cholesterol.13  
The presence of VLDL also decreases the level of serum HDL cholesterol.17,18 
Cholersteryl ester transfer protein (CETP) stimulates the transfer of triglycerides from 
VLDL to HDL, which produces a HDL-triglyceride particle that can be more easily 
cleared from circulation than normal HDL. Other studies suggest that key enzymes 
involved in the metabolism and synthesis of HDL cholesterol are altered in individuals 
with insulin resistance while tumour necrosis factor (TNF)-α has also been suggested to 
lower plasma levels of HDL cholesterol.17 The combination of the above events leads to 
the development of dyslipidaemia and ultimately CVD.13  
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1.4 Type-1 Diabetes 
T1D is characterized by absolute insulin deficiency resulting in increased levels of 
plasma glucose (hyperglycaemia). The insulin deficiency is due to the autoimmune 
destruction of the insulin producing β-cells resulting in a life-long need for exogenous 
insulin.20,21,1 Reports suggesting that at the time of diagnosis only 10-20% of the β–cell 
function remains and that the first sign of the cell mediated destruction of islet cells is 
the emergence of the four autoantibodies; insulin autoantibodies, islet cell antibodies, 
glutamate decarboxylase autoantibodies and autoantibodies to the tyrosine phosphatase-
related IA-2 molecule.1 As the disease was predominantly diagnosed in children under 4 
years of age, T1D was given the title of juvenile diabetes. Recent data suggests however 
that 50-60% of T1D sufferers are 16-18 years of age and that the disease is also present 
at low levels in adults.2 
One hypothesis for the cell mediated autoimmune attack suggests that each person is 
susceptible to the development of T1D with some more susceptible than others.2 Those 
with a greater susceptibility to autoimmune attack inherit this trait from their parents but 
the activation of these high susceptibility genes requires exposure to one or more 
external environmental triggers.2   
The genes encoding for high susceptibility are mainly found in the Human Leukocyte 
Anitgen (HLA) locus and this genotype is known as the HLA DR or HLA DQ 
genotypes. The HLA system is the name given to the human Major Histocompatability 
Complex (MHC) and is an essential component of the immune system functioning to 
present antigens from inside or outside the cell to immune cells, such as T cells or 
helper T cells, for example.14 It is thought that these genes are responsible for 50% of 
the occurrence of this high susceptibility with the environmental triggers such as viruses 
(e.g. enterovirus), environmental toxins or early exposure to foods such as milk 
proteins, gluten or cereals needed to “stimulate” β-cell destruction.1,2  
This hypothesis is supported by the fact that these individuals are also highly 
susceptible to other autoimmune diseases such as Hashimoto’s thyroiditis, Grave’s 
disease, Addison’s disease, coeliac disease and myasthenia gravis.2 Other hypotheses 
have been suggested that try to explain how these susceptibility genes are triggered. 
One such theory is the hygiene hypothesis. This hypothesis has been implicated as the 
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cause of other allergic diseases and is now gaining attention as a possible contributor to 
the occurrence of T1D. A lack of exposure to microbes at an early age can impact the 
development and programming of the immune system resulting in the prevalence of 
allergic diseases such as asthma.1,2 
1.4.1 Treatment and management 
The management and treatment of T1D involves the appropriate administration of 
insulin, the monitoring of blood glucose levels and nutritional planning. As T1D is an 
autoimmune disease, patients are regularly screened for other autoimmune conditions 
such as thyroid dysfunction and coeliac disease.2 Medications are also required to treat 
the micro- and macrovascular conditions described previously.2 
1.5 Type-2 Diabetes 
T2D is a complex metabolic disorder that is characterised by a loss of β-cell function 
and mass, impaired insulin secretion, an increase in hepatic glucose production and 
varying levels of insulin resistance in target tissues including the liver and muscle. It is 
a multifaceted metabolic disease that results from a combination of genetic and 
environmental factors such as diet, age and level of physical activity.22 Those that are 
destined to develop diabetes inherit genes from their parents that encode for traits such 
as loss of β-cell function and obesity.23  
Genetics and an inappropriate lifestyle lead to obesity which is responsible for a number 
of life-threatening diseases such as T2D, hypertension, dyslipidaemia and CVD. An 
important link between the above conditions and obesity is insulin resistance.7,16 An 
increase in adipose tissue, in particular visceral fat, stimulates the production and 
release of a series of mediators that affect insulin sensitivity.16 Free fatty acids (FFAs) 
and TNF-α, as well as interleukin (IL)-6 and leptin have all been implicated in the 
mechanism of obesity induced insulin resistance.16 The presence of obesity and insulin 
resistance may be present for many years before the development of conditions such as 
T2D.16   
Once a basal level of insulin resistance has been established, β-cell function and mass 
begins to be impaired.22 Insulin resistance causes the pancreatic β-cells to over-produce 
insulin to accommodate the reduction in insulin sensitivity.22 Hyperglycaemia ensues as 
the pancreatic cells are unable to produce enough insulin to compensate for the lack of 
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glucose uptake due to insulin resistance.16,22 Overtime the hypersecretion of insulin in 
response to hyperglycaemia causes β-cells to become exhausted and thus “wear out” 
halting the secretion of insulin via normal mechanisms.22,23 Although some reports 
suggest that the exact mechanism involved in β-cell dysfunction is not known, others 
postulate that the involvement of conditions such as dyslipidaemia and hyperglycaemia, 
contribute to this impaired function.24 Mechanisms such as oxidative stress and 
endoplasmic reticulum (ER) stress caused by hyperglycaemia and obesity, have been 
implicated in β-cell dysfunction by inducing β-cell dedifferentiation and apoptosis.24 
The progression to full-blown T2D occurs when the over production of insulin by β-
cells cannot compensate for insulin resistance with the rate of β-cell failure determining 
the rate at which T2D progresses.22,23 
1.5.1 Treatment 
The management and treatment of T2D involves increasing insulin secretion and 
improving insulin sensitivity and hyperglycaemia. A number of combined methods exist 
that focus around improving the metabolic syndrome. This generally occurs in the order 
of nutrition therapy and increased physical activity, oral antidiabetic pharmaceuticals 
and ultimately exogenous insulin therapy.25 
Improving ones diet, moving away from sedentary behaviour and increasing physical 
activity are key components when combatting T2D, particularly amongst overweight 
and obese patients. This involves strict control of food intake and requires regular 
monitoring of blood glucose levels. Occasionally this is satisfactory for controlling the 
diabetic condition; however in most cases when inadequate glycaemic control prevails, 
pharmaceutical intervention in the form of an antidiabetic agent is needed.26 When this 
does not rectify the problem, a second, complementary pharmaceutical may be needed 
with the addition of exogenous insulin.26,27  
1.5.1.1 Antidiabetic agents 
Numerous antidiabetic agents have emerged in the past number of years aimed at 
improving T2D, exerting their influence through a plethora of biological targets and 
allowing for a complementary cocktail of pharmaceutical agents to be used.7 This is in 
stark contrast to previous pharmaceutical strategies where sulfonylureas were the only 
antidiabetic agents available for treating T2D in the U.S before 1995.7 
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1.5.1.1.1 Sulfonylureas 
Although sulfonylureas are not used in the treatment of early stage diabetes they are still 
widely used later on in the progression of the disease.28 They bind to sulfonylurea 
receptors (SUR) where they work by stimulating the release of insulin from the 
pancreas by inhibiting ATP-activated K+ channels found in the plasma membrane.29,30 
Inhibition leads to the depolarization of the membrane and activation of voltage gated 
Ca2+ channels due to the changes in the electrical potential difference. This causes an 
intracellular influx of Ca2+ which increases the concentration of cytoplasmic Ca2+ 
causing the activation of the proteins involved in insulin secretion. These 
hypoglycaemic agents further increase serum levels of insulin by preventing the hepatic 
induced clearance of insulin.26  
Sulfonylureas are also known to act directly on the insulin secreting granules found in 
β-cells.29,30 A free-diffusion mechanism allows the sulfonylurea compound to move 
across the lipid membrane layer and enter the β-cell. Here the drug acts directly on the 
insulin secretory components inducing the release of insulin from the pancreas.29,30 This 
exocytosis is more common to second and third generation sulfonylureas due to their 
increased lipid-solubility.26 Glimepiride is an example of a third generation sulfonylurea 
(Figure 1.1).31  
         
         Figure 1.1. Structure of glimepiride.32 
As with most pharmacologically active substances, the family of sulfonylurea 
compounds have a number of adverse side effects to their use. Headaches, dizziness, 
and gastrointestinal issues are the less severe side effects while hypoglycaemia and 
hyponatraemia, a decrease in serum sodium levels, represent the more serious issues 
associated with their use.26,28,33 Ironically, sulfonylureas have also been implicated in 
causing weight gain amongst its users.26 
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1.5.1.1.2 Meglitinides 
Meglitinides are a class of non-sulfonylurea insulin secretagogues that work in a similar 
fashion to sulfonylureas by stimulating the release of insulin from the pancreas by 
inhibiting ATP-activated K+ channels.34 The principal meglitinide used is repaglinide 
(Figure 1.2). The K+ channels in question contain not only SUR but also consist of pore 
forming Kir6.x subunits that associate with the various SUR. Repaglinide is known to 
bind to both Kir6.2 and SUR1 where it stimulates the closure of the K+ channels.35 It 
has a better effect on post prandial glucose levels than on fasting glucose levels due to 
its relatively short elimination half-life of one hour. Elimination occurs via biliary 
excretion, a characteristic which allows its use in individuals with renal 
insufficiencies.28 As with the sulfonylurea family of antidiabetic drugs, repaglinide also 
induces hypoglycaemia, however it is slightly less effective in comparison to common 
sulfonylureas.28  
 
             Figure 1.2. Structure of repaglinide.35 
1.5.1.1.3 Biguanides 
Biguanides are a class of anti-hyperglycaemic drugs that have been used in the control 
and treatment of T2D for many years. Originally three biguanides, metformin, 
phenformin and buformin were all used; however metformin is the only drug of this 
class still administered to patients today. This is due to the fact that phenformin and 
buformin were found to cause lactic acidosis, while only 3 in 100,000 patients presented 
with lactic acidosis following the use of metformin.26  
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1.5.1.1.3.1 Metformin 
Metformin is a first-line antidiabetic drug used  in the treatment of T2D (Figure 1.3).28 
Although there is a slight risk of associated lactic acidosis, it is still the first drug of 
choice for many clinicians. This is due to the fact that metformin does not induce 
hypoglycaemia or weight gain like many other antidiabetic agents. It can also be used in 
combination with other antidiabetic agents, as well as insulin.36 Metformin works by 
decreasing the production of hepatic glucose, notably hepatic glucogenesis which is the 
synthesis of glucose from non-carbohydrate sources, as well as decreasing intestinal 
glucose absorption.26,36 It has also been suggested to slightly improve insulin sensitivity 
and stimulate fatty acid oxidation.26,36 Although the exact mechanism by which 
metformin exerts its antidiabetic effect in the body is not known, it has been found to 
activate Adenosine monophosphate-activated protein kinase (AMPK).36,37  
AMPK is a heterotrimeric protein complex that is involved in cellular energy 
homeostasis where it regulates energy levels by monitoring the amounts of ATP and 
AMP.38 AMPK regulates lipid and glucose metabolism and activation of AMPK by 
small molecules such as metformin has shown to stimulate the uptake of glucose by 
skeletal muscles and reduce hepatic gluconeogenesis.38,39 A commonly proposed 
mechanism for the metformin induced activation of AMPK is inhibition of 
mitochondrial respiration by acting at Complex I. 
 
Figure 1.3. Structure of metformin.40 
1.5.1.1.3.1.1 Mitochondrial respiration and the electron transport chain 
Cellular respiration is a cumulative process that consists of three metabolic stages; 
glycolysis, the citric acid cycle and oxidative phosphorylation (electron transport and 
chemiosmosis).14 Glycolysis and the citric acid cycle catabolically break down glucose 
and other organic substances. Glycolysis is the process by which glucose is metabolised 
to produce two molecules of pyruvate. This occurs in the cytosol of the cell and is 
followed by the citric acid cycle, which takes place in the mitochondrial matrix, and 
oxidizes a pyruvate derivative to carbon dioxide.14  
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Redox reactions are key processes of both the citric acid cycle and glycolysis. 
Dehydrogenase enzymes transfer electrons from substrates to NAD+ (nicotinamide 
adenine dinucleotide) thus forming the reducing agent NADH.14 The third step of 
cellular respiration involves the transport of electrons across a series of membrane 
bound proteins located in the inner membrane of the mitochondria. These proteins 
accept electrons from the redox processes that occur in the first two respiratory steps 
and pass electrons from one protein to another. This is known as the electron transport 
chain and culminates in the production of energy. The energy released at each step of 
the transport chain is used to make ATP (Adenosine-5'-triphosphate). This mechanism 
of ATP synthesis is called oxidative phosphorylation.14 
The electron transport chain is composed of a series of molecules that are located in the 
inner mitochondrial membrane. The formation of cristae, due to the folding of the inner 
membrane, increases the surface area of the mitochondria membrane which allows for 
thousands of copies of the transport chain to be present in each mitochondrion. The 
chain is mostly composed of proteins which are found in multiprotein complexes 
labelled complex I to IV (Figure 1.4).14  
Complex I, also known as NADH dehydrogenase (ubiquinone), is the first protein 
involved in the electron transport chain and catalyses the transfer of two electrons from 
NADH to ubiquinone (Q, Figure 1.4). It is composed of 45 different subunits and is one 
of the largest known membrane bound protein complexes with a size of ~ 980 kDa.41,42 
The binding site of NADH is located in the hydrophilic domain of Complex I where the 
primary electron acceptor, flavin mononucletide (FMN), is also located. Electrons are 
passed from NADH to FMN which then returns to its oxidized state as it passes 
electrons to the iron-sulphur group, Fe-S. The next redox reaction involves the 
oxidation of the Fe-S group and the reduction of the small hydrophobic ubiquinone 
molecule, Q. Ubiquinone is the only non-protein unit within the electron transport chain 
and is found within the membrane as opposed to being a component of a particular 
complex.14  
NADH is not the only source of electrons for the electron transport chain. Another 
product of glycolysis and the citric acid cycle, flavin adenine dinucleotide (FADH2), 
also contributes electrons. Unlike NADH however, FADH2 adds electrons at Complex 
II rather than Complex I (Figure 1.4). 
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Cytochromes (cyt) are responsible for the remaining transport of electrons. Several 
different cytochrome proteins are found in the mitochondrial membrane, each 
containing a heme group for transporting electrons.14 Water is formed when the last 
cytochrome, cyt a3, transfers its electrons to molecular oxygen which acquires two H
+ 
ions from the surrounding aqueous solution (Figure 1.4).  
The electron transport chain does not directly produce ATP. It serves to accommodate 
the flow of electrons from metabolites of food (i.e. NADH) to molecular oxygen where 
it breaks the free-energy drop into smaller steps that release energy in more reasonable 
and manageable amounts.14 The process of chemiosmosis is responsible for the 
production of ATP. This is the process by which energy stored in a ionic gradient is 
used to fuel cellular work.14  
 
Figure 1.4. The components of the electron transport chain.14 
The exergonic flow of electrons from Complex I to Complex IV pumps H+ ions from 
the mitochondrial matrix to the intermembrane space. Complex I pumps four H+ ions 
from the matrix into the intermembrane space while the other complexes pump two H+ 
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ions each (Figure 1.5). This creates an H+ gradient with the ions trying to move back 
across the membrane. This type of gradient is known as a proton-motive force.  
The protein complex ATP synthase is located in the inner membrane of mitochondria. 
This complex is an ion pump that uses the energy of an ion gradient to power the 
synthesis of ATP. The H+ gradient created from the electron transport chain powers the 
synthesis of ATP. ATP synthases are the only sites on the membrane through which H+ 
ions can permeate back into the mitochondrial matrix. The exergonic flow of H+ ions 
causes the synthesis of ATP from the phosphorylation of ADP (Figure 1.5).  
 
Figure 1.5. The electron transport chain.14 Yellow arrows represent the flow of 
electrons. 
Ouyang et al. suggested that the activation of AMPK by metformin involves an increase 
in the production of AMP.37 The mechanism by which this increase in AMP occurs has 
been postulated to involve the inhibition of mitochondrial respiration by acting at 
Complex I. Disrupting the action of Complex I would affect the production of ATP 
which would lead to elevated levels of free ADP.37 This would subsequently cause 
increased levels of AMP through the action of adenylate kinase. Inhibition of 
mitochondrial respiration is strongly linked to an increase in glucose transport into 
cells.37   
Chapter 1                                                                                                          Introduction 
15 
 
1.5.1.1.4 Thiazolidinediones 
Thiazolidinediones (TZDs) are a class of insulin-sensitizer antidiabetic agents that 
improve insulin resistance and maintain β-cell function.43 They do not increase the risk 
of hypoglycaemia when administered as a monotherapy or in combination with other 
insulin sensitizers like metformin.28 TZDs are agonists of the peroxisome proliferator 
activated receptor (PPAR) subtype PPAR-γ, with the TZD derivative, rosiglitazone, the 
most potent and selective PPAR-γ agonist (Figure 1.6).28,44,45 
 
      Figure1.6 Structure of rosiglitazone.45 
1.5.1.1.4.1 Peroxisome proliferator activated receptors (PPARs) 
PPARs are members of the nuclear hormone receptor superfamily of transcription 
factors that are activated by the binding of small ligands. These receptors are 
responsible for inducing or repressing the transcription of a number of genes that have a 
marked effect on cellular function including the regulation of glucose, cholesterol and 
lipid metabolism.43 They can be categorized into three subtypes: PPAR-α, -γ and -β/δ 
with PPAR-γ the most widely investigated subtype in T2D.44 
1.5.1.1.4.1.1 PPAR-γ 
The expression of PPAR-γ mainly occurs in adipose tissue with lower concentrations of 
the receptor found in heart, colon, kidney, intestine, skeletal muscles and 
macrophages.44 This PPAR subtype is crucial in adipogenesis which is the 
differentiation of preadipocytes into adipocytes. It plays a vital role in insulin 
sensitivity, cell cycle regulation and cell differentiation and has been implicated in the 
regulation of genes involved in the metabolism of glucose and lipids.  
Insulin resistance in muscle cells has been associated with increased levels of 
circulating FFAs and triglycerides resulting in impaired lipid storage. The role of TZDs 
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in treating T2D is thought to be through adipogenesis which improves this lipid 
storage.45 
1.5.1.1.4.2 Side effects 
The first reported antidiabetic TZD, troglitazone, was removed from the market as it 
caused rare life threatening hepatitis (Figure 1.7). The main side effects associated with 
the use of other TZD analogues include significant weight gain, fluid retention and 
CVD.44 Fluid retention can itself lead to heart failure in the cases of pre-existing CVD 
and in some cases has led to anaemia.28 Unlike the sulfonylurea antidiabetic agents, 
rosiglitazone does not cause hypoglycaemia when administered as a monotherapy or 
when used in conjunction with other diabetic pharmaceuticals such as metformin.28 
 
Figure 1.7. Structure of troglitazone.46 
1.5.1.1.5 Alpha-glucosidase inhibitors 
The polysaccharide starch is composed of numerous monosaccharides bound together 
by α- or β- glycosidic linkages.47 The process by which starch is metabolised to glucose 
within the human body is carried out by four hydrolytic enzymes. Salivary and 
pancreatic amylases hydrolyse starch into shorter linear and branched dextrin molecules 
by cleaving the starch α-1,4 bonds. Dextrins are then hydrolysed by maltase-
glucoamylase and sucrose-isomaltase producing the monosaccharide glucose which can 
be used for cellular respiration.47 
Inhibition of one of these enzymes presents itself as a possible target in the treatment of 
T2D as its inhibition would result in the lowering of glucose levels. The 
pseudotetrasaccharide acarbose does this by inhibiting the pancreatic α-amylase enzyme 
α-glucosidase, located in the small intestine (Figure 1.8).47,48 Inhibition of this enzyme 
delays the absorption of carbohydrates by the small intestine which results in decreasing 
the post prandial rise in plasma glucose. This molecule has been found to improve 
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insulin sensitivity and has not been associated with weight gain.48 Other molecules that 
also act on the glucosidase enzymes are miglitol and voglibose. The main side effects 
associated with their use are gastrointestinal problems such as flatulence, diarrhoea and 
digestive discomfort.28 
 
 
Figure 1.8. Structure of acarbose.47 
1.5.1.2 Alternative protein targets 
As the incidence of diabetes grows so too does the need for new antidiabetic 
therapeutics. Therapies are needed that can improve hyperglycaemia while preventing 
associate weight gain. The most recent antidiabetic pharmaceuticals involve targeting a 
number of proteins that differ to the previously mentioned protein targets. These include 
for example, the direct and indirect activation of incretin hormones and the inhibition of 
a sodium-glucose transporter. 
1.5.1.2.1 Dipeptidylpeptidase IV (DPPIV) inhibitors 
DPPIV is a membrane bound serine protease found on the surface of epithelial cells 
where it has been identified as an inhibitor of the incretin hormone glucagon-like 
peptide (GLP-1). This hormone is secreted by L-cells of the intestinal tract after food 
intake and promotes the secretion of insulin, improves insulin sensitivity, increases β-
cell mass and reduces appetite.25,49 Decreased levels of GLP-1 are found in T2D 
sufferers with inhibition of DPPIV shown to increase the levels of GLP-1 and therefore 
improve insulin secretion.50 
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There are currently five DPPIV inhibitors approved for use: sitagliptin, saxagliptin, 
vildagliptin, linagliptin and alogliptin, with sitagliptin the first DPPIV inhibitor 
approved in 2005 (Figure 1.9).50 These compounds have shown to reduce or not affect 
the incidence of CVD while hypoglycaemia does not occur as their effect on β-cells 
ends when glucose levels return to normal.28,51 
 
    Figure 1.9. Structure of sitagliptin.52 
1.5.1.2.2 Na+-coupled glucose co-transporters (SGLT) 
The kidneys play a substantial role in glucose homeostasis. They are involved in the 
consumption of glucose for metabolism, gluconeogenesis and the filtration and 
reabsorption of filtered glucose. Glucose circulates unbound throughout the body via 
the blood stream and is filtered at the glomerulus. It is reabsorbed by the kidneys to 
prevent large amounts of the monosaccharide being lost by filtration. The mechanism 
by which glucose enters cells and is reabsorbed involves the glucose transport (GLUT) 
proteins but a Na+-coupled glucose co-transporter (SGLT) is primarily responsible for 
the renal reabsorption of glucose. The SGLT proteins use the energy generated by a Na+ 
gradient to pump glucose across the apical membrane and back into the circulatory 
system.27 There are two known SGLT isoforms; SGLT1 and SGLT2.  
SGLT1 is mainly found in the intestinal tract but is also located in the heart and kidney. 
This is a low capacity glucose transporter that is responsible for only small amounts of 
glucose reabsorption in the kidneys.53 SGLT2 however, is a high capacity glucose 
transporter that is found predominantly in the renal convoluted tubule. SGLT2 is 
responsible for roughly ninety per cent of renal reabsorption of filtered glucose while 
SGLT1 accounts for the remaining ten per cent.27,54 
Mascitti et al. reported that inhibition of SGLT2 results in the loss of glucose in urine 
(glucosuria).55 This was supported by Jurczak et al. who stated that SGLT2 knockout 
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mice demonstrated reductions in plasma glucose and insulin levels while preventing the 
loss of β-cell mass.54 As the expression of SGLT1 is not restricted to the kidneys and its 
inhibition has been suggested to cause dehydration, drug candidates are required to 
demonstrate selectivity for SGLT2 over SGLT1.53 A number of pharmaceutical agents, 
such as tofogliflozin, are selective for SGLT2 and have the potential to be used as 
antidiabetic agents (Figure 1.10).53  
 
 
     Figure 1.10. Structure of tofogliflozin.53 
1.5.1.2.3 Retinol binding Protein 4 
The retinol transporter, retinol binding protein 4 (RBP4), has been implicated in the 
process of T2D. Elevated levels of serum RBP4 have been reported in insulin resistant 
humans with RBP4 having a possible involvement in preventing cellular responses to 
insulin, generating insulin resistance and the development of T2D.56,57 This protein 
therefore has the potential to be used as a target for the control and treatment of T2D.57  
The expression of the glucose transporter, GLUT4, responsible for the transport of 
glucose intracellularly, is downregulated in adipose tissue in conjunction with insulin 
resistance. Although adipose tissue contributes very little to glucose consumption and 
homeostasis, it does act as an endocrine organ by secreting molecules that can enhance 
(e.g. leptin) or impair (e.g. TNF- α) the action of insulin.58 Yang et al. reported that 
there is a decrease in the expression of GLUT4 from adipose tissues in the majority of 
insulin resistant states.  Although the mechanism by which this occurs is not known, it 
was found that RBP4 was upregulated in the adipose tissue of insulin resistant humans 
and that this elevated level of RBP4 may be a link between the decreased expression of 
GLUT4 in adipocytes and insulin resistance.58 This may also be another explanation for 
the link between obesity and insulin resistance.57 The elevated levels of RBP4 may also 
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be acting on muscle cells, causing insulin resistance, however the mechanism by which 
this occurs has yet to be clarified.57 
RBP4 is a member of the lipocalin family of proteins which are extracellular proteins 
that bind small, typically hydrophobic molecules, such as retinoids and steroids.59 The 
21 kDa monomeric RBP4 is synthesised primarily in the liver but also in adipose tissue 
and functions to transport vitamin A (retinol, ROH) to extrahepatic tissues.57 It is 
composed of an N-terminal coil, eight anti-parallel β-strands, which form a β-barrel, and 
a short α-helix near the C-terminus (Figure 1.11). There are four highly variable loops 
that connect the β-strands A and B, C and D, E and F and G and H.60 When transporting 
ROH, the vitamin molecule is accommodated within the β-barrel. The ring structure is 
innermost, buried within the protein cavity, the polyene chain is fully extended and the 
terminal hydroxyl functionality is almost solvent exposed in the region of the loops AB, 
CD, EF and GH.57,60 The protein cavity is lined with hydrophobic residues that make 
specific interactions with ROH, thus stabilising the vitamin within the β-barrel.61 
 
Figure 1.11. Structure of holo-RBP4 with ROH (yellow) bound and the structure of 
ROH.57 
Holo-RBP4 (i.e. RBP4 with ROH bound inside the β-barrel) is released from the liver 
complexed to a second, homotetrameric protein transthyretin (TTR). TTR is a thyroid 
binding hormone, synthesised in hepatic tissues, whose purpose is to distribute 
thyroids.60 It is a 55 kDa protein that binds to holo-RBP4 and stabilises the RBP4-ROH 
complex.60 The absence of ROH from the RBP4 β-barrel results in a weaker interaction 
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between RBP4 and TTR. As holo-RBP4 is small enough to be removed from circulation 
by renal filtration the formation of the 76 kDa RBP4-TTR prevents this renal filtration 
due to its increased size.  
There are multiple contacts between the entrance loops of RBP4 and TTR, with loop EF 
making the strongest interaction. The presence of ROH stabilises the RBP4-TTR 
complex in the form of a hydrogen bond between the hydroxyl group of ROH and the 
carbonyl of a TTR glycine amino acid residue.61,62 As apo-RBP4 (i.e. RBP4 without 
ROH bound inside the  β-barrel) has a reduced affinity for TTR, once the RBP4-TTR 
complex has delivered ROH to its target tissues, the proteins disassociate resulting in 
the renal filtration of apo-RBP4.62 This highlights the importance of ROH in the 
formation of the RBP4-TTR complex and demonstrates that replacing ROH with an 
alternative ligand may disrupt the formation of the RBP4-TTR complex, which will 
result in the renal filtration of RBP4. Thus, the serum levels of RBP4 will be reduced 
and may improve the diabetic condition.  
Kahn et al. discovered that the synthetic retinoid, Fenretinide (Fen) possessed the ability 
to compete with ROH for binding within RBP4, causing the disruption of the RBP4-
TTR complex resulting in the renal filtration of RBP4 (Figure 1.12). This ultimately led 
to a reduction in the levels of serum RBP4 which prevented high-fat diet-induced 
obesity, insulin resistance and hepatic steatosis.56 Like ROH, Fen is accommodated 
within the RBP4 β-barrel with the cyclohexene ring innermost and the polyene chain 
extended out towards the opening of the protein cavity. Fen however, possesses a 
hydroxyphenyl amide group, replacing the hydroxyl group found in ROH. The presence 
of the aromatic ring not only prevents the formation of the stabilising hydrogen bond 
between ROH and a TTR glycine residue, it may also interfere with the position of the 
loops at the entrance of the cavity, through steric hindrance. These interactions are 
essential for the formation of a stabile interaction between RBP4 and TTR their absence 
prevents the formation of the RBP4-TTR complex. The ability of Fen to improve 
insulin resistance indicates that the RBP4 protein is a viable target in the battle against 
T2D. 
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   Figure 1.12. Structure of Fen.57 
1.5.1.3 Pharmacokinetics and Pharmacodynamics 
The above antidiabetic drugs manage to overcome the long and arduous journey 
involved in reaching their target protein. To do this they must possess the necessary 
pharmacokinetic properties and appropriate ADME profile.63,64 Pharmacokinetics is the 
study of how a drug behaves in the human body.63 The four main topics in this branch 
of pharmacology are the absorption, distribution, metabolism and excretion of a drug 
within the body, which is often referred to as the ADME scheme. Once a drug has 
overcome the many hurdles encountered on its journey to its protein target, the drug 
must possess the necessary binding properties. Pharmacodynamics is the study of how a 
drug binds to its target and the effect it has on the body.63 
1.5.1.3.1 Pharmacokinetics 
A compound with the best binding affinity does not always make the best drug 
candidate. The drug has to be able to traverse the many obstacles present in vivo such as 
stomach acid, digestive enzymes, hepatic enzymes etc. and when necessary pass 
through the appropriate membranes to reach its target. Orally administered drugs have 
to survive the challenges present during absorption, distribution, metabolism and 
excretion to reach the target protein. To survive these obstacles the drug has to possess 
the appropriate ADME characteristics.63 
1.5.1.3.1.1 Absorption 
Drug absorption describes how a drug reaches the blood supply which is the deciding 
factor in how the drug is administered.  Oral administration is generally the method of 
choice and is the most common form of administration.63  
Orally administered drugs enter the gastrointestinal (GI) tract where they are met by 
digestive enzymes, gastric juices and hydrochloric acid. For a compound to be a 
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successful orally administered drug it must be stable to these inhospitable conditions. 
For example, insulin is acid labile and is degraded by the HCl in the stomach. For this 
reason it is administered intravenously. A drug that is stable to these conditions then 
passes through the fatty cell membrane of the GI tract and into the blood stream. Once 
in the blood stream the drug is transported to the liver where it must withstand the 
degradative hepatic enzymes.63  
For a drug to be able to pass through the lipid membrane of the GI tract, it must have 
the appropriate hydrophilic and hydrophobic character. If the drug is too hydrophilic it 
will not be able to pass through the lipid membrane however, if it is too hydrophobic it 
will not be solubilized in the gut and may be dissolved by globules of fat. The presence 
of amines in a drug can be used to combat this hydrophobic-hydrophilic issue. As 
amines are weak bases, they can be ionized in the blood and equilibrate between the 
ionized and unionized form. Ionized drugs have better hydrophilic properties and can 
give the drug adequate water solubility. The unionized form can improve the 
hydrophobic character and allow for the drug to pass through lipid membranes. From 
this it is clear that the pKa of a drug molecule is an important pharmacological property. 
Orally absorbed drugs usually adhere to Lipinski’s rule of five. These rules are a set of 
general guidelines for a drug to be successfully administered orally, but do not 
determine if a compound will be a successful drug candidate.65 They state that:  
 the drug has a molecular weight less than 500 g/mol 
 contains no more than five hydrogen bond donor groups 
 contains no more than ten hydrogen bond acceptor groups 
 has a calculated logP (a measure of a drug’s hydrophobicity) value less than +5. 
Most orally administered drugs follow these rules but another criterion involves the 
number of rotatable bonds. The number of rotatable bonds can be used to describe the 
flexibility of the molecule. It was found that the more flexible a molecule is, the less 
likely it is to be orally active.65 A polar surface area (PSA) of less than or equal to 140 
Å2 has also been suggested as recommended feature for a compound to be a successful 
drug.65 
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1.5.1.3.1.2 Distribution 
Once in the blood stream, a drug is distributed throughout the body to various tissues 
and organs. Hydrophobicity is again an important factor and can determine if a drug is 
able to pass from the blood stream and into its target cell. If a drug is too hydrophobic it 
can be absorbed by fatty tissue and removed from the circulatory system however, if it 
is not hydrophobic enough it will not be able to pass through the lipid membrane. 
Ionized drugs also face distributary issues. They can bind to various macromolecules 
and be expelled from the blood stream or interact with plasma proteins such as albumin. 
Interactions involving plasma proteins results in an inadequate concentration of free 
drug reaching the target protein. Other barriers that some drug molecules have to 
overcome include the blood brain barrier. Here the capillaries are lined with tightly 
compacted cells which do not contain pores and contain a lipid rich coating. This makes 
it difficult for polar drugs such as penicillin to reach the brain.63 
1.5.1.3.1.3 Metabolism 
Drugs can be metabolised by a number of enzymes which cause a number of structural 
modifications, rendering the molecule biologically inactive or can increase the chance 
of renal clearance. This can occur in a number of tissues but generally most of these 
enzymatic transformations occur in the liver. Orally administered drugs experience what 
is known as the “first pass effect” which describes how drugs, taken orally, are directed 
to the liver once they enter the circulatory system. Here a certain percentage of the drug 
is metabolised by the hepatic enzymes before it can reach its target protein.63  
The metabolism of drugs typically involves Phase I and Phase II metabolic reactions. 
Phase I one reactions generally involve the action of cytochrome P450 which is 
responsible for the majority of the metabolic transformations that occur. These reactions 
involve the addition of polar groups to the drug molecules by oxidase, reductase and 
hydrolase enzymes. N-Methyl groups and aromatic rings are examples of groups that 
are vulnerable to oxidation by oxidase enzymes while nitro and azo groups are 
susceptible to reductase enzymes. Cytochrome P450 can add such polar groups to 
foreign drug molecules to increase their water suability so they are more likely to be 
cleared via renal filtration. One example is the reduction of a keto group to an alcohol 
by the reductase enzyme NADH dehydrogenase.64 
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Highly polar functional groups can be added to drug molecules in Phase II metabolic 
reactions. The enzyme uridine-5'-diphospho (UDP) glucuronosyl transferase is 
responsible for attaching the highly polar glucuronic acid group to drug molecules.  
This results in the formation of O-glucuronides which are extremely polar and readily 
excreted. 
1.5.1.3.1.4 Excretion 
Drugs can be excreted in sweat, bile or exhaled but the kidneys are responsible for the 
majority of drug excretion. The kidneys remove chemicals, which are deemed as waste 
by the body, from the blood stream. Thus drugs and their metabolites are eventually 
removed in urine. Drugs and their metabolites enter the nephron of the kidneys through 
filtration; however each compound that enters is not directly removed. Non-polar drugs 
are reabsorbed into the blood supply while polar drugs, which can include the products 
of metabolism in the liver, remain in the nephron where they can be excreted in urine 
due to their increased aqueous solubility.63  
1.5.1.3.1.5 Drug delivery 
The ways in which the body can metabolise and destroy a drug molecule are vast. To 
combat this, there exist a number of drug delivery methods that protect the drug 
molecule from degradation allowing it to reach its target. Methods also exist that 
improve properties such as water solubility, which further increase the likelihood of a 
drug interacting with its target protein. These methods include the use of prodrugs or 
macromolecules such as cyclodextrins.66,67 These methods will be explained in further 
detail in Chapter 5. 
1.5.1.3.2 Pharmacodynamics 
Pharmacodynamics is the study of how a drug binds to its target protein and evokes a 
biological response. It focuses on the key interactions such as hydrogen bonding, van 
der Waals forces and ionic interactions, to name a few, that are necessary for a drug to 
interact and sufficiently bind to a target protein. Structure activity relationship (SAR) 
studies can be used to identify the functional groups necessary for biological activity. 
This can involve preparing analogues where a particular functional group is altered or 
removed in order to determine if it will cause a change to activity. Certain functional 
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groups can also be important to activity as they can play a key role in the 
pharmacokinetics of a molecule. They can affect certain properties such as logP and pKa 
for example. A pharmacophore model summarizes all the functional groups that are 
essential for activity, whether they are required for binding to a protein or improving the 
pharmacokinetic properties of the molecule.63 
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1.6 Aims 
The aims of this project include: 
 The identification of a lead molecule with the ability to disrupt the RBP4-TTR 
complex, with the goal of treating/managing T2D. 
 Confirm its ability to disrupt the RBP4-TTR complex by means of biological 
assays including a fluorometric binding assay and a surface plasmon resonance 
assay. 
 Assess its ability to treat/manage T2D in an animal model. 
 The synthesis and characterisation of this lead molecule. 
 A SAR study of the active lead compound to identify the key functional groups 
necessary for biological activity using the high throughput glucose uptake assay. 
 Use the information gathered from the SAR study to possibly identify 
compounds that are more active than the initial lead compound. This will 
include the subsequent synthesis and characterization of these molecules. 
 The design of a method for the identification of the secondary protein target. 
This will involve the derivitization of active compounds. 
 The identification and synthesis of structurally distinct families of compounds 
which are also capable of inhibiting the RBP4-TTR complex with the aim to 
treat/manage T2D. 
 Improve the ADME properties of an active compound to allow its use in 
aqueous solutions. 
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2.  Identification of hit compounds 1, 2 
and 3. 
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2.1 Computational studies leading to compound 1, 2 and 3. 
The computational studies carried out by our collaborator Prof. Colin Fishwick 
(University of Leeds), involved the use of the eHiTS (electronic High Throughput 
Screening) software package (SimBioSys Inc.). The software docked flexible ligands 
within the RBP4 receptor (PDB: 1FEL) and rapidly and systematically counted 
mappings of interacting atoms between the RBP4 receptor and the ligand database using 
an exhaustive search algorithm. The binding pocket was first determined from the X-ray 
crystal structure of RBP4. 
The software used a flexible docking method which allowed both the receptor and 
ligand to adopt numerous conformations and poses, thus avoiding severe steric clashes 
between the receptor and ligand. The binding mode for each conformation was 
determined and a binding score was assigned based on binding affinity for RBP4.  
From a database of 57,576 compounds, compound 3, 2 and 3 were uncovered (Figure 
2.1). These compounds passed Lipinski’s guidelines (< 5 hydrogen bond donors; < 10 
hydrogen bond acceptors; molecular weight < 500; logP < 5), which indicated that the 
compound had potential to be used as a bioavailable and orally administered drug. The 
compounds were purchased from Maybridge (www.Maybridge.com) and tested in an 
assay to elucidate if it was capable of disrupting the RBP4-TTR complex formation. 
The assay used was surface plasmon resonance (SPR). 
 
Figure 2.1. Structure of compounds 1, 2 and 3. 
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2.2 Surface Plasmon Resonance (SPR) analysis of 1, 2 and 3 
Surface Plasmon Resonance (SPR) is an optical method used for measuring molecular 
interactions.68 SPR involves immobilizing a binding molecule (e.g. holo, His-RBP4) 
onto the surface of a sensor chip. A certain concentration of compound (e.g. 1, 2 or 3) is 
then injected over the chip surface in a solution of SPR running buffer. This is followed 
by an injection of another binding molecule (e.g. untagged TTR).69 Binding of 
molecules (i.e. formation of a complex) causes a change in mass on the sensor chip 
resulting in changes in the refractive index of the SPR running buffer. Changes to the 
refractive index indicate if binding has occurred and appears as an increase in resonance 
units (RU).70 
The SPR experiments involving compounds 1, 2 and 3, carried out by our collaborator 
and it required holo, His-tagged RBP4 to be immobilized on the surface of a sensor 
chip.69 Both TTR and the natural ligand ROH were then injected over the surface. This 
was followed by compound 1, 2 and 3 which were tested at a range of varying 
concentrations (0-10 µM). At 0 µM of each compound formation of the RBP4-TTR 
complex occurred. This resulted in an increase in mass at the surface of the chip, 
causing changes to its refractive index which caused changes in the RU (Figure 2.2). 
As the concentration of each compound increased from 0-10 µM, a decrease in RU 
occurred. This was due to the fact that compounds 1, 2 and 3 are capable of docking 
within the β-barrel of RBP4 and disrupting/preventing the formation of the RBP4-TTR 
complex. 
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Figure 2.2: SPR analysis of (a) compound 1, (b) compound 2 and (c) compound 3 
Increasing concentrations of 1, 2 and 3 result in a decrease in RU which corresponds to 
the inhibition of the interaction between 200 nM His-tag, bound RBP4 and 1 µM 
TTR.69 
Figure 2.3 (a) is a 2D representation of the binding of 1 within RBP4. Compound 1 is 
predicted to bind with its pyridine ring buried in the protein cavity and its thiophene 
ring exposed at the loops of RBP4. Compound 1 exhibited key interactions with the 
residues Tyr90 and Arg121 in the RBP4 cavity. These interactions were also observed 
with the binding of the compound A1120 (Figure 2.3 (b)). This compound is a known 
inhibitor of the RBP4-TTR complex. It is believed that its binding within the RBP4 
protein causes a conformational change at the entrance to the protein pocket by 
interfering with the position of the loops.71,72 This prevents RBP4 from forming a stable 
interaction with TTR thus causing renal clearance of RBP4.71 Compound 1 may act 
similarly to A1120 when disrupting the formation of the RBP4-TTR complex. The 
thiophene ring may serve to affect the position of the loops at the entrance of the protein 
cavity through steric hindrance. As previously mentioned, the hydroxyl group, found in 
ROH, is important for stabilizing the RBP4-TTR interaction. Therefore the removal of 
this group and its replacement with a thiophene ring, as found in compound 1, may 
further destabilize the RBP4-TTR interaction.  
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Figure 2.3. (a) Two dimensional (2D) depiction of the binding pose of 1 within RBP4, 
as depicted using the computer program MOE. Blue arrow indicates hydrogen bond 
interactions with the group at the base of the arrow the HBD and the group at the head 
of the arrow the HBA, blue shadow indicates solvent exposed residues, hydrophobic 
residues are all coloured with a green interior, polar residues are coloured with a purple 
interior (b) Structure of A1120.  
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2.3 Animal studies using compound 1, 2 and 3. 
From the SPR assay, compounds 1, 2 and 3 proved to be effective disruptors of the 
RBP4-TTR complex. As described in Chapter 1, the ability to disrupt the RBP4-TTR 
complex, thus lowering serum RPB4, is linked to improvements in insulin resistance. 
The use of the retinoid like compound Fen has shown this to be true as its use prevented 
high-fat diet (HFD) induced obesity, and the development of insulin resistance in mice, 
through the lowering of serum RBP4 levels.56 Following this logic, the ability of 
compounds 1, 2 and 3 to control/treat/reduce insulin resistance in mice, was 
investigated. A study examining the effects of these compound on a group of mice 
exposed to a HFD was thus performed by our collaborator.69  
Two groups consisting of eight mice were exposed to a HFD so as to induce insulin 
resistance. Group A was exposed to a HFD which included either compound 1, 2 and 3 
at 0.04% w/w, relative to the quantity of food given.69 This involved 400 mg of each 
compound be dissolved in 10 mL of DMSO which was then mixed in a 1 kg batch of 
HFD food.69 Group B (control) only received a HFD with 10 mL of DMSO.69 
2.3.1 Glucose tolerance testing (GTT) and insulin tolerance testing (ITT) of 
compound 1. 
After 8 weeks, Group A and Group B (control) were both subjected to a glucose 
tolerance test (GTT), which examined how quickly glucose is cleared from the blood 
after a bolus of glucose is administered. An insulin tolerance test (ITT) was also 
performed which examined insulin sensitivity. Mice underwent a period of fasting (12 
hours for GTT and 4 hours for ITT) before whole blood sampling was performed. An 
intra-peritoneal injection of either glucose or insulin was administered and whole blood 
sampling was subsequently performed on conscious mice at 30 minute intervals (Figure 
2.4).69  
Improved glucose handling and the ability to clear glucose more rapidly was observed 
in mice treated with 1, compared to control.69 Also, results from the ITT showed that 
mice treated with 1 also experienced improved insulin sensitivity.69 Lower glucose 
levels at the varying time point indicates a more sensitized response to insulin (Figure 
2.4 (ITT)). 
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Figure 2.4: GTT and ITT results for Group A (drug treated; 1 (blue)) and Group B 
(Control (black)) insulin resistant mice. The decrease in glucose concentrations for both 
GTT and ITT indicate improved glucose handling with the use of compound 1. 
2.3.2 Glucose tolerance and insulin tolerance testing of compound 2 and 3. 
Improved glucose handling and the ability to clear glucose more rapidly was observed 
in mice treated with compound 2, compared to control (Figure 2.5 (a)). Compound 1 
proved to be more effective than compound 2. Insulin sensitivity was not greatly 
improved in mice treated with compound 3, as seen from the results of the ITT 
(Figure2.5 (b)). 
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Figure 2.5: (a) GTT for drug treated (compound 2 and 3) and insulin resistant (control) 
mice and (b) ITT results for drug treated (compound 2 and 2) and insulin resistant 
(control) mice. 
2.3.3 Weight loss studies with compounds 1 and 2. 
Obese individuals are at a greater risk of T2D as increased fat mass leads to reduced 
insulin sensitivity. The link between obesity and insulin resistance described in Chapter 
1. Ford et al. have reported that the risk of diabetes increases by 4.5% to 9% for every 1 
kg increase in weight.73 Obesity can also lead to other life threatening conditions such 
as dyslipidemia and cardio vascular disease. A number of current pharmaceuticals cause 
weight gain, which results in a worsening glycaemic control over time. Therefore 
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weight loss is a corner stone in the treatment and management of T2D.56,74,16,7 New 
pharmaceuticals are therefore needed that improve insulin resistance without causing 
weight gain.  
As well as showing improved the insulin and glucose profiles in mice, mice treated with 
1 also exhibited a reduced weight gain over the 8 week period when compared to a 
control (Figure 2.6 (a)). Trials performed by our collaborators proved that this reduced 
weight gain was not due to a preference in food nor was it due to a reduced food 
intake.69 This reduced weight gain was most likely a secondary effect as a result of the 
improved insulin resistant profile caused be the use of 1. Although compound 2 was not 
as effective at reducing weight gain as compound 1, a reduction in weight was still 
observed (Figure 2.6 (b)). This ability to cause a reduced weight gain is a remarkable 
characteristic of an antidiabetic drug.  
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Figure 2.6: Weight variation in diabetic mice over an 8 week period (a) 
Compound 1 (b) Compound 2. 
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2.4 Initial structure activity relationship (SAR) study of compounds related to 
compound 1. 
The excellent results obtained from both the SPR assay and the animal studies led to a 
desire to optimize compound 1 in terms of its antidiabetic properties. Eight compounds, 
4-11, were initially identified by systematically removing functional groups from the 
amide 1 (Table 2.1). For example, the aromatic nitrogen and the sulphur atom in the 
alkyl chain were removed to investigate their possible roles as HBA, while a carbonyl 
group was introduced into the alkyl as an alternative HBA. The chlorine atom was 
removed to examine its effect on the electronic properties of the aromatic ring. These 
compounds were subsequently synthesised and underwent a series of assays, namely 
fluorometric binding assay, SPR and glucose uptake assay. 
                     
Compound R X1 X2 
1 Cl N S 
4 H CH CH2 
5 H CH C=O 
6 H N C=O 
7 Cl N C=O 
8 H N CH2 
9 Cl N CH2 
10 H CH S 
11 Cl CH CH2 
Table 2.1: Structures of compounds 1-11. 
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2.4.1 Fluorimetric Binding Assay 
The Fluorimetric Binding Assay quantitatively measures a compounds ability to dock 
within apo-RBP, by measuring the level of tryptophan fluorescence quenching that 
occurs.57 A compounds ability to quench tryptophan fluorescence was evaluated at 280 
and 350 nm. ROH and Fen, both known ligands of RBP4, showed the expected 
quenching of the tryptophan residue. However, the amide 4 and its analogue 5 both 
showed an unexpected increase in fluorescence Figure 2.7 (a). Although this increase 
was not expected, conformational changes at or around the tryptophan residue may be 
responsible and this increase may still indicate some level of interaction between 4/5and 
RBP4.75 
Other analogues however showed no increase in fluorescence but showed a slight 
quenching affect indicating binding had occurred. Compound 9 was shown to quench 
the tryptophan residue better than the non-retinoid A1120 (Figure 2.7 (b)).71,72 
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Figure 2.7. Fluorometric binding assay of (a) ROH, 4, 5 and Fen (b) ROH, 6, 9 
and A1120. The binding of compounds to His tagged, apo-RBP4 was monitored 
by titration of the intrinsic fluorescence emission of the protein in the presence 
of increasing concentrations of compounds (0, 0.2, 0.4, 0.6, 1.0, 1.5, 2.0, 5.0, 
10.0, 15.0 μM). The quenching of protein fluorescence due to the transfer of 
energy to the ligand was evaluated using excitation and emission wavelengths of 
280 and 350 nm, respectively. 
2.4.2 Surface Plasmon Resonance analysis of the derivative of the compound 1, 
compound 4. 
SPR analysis was carried out by our collaborators in the same manner as previously 
mentioned in section 2.2.69 His-RBP4 was immobilized on the surface of the chip, 
while TTR, ROH and 4 were consecutively injected over the surface. Results of the 
SPR assay show compound 4 to be a highly effective disruptor of the RBP4-TTR 
complex with results indicting that it was more potent than 4.69 The potency of 4 as a 
disruptor of the RBP4-TTR complex is more evident when the SPR results are 
compared to that of Fen.56 From the SPR assay it is clear that the activity of 1 as a 
disruptor of the RBP4-TTR complex was further optimized in the form of 4 (Figure 
2.8). 
Compounds 5-11 were not tested in the SPR assay. However, their activity was 
examined in a glucose uptake assay. 
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Figure 2.8: SPR assay results of 1 µM TTR exposed to 10 µM of 1, 4 and Fen. SPR 
assay performed in SPR running buffer at a flow rate of 10 µL/min at 25 ºC. 
2.4.3 Glucose Uptake Assay and the derivatives of compound 1 and compound 4. 
Muscle cells are the main consumers of glucose within the body and extract glucose 
from the blood via an insulin dependent mechanism. Glucose is metabolised 
intracellularly by a process known as glycolysis.14 This is a multi-step, catabolic process 
consisting of the breakdown of glucose into pyruvate, a pivotal point of aerobic 
respiration.14 An example of a key step in glucose metabolism, glycolysis, is the 
phosphorylation of glucose by the enzyme hexokinase into glucose-6-phosphate.14  
A distinct characteristic of T2D is the decreased sensitivity of muscle cells to insulin.76 
When insulin is used as a treatment, it stimulates the uptake of glucose by muscle cells. 
Therefore, a compound that is capable of stimulating this uptake of glucose within 
muscle cells would be useful as a diabetic treatment. Compounds were subsequently 
tested for their ability to induce the uptake of radiolabelled glucose within muscle cells. 
The glucose uptake assay measures the amount of 3H deoxy-2-glucose, a tritiated 
analogue of deoxy-2-glucose, taken up by muscle cells. 3H deoxy-2-glucose is used as 
its biochemical properties allow for it to be easily traced and measured within a cell.77 
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As with glucose, the glucose transporter GLUT4 also transports 3H deoxy-2-glucose 
into muscle cells. Here it is phosphorylated by hexokinase to give 3H deoxy-2-glucose-
6-phosphate which is then susceptible to hydrolysis by the enzyme glucose-6-
phosphatase.77 As muscle cells have extremely low levels of this enzyme, the tritiated 
substance remains in the cell where it can be quantitatively measured.77 
2.4.3.1 Compound 4 induced glucose uptake 
The glucose uptake assay was carried out by our collaborator Dr. Darren Martin.69 
Incubation of C2C12 muscle cells with 10 µM of compound 4 followed by exposure to 
1μCi/ml 3H deoxy-2-glucose, stimulated the uptake of 3H deoxy-2-glucose within the 
cells. This stimulation was significant compared to basal (i.e. a control), which are cells 
exposed to 3H deoxy-2-glucose in the absence of a drug. This stimulation was time 
dependent with 4 only causing the uptake of glucose after cells were incubated with 
compound 4 overnight (Figure 2.9). 
 
Figure 2.9: Time dependent compound 4 induced glucose uptake. C2C12 muscles cells 
incubated for 1 hr or overnight in the presence of compound 4. Cells then exposed to 3H 
deoxy-2-glucose for 10 mins and a scintillation count of the C2C12 muscle cells 
performed. 
Surprisingly, when other compounds such as 1 and Fen, which were both highly active 
in the SPR assay, were tested for their ability to stimulate glucose uptake, they were 
found to be inactive (Figure 2.10). 
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Figure 2.10: Glucose uptake assay results for 1, 4 and Fen. C2C12 muscle cells 
incubated overnight at 37 ºC in the presence 10 µM of each compound. Cells then 
exposed to 3H deoxy-2-glucose for 10 mins and a scintillation count of the C2C12 
muscle cells performed. 
The success of 4 in the glucose uptake assay, and its increased potency compared to 1, 
rendered it necessary to identify the functional groups responsible for evoking the 
biological response. A structure activity relationship (SAR) study was carried out to 
ascertain the functional groups responsible and their possible role in stimulating glucose 
uptake. 
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2.5 Conclusion. 
The aims of this section of the project were achieved with the identification of three 
RBP4-TTR inhibitors. Compounds 1, 2 and 3 proved to be active in the SPR assay 
confirming their ability to inhibit the formation of the RBP4-TTR complex. Animal 
studies were also encouraging as these compounds were successful in controlling 
glucose levels but also improving insulin sensitivity in mice. 
An additional important result was the reduced weight gain observed with the use of 
compound 1. As many current antidiabetic drugs have the unwanted side effect of 
weight gain, a compound that can act as an insulin substitute while reducing weight gain 
would be highly beneficial to the diabetic patient.  
A SAR study was performed on the amide 1 which led to the design and synthesis of 
eight compounds, 4-11, which were tested in a number of assays such as the 
fluorometric binding assay and the glucose uptake assay. Compound 4 proved to be 
more active than compound 1 in the SPR assay and the glucose uptake assay. 
Chapter 3 Synthesis of compounds 1 and its derivatives, 4-81 
46 
 
 
 
 
 
 
 
 
3. Synthesis of compound 1 and its 
derivatives, 4-81. 
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3.1 Introduction 
The piperazine heterocycle is found in a wide range of biologically active molecules. 
For example, it is present in drugs responsible for the treatment of HIV and 
osteoarthritis while the piperazine containing N-substituted-6-acylbenzothiazolones are 
active analgesics.78,79 The piperazine molecule itself is of biological interest as it has 
been reported to function as a potent anthelmintic, removing either Enterobius or 
Ascaris from humans.80 
The biogenic amine, 5-hydroxtryptamine (5-HT), commonly known as serotonin, is a 
neurotransmitter that controls a number of important biological processes by interacting 
with a family of receptors known as 5-HT receptors.14,81 The serotonin receptors are 
subdivided into the seven classes 5-HT1-7, with 5-HT6 the most recently discovered.
81 A 
number of antipsychotic and antidepressant drugs are known to bind to this receptor. 
The below piperazine containing antagonists, 12 and 13, have been shown to have a 
high affinity for the 5-HT6 receptor (Figure 3.1). 
 
Figure 3.1. 5-HT6 antagonists, 12: Ar = 5-chloro-2-methoxy-4-methylphenyl, 13: Ar = 
5-(dimethylamino)napthyl.81 
Interestingly, it has been shown that antagonists of this receptor cause a reduction in 
appetite and an increase in weight loss. As a result, this receptor is being investigated 
for its role in the treatment of obesity.81 
3.1.1 Arylpiperazines and their synthesis 
Numerous antifungal, antibacterial, antidepressant, antipsychotic, antihypertensive and 
even recreational drugs, contain arylpiperazines. As previously described, they are 
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particularly common in the field of neuroscience where they are often found in ligands 
for dopamine and serotonin receptors.82 As the arylpiperazine moiety is present in a 
broad and diverse range of pharmaceuticals and biologically active compounds, various 
synthetic approaches are needed to allow access to the necessary arylpiperazine 
derivatives. The formation of the C-N arylpiperazine bond can be performed using a 
variety of synthetic approaches, including metal catalysed reactions, nucleophilic 
aromatic substitutions (SNAr) and cyclocondensations involving anilines.
83,84,85 
3.1.2 Metal catalysed arylpiperazine synthesis 
3.1.2.1 Ullmann reaction 
First reported in 1901, the traditional Ullmann reaction involves the homocoupling of 
aryl halides in the presence of copper powder, with reaction temperatures generally in 
excess of 200 °C.86,87,88,89 Attempts have been made throughout the years to improve 
these harsh conditions with the use of activated and alternative metals, such as nickel 
and palladium. Work by Nadri et al. has allowed for the homocoupling of 
bromobenzene using palladium diacetate and a phosphine ligand at 100 °C with the 
biaryl product isolated in a quantitative yield.90  
Ullmann type reactions involve the coupling of nucleophiles such as phenols or amines 
with aryl halides. This generally involves the use of copper salts such as CuI with 
reaction temperatures typically ranging from 100-150 °C.88,91 For example, Ma et al. 
reported the CuI catalysed coupling of an aryl halide with an amino acid, while 
Hoffmann-la Roche et al. utilised the Ullmann type aryl-amine bond formation in the 
synthesis of the below arylpiperazine 14 (Scheme 3.1).88,92 The proposed mechanism 
for the copper catalysed Ullmann reaction is shown in Scheme 3.2 where the 
mechanism is thought to proceed through two possible pathways; (A) oxidative addition 
of the aryl halide occurs primarily or (B) transmetallation is the first step in the 
pathway. Both pathways culminate in the formation of a Cu(II) species followed by an 
elimination step to give the coupled product and the regeneration of the Cu(I) halide.93 
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Scheme 3.1: The Ullmann type C-N bond formation, (i) CuI, N, N-dimethylglycine 
hydrochloride, K2CO3, DMSO, 16 hrs, 120 °C, 80%.
92 
 
    Scheme 3.2: The proposed mechanism for cooper catalysed Ullmann coupling.93 
3.1.2.2 Buchwald-Hartwig amination 
Discovered by Stephen L. Buchwald and John F. Hartwig, this amination involves aryl-
amine couplings mediated by a palladium catalyst and typically a suitable phosphine 
ligand.94 In 1994, both Buchwald and Hartwig independently reported aryl-amine 
couplings employing a combination of palladium and tin.95,96 However, due to the 
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toxicity associated with the use of stannanes, this was quickly followed by a tin-free 
synthesis (Scheme 3.3).97,98 
 
    Scheme 3.3: Tin-free, palladium catalyzed aryl-amine coupling.98 
The mechanism of the Buchwald-Hartwig amination proceeds through steps similar to 
that of a palladium catalyzed C-C bond formation. Reduction of Pd(II) to Pd(0) (15) is 
followed by oxidative addition of the aryl halide (16) to the Pd(0) species. This affords 
a dimeric aryl halide complex (17). The dimer is then cleaved by the amine to give a 
monometallic aryl halide intermediate which contains a single phosphine and a single 
amine ligand (18). The acidity of the amino proton is increased due to coordination of 
the amine to the palladium. This allows for the deprotonation of the acidic proton by a 
suitable base such as LHMDS or NaOtBu (8). Reductive elimination of the amine 
containing complex produces the arylamine (20) and regenerates the Pd(0) complex. 
This palladium catalyzed reaction was used for the synthesis of the below arylpiperazine 
(21), which was a precursor for the adenosine receptor subtype, A2A, antagonist 22 
(Scheme 3.4). The A2A receptor is expressed in the striatum of the brain and stimulates 
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adenylate cyclase activity which controls AMP levels and thus plays a vital role in 
motor function. It is known that A2A antagonists prevent motor function disturbances 
and have the potential to act as a new class of anti-symptomatic drug for conditions 
such as Parkinson’s disease.99 
 
Scheme 3.4: Buchwald-Hartwig amination for the synthesis of arylpiperazines,  
(i) Pd2(dba)3, NaO
tBu, BINAP, toluene, 80 °C, overnight, 70% (ii) DMF, 90 °C, 5 hrs, 
60%.99 
3.1.3 Nucleophilic aromatic substitution (SNAr) 
Nucleophilic aromatic substitution is an addition-elimination reaction where a 
nucleophile is added to an aromatic ring resulting in the loss of a suitable leaving group. 
Common nucleophiles include groups containing nitrogen or oxygen such as cyanides, 
while halides generally act as the leaving group. The presence of an electron 
withdrawing group, such as a nitro or CF3 group, ortho and/or para to the leaving 
group, is required in order to create an electron poor, hence electrophilic aromatic 
ring.100  
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The addition of the nucleophile to the aromatic ring is the slow rate determining step as 
it disrupts aromaticity, while the elimination of the leaving group is the faster step as it 
involves the restoration of aromaticity  (Scheme 3.5).100  
 
Scheme 3.5: Nucleophilic aromatic substitution: The addition-elimination 
mechanism.100 
As can be seen from the above scheme, fluoride is a useful leaving group in SNAr 
reactions.  F- is regarded as poor leaving group in other transformations, due to the 
strength of the C-F bond. However its enormous inductive effect, which stabilises the 
anionic intermediate, aids in the aromatic ring’s acceptance of the nucleophiles 
electrons.100 
3.1.3.1 SNAr reactions and microwave (MW) irradiation 
SNAr reactions generally employ conventional heating methods in the synthesis of 
arylpiperazines, and typically involve heating at reflux in a suitable solvent. However, 
reaction times can be long. In general, the use of MW irradiation can shorten the 
reaction time and in some cases, improve yields. MW irradiation has been successfully 
employed in the synthesis of arylpiperazines.101 
3.1.3.2 Microwave Synthesis 
Since Gedye and Majetich first reported the use of MW for the acceleration of organic 
reactions, the use of MW heating has become a valuable tool to synthetic chemists.102 
MW synthesis is capable of decreasing reaction times and improving yields due to its 
efficient method of energy transfer.102  
A MW is a form of electromagnetic energy that consists of  an electric field and a 
magnetic field.102 Microwaves are found at the lower end of the electromagnetic 
spectrum, between radio and infrared frequencies, and are characterized in the 0.3 to 
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300 GHz frequency range.103 The energy of a MW photon at this range only affects 
molecular rotation and does not possess sufficient energy to cleave molecular bonds, 
therefore molecular structure is unaffected.103 MW assisted heating can involve the 
direct coupling of microwaves with the reactant molecules. The ability of microwaves 
to heat a substance depends on a materials capacity for absorbing energy and converting 
it into heat.103 Unlike conventional heating methods which rely on conduction or 
convection for the transfer of energy, MW energy is primarily transferred by dielectric 
loss. The electric field is responsible for the transfer of energy from MW to material via 
dipole rotation or ionic conduction. 
MW irradiation can cause an increase in the rate of reaction. The rapid increase in 
temperature provides the reaction system with a large amount of energy relative to the 
energy needed to overcome the activation barrier. This fact is responsible, not only for 
the increase in reaction rates, but also for the improved yields. From the Arrhenius 
equation (Equation 3.1), it is clear that an increase in temperature results in an increase 
in the rate of reaction.104 
k = Ae-Ea/RT 
Equation 3.1: The Arrhenius equation. 
3.1.3.3 Arylpiperazine synthesis 
Although the scope of metal catalysed arylpiperazine synthesis is broad, one 
disadvantage associated with this synthetic approach is the cost of the metal catalysts 
and if required, the ligand.105 MW irradiation offers a facile and versatile approach to 
arylpiperazine synthesis without the use of costly metal catalysts or ligands. This was 
evident in the synthesis of a series of substituted arylpiperazines carried out by Meng et 
al..105 Here piperazine, N-methylpiperazine or morpholine were reacted with a variety of 
substituted fluorobenzene derivatives using N-methyl-2-pyrrolidone (NMP) as a 
solvent. In one such example, 1,2,4,5-tetrafluorobenzene was reacted with all three 
amines to give the arylpiperazines in excellent yields and short reaction times (Scheme 
3.6).105 
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Entry X Time (hrs) Yield (%) 
1 NH 1.5 87 
2 N(CH3) 1 90 
3 O 1 86 
Scheme 3.6: Synthesis of fluorinated arylpiperazines using MW irradiation (i) K2CO3, 
NMP, MW.105 
Aromatase is a member of the cytochrome P450 family that is involved in the catalytic 
conversion of C19 steroids to oestrogens.106,107 Exposure to oestrogens has been linked 
to the promotion of hormone related diseases such as breast cancer with expression of 
aromatase more significantly induced in cancerous breast tissue compared to healthy 
tissue.106, 108 For this reason aromatase inhibitors provide a viable option for the 
decrease in oestrogen production and thus the treatment of breast cancer.106,107,108 
The compound letrozole (Scheme 3.7) is an active aromatase inhibitor used in the 
clinical treatment of breast cancer.109 Compound 23 is a letrozole analogue synthesised 
in the search for a new lead compound where MW assisted arylpiperazine synthesis was 
used to generate the arylpiperazine from the fluorobenzene precursor.109 The compound 
was synthesised in an extremely short reaction time and in an excellent yield, 
demonstrating the efficiency of MW assisted arylpiperazine synthesis. 
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Scheme 3.7: Structure of letrozole and the synthesis of compound 23 with similar 
biological activity to Letrozole, (i) NMP, MW, 15 mins, 95%.109 
The efficiency of arylpiperazine synthesis using MW conditions was apparent in the 
synthesis of the piperazine 1-(pyridin-2-yl)piperazine (Scheme 3.8, 24). Bromopyridine 
was reacted with piperazine in the absence of a solvent to give the arylpiperazine in a 
54% yield after twenty minutes.110 When Milkiewicz et al. attempted the synthesis of 24 
using metal catalysis, a substantial reduction in yield was observed. 2-Bromopyridine 
and piperazine were reacted in the presence of the palladium catalyst tris-
(dibenzylideneacetone)dipalladium(0) and 2,2'-bis-(diphenylphosphino)-1,1'- binaphthyl. 
The reaction was heated at reflux in toluene for eighteen hours, however an almost 
twenty per cent reduction in yield compared to the MW assisted approach, was 
observed.111  
 
    Scheme 3.8: Synthesis of the arylpiperazine 24, (i) 150 °C, 20 mins, 54%.111 
3.1.4 Cyclocondensations 
Previous examples saw the arylpiperazine moiety synthesised from aryl halides and 
piperazine via a nucleophilic aromatic substitution. An alternative approach to this 
involves a cyclocondensation reaction between anilines and N, N-bis(2-
haloethyl)amines (Scheme 3.9). 
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Scheme 3.9: Synthesis of arylpiperazines via cyclocondensation of anilines and N, N-
bis(2-haloethyl)amines. 
A broad range of anilines can be used in this cyclocondensation approach, resulting in 
the synthesis of a vast array of arylpiperazine derivatives. This was demonstrated by Liu 
et al. who heated the appropriate aniline and N,N-bis(2-chloroethyl)amine in diethylene 
glycol monomethyl ether at 150 °C resulting in the formation of the HCl salt of the 
arylpiperazine.82 The nature of the aniline substituent did not greatly affect the 
cyclocondensation with arylpiperazines generated in yields ranging from 66-95% 
(Scheme 3.10). 
 
    
 
 
  
 
Scheme 3.10: Synthesis of arylpiperazines via cyclocondensation (i) diethylene glycol 
monomethyl ether, 150 °C, *Isolated yields based on free amine.82 
This approach was also employed by Juvale et al. to produce a series of arylpiperazine 
derivatives which were subsequently used to synthesise a number of quinazoline 
piperazole analogues (Scheme 3.11, 25).112 
Entry R Yield(%)* 
1 H 79 
2 4-nitro 90 
3 3-CO2Et 90 
4 3-OMe 95 
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Scheme 3.11: Preparation of arylpiperazines via a cyclocondensation approach and 
subsequent synthesis of quinazoline piperazoles, (i) diethyleneglycol monomethyl ether, 
reflux, 6–12 hrs, 55-65% (ii) K2CO3, isopropanol, reflux, 10–12 hrs, 45–64%.112 
3.1.5 Synthesis of amide bonds 
Amide bonds can be synthesised in a variety of ways, with the most common method 
involving the use of coupling reagents to activate the carboxylic acid in situ. In the 
absence of coupling reagents, the merger of these two groups, with the required loss of 
water, can only happen at high temperatures and such conditions can be damaging to the 
overall integrity of the reactants. Therefore coupling reagents are often used to increase 
the reactivity of one of the reagents. The simplest way of doing this is by activating the 
carboxylic acid with the use of coupling reagents; thus forming an activated species 
(Scheme 3.12).113 Coupling reagents are used to generated more reactive intermediates 
such as acid chlorides, anhydrides, carbonic anhydrides or activated esters.113  
 
Scheme 3.12: Activation of carboxylic acid leading to amide bond formation.113 
3.1.5.1 Types of coupling reagents 
A wide variety of coupling reagents exist ranging from carbodiimides, the very first 
coupling reagents synthesised, to the potentially explosive benzotriazoles.113 Such a 
variety of reagents exist as the coupling reagent needs to be able to deal with a broad 
range of substrates and their differing reactivities.113 Two of the more common reagents 
are described in more detail below. 
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3.1.5.1.1 Carbodiimides 
Carbodiimides were the first coupling reagents employed in amide bond formation and 
are still widely used to this day. One of the most commonly used carbodiimides is 
dicyclohexylcarbodiimide (DCC), which has been used as a coupling reagent since 
1955.114 Its use produces the white, and generally insoluble, by-product dicyclohexyl 
urea (DCU), which can be easily removed by filtration.113  
The mechanism of action first involves the formation of the activated ester intermediate, 
the O-acylurea (26), which is then attacked by the nucleophilic amine to yield the amide 
product and the DCU (27) by-product (Scheme 3.13). Formation of an amide via an 
anhydride species (28) can also occur if enough carboxylic acid is present in the 
reaction mixture. In this case, the carboxylate anion attacks the activated ester forming 
the anhydride. This is subsequently attacked by the amine giving the desired amide 
product. The O-acylurea species can also give rise to an N-acyl urea by product (29) 
(Scheme 3.13). 
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      Scheme 3.13: Amide bond formation using DCC coupling reagent.113 
3.1.5.1.2 Hydroxy benzotriazoles 
Benzotriazoles react with carboxylic acids in the same manner as carbodiimides to form 
the OAt/OBt activated esters.114 Although benzotriazoles are often used as the uronium 
or aminium salts, the presence of the counter ion was not found to affect its ability to 
assist in the formation of amide bonds.114 
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3.2 Synthesis of compound 1 and the derivatives of compound 1. 
The final step in the synthesis of compound 1 and many of its derivatives, involved the 
generation of an amide (Scheme 3.14). The below scheme shows the retrosynthetic 
pathway for the synthesis of the amide 1 from a substituted arylpiperazine and the 
carboxylic acid 30. 
 
Scheme 3.14: The formation of an amide bond from an amine and a carboxylic acid. 
3.2.1 Synthesis of compound 1 
Synthesis of the amide 1 involved a two-step process. Firstly, the carboxylic acid, 3-
(thiophen-2-ylthio)propanoic acid (30), was synthesized from 3-bromopropanoic acid 
and thiophene-2-thiol. We first employed a literature procedure where nucleophilic 
attack by the thiol on the electron deficient carbon-halide bond, in the presence of base 
at rt, produced the desired carboxylic acid in a 50% yield.115 We then used an improved 
synthesis, reported by Hammam et al.,  which saw the reagents heated at reflux in EtOH 
for 5 hours.116 This gave the carboxylic acid 30 in an 85% yield (Scheme 3.15). 
 
     Scheme 3.15: Synthesis of compound 30, (i) K2CO3, EtOH, reflux, 5 hrs, 85%. 
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Formation of the amide bond was conducted using the hydroxyl benzotriazoles HOBt 
and TBTU. The activated OBt ester underwent nucleophilic attack by the electron rich 
substituted piperazine, 3-chloro-5-(trifluoromethyl)pyridin-2-yl)piperazine, resulting in 
the formation of the desired amide 1 in a 71% yield (Scheme 3.16).  
 
Scheme 3.16: Synthesis of 1, (i) HOBt, TBTU, NEt3, DMF, N2, rt, overnight, 71%. 
NMR spectroscopy verified the formation of 1 with two triplets present at 3.11 and 2.68 
ppm, both with coupling constant values of 7.1 Hz. These peaks resonating at this 
chemical shift are characteristic of the two methylene groups found in the alkyl chain of 
1. The presence of the CF3 group in compound 1, and other compound 1 derivatives 
containing the trifluoromethyl phenyl group, is evident from the 13C NMR spectra 
shown below. The 100% natural abundance and the spin of I = ½ of 19F, allows 
heteronuclear coupling between 13C and 19F to occur. The observed quartet, resonating 
at 123.8 ppm with a coupling costant of 270.0 Hz, is indicative of the CF3 carbon atom 
while the quartet resonating at 121.2 ppm with a coupling constant of 33.0 Hz is 
characteristic of the ipso C-CF3 carbon (Figure 3.2). The formation of the amide bond 
was confirmed by IR spectroscopy due to the presence of the band at 1636 cm-1. 
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Figure 3.2. Expanded view of a region of the 13C NMR spectrum of 1 in CDCl3. 
The J values diminish as the carbons become more distant from the fluorine atoms. 
Thus the quartet with coupling constants of 4.1 and 3.3 Hz at 143.6 and 136.7 ppm 
respectively represent the carbon atoms meta to the piperazine ring (Figure 3.3). 
 
Figure 3.3. Expanded view of a region of the 13C NMR spectrum of 1 in CDCl3. 
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3.2.2 Synthesis of derivatives of compound 1. 
The synthetic strategy for the synthesis of the derivatives of the amide 1 centered on a 
final coupling reaction. In many cases either the piperazine unit or the carboxylic acid 
unit had to be synthesised prior to the coupling (Scheme 3.19). 
 
       Scheme 3.19: Synthetic strategy for the synthesis of derivatives of compound 1. 
3.2.2.1 Synthesis of derivatives of compound 1 with changes to the arylpiperazine 
The synthesis of derivatives of compound 1 with changes to the arylpiperazine group 
involved the coupling of a variety of different arylpiperazines with 4-(2-thienyl)butyric 
acid (Scheme 3.20). For example, derivatives were synthesised where R was equal to 
groups such as CF3 or NO2, X
1 and X2 were nitrogen atoms or a -CH and Z was a sigma 
bond or a methylene group. A number of the necessary arylpiperazines were 
commercially available while other piperazines were synthesised using nucleophilic 
aromatic substitutions (SNAr) and the palladium catalyzed Buchwald-Hartwig 
amination. The construction of the piperazine moiety from anilines was also utilized in 
the synthesis of a selection of piperazines.83,84,85 
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Scheme 3.20: Retrosynthesis of derivatives of compound 1 with changes to the 
arylpiperazine. 
3.2.2.1.1 Synthesis of piperazines via SNAr 
The preparation of compound 11 involved the synthesis of the substituted piperazine, 1-
(2-chloro-4-(trifluoromethyl)phenyl)piperazine (31, Scheme 3.21), from 2-chloro-1-
fluoro-4-(trifluoromethyl) benzene and piperazine via a nucleophilic aromatic 
substitution. The aryl halide and piperazine were heated at reflux in DMF overnight in 
the presence of base. However, this afforded a complex mixture which included the 
mono- (31) and di- substituted (32) products (Scheme 3.22). An alternative approach 
was then chosen in which the piperazine was Boc protected. The protected piperazine 
was subsequently heated at reflux in DMF in the presence of the aryl halide. This gave 
rise to the Boc protected product, albeit in a 10% yield.  
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Scheme 3.22: Synthesis of 31 via SNAr, (i) K2CO3, DMF, reflux, overnight. 
3.2.2.1.2 Buchwald-Hartwig amination in the synthesis of arylpiperazines 
The arylpiperazine 33, which was previously commercially available, became restricted 
during the course this project. As this piperazine was a key intermediate in the synthesis 
of our lead compound, 4, its synthesis was necessary. The literature focused our 
attention on a palladium catalysed Buchwald-Hartwig amination. This involved the use 
of 2-(2',6'-dimethoxybiphenyl)dicyclohexylphosphine (SPhos) and 
bis(dibenzylideneacetone)-palladium (0) (Pd(dba)2) (Scheme 3.23). The product, 
compound 33, was isolated in a 40% yield.83 
 
Scheme 3.23: Synthesis of piperazine 33, (i) Pd(dba)2, THF, Toluene, NaO
tBu, 90 °C, 8 
hrs, 40%. 
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3.2.2.1.3 MW assisted, SNAr synthesis of arylpiperazines 
As the commercial availability of the piperazine 33 became restricted and a low yield of 
10% was obtained in the synthesis of the piperazine 31 using conventional heating 
methods, an improved and more economical synthetic approach to arylpiperazines was 
sought. Our aim was to synthesise the arylpiperazines in shorter reaction times and in 
greater yields. We were attracted to a palladium free synthesis described in the literature 
where only the aryl halide, piperazine and 1-methyl-pyrrolidin-2-one (NMP) were 
employed. It involved a nucleophilic aromatic substitution (SNAr), facilitated by 
microwave irradiation.101 Our efforts using this methodology are described below. 
The microwave assisted synthesis of the arylpiperazines consisted of heating the 
appropriate benzotrifluoride at 200 °C, in a microwave reactor, and in the presence of 
piperazine, for 30 minutes. Piperazine 31 was successfully synthesised in a 61% yield 
(Scheme 3.24). The increase in yield, compared to the previously discussed 
conventional heating method, highlights the effectiveness of MW irradiation in organic 
synthesis (Table 3.1).  
      
       Scheme 3.24: Synthesis of 31, (ii) NMP, MW (300 W), 200 °C, 20 mins, 61%. 
These conditions were also employed in the synthesis of piperazine 33. Although an 
increase in yield was observed compared to the palladium synthesis of 33, the yield was 
lower than that for 31. This lower yield can be explained due to the presence of a 
chlorine atom, instead of a fluorine atom, para to the CF3 group as seen in the synthesis 
of 31. As previously described, the presence of fluorine increases the rate of reaction 
due to its enormous inductive effect.100  
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Compound Reaction type Yield (%) 
31 Conventional heating 10 
31 MW assisted heating 61 
33 Palladium catalysed 
reaction 
40 
33 MW assisted heating 50 
Table 3.1: MW assisted synthesis of arylpiperazines 31 and 33. 
The MW conditions were also applied to the synthesis of piperazine 34 (Scheme 3.25). 
The product was carried forward and used in the coupling with 4-(2-thienyl)butyric acid 
without any further purification. 
         
Scheme 3.25: Synthesis of 34, (i) NMP, MW (300 W), 200 °C, 20 mins. 
The importance of the electron withdrawing CF3 group was evident during the 
attempted synthesis of 35 (Scheme 3.26). Even with the aid of MW irradiation the 
desired substituted piperazine could not be formed, instead starting materials were 
recovered. We believe that the lack of reactivity was due to the presence of a para CH3 
group instead of a CF3. CH3 groups are slightly electron donating whereas CF3 groups 
are strongly electron withdrawing. As such a CF3 activates an aromatic ring towards 
nucleophilic substitution whereas a CH3 group would have the opposite effect. 
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Scheme 3.26: Attempted synthesis of 35 using MW irradiation, (i) NMP, MW (300 W), 
200 °C, 20 mins, product not isolated. 
The CF3 group stabilises the anionic charge formed after nucleophilic attack on the 
aromatic ring. Unlike other electron withdrawing groups, such as a nitro group, which 
stabilizes an anionic charge by conjugation, the CF3 group stabilises a charge through 
an inductive effect.100 The electron withdrawing properties of fluorine polarize C-F 
bonds allowing it to stabilise an anionic charge.100 An alternative approach was 
therefore necessary for the synthesis of 35. 
3.2.2.1.4 Cyclocondensations 
An alternative method for the preparation of substituted piperazines consisted of the use 
of anilines and bis(2-chloroethyl)amine.HCl. This SN2 reaction constructs the 
piperazine ring from a disubstituted amine salt to give the HCl salt of the arylpiperazine. 
This method relies on the nucleophilic nature of the aniline and does not require an 
electron withdrawing group, as with SNAr reactions. In fact, the presence of an electron 
withdrawing group would be detrimental as it would reduce the nucleophilicty of the 
primary amine.  
Piperazine 35 was therefore synthesised from p-toluidine and bis(2-
chloroethyl)amine.HCl by heating at reflux in bis(2-methoxyethyl) ether for 16 hours.85 
This gave the HCl salt of the arylpiperazine, which was then stirred in a 5% NaOH 
solution to afford the free amine (Scheme 3.27). A high boiling solvent was used for 
this coupling as high temperatures were required due to the reduced nucleophilicty of 
aromatic amines. This reduced nucleophilicty is characteristic of anilines due to the 
delocalisation of electrons into the aromatic ring.100  
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Scheme 3.27: Synthesis of 35, (i) bis(2-methoxyethyl) ether, reflux, 16 hrs (ii) 5% 
NaOH, rt, 4 hrs, 13%. 
 
This method was also used to synthesise the piperazine 36. As with 35, an aniline 
derivative, 4-(tert-butyl)aniline, was reacted with bis(2-chloroethyl)amine.HCl in the 
dissolved in bis(2-methoxyethyl) ether. The HCl salt of the substituted piperazine was 
isolated in a 63% yield. The free amine was then isolated using 5% NaOH (Scheme 
3.28). 
 
Scheme 3.28: Synthesis of 36, (i) bis(2-methoxyethyl) ether, reflux, 16 hrs, 63% (ii) 5% 
NaOH, rt, 4 hrs, 87%. 
3.2.2.1.5 Synthesis of alkyl/acyl piperazines 
Introduction of a carbonyl group or methylene group between the piperazine and 
trifluoromethyl phenyl group first required the synthesis of the arylpiperazines 37 and 
38. Nucleophilic substitution of the appropriate benzotrifluoride derivative, using 
piperazine, gave access to the required amines. 
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Compound 37 was synthesised using an excess (2 eq) of piperazine. Piperazine was 
added to a solution of 4-(trifluoromethyl)benzoyl chloride in DCM at 0 °C. Although an 
excess of piperazine was used, the major product isolated was the disubstituted product 
(39). However, a sufficient amount of the monosubstituted product was isolated for use 
in the subsequent coupling reaction (Scheme 3.29).  
 
 
Scheme 3.29: Synthesis of 37, (i) DCM, DIPEA, 0 °C-rt, 2 hrs, 3% for compound 37 
and 82% for 39. 
A fourfold excess of piperazine was also used in the synthesis of 38, which involved 
heating the reaction mixture containing piperazine and 1-(bromomethyl)-4-
(trifluoromethyl)benzene at 85 °C in toluene (Scheme 3.30).117 An excess was used to 
prevent the disubstitution of the piperazine. The monosubstituted product was isolated 
in a 57% yield. 
 
Scheme 3.30: Synthesis of 38, (i) Toluene, 85 °C, 2 hrs, 57%. 
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3.2.2.2 Condensations 
The final derivatives of compound 1 were prepared in a similar fashion to compound 1 
with the use of the coupling agents HOBt and TBTU in the last step (Table 3.2). Some 
of the required piperazines were synthesised as described previously and then coupled 
with 4-(2-thienyl)butyric acid to give the final derivatives. As a number of the 
piperazines and functionalised carboxylic acids, needed to synthesise the necessary 
derivatives, were commercially available these derivatives could be synthesised in one 
step by reacting the appropriate piperazine and carboxylic acid. The following tables 
provide the yields and structures of the derivatives of compound 1. 
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Compound R X Z Yield (%) 
4 p-CF3 CH - 80 
8 p-CF3 N - 80 
9 o-Cl, p-CF3 N - 64 
11 o-Cl CH - 80 
40 p-F CH - 71 
41 o-CF3 CH - 63 
42 p-NO2 CH - 75 
43 bis(m-CF3) CH - 39 
45 3-Cl, 4-CF3 N - 68 
46 o-Br,  p-CF3 CH - 50 
47 H CH - 59 
48 p-CH3 CH - 24 
49 p-tBu CH - 86 
50 p-CF3 CH C=O 50 
51 p-CF3 CH CH2 73 
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10 
Table 3.2: Yields (%) of amide products, (i) HOBt, TBTU, NEt3, DMF, N2, rt, 
overnight, - = sigma bond. 
The amide 4 was synthesised in an 80% yield with NMR spectroscopy used to support 
its synthesis. The presence of the peak at 171.0 ppm in the 13C NMR spectrum supports 
the presence of the amide carbon atom. The presence of this group is further supported 
by IR spectroscopy due to the band at 1653 cm-1. The presence of the CF3 group is 
evident due to the quartets resonating at 126.5 ppm (J = 3.6 Hz), 24.6 (J = 270.0 Hz) 
and 121.2 (J = 33.0 Hz). The synthesis of compound 4 was also supported by HR-MS. 
The mono fluorinated derivative of compound 4, the amide 40, was characterized using 
the splitting pattern resulting from the presence of the fluorine atom. The ipso carbon 
atom was identified as a doublet with the characteristic J value of 238.1 Hz, while the 
ortho (J = 22.0 Hz), meta (J = 7.3 Hz), and para (J = 2.2 Hz), carbon atoms were 
identified based on the size of their J values. Again, the size of the J value decreased as 
the fluorine atom became more distant (Figure 3.4). 
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Figure 3.4 (a) and (b) Expanded view of portions of the 13C NMR spectrum of amide 
40 in CDCl3. 
Compounds 52, 53 and 54, Table 3.3, were also synthesised to investigate the 
biological importance of the phenyl ring and the piperazine ring. All three were 
synthesised in one coupling step from the same carboxylic acid and corresponding 
amine; (1-cyclohexylpiperazine for 52, (4-(trifluoromethyl)phenyl)hydrazine for 53 and 
4-(4-(trifluoromethyl)phenyl)piperidine for 54. Their structures and yields are shown in 
Table 3.3. 
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Compound Structure Yield (%) 
52 
 
70 
53 
 
69 
54 
 
48 
 
 
 
Table 3.3: Structures and yields (%) of compounds 52, 53 and 54. 
The successful synthesis of 53 was supported by the 1H NMR spectrum where the peak 
resonating at 6.38 ppm, integrating for one proton, indicated the presence of the amide 
proton. The presence of the amide proton is also clear from the IR spectrum where an 
N-H stretch at 3309 cm-1 and an N-H bend at 1614 cm-1 are present. The synthesis of 53 
was also supported by HR-MS. 
A number of the carboxylic acids, needed to synthesize the necessary derivatives of 
compound 1 with changes to the alkyl chain or thiophene ring, were commercially 
available. These acids were reacted with the arylpiperazine 33 to afford the desired 
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derivatives (Table 3.4). The derivatives synthesised contained variations in X or Z. For 
example, X was varied by increasing or decreasing the length of the carbon chain or by 
introducing heteroatoms such as sulphur. The Z group was varied by introducing groups 
such as a furanyl heterocycle or a carboxylic acid. 
 
Compound X Z Yield (%) 
5 (CH2)2C=O 2-thienyl 81 
10 (CH2)2S 2-thienyl 63 
55 (CH2)4 2-thienyl 25 
56 (CH2)5 2-thienyl 75 
57 (CH2)6 CH3 63 
58 CH3 - 57 
59 (CH2)2 2-thienyl 44 
60 (CH2)3 CH3 57 
61 CH2 2-thienyl 20 
62 (CH2)2 2-furanyl 31 
63 (CH2)3 4-pyrazolo 10 
64 (CH2)4 Ph 44 
65 - 2-thienyl 73 
Table 3.4: Yields (%) of amide products, (i) HOBt, TBTU, NEt3, DMF, N2, rt, 
overnight, - = sigma bond. 
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Good to moderate yields were generally encountered, with the exception of 55, 61 and 
63. A lower isolated yield was obtained for 55 and 61 as multiple purification steps 
were required to provide a pure compound. A 10% yield was observed for 63 due to the 
presence of a secondary amine in the pyrazole ring. The secondary pyrazole amino 
group would have been expected to be less nucleophilic than the piperazinyl amino 
group due to the delocalization of its lone pair of electrons into the aromatic ring.100 
However, its reactivity may still have been sufficient to also attack the OBt activated 
ester, resulting in the possible production of undesired side products. Presence of 
unwanted side products and the difficulty in isolating a free amine made purification via 
column chromatography difficult resulting in a reduced yield.  
Amides 6 and 7 are derivatives of compound 1 which were synthesised with changes to 
both the arylpiperazine and the alkyl chain. Both 6 and 7 were synthesised in one 
coupling step from the corresponding commercially available piperazine and carboxylic 
acid. The structures and yields for these products are shown in Table 3.5. 
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Compound Structure Yield (%) 
6 
 
63 
7 
 
70 
Table 3.5: Structures and yields (%) of compounds 6 and 7, (i) HOBt, TBTU, 
NEt3, DMF, N2, rt, overnight. 
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3.2.2.3 Synthesis of compound 66 
An alcohol group was introduced into the alkyl chain by reduction of the keto group in 
5 (Scheme 3.31). NaBH4 was used as the reducing agent
118 and 66 was produced in an 
81% yield. 
 
Scheme 3.31: Synthesis of 66, (i) NaBH4, MeOH, 50 °C, overnight, 81%. 
The introduction of an alcohol group into the alkyl chain was evident from the IR 
spectrum with a peak at 3383 cm-1, characteristic of a secondary alcohol. 1H NMR 
spectroscopy confirmed the reduction was successful, due to the presence of the C-H 
signal as a multiplet ranging from 5.08–5.04 ppm and integrating for one proton. The 
chemical shift of this proton is indicative of a proton adjacent to an electronic 
withdrawing group such as an oxygen atom. The chemical shift of the carbon atom 
resonating at 68.6 ppm was suggestive of a carbon next to an electron withdrawing 
oxygen atom. HSQC experiments confirmed the correlation between the 
aforementioned proton and carbon.  
3.2.2.4 Synthesis of compound 67 
In the first attempt to synthesise 67, methyl piperazine and 1-chloro-4-
(trifluoromethyl)benzene were heated at reflux in toluene for 24 hours (Scheme 3.32, 
(i)) Only starting materials were recovered and hence different conditions were 
subsequently employed (Scheme 3.32). The reagents were heated at reflux in DMF but 
the use of a higher boiling solvent did not have any effect and again starting materials 
were recovered (Scheme 3.32, (ii)). MW irradiation was employed and the two reagents 
were heated at 200 °C (300W). The SNAr was successful although the yield was low 
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and purity poor (Scheme 3.32, (iii)). Finally, an alternative approach was employed 
which did not involve the synthesis of 67 via a SNAr.  
The arylpiperazine 33 was methylated using an excess of formic acid and formaldehyde. 
This reductive amination, known as an Eschweiler-Clarke reaction, involves the 
reduction of the formed imine by a formate anion (Scheme 3.32, (iv)). The methylated 
piperazine 67 was isolated in 72% yield and its presence was supported by 1H NMR 
spectroscopy. A singlet resonating at 2.32 ppm and integrating for three protons is 
indicative of a methyl group adjacent to an electron withdrawing nitrogen. HR-MS also 
supported the formation of 67. 
 
Scheme 3.32: Retrosynthetic route and attempted synthesis of 67, (i) Toluene, reflux, 
24 hrs (ii) DMF, reflux, 24 hrs (iii) NMP, MW (300 W), 200 °C, 20 mins, 9% (iv) 
formaldehyde, formic acid, EtOH, reflux, 3 hrs, 72%. 
3.2.2.5 Synthesis of compound 70 
Given the role of amide bonds in biological systems, it was necessary to investigate the 
importance of the amide bond of compound 4 for glucose uptake assay. As such 70 was 
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designed and synthesised as it differed from 4 only in the absence of the amide 
carbonyl. The synthetic route, outlined in Scheme 3.33, involved the reduction of 4-(2-
thienyl)butyric acid to 4-(thiophen-2-yl)butan-1-ol (77), using lithium aluminium 
hydride.119 The desired substitution of the alcohol 68, with compound 33, first required 
the conversion of the alcohol into a better leaving group. In this case, the alcohol was 
converted into the methanesulfonate derivative (69) using methanesulfonyl chloride. 
Scheme 3.33: Synthetic route for the synthesis of compound 70. 
The mesylation mechanism involves the elimination of HCl from the sulfonyl chloride 
(71) to give the sulfene (72) (Scheme 3.34). This is followed by attack of 68 on the 
electrophilic sulphur by to give 69.120 
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Scheme 3.34: Formation of 69 and the mechanism for the mesylation of an alcohol.120 
The heating of compounds 33 and 69 in refluxing acetonitrile, in the presence of 
Na2CO3, gave derivative 70 in a 91% yield (Scheme 3.35). The absence of the carbonyl 
group was supported by the 1H NMR spectrum with the presence of the additional CH2 
peak resonating at 2.86 ppm, with a coupling constant value of 7.2 Hz and integrating 
for two protons. The chemical shift, the size of the coupling constant and the 
multiplicity are all suggestive of the presence of a methylene group adjacent to both an 
electron withdrawing substituent, such as a nitrogen a methylene group. The absence of 
the carbonyl group in the IR and the 13C NMR spectrum was clear, while the presence 
of the peak at 29.7 ppm in the 13C NMR spectrum supported the presence of the 
methylene group. The peak at 29.7 ppm was also observed out of phase in the DEPT135 
experiment confirming it was due to a CH2. 
  
Scheme 3.35: Synthesis of 70, (i) Na2CO3, CH3CN, reflux, 24 hrs, 91%. 
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3.2.2.6 Synthesis of compound 73 
Compound 73 was synthesised in order replace the electron withdrawing CF3 group 
with an electron donating amino group. The first attempt at the synthesis of this 
derivative involved the use of the coupling reagents HOBt an TBTU to couple the 
arylpiperazine 4-(piperazin-1-yl)aniline with 4-(2-thienyl)butyric acid. Due to the 
presence of the aniline functional group, a complex mixture was obtained and 73 was 
isolated in only 10% yield. An alternative approach was taken which employed the 
reduction of 42 using the platinum oxide catalyst, known as Adams catalyst, in a 
hydrogen atmosphere. This gave rise to the formation of 73 in an isolated of 57% yield 
(Scheme 3.36). 
 
       Scheme 3.36: Synthesis of 73, (i) PtO2, H2, MeOH, rt, overnight, 57%. 
3.2.2.7 Synthesis of functionalized thiophene derivatives 
Due to the ability of thiophene heterocycles to undergo electrophilic aromatic 
substitutions, it was maybe considered possible to substitute the C2 position of the 
thiophene ring found in the amide 4. N-Bromosucinimide was used to brominate 4, 
however a complex mixture was obtained, possibly due to unwanted bromination of the 
trifluoromethylphenyl group. An alternative strategy was needed. The methyl ester 74 
was treated with the brominating reagent, resulting in the selective bromination at the 
C2 position of the thiophene ring. The radical mechanism for this bromination is shown 
in Scheme 3.37. This gave the brominated derivative 75 which was hydrolysed to the 
carboxylic acid derivative 76 using base catalysed ester hydrolysis (Scheme 3.38). The 
carboxylic acid 76 was then coupled to the piperazine 33 using HOBt and TBTU 
(Scheme 3.38). Compound 77 was isolated in a 55% yield. 1H NMR spectroscopy 
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supported the synthesis of the amide 77 with two doublets, both integrating for one 
proton, resonating at 6.84 and 6.56 ppm. The chemical shift and the multiplicity indicate 
that these peaks are due to the presence of the aromatic thiophene protons. The size of 
the coupling constant, J = 3.3 Hz, may be explained due to the presence of the electron 
withdrawing bromine at C5. The presence of this electron withdrawing group can 
remove electron density from the thiophene ring, which may weaken the 
communication between the two aromatic protons therefore resulting in the observed 
small coupling constant of 3.3 Hz. The peak at 652 cm-1 in the IR spectrum is also 
indicative of a C-Br bond. 
 
Scheme 3.37: Mechanism for the bromination of compound 75. 
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Scheme 3.38: Synthesis of 77, (i) THF, 0 °C-rt, 4 hrs, 80% (ii) KOH, EtOH, 3 hrs, 35% 
(iii) HOBt, TBTU, NEt3, DMF, N2, overnight, 55%. 
The amide 77 was then used to further functionalise the thiophene ring. The palladium 
catalysed Suzuki reaction generated compound 78 from 77 and trifluoromethylphenyl 
boronic acid in an 82% yield (Scheme 3.39). 
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Scheme 3.39: Palladium catalysed synthesis of 78, (i) Pd(PPh3)4, Na2CO3, THF, N2, 
reflux, 6 hrs, 82%. 
As H14, H17 and H15, H16 have similar chemical shifts, the observed splitting 
followed a second order splitting pattern (Figure 3.5). This occurred as the difference 
between the chemical shifts of the two protons (∆δ) was similar to the J value, with ∆δ 
equal to 15 Hz and J equal to 8.6 Hz. This phenomenon allowed for the differentiation 
between the aromatic protons of the two different trifluoromethyl phenyl groups as the 
splitting observed for H1, H5 and H2, H4 followed a first order splitting pattern, with a 
∆δ equal to 177.8 Hz and a J value of 8.7 Hz. It was then possible to differentiate 
between the protons in the ortho and meta positions of both trifluoromethyl phenyl 
groups due to the splitting pattern observed in the 13C NMR spectrum resulting from the 
CF3 group and combining this with a HSQC spectrum. 
         
Figure 3.5. Expansion of two distinct regions of the 1H NMR spectrum of 78 in CDCl3. 
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3.2.2.8 Synthesis of compound 79 and 81. 
The arylpiperazine 33 and azelaic acid were used in the synthesis of the biologically 
active compound 79 (Scheme 3.40). HOBt and TBTU were used to form the amide 
bond, with 79 produced in a 30% yield. The observed low yield was due to the 
formation of the disubstituted product, 80, which was isolated by flash chromatography. 
 
Scheme 3.40: Formation of 79 and  80, (i) 2 eq of carboxylic acid, 1 eq of 33, HOBt, 
TBTU, NEt3, DMF, N2, rt, 5 hrs, 79 (30%), 80 (63%). 
Due to the high biological activity of 79 large amounts were required for subsequent 
biological testing. As a result, it was necessary to optimise its synthesis. To avoid the 
disubstitution, the methyl ester, monomethyl azelate, was coupled to 33 using an 
alternative benzotriazole, benzotriazol-1-yloxytris(dimethylamino)-phosphonium 
hexafluorophosphate (BOP) (Scheme 3.41). The methyl ester product, 52, which was 
also highly active in the glucose uptake assay, was isolated in a 98% yield. The 
presence of 81 was supported by HR-MS, 1H NMR and 13C NMR spectroscopy. The 
presence of the singlet, integrating for three protons, at 3.66 ppm in the 1H NMR 
spectrum indicated the methyl ester peak. 2D HSQC experiments suggested the 
presence of the methyl ester carbon at 54.4 ppm in the 13C NMR. The 13C NMR further 
supported the synthesis of the product with the quartets resonating at 126.4 ppm (J = 3.3 
Hz), 124.5 ppm (J = 269.7 Hz) and 121.2 ppm (J = 32.8 Hz) indicating the presence of 
the trifluoromethyl phenyl group. The ester was converted to the carboxylic acid via 
base catalysed ester hydrolysis to give 79 in an 80% yield (Scheme 3.41). The 
hydrolysis of the ester was evident from the 1H NMR and the 13C NMR spectrum, 
where the peaks at 3.66 ppm and 54.4 ppm were no longer observed. The broad singlet 
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resonating at 10.30 ppm in the 1H NMR spectrum is also characteristic of the carboxylic 
acid -OH peak. HR-MS also supported the presence of 79. 
Scheme 3.41: Synthesis of 79 and 81, (i) BOP, NEt3, DCM, N2, rt, overnight, 98% (ii)  
KOH, EtOH, reflux, 4 hrs, 80%. 
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3.3 Conclusion 
Amide bond formation was the key final step in the synthesis of the compound 1, 4 and 
the derivatives of these compounds. The coupling reagents HOBt and TBTU were used 
in most cases with the amide product generally isolated in acceptable yields. A large 
number of target compounds were synthesised and made available for biological 
evaluations. 
The synthesis of a number of arylpiperazines, required to investigate the importance of 
this functional group, involved the use of a number of different synthetic methods. 
Metal catalysed reactions were used in some cases, but MW assisted SNAr gave access 
to the same arylpiperazines in an improved yield and reduced reaction time. From the 
synthesis of arylpiperazines, it was clear that: 
 MW synthesis was useful to access arylpiperazines containing electron 
withdrawing groups, 
 The cyclocondensation approach was useful to access arylpiperazines that did 
not contain an electro withdrawing group, 
 MW conditions improved yields and reduced reaction times. 
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4.  Synthesis of compound 2 and its 
derivatives 92 and 104-122 and 
compound 3 and its derivatives, 
138-144. 
 
 
 
 
 
 
 
 
 
 
 
 
 
Chapter 4                                          Synthesis of compounds 2, 3 and their derivatives 
91 
 
4.1 Introduction 
The pyrazole motif is found in a diverse array of biologically active molecules ranging 
from antimicrobials and anti-inflammatories to compounds with analgesic activities.121 
The agrochemical industry also avails of the activity of this heterocycle with the 
pesticides cyanopyrafen and tebufenpyrad both bearing pyrazole functionalities.122,123 
Whether it is present as the core scaffold or simply as a pendant functionality, the 
pyrazole heterocycle is an extensively used functional group in medicinal chemistry. 
For example, a number of blockbuster drugs, such as celebrex and viagra, boast  the use 
of this aromatic  moiety (Figure 4.1).124,125 
 
    Figure 4.1. Structures of the pyrazole containing (a) celebrex and (b) viagra. 124,125 
4.1.1 Synthesis of pyrazoles from 1,3-diketones 
Owing to the medicinal importance of this heterocycle, much attention has been given 
to the development of methods that give access to a variety of substituted derivatives. 
The most common and efficient route exploits the use of 1,3-diketones and 
hydrazines.126 This cyclocondensation reaction allows for the synthesis of a variety of 
substituted pyrazoles as the nature of the pyrazole substituent can be simply changed 
through altering the 1,3-diketone or hydrazine employed.  
The general procedure for the synthesis of pyrazoles from these two reactants involves 
heating the 1,3-diketone in a suitable organic solvent, at reflux, in the presence of the 
hydrazine. Synthesis of the 1,3-diketone from either acid chlorides or ketones, in the 
presence of a strong base, is often required making the pyrazole synthesis a two-step 
process. However, Heller et al. reported a one-pot synthesis of a number of  3,4,5- and 
N-substituted pyrazoles.126 The initial preparation of 1,3-diketones in situ from acid 
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chlorides and a lithium enolate, before the substituted hydrazine was added to give the 
desired pyrazole product, with yields in the range of 43% to 89% (Scheme 4.1).  
  Scheme 4.1: The synthesis of substituted pyrazoles.126 
4.1.1.1 Synthesis of pyrazoles using 1,3-diketones: Solvent-free approach 
Recently this method of synthesising substituted pyrazoles has evolved beyond the use 
of organic solvents. A “greener” approach involves the grinding of the familiar 1,3-
diketones with solid hydrazinium carboxylate, where the grinding of the reactants 
accelerates the chemical process.127 The use of the solid zwitterionic hydrazinium 
carboxylate avoids the use of solvents and the toxic liquid hydrazine, allowing the 
formation of pyrazoles at relatively moderate temperatures (70 °C).128 
Hydrazinium carboxylate is synthesised as a solid crystalline material from hydrazine 
and supercritical carbon dioxide.127 The solid hydrazinium carboxylate and the 1,3-
diketone are ground in air, causing the decomposition of the hydrazinium carboxylate to 
reveal an anhydrous source of hydrazine. The mixture is then placed in a vial for a 
suitable period of time and at an appropriate temperature. This results in the formation 
of the pyrazole compound in high yields (> 96%) and excellent selectivity.128 Lee et al. 
synthesised a number of substituted pyrazoles, such as 3,4,5-trimethyl-1H-pyrazole 
using this method (Scheme 4.2).128 
 
     Scheme 4.2: Synthesis of 3,4,5-trimethyl-1H-pyrazole, (i) 70 °C, 2 hrs, 96%.128 
Chapter 4                                          Synthesis of compounds 2, 3 and their derivatives 
93 
 
3,4,5-Trimethyl-1H-pyrazole was synthesised by heating either a neat solution of 
hydrazine hydrate and 3-methylpentane-2,4-dione at 70 °C for two hours or in THF at 
reflux for two hours. Both of these methods culminated in a reduced yield, with the 
pyrazole isolated in a 77% yield for the neat solution and a 90% yield when heated at 
reflux in THF. Unknown side products were also observed resulting in a need for a 
purification step, which was not necessary when hydrazinium carboxylate was used. 
The efficiency of the solid state approach was claimed to be due to the anhydrous 
hydrazine that was produced when the hydrazinium carboxylate sublimes.128 The lack of 
water present in the hydrazine produced from the hydrazinium carboxylate was said to 
prevent the formation of side products, as seen with the other two approaches.  
4.1.1.2 Substituted 1,3-diketones 
Substituting 1,3-diketones at the α-carbon can give access to a variety of carbonyl 
containing pyrazole derivatives. This approach involves synthesising highly active 
enaminone intermediates from dicarbonyls and formamide acetals. This is then followed 
by a reaction with substituted hydrazines giving the carbonyl containing pyrazole 
(Scheme 4.3). This approach can also be extended to the use of β-ketoesters and 
malonates, showing the diversity of dicarbonyls that can be exploited.129 Carboxylic 
acid containing derivatives can then be obtained from the ester derivatives through 
hydrolysis. 
Scheme 4.3: Synthesis of enaminones from dicarbonyl compounds and reaction to give 
pyrazoles.129 
4.1.1.3 Use of β-substituted ketones 
While 1,3-diketones and substituted 1,3-diketones allow for the synthesis of a variety of 
substituted pyrazoles the use of β-ketonitriles and hydrazines allows for the preparation 
of a number of 5-aminopyrazole derivatives.130 The nature of the β-ketonitrile can be 
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modified with relative ease via variation of the ketoester from which it is derived. This 
allows access to an array of substituted 5-aminopyrazoles.130 In addition, Bagely et al. 
reported the synthesis of these aminopyrazoles in methanol at 120 °C using MW 
irradiation, giving substituted 5-aminopyrazoles in excellent yields (> 80%) after forty 
minutes.130 
4.1.2 Synthesis of pyrazoles using a 1,3-dipolar cycloaddition 
Copper mediated Huisgen 1,3-cycloaddition has been extensively reported for the 
formation of 1,2,3-triazoles and this approach can also be applied to the formation of 
alternative nitrogen containing five membered heterocycles.131 Hanamoto described a 
copper free synthesis of substituted pyrazoles using 1,3-cycloadditions where the 
addition of the 1,3-dipole, azidomethane, to the dipolarophile, tributyl(3,3,3-
trifluoroprop-1-yn-1-yl)stannane, resulted in the substituted pyrazole, 82 (Scheme 
4.4).131 Furthermore, the metal catalysed cross coupling reaction of 82 with a variety of 
halogenated reactants gave access to a number of substituted pyrazoles. For example, 
the substituted pyrazole, 83, was isolated in an impressive 81% yield. 
 
Scheme 4.4: Pyrazole synthesis via 1,3-cycloaddition followed by metal catalysed 
substitution, (i) Et2O, 0 °C, 1.5 hrs, 70% (ii) Pd(PPh3)4, LiCl, CuTC, DMSO, 81%.
131 
While the Hanamoto approach, described above, required a metal catalysed step to 
introduce functional diversity, Aggarwal et al. reported a metal free approach where by 
the functional diversity was introduced by first derivitizing the 1,3-dipole and/or the 
dipolarophile.131,132 Functional diazo 1,3-dipoles were generated in situ, avoiding the 
handling of the toxic and potentially explosive material.132 The condensation of 
tosylhydrazine with aldehydes followed by treatment with aqueous sodium hydroxide 
gave a solution of a tosylhydrazone sodium salt. Heating of the tosylhydrazone at 50 °C 
generated the diazo compound in situ. Addition of the alkyne followed by heating at 50 
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°C allowed for the generation of a number of derivatized pyrazoles in good yields (24-
67%) and with good selectivity (Scheme 4.5).132 
 
Scheme 4.5: Synthesis of 3,5-disubstituted pyrazoles, (i) CH3CN, rt, 3 hrs (ii) 5 M 
aqueous NaOH, rt, 20 mins (iii) 50 °C (iv) 50 °C, 48 hrs 24-67%.132 
4.1.3 Metal catalysed pyrazole synthesis 
Work published by Martin et al. provided an insight into the formation of pyrazoles via 
copper mediated processes.133 This consisted of an initial copper catalysed amidation of 
a haloenyne, by a Boc protected hydrazine, followed by an intramolecular 
hydroamidation. A subsequent deprotection step, involving the use of trifluoroacetic 
acid provided the free pyrazoles product in excellent yields. By varying the nature of the 
hydrazine as well as the substitution pattern on the haloenyne, a high level of 
derivitization was achieved (Scheme 4.6).  
 
Scheme 4.6: Copper catalysed pyrazole formation, (i) CuI (5 mol%), L (20 mol%), 
Cs2CO3, THF, 80 °C, 6-16 hrs (ii) TFA, DCM, rt.
133 
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Transition metals can also be used to generate N-arylated pyrazoles with the previously 
described palladium catalysed Buchwald-Hartwig amination or variations of the copper 
mediated Ullmann reaction commonly used.134,135,136 
4.1.4 Regioselectivity 
The synthesis of pyrazoles can be somewhat challenging due to the difficulties in 
controlling the regioselectivity. If the two electrophilic sites have similar electronic 
properties or if the hydrazine nitrogen atoms have similar nucleophilicities, a mixture of 
regioisomers can occur.137 One such example is the synthesis of N-methylpyrazoles. 
When Olivera et al. attempted the synthesis 4,5-bis(2-bromo-4,5-dimethoxyphenyl)-1-
methyl-1H-pyrazole from the enaminoketone 84, an almost 50:50 mixture of 
regioisomers 85 and 86 was obtained.137 This was due to the similar reactivities of the 
hydrazine nitrogen atoms.138,139,140 The influence that the hydrazine molecule has on 
regioselectivity is further exemplified in the use of N-phenylhydrazine, which was used 
to synthesise the pyrazole 87. This resulted in the isolation of only a single N-
substituted isomer (Scheme 4.7). This was due to the differences in the reactivities of 
the hydrazine nitrogen atoms, with the nitrogen atom bound to the aromatic ring less 
nucleophilic due to the delocalisation of its lone pair of electrons into the aromatic ring. 
Other factors that can affect regioselectivity include the steric interactions of the 
substituents on the reactants and the pyrazole tautomerism.132, 137 When Olivera reacted 
the enaminoketone 84 with hydrazine, this afforded a mixture of the pyrazole tautomers 
88 and 89.137 The similar reactivities observed for the two nitrogen atoms allowed either 
nitrogen atom to attack either of the electrophilic sites.137 
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        Scheme 4.7: Regioselectivity during pyrazole synthesis.137 
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4.2 Synthesis of derivatives of compound 2 
Synthesis of derivatives of compound 2 involved the construction of the pyrimidone 
scaffold from substituted β-ketoesters and amino pyrazoles. This methodology required 
heating the two starting materials at reflux in acetic acid for the appropriate amount of 
time. Introduction of various substituents at the C2 position involved the use of an 
amino pyrazole with the desired substituent in the 3-position of the heterocycle. 
Similarly, introduction of various substituents at the C7 position involved the use of an 
appropriate β-ketoester, as shown in Scheme 4.8. The mechanism for the formation of 
the pyrimidinone product is shown in Scheme 4.9. 
 
Scheme 4.8: Retrosynthesis of derivatives of compound 2 (i) HOAc, reflux, 4 hrs. 
 
Scheme 4.9: Mehanism for the formation of the pyrimidinone scaffold. 
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A number of derivatives of compound 2 were synthesised to investigate the effect that 
altering the substituents at various positions would have on biological activity. In order 
to produce these analogues, we first had to synthesise the appropriate substituted amino 
pyrazole and/or β-ketoester in several cases. Once synthesised, the pyrimidone structure 
was constructed as before by refluxing the two reagents in acetic acid for the 
appropriate amount of time. The following section discusses the synthesis of these 
building blocks. 
4.2.1 Synthesis of amino pyrazole building blocks for derivatizing compound 2 at 
the C2 position 
4.2.1.1 Synthesis of compound 91 
The first derivative of interest required replacement of the tert-butyl group at the C2 
position with a hydrogen, thus, 1H-pyrazol-5-amine was required. The proposed 
retrosynthetic route for the preparation of this derivative (92) is outlined in Scheme 
4.10. This involved the synthesis of the substituted nitrile, 90, which would be used to 
prepare 1H-pyrazol-5-amine (91). The previously mentioned condensation reaction 
conditions would then be used to synthesise the functionalised pyrimidone 92. 
 
Scheme 4.10: Retrosynthesis of compound 92. 
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The synthesis of the aminopyrazole 91 first required the synthesis of the precursor (E)-
3-(dimethylamino)acrylonitrile (90) (Scheme 4.11). The condensation of 
dimethylformamide dimethyl acetal and cyanoacetic acid gave 90 in 87% yield. The 
presence of the product was supported by the 1H NMR spectrum with the two doublets 
resonating 6.88 ppm and 3.61 ppm indicative of the two alkene protons. The coupling 
constant (J = 13.5 Hz) between the two protons indicated the predominance of the E 
isomer. This large coupling constant is characteristic of a trans product as the C-H 
bonds are 180° to each other.100 This value would have been larger only for the presence 
of the electronic withdrawing nitrile which withdraws electrons from the C-H bond 
weakening through bond communications.100 Compound 90 was also verified by HR-
MS, where the [M + H]+ ion of mass 97.0763 m/z was found. 
Once synthesised, the substituted nitrile was reacted with hydrazine monohydrate, using 
the method reported by Cuny et al.141 This method involved heating 90 and hydrazine 
monohydrate at 110 °C, for 2 days, in an EtOH/H2O solution. The desired amino 
pyrazole, 91, was obtained, albeit in a 25% yield (Scheme 4.11). 
 
Scheme 4.11: Synthesis of 90 and 91, (i) 1,4 dioxane, reflux, 2 hrs, 87% (ii) EtOH, 
H2O, 110 °C, 2 days, 25%. 
We were keen to improve the yield, and reduce the reaction time, and a search of the 
literature found a report by Bagley et al. using MW irradiation. This synthetic route 
involved the use of  β-ketonitriles and substituted hydrazines for the synthesis of 
substituted amino pyrazoles (Scheme 4.12).130  
 
Scheme 4.12: MW assisted synthesis of 3-substituted amino pyrazoles.130 
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For this reason, 3-oxopropanenitrile was prepared in situ from 3,3-diethoxypropionitrile 
using standard acetal deprotection conditions, as was reported by Yin et al. and El-
Araby et al. (Scheme 4.13).142,143 The substituted nitrile was reacted with hydrazine 
monohydrate using the MW conditions described by Bagley et al.130 Unfortunately, a 
complex mixture was observed and 1H-pyrazol-5-amine was not isolated. 
 
Scheme 4.13: Synthesis of 3-oxopropanenitrile, (i) TFA, H2O, 6 hrs, 5 °C (ii) 
NH2.NH2.H2O MeOH, MW, 100 W, 40 mins, 120 °C. 
The previous attempt to synthesis 1H-pyrazol-5-amine involved the use of 90 and 
conventional heating conditions. We wondered if the conditions reported by Bagley et 
al. could be used in the preparation of 1H-pyrazol-5-amine.130 The nitrile 90 and 
hydrazine monohydrate were again reacted, however, this time they were heated in 
MeOH at 120 °C for forty minutes at 300 W. This method allowed for the isolation of 
1H-pyrazol-5-amine (91) in an 80% yield and provided a facile, efficient and novel 
synthetic route to 1H-pyrazol-5-amine from (E)-3-(dimethylamino)acrylonitrile 
(Scheme 4.14). 
 
    Scheme 4.14: Synthesis of 91 (i) MeOH, MW, 120 °C, 300 W, 40 mins, 80%. 
4.2.1.2 Synthesis of compounds 93 and 96 
The introduction of aromatic substituent at the C2 position required the synthesis of 
amino pyrazoles containing the appropriate aromatic substitution at the 3-position of the 
pyrazole heterocycle. The microwave assisted synthesis of substituted amino pyrazoles 
reported by Bagley et al. proved to be a highly effective method for synthesising the 
pyrazole 91.130 As such, the same methodology was applied to the synthesis of 
pyrazoles 93 (Scheme 4.15) and 96 (Scheme 4.16). 
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A simple phenyl group was introduced at the C3 position of 93. The substituted 
pyrazole 93 was synthesised from 3-oxo-3-phenylpropanenitrile and hydrazine 
monohydrate (Scheme 4.15). 
 
Scheme 4.15: Synthesis of pyrazole 93, (i) MeOH, MW, 300 W, 40 mins, 120 °C, 75%. 
Heterocycles can have positive effects on the biological efficacy of a compound. The 
heteroatom can become involved in hydrogen bonding and the presence of p orbitals 
can stabilise the drug:protein interaction through pi stacking.63 To synthesise the 
necessary amino pyrazole, 3-(thiophen-2-yl)-1H-pyrazol-5-amine (96), via the method 
by Bagley et al., we first needed to synthesise the β-ketonitrile 95 (Scheme 4.16).130 
Scheme 4.16: Synthesis of pyrazole 96, (i) DMAP, DCC, EtOAc, 0 °C-rt, overnight, 
99% (ii) n-BuLi, THF, -78 °C, 3 hrs, 70% (iii) MeOH, MW, 300 W, 40 mins, 120 °C, 
55% 
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Chapter 3 saw the use of coupling reagents to increase the activity of a carboxylic acid 
by generating an activated ester in situ. These activated esters are generally not isolated 
as they are highly reactive. The synthesis of 95 required the activation of thiophene-2-
carboxylic acid and this was achieved through its reaction with benzotriazole in the 
presence of DMAP and DCC. In this case the reactivity of the carbonyl carbon was 
increased by the formation of the benzotriazole derivative 94. Unlike previously 
mentioned activated species, it was possible to isolate this benzotriazole in an excellent 
yield of 99%. Compound 94 was not susceptible to hydrolysis by atmospheric water and 
therefore was isolated and used without the need for anhydrous conditions.  
To produce the β-ketonitrile 95, the method reported by Katritzky et al., involving the 
use of n-BuLi and acetonitrile at -78 °C, was employed.144 This involved the n-BuLi 
mediated depotonation of acetonitrile followed by its reaction with compound 94. 
Compound 95 was formed in a 70% yield and was subsequently reacted with hydrazine 
monohydrate using the conditions inspired by Bagley et al.130  
Nenaidenko et al. previously reported the synthesis of 96 from trichloroacetonitrile and 
hydrazine monohydrate using conventional heating, with the amino pyrazole reported to 
be isolated in a 53% yield after four hours.145 The use of MW irradiation to synthesise 
96 from 95 and hydrazine monohydrate represents a novel and efficient method for 
synthesising the amino pyrazole in a shorter reaction time without any reduction in 
yield.  
4.2.2 Synthesis of β-ketoester building blocks for derivatizing compound 2 at the 
C5 position. 
To investigate the importance of the substituent at the C5 position, a number of β-
ketoester building blocks were required. A number of methodologies were used to 
synthesize these building blocks and this will be discussed in the following sections. 
4.2.2.1 Synthesis of compound 98 
4.2.2.1.1 Acetal deprotection 
Substitution of the bis(trifluoromethylphenyl) at the C5 position, group first required the 
synthesis of the appropriate precursors. For example, to replace the aryl motif with a 
hydrogen atom, it was first necessary to synthesise compound 97. The synthetic 
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approach involved the deprotection of the acetal, ethyl 3,3-diethoxypropanoate, using 
standard acetal deprotection conditions, as described by Lu et al.146 The characteristic 
aldehydic peak, which resonated at 9.81 ppm, was present in the crude 1H NMR 
spectrum, however 97 was not isolated. Edvinsson et al. suggested that formyl acetic 
esters can be thermally unstable leading to decomposition.147 In addition, Sato reported 
the polymerization of 97 at room temperature.148 For these reasons, compound 97 was 
generated in situ and reacted directly with 3-iso-propyl-1H-pyrazol-5-amine (Scheme 
4.17). However, this method did not yield the desired derivative of compound 2 with a 
complex mixture being obtained. Therefore an alternative synthetic approach was taken. 
 
Scheme 4.17: Preparation of 98 from 97, (i) TFA, DCM, H2O, rt, 5 hrs (ii) HOAc, 
reflux, no product isolated. 
4.2.2.1.2 Synthesis of compound 97 from 2,2-dimethyl-1,3-dioxane-4,6-dione 
(Meldrum’s acid) 
The use of Meldrum’s acid is a well-known method for the preparation of β-ketoesters 
(Scheme 4.18). This method relies on the acidity of the α-protons, allowing for simple 
alkylation at this position. Once alkylated, the desired ketoester can be obtained through 
a ring opening step by heating the substituted Meldrum’s acid in an appropriate alcohol. 
The nature of the ester substituent is determined by the type of alcohol used, while the 
substituent at the α-carbon determines the nature of the ketone functionality (Scheme 
4.18). According to Sato et al., once heated the formation of the desired β-ketoester 
from the substituted Meldrum’s acid can proceed via two different mechanisms; either 
by in situ formation of a ketene or through alcoholysis.148 
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Scheme 4.18: Retrosynthesis of ketoesters from Meldrum’s acid. 
The use of Meldrum’s acid can also be adapted to allow the formation of formyl acetic 
esters.147 To synthesize 97 using this method, it was first necessary to synthesis formyl 
Meldrum’s acid (99, Scheme 4.19). To introduce a formyl group at the α-carbon, 1,1'-
carbonyldiimidazole (CDI) was used to activate formic acid in the presence of DMAP 
and pyridine. This approach was developed from the method proposed by Dolle et al. 
which saw the introduction of an acetyl group at the α-carbon of Meldrum’s acid.149 
Various reports detailed the isolation of this acetyl Meldrum’s acid in good to moderate 
yields.150,151,152 However, this approach did not prove effective for the synthesis of 97. It 
was not possible to isolate formyl Meldrum’s acid (99) due to the complexity of the 
reaction mixture. Also, when the reaction was mixture carried forward, without any 
further purification and heated at reflux in the presence of EtOH, a complex mixture 
was still observed with the 1H NMR void of any characteristic peaks for 97. The 
absence of 97 may have been due to its instability, as described by Sato and Edvinsson, 
or due to the volatility of formic acid. 148,147 
 
Scheme 4.19: Synthesis of compound 99, (i) CDI, DMAP, DCC, DCM, N2, rt, 
overnight, product not isolated (ii) EtOH, reflux, 5 hrs, product not isolated. 
An alternative approach for the synthesis of formyl Meldrum’s acid was therefore 
needed. Again, the literature directed our search towards an appropriate method 
involving the use of triethyl orthoformate. Here the condensation of triethyl 
orthoformate with Meldrum’s acid provided compound 100 quantitatively. 1H NMR 
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spectroscopy supported the formation of the product with the presence of the alkenyl 
proton at 8.23 ppm. The quartet and triplet resonating at 4.42 ppm and 10.36 ppm, 
integrating for two and three protons respectively, with a coupling constant value of 7.0 
Hz, is indicative to the presence of an ethylene group. Acid catalyzed hydrolysis of 100 
then afforded the necessary formyl Meldrum’s acid, 99, in an acceptable yield (Scheme 
4.20). This was confirmed by 1H NMR spectroscopy, where the ethyl group, observed 
in the 1H NMR spectrum for 100, was no longer present. The alkene proton was still 
present at 8.64 ppm and a broad singlet, corresponding to the presence of the hydroxyl 
group, resonated at 8.20 ppm. This product was not subsequently used in the synthesis 
of compound 98 due to the success of an alternative method for the synthesis of 
compound 98. 
 
Scheme 4.20: Synthesis of 99 and 100, (i) 85 °C, quantitative (ii) 2 M aqueous HCl, 2 
hrs, 50%. 
4.2.2.1.3 Use of the sodium salt of compound 97 in the synthesis of 98 
During the course of the Meldrum’s acid work, we were simultaneously trying to 
synthesize 98 using a different method (Scheme 4.21). This alternative approach, 
described by Senga et al., involved the synthesis of the enol tautomer of 97, as the 
sodium  salt.153 The method consisted of heating a suspension of EtOAc, ethyl formate 
and elemental sodium at 27 °C under an inert atmosphere. From this, the sodium salt of 
97 was generated in situ and reacted immediately with 3-iso-propyl-1H-pyrazol-5-
amine. The preparation of 97 as the sodium salt possibly prevented the polymerization 
of the product, a problem suggested by Sato.148 This allowed for the subsequent 
synthesis and isolation of 98 in an adequate yield (Scheme 4.21). The two doublets, 
resonating at 7.80 ppm and 5.63 ppm in the 1H NMR spectrum, both with an integral 
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value of one and both with a coupling constant of 7.50 Hz, is highly indicative to the 
presence of the alkene protons of the product 98. The doublet resonating at 1.24 ppm, 
integrating for six protons verifies the presence of the iso-propyl. IR spectroscopy 
confirmed the formation of the amide bond, with the presence of the carbonyl signal at 
1675 cm-1. Elemental analysis also supported the presence of this derivative of 
compound 2. 
 
Scheme 4.21: Synthesis of 98 from the sodium salt of 97 (i) Na, 27 °C, 12 hrs (ii) 
EtOH, reflux, 5 hrs, 15%. 
A viable method for the synthesis of 98 has been identified and this process was then 
used for the synthesis of 101 (Scheme 4.22). The same conditions were used, with 
exception to the amino pyrazole, with 3-(tert-butyl)-1H-pyrazol-5-amine added to the 
sodium salt of 97. A similar yield was observed, with compound 101 isolated in a 13% 
yield. The low yield of 98 and 101 may be due to the decomposition of the sodium 
enolate of compound 97. 13C NMR spectroscopy supported the formation of the product 
with the signal resonating at 161.2 ppm arising due to the presence of the amide 
carbonyl. The formation of the carbonyl was further supported by IR spectroscopy with 
the presence of the carbonyl signal at 1673 cm-1. The two alkenyl carbons were 
confirmed by the 2D HSQC experiment and were found to resonate at 138.8 ppm and 
95.2 ppm. 
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Scheme 4.22: Synthesis of 101 from the sodium salt of 97 (i) Na, 27 °C, 12 hrs (ii) 
EtOH, reflux, 5 hrs, 13%. 
4.2.2.2 Synthesis of compound 102 
The position of the CF3 group within the bis(trifluoromethylphenyl) at the C5 position 
was also investigated. Construction of this derivative first required the synthesis of the 
β-ketoester, 102. An alternative approach, deviating from the use of Meldrum’s acid 
was employed and saw 102 being synthesized from 1-(4-(trifluoromethyl) 
phenyl)ethanone, sodium hydride and a large excess of diethyl carbonate (Scheme 
4.23). The formation of the product was supported by 1H NMR spectroscopy with the 
two doublets, both integrating for two protons and both with a coupling constant value 
of 8.0 Hz, resonating at 8.06 and 7.75 ppm, indicative of the aromatic protons ortho and 
meta to the trifluoromethyl phenyl group. This data corresponded to the 1H NMR data 
published by Pidathala et al.154 Compound 102 was not isolated but was used as the 
crude product. 
 
Scheme 4.23: Synthesis of compound 102, (i) NaH, 80 °C, 1.5 hrs, 71% (crude yield). 
4.2.2.3 Synthesis of compound 103 
The synthetic procedure involving the use of Meldrum’s acid was revisited to synthesise 
the β-ketoester 103 (Scheme 4.24). Here 103 was synthesised from thiophene-2-
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carboxylic acid and Meldrum’s acid by way of an intermediate which in turn underwent 
a ring opening, in the presence of EtOH and para toluene sulfonic acid, to allow the 
formation of 103 in 39% yield. The synthesis of the β-ketoester 103 was confirmed by 
1H NMR spectroscopy by the presence of the singlet, resonating at 3.83 ppm, 
integrating for two protons, which was indicative of the presence of the alpha 
hydrogen’s. The thiophene ring was characterised by the presence of three multiplets, 
all integrating for one proton and all resonating in the aromatic region of the 1H NMR 
spectrum. They were found in the ranges of 7.66-7.65 ppm, 7.62-7.60 ppm and 7.07-
7.04 ppm respectively. The 1H NMR data for compound 103 was in agreement with the 
reported literature data.155 
 
Scheme 4.24: Synthesis of 103 (i) DMAP, DCC, DCM, N2, 0 °C-rt, 2 hrs (ii) EtOH, p-
TSA, N2, reflux, 1 hr, 39%. 
4.2.3 Condensation 
The derivatives of compound 2 were synthesised using the condensation conditions 
described above. Table 4.1 shows the yields for each derivative. 
 
Compound R1 R2 % Yield Charton 
value for R1.156 
2 bis(m-CF3) tBu 18 * 
92 bis(m-CF3) H -
b - 
104 Me tBu 78 0.52 
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Table 4.1: Structures and yields (%) of derivatives of 2 (i) HOAc, reflux, 4 hrs. 
*Charton value for bis(m-CF3) not available. Charton value for phenyl = 1.66 and CF3 = 
0.91. a low yield may be due to issues associated with the purification of the compound 
and is not indicative of a decrease in yield due to the presence of the Et substituent. b 
product not isolated. c crude starting material used. 
From Table 4.1, it could be suggested that when the ketone R1 substituent is a bulky, 
sterically hindered group, low yields are obtained. The increasing Charton values for 
these substituents correspond somewhat to a decrease in yield, i.e. an increase in steric 
effects causes a decrease in yield. The presence of the methyl substituent (Charton value 
= 0.52) for example, resulted in the isolation of compound 104 in a 78% yield. When a 
105 Et tBu 33a 0.56 
106 iPr tBu 65 0.76 
107 tBu tBu 23 1.24 
108 Ph tBu 40 1.66 
109 Me iPr 69 0.52 
110 Et iPr 63 0.56 
111 nPr iPr 72 0.68 
112 iPr iPr 66 0.76 
113 tBu iPr 13 1.24 
114 Ph iPr 30 1.66 
115 bis(m-CF3) iPr 27 * 
116 2-thienyl iPr -b - 
117 bis(m-CF3) Me 49 * 
118 bis(m-CF3) Et 42 * 
119 bis(m-CF3) Ph 21 * 
120 bis(m-CF3) 2-thienyl 30 * 
121 p-CF3 iPr 30
c * 
122 mono(m-CF3) iPr 30 * 
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tert-butyl substituent (Charton value = 1.24) was introduced, a significant reduction in 
yield was observed with compound 107 isolated in a 23% yield. The presence of a 
bulky group may hinder the primary nucleophilic amine of the pyrazole group from 
attacking the ketone carbonyl, resulting in a low yield. This hypothesis may also explain 
the low yields observed for 113, 114, 116, 121 and 122 compared to those obtained for 
109, 110, 111 and 112. The low yield obtained for compound 105 may be due to a work 
up issue. Several purification steps were required to purify this derivative.  
To produce compound 92 (Scheme 4.25), the previously synthesised pyrazole 91 and 
the commercially available ethyl 3-(3, 5-bis(trifluoromethyl)phenyl)-3-oxopropanoate 
were heated at reflux, in acetic acid, for four hours. The reaction yielded a complex 
crude mixture and the presence of the product was uncertain from the 1H NMR 
spectrum. Flash chromatography was used to reduce the complexity of the mixture 
however the product could not be isolated. 
 
Scheme 4.25: Attempted synthesis of compound 92 (i) HOAc, reflux, 4 hrs. 
The importance of the position of the CF3 functionality within the 
bis(trifluoromethylphenyl) at the C5 position was also investigated. To produce 
compound 121, the previously described crude mixture containing the ketoester 102 and 
3-iso-propyl-1H-pyrazol-5-amine were heated at reflux, in acetic acid, for four hours 
(Scheme 4.26). The desired pyrimidinone was isolated in a 30% yield. 
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Scheme 4.26: Synthesis of compound 121 (i) HOAc, reflux, 4 hrs, 30%. 
To access the derivative of compound 2, 116, in which a thiophene heterocycle would 
be introduced at the C5 position to replace the bis(trifluoromethylphenyl) moiety, the 
previously synthesised β-ketoester 103 and 3-iso-propyl-1H-pyrazol-5-amine were 
heated at reflux for 4 hrs. Although the trusted method used to synthesise the 
pyrimidone derivatives was employed, the pyrimidone 116 could not be isolated. 
Various purification attempts were made, however 116 was not isolated in an acceptable 
level of purity (Scheme 4.27). The synthesis of 116 was not reattempted. 
 
Scheme 4.27: Attempted synthesis of compound 116 (i) HOAc, reflux, 4 hrs. 
4.2.4 Synthesis of compound 123 
A derivative of compound 4 was also synthesised in which changes were made to the 
pyrimidone scaffold. This involved the alkylation of the secondary amine, in the 4-
position of the ring, to give the derivative, 123. The synthesis was carried out by heating 
a suspension of compound 115, potassium carbonate and DMF at reflux for eight hours 
in the presence of iodoethane (Scheme 4.28). Although compound 123 was isolated in a 
less than desirable yield, it was obtained in high purity.  
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Scheme 4.28: Synthesis of compound 123 (i) K2CO3, DMF, 8 hrs, reflux, 18%. 
 
4.3 Synthesis of derivatives of compound 3 
The synthesis of compound 2 and its family of derivatives saw the use of β-ketoesters 
and pyrazoles to produce the pyrimidone scaffold, with MW irradiation used to 
synthesise the 5-amino-1H-pyrazoles precursors. The construction of the derivatives of 
compound 3 also employed the use of β-ketoesters, hydrazines and pyrazoles; however, 
here substituted hydrazines and substituted β-ketoesters were manipulated to produce 
the N-substituted pyrazoles from which the 3 analogues were derived (Scheme 4.29). 
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Scheme 4.29: Retrosynthetic route for the synthesis of derivatives of compound 3. 
The synthesis of two fragments, an N-substituted pyrazole building block and an 
arylpiperidine building block were required. The N-substituted pyrazoles were 
synthesised by reacting a substituted phenylhydrazine derivative with the activated β-
enamino ketoester. The arylpiperazines were synthesised using the methods described in 
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Chapter 3 while the palladium catalysed Suzuki coupling was used in the formation of 
the arylpiperidine. Selective reduction using Adams catalyst gave access to the desired 
arylpiperidine. Once the necessary fragments were synthesised, compound 3 was 
obtained using the HOBt/TBTU coupling conditions described in Chapter 3. This 
synthetic approach was used to generate a number of derivatives of compound 3 
(Scheme 4.29). 
4.3.1 Synthesis of N-substituted pyrazole building blocks  
Synthesis of the N-substituted pyrazoles first required the synthesis of the necessary 
substituted β-enamino ketoester, using the mild conditions reported by Bach et al..157 
This method was used to allow access to compounds 124 and 125 (Scheme 4.30), from 
which the N-substitute pyrazole was synthesised. 
 
Scheme 4.30: Synthesis of β-enamino ketoesters 124 and 125 (i) rt, overnight, 124 
(83%), 125 (96%, crude yield) 
The synthesis of N-substituted pyrazoles from β-enamino ketoesters involved the use of 
N-substituted hydrazines. This process can be described as involving the use of [3+2]-
atom fragments where the β-enamino ketoester is used as a 3-atom building block while 
the substituted hydrazine contributes a 2-atom fragment.158  
The nature of the substituted N-hydrazine can affect regioselectivity with a mixture of 
regioisomers observed in some cases.137 For example, Olivera et al.137 reported that the 
use of N-methylhydrazine can produce a mixture of isomers, however this phenomenon 
is not observed with the use of N-phenylhydrazines.137 In this case only the single 
isomer of the pyrazole is produced and can be explained due to the differences in the 
nucleophilicities of the nitrogen atoms found in N-phenylhydrazines.137  
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With compounds 124 and 125 synthesised, the N-substituted pyrazoles were then 
generated. As substituted phenylhydrazines were used, regioselectivity was not an issue 
with the single isomer of each pyrazole isolated. Table 4.2 shows the synthesis of these 
pyrazoles.  
 
Compound R2 R3 Yield (%) 
126 Me F 90 
127 Me H 97 
128 Me Cl 94* 
129 Me OMe 94* 
130 Et F 90 
Table 4.2: Synthesis of  N-substituted pyrazole (i) KOH, EtOH, reflux, 5 hrs. *Crude 
yield. 
Base catalysed ester hydrolysis was then used to generate the 4-carboxylic acid 
derivatives (Table 4.3). 
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Compound R2 R3 Yield (%) 
131 Me F 80 
132 Me H 93 
133 Me Cl 58 
134 Me OMe 33 
135 Et F 96 
Table 4.3: Synthesis of  N-substituted pyrazole (i) EtOH, reflux, 2 hrs. 
4.3.2 Synthesis of compound 137 
With the pyrazole fragment synthesised, the next task involved the synthesis of 4-(2-
methoxyphenyl)piperidine 137. The synthesis was performed using the approach 
reported by Zhang et al., in which palladium catalysed Suzuki conditions were 
exploited to yield the first building block of the arylpiperidine.159 This involved the 
palladium catalysed coupling of (2-methoxyphenyl)boronic acid and 4-bromopyridine 
hydrochloride to afford 136, which was then selectively reduced using Adam’s catalyst 
to give the substituted arylpiperidine in a 18% yield (Scheme 4.31).  
Scheme 4.31: Synthesis of compound 137 (i) Pd(PPh3)4, Cs2CO3, toluene, reflux, 24 hrs 
(ii) PtO, MeOH, H2, overnight, 18%. 
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4.3.3 Condensation  
Once the two building blocks were isolated, compound 3 and the derivatives of 
compound 3 were synthesised using the HOBt/TBTU coupling conditions. Table 4.4 
shows the structures and yields of the final amide containing derivatives. 
 
Compound  R1 R2 R3 X Z Yield (%) 
3 o-OMe Me F CH CH 77 
138 p-CF3 Me H N CH 36 
139 o-Cl, 
 p-CF3 
Me Cl N N 46 
140 o-OMe Me OMe CH CH 62 
141 o-OMe Et F CH CH 67 
142 o-OMe Me F N CH 71 
143 H Me F N CH 81 
144 H Me F CH CH 60 
Table 4.4: Synthesis of compound 3 and the derivatives of compound 3 (i) HOBt, 
TBTU, NEt3, DMF, rt, overnight. 
The synthesis of compound 3 was supported by 13C NMR spectroscopy where the 
presence of the NMR active fluorine atom, para to the pyrazole ring, caused the 
splitting of the ipso, ortho, meta and para carbons. This was evident by the presence of 
the doublets at 115.8 ppm (J = 23.1 Hz), 127.3 ppm (J = 8.0 Hz), 135.8 ppm (J = 3.4 
Hz) and 162.0 ppm (J = 244.2 Hz), where the size of the coupling constant decreased 
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with an increase in distance from the fluorine atom. The presence of the methoxy group 
was also supported by 1H NMR spectroscopy with the sharp singlet, integrating for 
three protons, resonating at 3.86 ppm. HR-MS further supported the formation of the 
product with the peak of mass 394.1944 m/z corresponding to the M+H ion of 
compound 3. 
1H NMR data of compound 3 recorded at room temperature showed two broad signals 
at 4.43 ppm and 3.06 ppm, both integrating for two protons. These peaks arose from the 
piperidine methylene protons, adjacent to the amide bond, experiencing restricted 
rotation about the N-CO bond. The amide group is likely to exhibit partial double-bond 
character as the lone pair of electrons on the amide nitrogen delocalise into the carbonyl 
group. This restricted rotation would have resulted in the two methylene groups being 
non-equivalent (at low temperatures) and would have also caused the emergence of 
rotational isomers in the NMR spectrum. At temperatures below room temperature, 
these rotational isomers would likely have been visible in the 1H NMR spectrum, as the 
rotation about the amide bond would have been expected to be sufficiently slow. As the 
temperature increased however, the signals coalesce and an average of the signals is 
observed, thus causing the broad signals seen in the 1H NMR spectrum at 30 °C (Figure 
4.2). As the temperature was further increased, the rate of rotation about the amide bond 
increases and thus the peaks further coalesce resulting in the formation of the well-
defined peaks, (Figure 4.2, T = 60 °C).  
 
                  
Figure 4.2. Expanded view of the variable temperature 1H NMR study of 3 in CD3CN. 
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4.4 Conclusion. 
A number of derivatives of compound 2 were synthesised that contained changes to the 
groups at the C2 and C5 positions. It was found that the presence of a sterically bulky 
group at the C5 position results in a reduced yield. Generally, an increase in Charton 
value corresponded with a decrease in yield, as seen for compounds 113 and 114. These 
compounds are awaiting biological testing. 
A number of derivatives of compound 3 was also synthesised, with a number of 
compounds which probed the importance of the fluorophenyl and methoxy groups for 
example, synthesised. These compounds are also awaiting biological testing. 
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5.  Biological evaluation of compound 
1 and its derivatives, 4-81. 
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5.1 Structure activity relationship (SAR) study of compounds related to 4 using 
the glucose uptake assay. 
Molecular modelling led to the selection of compound 1 from a library of compounds 
and its ability to disrupt the RBP4-TTR complex was verified by means of SPR. The 
initial hit-to-lead efforts produced eight derivatives of 1 and uncovered compound 4 
(Figure 5.1) as our lead compound as it exhibited greater potency than its parent 
compound in both the SPR and glucose uptake assays. Therefore, our aim was to 
develop a SAR study around 4 with the possibility of further optimization. Fifty 
compounds, including compounds 5-11, were designed and synthesised and their 
activity within the glucose uptake assay was assessed. 
 
Figure 5.1: Structure of compound 4. 
5.1.1.1 Effect of altering trifluoromethyl phenyl group 
Several pharmaceuticals, such as fluoxetine (prozac), the active ingredient of many anti-
depressants, contain a trifluoromethyl (CF3) group (Figure 5.2).
160 The presence of a 
fluorine atom, in the form of single fluorine or a trifluoromethylated group, can alter 
numerous properties of a drug. For example, a SAR study of fluoxetine showed that 
removal of the para CF3 from the phenolic ring greatly reduced its biological 
efficacy.161 The absence of the sterically bulky CF3 group caused the molecule to adopt 
a less favourable conformation which inhibited its ability to bind to its target protein.161 
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Figure 5.2: Structure of fluoxetine.160 
As a trifluoromethyl phenyl group was present in both 1 and 4, the importance of this 
group was investigated. Several compounds were designed, synthesised and tested in 
which alterations to the trifluormethylphenyl group were made (Table 5.1). Compound 
1 was also synthesised at this stage. Although the glucose uptake assay produced a 
consistent result for each compound relative to basal and compound 4, the absolute 
level of 3H deoxy-2-glucose taken up by the cells varied from assay to assay. As a result 
a qualitative measurement of activity is reported. This produced a trend for each 
compound with compounds labelled as active or inactive compared to basal levels or 
active but less active than 4. 
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Compound R1 R2 R3 R4 X Z Glucose uptake 
assay activity* 
1 Cl H CF3 H N S Inactive 
4 H H CF3 H H CH2 Active 
6 H H CF3 H N C=O Inactive 
7 Cl H CF3 H N C=O Inactive 
8 H H CF3 H N CH2 Inactive 
9 Cl H CF3 H N CH2 Inactive 
11 Cl H CF3 H H CH2 Inactive 
40 H H F H H CH2 Inactive 
41 CF3 H H H H CH2 Inactive 
42 H H NO2 H H CH2 Active ** 
43 H CF3 H CF3 H CH2 Active** 
45 H H CF3 Cl N CH2 Inactive 
46 Br H CF3 H H CH2 Inactive 
47 H H H H H CH2 Inactive 
73 H H NH2 H H CH2 Inactive 
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44 
 
Inactive 
53 
 
Inactive 
Table 5.1: Structure and activity of derivatives of compound 4, *Activity of compounds 
in glucose uptake assay compared to basal level **Active, but less active than 4. 
The removal of the para CF3 group resulted in a loss of or reduced activity in the 
glucose uptake assay, as seen in the below histograms (Figure 5.3). Derivatives 40, 41, 
47, 52 and 73 were all inactive while, 42 and 43 were only marginally active when 
compared to 4. The absence of the para CF3 group may have resulted in a loss of 
activity for a number of reasons, which will be discussed in the following pages. 
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Figure 5.3. Glucose uptake assay results of derivatives of compound 4. C2C12 muscle 
cells incubated overnight at 37 ºC in the presence 10 µM of each compound. Cells then 
exposed to 3H deoxy-2-glucose for 10 mins and a scintillation count of the C2C12 
muscle cells performed. 
5.1.1.1.1 Role of CF3 substituent 
5.1.1.1.1.1 Steric Bulk 
Firstly, like fluoxetine, the steric bulk of the para CF3 group may have caused the 
compound to adopt a suitable conformation for binding to its target protein.161 Loss of 
this steric bulk could cause the molecule to adopt a less favourable conformation 
resulting in a loss of/decreased activity. This could be the case for compounds 40, 42, 
47, 52 and 73. 
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The position of the bulky CF3 group was also important. When the derivatives 
containing an ortho or meta CF3 substituent were tested, it was found that the 
compounds were less active than 4 (e.g. 43) or completely inactive (e.g. 41). 
5.1.1.1.1.2 Lipophilicity 
CF3 substituents also contribute to the overall lipophilicity of a molecule.
161 
Lipophilicity governs a drugs ability to permeate lipid membranes and dock within a 
hydrophobic protein cavity.162 It affects aqueous solubility and can play a role in drug 
metabolism, pharmacokinetics, pharmacodynamics and toxicology.162 Lipophilicity is 
measured in terms of the logP where P, the partition coefficient, describes the tendency 
of an uncharged substance to dissolve in an immiscible biphasic system at 
equilibrium.161 This is generally calculated experimentally using octanol and water as 
the biphasic system and measures the concentration of the neutral substance found in 
the octanol or water layers.161 
The greater the logP value, the greater the lipophilicity, while the lower the logP value, 
the greater the hydrophilicity (i.e. the greater the aqueous solubility).161 Waring et al. 
reported that compounds with large logP values tend to exhibit increased toxicity, 
decreased solubility, poor metabolic clearance and reduced specificity for binding to 
protein receptors.162 Purser et al. eluded to the fact that an inadequate lipophilicity can 
have deleterious effects with regards to crossing lipid membranes.161 Drugs require an 
adequate lipophilicity to be able to pass through the lipid membrane but not become 
trapped within it.161 As passive transport is the most common mode of cell permeation 
for drugs, an adequate lipophilicity is essential.  
Drug molecules are exposed to a variety of different environments in the body, 
depending on the method of administration. The pH for example, can vary significantly 
from 2.0 in the stomach to 7.4 in the blood stream.163 As many drugs contain functional 
groups that are susceptible to ionization, and as logP refers to the unionized neutral state 
of a molecule, a method for quantifying the aqueous solubility of ionized molecules is 
needed.163 LogD is the pH dependent distribution factor that is related to logP by the 
acid dissociation constant pKa.
163 This coefficient more accurately describes the 
aqueous solubility of a drug in vivo. 
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Table 5.2 shows the logP values, calculated by Chemdraw software, for 4, 40, 47, 52, 
and 73. The loss of the CF3 decreased the logP value thus decreasing the lipophilicity, 
this may have rendered the compounds incapable of crossing the lipid membrane and 
evoking a biological response.162 Alternatively, if the derivatives were capable of 
crossing the lipid membrane, the reduced lipophilicity may have prevented the 
compounds from binding to their target protein.162 
 
 
 
 
 
 
 
Table 5.3: LogP and logD values of compound 4 and its derivatives, *calculated using 
Chemdraw software, ** calculated using MarvinSketch software. 
5.1.1.1.2 Effect of substituting the phenyl ring 
Altering the phenyl ring, replacing the CF3 group or completely substituting the 
trifluoromethyl phenyl group, led to a decrease in activity (Table 5.1, Figure 5.3).  
Replacing the para CF3 group, with a nitro or amino group, altered the electronic 
properties of the aromatic ring. In both cases, a reduction in glucose uptake was 
observed. As a para nitro substituent is more electron withdrawing than a para CF3 
group, this would have reduced the electron density of the aromatic ring.100 The electron 
withdrawing chlorine and bromine atoms will also have affected the electronic 
properties of the aromatic ring and may have contributed to loss of activity in 
compounds 1, 7, 9, 11, 45 and 46.  
The presence of a primary amine in the para position would have increased electron 
density, as the lone pair of electrons can delocalise into the aromatic ring. This may also 
be the case for compounds 6 and 8, and may also contribute to the loss of activity seen 
in 1, 7, 9 and 45. Changes to the electron density of the aromatic ring may have had a 
Compound logP* logD** 
4 4.79 4.67 
40 4.02 3.93 
47 3.87 3.79 
52 3.34 2.79 
73 3.06 2.95 
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negative influence on the binding mode of the aromatic ring to the protein target.63 The 
substituent itself could directly affect binding as an F, NH2 or NO2 group will have 
markedly different binding characteristics e.g. H-bonding (donor or acceptor), 
hydrophobicity and electrostatic interactions. 
5.1.1.1.3 Loss of six membered aromatic ring 
Although the loss of activity observed from 52 may be attributed to the loss of the para 
CF3 group, the absence of the planar aromatic ring may also have influenced this change 
in activity. As aromatic rings are hydrophobic planar structures, they can interact with 
flat hydrophobic regions of a protein binding site via van der Waals forces or 
hydrophobic interactions.63 Also, aromatic rings present the opportunity for a molecule 
to be involved in π-π stacking, which would further stabilise a ligand-protein 
interaction.164  
Cyclohexane rings adopt non planar conformations such as the boat and chair.100 
Although axial protons can interact, albeit weakly, with the protein, it keeps the rest of 
the cyclohexane ring at a distance (Figure 5.4).63 This prevents further stabilising 
interactions. 
 
Figure 5.4. A comparison of binding between a planar aromatic ring or a non-planar 
cyclohexyl ring. 
This could explain the loss of activity observed for compound 2. Also, as the unknown 
binding site may be a flat, narrow hydrophobic pocket, which would accommodate the 
planar aromatic ring in 4, the non-planar cyclohexyl ring in 52 may not be able to fit 
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within the protein binding site, resulting in a loss of activity.63 Also, the absence of 
stabilising π- π stacking could also play a role in the loss of activity.  
The importance of the aromatic group can also be seen from the glucose uptake assay 
results for 44. Removal of the trifluoromethyl phenyl group resulted in a loss of activity. 
This can be attributed to the reasons described above. 
Overall, alterations to the trifluoromethyl phenyl group resulted in a decrease or a loss 
of activity for all compounds. Therefore, the presence of a trifluoromethyl phenyl group 
at this position is considered necessary for biological activity. 
5.1.1.2 Effect of altering the substituted piperazine ring 
Piperazine rings are commonly found in biologically active compounds and their 
importance has been reported extensively in the literature. The derivatives of compound 
4, 53, 54 and 74 were designed and synthesised with a view to determine the importance 
of the piperazine ring (Table 5.4). 
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Compound Structure Glucose uptake 
assay activity* 
4 
 
Active 
 
 
 
 
 
53 
 
Inactive 
54 
 
 
Active** 
74 
 
Inactive 
Table 5.4: Structure and activity of derivatives of compound 4, * Activity of 
compounds in glucose uptake assay compared to basal level **Active compared to 
basal, but less active than 4. 
Changes to the piperazine ring resulted in a loss/ decrease of activity in the glucose 
uptake assay (Figure 5.5). Compound 74, in which the arylpiperazine was replaced by a 
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methyl ester, proved to be inactive, highlighting the importance of the substituted 
piperazine with respect to induced glucose uptake. 
           
Figure 5.5. Glucose uptake assay results of compound 4 derivatives. C2C12 muscle 
cells incubated overnight at 37 ºC in the presence 10 µM of each compound. Cells then 
exposed to 3H deoxy-2-glucose for 10 mins and a scintillation count of the C2C12 
muscle cells performed. 
The importance of the piperazine ring itself was investigated through a study of 
compound 53. Here the ring was removed and replaced with a hydrazine functionality. 
The removal of the piperazine proved to be deleterious and the compound was unable to 
stimulate glucose uptake. The piperazine ring in compound 4 may allow the molecule to 
adopt an appropriate conformation for binding to the protein. It may orientate the 
molecule so as to form more stable interactions with its target. 
The role of the nitrogen atom adjacent to the aromatic ring was also probed, with 54 
exhibiting a reduced activity compared to 4. Removal of this nitrogen can affect the pKa 
of the molecule which may cause changes to the pharmacokinetics of the molecule and 
how the drug molecule interacts with the protein target.165 This nitrogen atom cannot act 
as a hydrogen bond donor as it is a tertiary amine, nor can it act as a hydrogen bond 
acceptor due to the delocalization of its lone pair of electrons into the aromatic ring.63 
This amine however, may participate in ionic bond formation. Thus, removal of the Ar-
N nitrogen may have removed the possibility of forming an ionic bond with the target 
protein, therefore reducing its biological effect.  
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There was an overall reduction in activity when changes were made to the piperazine 
ring, demonstrating the importance of this group in 4. 
5.1.1.3 Effect of removing the amide carbonyl 
Amide bonds are found in a wide variety of biologically active compounds ranging 
from met-enkephalin, the body’s natural pain killer, to atorvastatin and penicillin.63 
Amide bonds can interact with protein targets through hydrogen bonding.63 The 
carbonyl oxygen can form two hydrogen bonds as it possesses two lone pairs of 
electrons (Figure 5.6). The amide N-H can only serve as a hydrogen bond donor as its 
single lone pair of electrons delocalise into the adjacent carbonyl group.63 The amide 
group is therefore an important functional group for protein-ligand interactions. 
 
   Figure 5.6. Hydrogen bond interactions of amides.63 
The amide group in 4 could have functioned in a similar fashion to that described 
above, however without the amide nitrogen acting as a hydrogen bond donor due to the 
fact it is a tertiary amide. It was hypothesised that the removal of the amide carbonyl 
would diminish the biological activity of the compound. This was the case, as seen in 
Figure 5.7, where 70 did not induce glucose uptake within C2C12 muscle cells. 
Removal of the carbonyl may have prevented the formation of a hydrogen bond 
interaction between the protein target and 70. 
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Figure 5.7. Glucose uptake assay results of 70. C2C12 muscle cells incubated overnight 
at 37 ºC in the presence 10 µM of each compound. Cells then exposed to 3H deoxy-2-
glucose for 10 mins and a scintillation count of the C2C12 muscle cells performed. 
As 4 contained an amide bond, it would have experienced some restricted rotation.100 
This would have reduced the number of conformations that compound 4 could adopt. 
Introducing free rotation about the nitrogen atom, by removing the carbonyl group, may 
have allowed the compound to adopt numerous conformations. Therefore, the difficulty 
in adopting the suitable conformation for interacting with the protein target may have 
increased.  
The loss of activity observed when the amide carbonyl was removed highlights the 
important role that this group plays in the biological activity of compound 4. 
5.1.1.4 Effect of altering the alkyl chain 
Introducing a carbonyl group into the alkyl chain diminished biological activity, as was 
seen with 5. Although the loss of activity observed for 6 and 7 may be due to the 
presence of the aromatic nitrogen atom, they also contain a carbonyl group on the alkyl 
chain. 
The presence of the π-bond would have affected the polarity of the molecule.100 This 
may have affected its ability to bind to the target protein, thus reducing activity (Figure 
5.8, Table 5.5).  
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When a primary alcohol (66), or a sulphur atom (10), was introduced into the alkyl 
chain, a complete loss of activity was not observed. Both compounds 66 and 10 
remained active compared to the control, but were not as active as 4. Compound 66 may 
have acted as a hydrogen bond acceptor and donor due to the presence of the primary 
alcohol.63 The sulphur atom may have functioned by acting as a hydrogen bond 
acceptor.166 These interactions may have assisted in the ligand-protein binding 
interaction.  
Both 1 and 10 contain a sulphur atom in the alkyl chain. However, a loss in activity was 
observed for 1 and not for 10. Therefore, the loss of activity can be attributed to the 
substitution of the arylpiperazine. 
  
Figure 5.8. Glucose uptake assay results of compound 4 derivatives. C2C12 muscle 
cells incubated overnight at 37 ºC in the presence 10 µM of each compound. Cells then 
exposed to 3H deoxy-2-glucose for 10 mins and a scintillation count of the C2C12 
muscle cells performed. 
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Compound Z Glucose uptake assay 
Activity* 
4 CH2 Active 
5 C=O Inactive 
10 S Active** 
66 CHOH Active** 
Table 5.5: Structure and activity of derivatives with varying alkyl chain lengths, 
*Glucose uptake assay activity compared to basal **Active compared to basal, but less 
active than 4. 
When the section of the molecule, from the amide carbonyl to C5 of the thiophene ring 
was altered, a significant change in the biological activity of these derivatives was 
observed. Increasing the length of this section of the molecule generated the active 
compounds 55 and 56, with 55 proving to be as active as 4 (Figure 5.9, Table 5.6). 
Increasing the length of this section of the molecule may not affect the relative position 
of the arylpiperazine moiety within the protein target and therefore does not affect 
activity. Alternatively, it may be that the position of the arylpiperazine is in fact affected 
but that the new position allows for interactions to occur, which are as stable as the 
interactions observed between compound 4 and the protein target. 
Replacing the thiophene ring with a butyl group (57) also resulted in a compound that 
was as active as 4 in the glucose uptake assay (Figure 5.9, and Table 5.6). As both 
compound 4 and 57 were similar in length, it could be concluded that it is the length of 
the molecule that is important for activity, and not the presence of a heterocycle.  
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A significant reduction in the length of the molecule greatly impacted the ability of 
certain compounds to stimulate glucose uptake, with compounds 58 and 67 both 
proving to be inactive (Figure 5.9, Table 5.6). This was also the case for 59, where the 
length of the molecule from the amide carbonyl to the carbon in the C5 position of the 
thiophene ring was only 7.71 Ǻ, compared to 10.233 Ǻ observed for compound 4. Only 
a slight loss of activity was observed when compound 60 was tested in the glucose 
uptake assay. Here the length of this section of the molecule, from the amide carbon to 
terminal methyl group, was shortened 6.078 Ǻ. Similar resulted were observed for the 
amide 61 where the length of the molecule from the amide carbonyl to the carbon in the 
C5 position of the thiophene was 7.187 Ǻ (61) (Figure 5.9, Table 5.6). 
Reducing the length of the molecule, as was seen in compounds 58, 59 and 67 could 
have several affects, for example it may change the relative position of the substituted 
phenyl ring within the protein which in turn may have affected binding of the molecule 
within the target.63 The alkyl chain may conceivably take part in a hydrophobic binding 
interaction with the target, which could be reduced with the reduction in the length of 
this part of the molecule. 
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Figure 5.9. Glucose uptake assay results of compound 4 derivatives. C2C12 muscle 
cells incubated overnight at 37 ºC in the presence 10 µM of each compound. Cells then 
exposed to 3H deoxy-2-glucose for 10 mins and a scintillation count of the C2C12 
muscle cells performed. 
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Compound Structure Length (Ǻ)† Glucose uptake 
assay activity* 
4 
 
10.233 Active 
55 
 
11.756 Active*** 
56 
 
13.279 Active** 
57 
 
10.647 Active*** 
58 
 
1.509 Inactive 
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59 
 
7.710 Inactive 
60 
 
6.078 Active** 
61  
 
7.187 Active** 
67 
 
 
 
             R =  
 
 
         
1.438 Inactive 
Table 5.6: Structures and activities of derivatives of compound 4, *Glucose uptake 
assay activity compared to basal **Active but not as active as 4, ***As active as 4,† 
bond length measured from amide carbonyl to C5 position of thiophene or to the 
terminal alkyl carbon. 
5.1.1.5 Effect of replacing the thiophene heterocycle 
A heterocycle is an aromatic or saturated cyclic moiety that contains one or more 
heteroatoms such as N, O, S, Si, B, Se or P.167 Heterocycles are extremely important 
functionalities in drug discovery. Numerous pharmaceuticals exist that contain one, if 
not more, heterocycles. They can be found in therapeutics responsible for the treatment 
of cancer, cardiovascular disease and diabetes.167,168  
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A heterocycle can interact with a protein binding site through various bonding 
interactions.63 For example, the heteroatom can interact through hydrogen bonding or 
ionic bonding, while the heterocycle as a whole can interact via hydrophobic 
interactions, van der Waals forces or π-stacking.63,164 
3-(Furan-2-yl)propanoic acid was the only relevant commercially available starting 
material that could have been used in the synthesis of a furan containing derivative of 
compound 4. This resulted in compound 62, a compound of reduced length, compared 
to compound 4, which also contained a furanyl heterocycle.  
Like the sulphur atom in the thiophene ring, the oxygen atom in the furan ring has two 
lone pairs of electrons. Both heterocycles find one of their lone pairs delocalised into 
the aromatic ring, while the other lone pair is found in the sp2 hybrid orbital in the same 
plane as the heterocyclic ring.167 The lone pair of electrons in the sp2 hybridised orbital 
allows these heteroatoms to serve as a hydrogen bond acceptor.  
The thiophene ring was also replaced with a pyrazole heterocycle to give derivative 63 
(Table 5.7). The presence of a secondary amine allows this heterocycle to act as a 
hydrogen bond donor.  
Compound 63 remained active in the glucose uptake assay, while 62 proved to be 
inactive (Figure 5.10). When the glucose uptake assay results for compound 59 and 62, 
which are both similar in length (7.71 Ǻ and 8.696 Ǻ) and only differ in the heterocycle 
(thiophene or furan respectively), were compared, it was found that the results were 
similar. This indicated that replacing the thiophene ring with a furanyl derivative did not 
affect biological activity. The equivalent comparison for the pyrazole containing 
derivative is between 4 and 63, where a slight reduction in activity was observed for 63.  
These results again suggest that the nature of the heterocycle is not of critical 
importance and that it is the overall length of the molecule that may be crucial for 
activity.  
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Figure 5.10. Glucose uptake assay results of compound 62 and 63. C2C12 muscle cells 
incubated overnight at 37 ºC in the presence 10 µM of each compound. Cells then 
exposed to 3H deoxy-2-glucose for 10 mins and a scintillation count of the C2C12 
muscle cells performed. 
Compound Structure Length 
(Ǻ)† 
Glucose uptake 
assay Activity* 
4a 
 
10.233 Active 
62a 
 
 
8.696 Inactive 
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63b 
 
 
10.108 Active** 
Table 5.7: Structure and activity of derivatives of 4 with alternative heterocycles, 
*Glucose uptake assay activity compared to basal **Active compared to basal, but less 
active than 4, a heterocycle substituted at the C2, b heterocycle substituted at C4. † bond 
length measured from amide carbonyl to C5 position of thiophene or furanyl ring or to 
the N1 nitrogen of the pyrazole. 
The thiophene ring was also replaced by a benzyl group. This gave rise to the derivative 
64, which proved to be more active than 4 at stimulating glucose uptake (Figure 5.11). 
As described previously, aromatic rings are hydrophobic moieties that can interact with 
hydrophobic regions of a protein.63 They can also form binding interactions via van der 
Waals forces and become involved in π-stacking with other aromatic groups.164 Such 
interactions may have resulted in the improved activity 
Steric factors may also have influenced the molecules binding mode due to the presence 
of a different aromatic ring.63 This may have altered the orientation of the ligand 
resulting in a superior binding and thus increased activity.63 Similarly, the presence of 
an alternative aromatic ring may have allowed for a better fit of this part of the molecule 
in the protein binding site. 
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Figure 5.11: Glucose uptake assay results and structure of 64. C2C12 muscle cells 
incubated overnight at 37 ºC in the presence 10 µM of each compound. Cells then 
exposed to 3H deoxy-2-glucose for 10 mins and a scintillation count of the C2C12 
muscle cells performed. 
Previous results suggested that the presence of a heterocycle at the terminus of the alkyl 
chain was not required for activity. Consequently, we investigated the effect of 
introducing an alternative functional group at this position would have on glucose 
uptake. We chose to introduce a carboxylic acid functionality at the alkyl chain terminus 
as these groups are found in a variety of biologically active compounds. They serve as 
hydrogen bond donors or acceptors or, alternatively, they can exist as the carboxylate 
ion and form ionic interactions.63 Introduction of this group would also allow for the 
compound to be easily derivatized due to the reactivity of the carboxylic acid. This 
activity would prove to be important when we came to immobilising the compound on a 
solid support, see Chapter 7. 
As a result, compound 79 was synthesised and tested in the glucose uptake assay. The 
presence of the carboxylic acid resulted in a compound that was more active than 4 and 
57 (Figure 5.12). The ability of the carboxylic acid group to form hydrogen bonds or 
ionic bonds may be responsible for this increase in activity. 
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Figure 5.12: Glucose uptake assay results and structure of compound 79. C2C12 
muscle cells incubated overnight at 37 ºC in the presence 10 µM of each compound. 
Cells then exposed to 3H deoxy-2-glucose for 10 mins and a scintillation count of the 
C2C12 muscle cells performed. 
A methyl ester was also introduced at the alkyl chain terminus; compound 81. This 
compound proved to be more active than 4 and 57 and as active as 79 at stimulating 
glucose uptake (Figure 5.13). Again, the presence of a hydrogen bond acceptor in the 
form of a carbonyl group may be responsible for the increase in activity compared to 4 
and 57. 
  
Figure 5.13: Glucose uptake assay results and structure of compound 81. C2C12 
muscle cells incubated overnight at 37 ºC in the presence 10 µM of each compound. 
Cells then exposed to 3H deoxy-2-glucose for 10 mins and a scintillation count of the 
C2C12 muscle cells performed. 
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5.2 Animal studies on compound 4. 
A 16 week animal study was carried out in a similar fashion to that mentioned in 
section 2.3. The study was comprised of three groups: Group A contained 12 mice on a 
HFD that were exposed to 4 dissolved in DMSO; Group B contained 12 mice on a HFD 
that contained only DMSO; and Group C contained 8 mice that were fed a normal 
CHOW diet. All animals were exposed to the given diet 1 week prior to the introduction 
of 4 or DMSO. This was to allow the animals to acclimatise to the change in diet.69 
5.2.1 Glucose tolerance and insulin tolerance testing. 
After 16 weeks, GTT and ITT were performed as before. Figure 5.14 shows that 4 
dramatically improved the animal’s ability to clear glucose, when compared to animals 
on a HFD only. Also, improved insulin sensitivity can be observed as lower glucose 
levels at the varying time point indicates a more sensitized response to insulin. 
An intervention study was also performed. Compound 4 was administered to animals 
after 17 weeks, once insulin resistance had been established. Compound 4 was found to 
restore both glucose and insulin sensitivity to normal levels (Figure 5.14).  
These exceptional results confirm that 4 can actively improve the hyperglycaemic 
profile of a diabetic animal model. The results from the intervention study also show 
that 4 has the potential to be used as an antidiabetic agent in the treatment of T2D. The 
use of a small molecule as an insulin substitute would have many positive effects for 
those requiring insulin therapies. It could prevent the need for daily injections and 
would therefore greatly improve the quality of life. 
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Figure 5.14. Results for compound 4, Glucose and Insulin Tolerance Test and 
Intervention Study. 
 
5.3 A pharmacophore model for compound 4. 
5.3.1 Pharmacophores 
The results of the glucose uptake assay identified functional groups in the compound 4 
required for activity. Changes to the trifluoromethyl phenyl group, the piperazine ring 
and/or the carbonyl group all resulted in a loss of activity. However, changes to the 
alkyl chain and/or thiophene ring were tolerated. Once the active groups were 
established, this information was used to identify a suitable pharmacophore. 
A pharmacophore can be defined as the spacial orientation of necessary features 
(functional groups) required for activity while disregarding the molecular framework 
that holds them together.64,169 Applications can include mining of virtual libraries 
(virtual screening) for hit discovery and hit to lead optimization.170 
The CATALYST software, as implemented in Accelrys Discovery Studio 3.5, can be 
used to generate 3D pharmacophore models from a collection of molecules that are 
diverse in both structure and activity by employing programs such as HipHop and 
Hypogen.  
HipHop provides feature-based alignment of a collection of compounds and matches the 
chemical features of a new molecule, against drug candidate molecules. The resulting 
models can be used to search chemical databases to find new lead candidates. Inactive 
molecules can also provide vital information which can be used to place excluding 
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volume features. Hypogen generates predictive 3D models based on values which can 
be used to quantitatively predict the activity of new compounds. 
To develop a pharmacophore model, the bioactive conformation of a ligand can be 
obtained from the co-crystallised structure of the target protein, if available.64 
Alternatively, if the bioactive conformation is not known, the conformations of a range 
of active compounds can be aligned and a common feature pharmacophore can be 
generated.64 
5.3.2 Development of Training set 
Each active and inactive compound was assigned a principal number, with 2 being most 
active, 1 being active and 0 being inactive based on the results from the glucose uptake 
assay (Table 5.8).  
Table 5.8: Active and inactive compounds based on results from glucose uptake assay. 
Compound Principal No Compound Principal No. 
4 2 5 0 
64 2 6 0 
79 2 7 0 
81 2 8 0 
146 2 9 0 
10 1 11 0 
42 1 38 0 
43 1 40 0 
55 1 41 0 
56 1 45 0 
57 1 47 0 
59 1 52 0 
60 1 53 0 
61 1 54 0 
62 1 58 0 
63 1 67 0 
66 1 73 0 
1 0 74 0 
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All the active compounds with a principal number of 2 were included within the 
training set. Five inactive compounds, selected by means of clustering, were also 
included so as to incorporate excluded volumes. 
5.3.2.1 Clustering 
Clustering involves assigning a set of molecules into subsets, or clusters, so that each 
molecule in that cluster has similar characteristics. The aim is to create a number of 
subsets so that molecules in the same subset are similar while molecules in different 
subsets are as dissimilar as possible.171 For example, the compounds in cluster 2 all lack 
a para CF3 group while the compounds in cluster 3 all contain a pyridine ring in the 
place of a phenyl ring. This method was applied to all inactive compounds with a 
principal number of 0 (Table 5.9). 
Compound Cluster Compound Cluster 
58 1 45 3 
67 1 6 3 
70 1 8 3 
40 2 9 3 
52 2 1 3 
47 2 53 4 
74 2 54 4 
41 2 5 5 
73 2 46 5 
7 3 11 5 
Table 5.9: Clustered inactive compounds, with cluster centres shown in red. 
Five clusters were created that included varying numbers of compounds. A member of 
each cluster, the cluster centre (shown in red in Table 5.9), was chosen to be included 
within the training set. From this we had established a training set that included 4, 9, 46, 
47, 54, 64, 67, 79, 81 and 146. 
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5.3.2.2 Excluded Volumes 
While the features of the pharmacophore were derived from the active compounds, the 
information about the inactive compounds was used to allow the algorithm to place 
excluded volumes. 
Excluded volumes are volume locations that active compounds cannot occupy; they 
represent a single steric constraint.172 They are acquired by using inactive ligands and 
are represented by grey spheres. 
5.3.3 Methods 
The HipHop module in Discovery Studio elucidated 10 common feature 
pharmacophores from a set of active ligands. The algorithms used information from 
inactive ligands to place excluded volumes. Compounds were defined as most active, 
active or inactive based on their performance in the glucose uptake assay. The 
conformation generation method was set to “BEST”. MaxOmitFeature was set at 0 or 1 
with 1 indicating that the compound must map to all but one of the features in the 
generated pharmacophore model. The validation fitting method was set to flexible or 
rigid, with the flexible setting allowing for each conformation of the ligand to be 
slightly modified to better fit the pharmacophore. The number of excluded volumes, 
developed from the inactive compounds, was set at 0, 5 or 10.  
A set of features, from which the pharmacophore could be composed of, were selected 
from a catalogue of available features. From analysis of the active compounds, the 
features were selected based on the features most likely to make up the pharmacophore. 
The set included: Hydrogen bond acceptor (HBA), Hydrogen bond donor (HBD), 
Hydrophobic (H), Hydrophobic aromatic (HAr), Hydrophobic aliphatic (HA), Positive 
charge (PC), Ring Aromatic (RAr).  
Ten models were then developed from the previously prepared training set which 
included both active and inactive compounds. 
5.3.3.1 Generation of Conformations 
As the bioactive conformation of our compounds was not experimentally available, a 
common feature method was used to generate the pharmacophore. The “BEST” method 
was used to generate 255 conformations for each compound within the training set. 
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Unlike the alternative “FAST” method which generates conformations systematically, 
the “BEST”  method generates conformations stochastically.173 The “BEST” mode is 
able to replicate the ligand-bound conformation of molecules. However, computation 
times are significantly longer compared to the “FAST” method.173 
5.3.3.2 Validation of Pharmacophore Models (Receiver Operating Characteristic 
curves) 
As the pharmacophore analysis produced 10 models for each set of conditions used, 
subsequent refinement was required so as to identify the model with the most relevance. 
A validation protocol was used to test the models ability to identify active compounds 
from a larger set of decoys (validation/ test set). The test set included all other 
experimentally tested compounds, active (12) and inactive (20), which were not 
included in the training set. Receiver Operating Characteristic (ROC) curves were used 
to quantify this ability. 
ROC curves (Figure 5.15) can be used to test the ability of a pharmacophore model to 
determine between active and inactive compounds within a test set.174 These curves plot 
the true positive rate (sensitivity, y-axis) against the false positive rate (1 minus 
specificity, x-axis).175 The closer the ROC score value is to 1, the more relevant the 
pharmacophore model.174  
  
Figure 5.15. ROC curves of varying accuracy.  
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5.3.4 Pharmacophore Development and Validation 
From the initial 10 pharmacophore models generated using the conditions described in 
Entry A, (Table 5.9, section 5.3.4) the pharmacophore with a ROC score of 0.642, 
proved to be the best model). Features included hydrogen bond acceptor, hydrophobic, 
hydrophobic aromatic and ring aromatic. To identify the necessary features and to 
improve the quality of the pharmacophore, the model was refined by altering various 
settings such as number of excluded volumes, maximum omitted features (max. omit 
features), types of features and alternating the validation fitting method between rigid 
and flexible. Altering the maximum number of omitted features, from 0 to 1, meant that 
compounds must include all but one feature in the generated pharmacophore. 
Alternating between rigid and flexible within the validation fitting method, allowed for 
each conformation of the ligand to be slightly altered to better fit the pharmacophore 
model. 
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Entry Max. 
Omit 
Feature 
Flexible/ 
Rigid fit 
Max. 
Excluded 
Volume 
Best 
ROC 
score 
Features 
A 0 Flexible 0 0.642 HBA, H, HAr, 
RAr. 
B 1 Rigid 0 0.808 HBA, H, HAr, 
RAr 
C 1 Flexible 0 0.825 HBA, H, HAr, 
RAr 
D 1 Flexible 10 0.842 HBA, H, HAr, 
RAr 
E 0 Flexible 5 0.713 HBA, H, HAr, 
RAr 
F 1 Flexible 5 0.871 HBA, H, HAr, 
RAr 
G 0 Flexible 5 0.877 HBA, H x 2, 
RAr.* 
Table 5.9: Results from Pharmacophore development. HBA = Hydrogen bond donor, 
HBD = Hydrogen bond donor, H = Hydrophobic, HA = Hydrophobic Aliphatic, HAr = 
Hydrophobic Aromatic, RAr = Ring Aromatic.* HAr feature at alkyl chain terminus 
removed. 
Pharmacophore A underwent additional refinement to improve the pharmacophore. 
Encouraging results were observed when the max. omit. feature was set at 1 and the 
fitting method set to rigid. From the 10 pharmacophore models generated using the 
conditions described for pharmacophore B (Table 5.9, Entry B), the pharmacophore 
model B, with a ROC score of 0.808, proved to be the best. However, when the 
validation fitting method was set at flexible, a pharmacophore with an improved ROC 
score of 0.825 was obtained (Table 5.9, Entry C, Figure 5.16)  
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Figure 5.16. Pharmacophore Entry C, ROC score 0.825, with 4 mapped. Blue = H, 
orange = RAr, green = HBA, cyan = HAr 
The model was further refined by introducing excluded volumes. This uncovered Entry 
D, with a ROC score of 0.842 (Figure 5.17). The inactive derivative 67 is also mapped 
to the pharmacophore, Entry D, in the below diagram. As can be seen from the 
illustration, 67 does not contain the HBA or the HAr features present in 4. 
 
Figure 5.17. Pharmacophore Entry D (ROC score = 0.842) with 4 (active) and 67 
(inactive) mapped. Grey = Excluded volumes, blue = H, orange = RAr, green = HBA, 
cyan = HAr 
Reducing the number of excluded volumes, from 10 to 5, and allowing for no features 
to be omitted, gave pharmacophore Entry E with a ROC score of 0.713. However, it 
was found that allowing one feature to be omitted resulted in a pharmacophore with an 
improved ROC score of 0.871 (Table 5.9, Entry F). 
From results of the glucose uptake assay, the thiophene heterocycle, represented by the 
hydrophobic aromatic (HAr) feature, proved to be non-essential for activity. Therefore, 
the presence of a feature at the alkyl chain terminus was removed. As a feature was 
removed, it was necessary to set the max. omit feature equal to 0. This was to ensure the 
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pharmacophore had an acceptable number of 4 features. The excluded volumes were 
also set at 5 (Table 5.9, Entry G). The pharmacophore, Entry G, with a ROC score of 
0.877 (Figure 5.18) best represents the functional groups within the family of 
compound 4 derivatives that are responsible for evoking a biological response. Figure 
5.19 shows both 4 and 79 mapped. 
               
     Figure 5.18. ROC curve for Entry G. 
 
Figure 5.19. 4 and 79 mapped to pharmacophore G. Blue = H, orange = RAr, green = 
HBA. 
Both active compounds have groups that match all the features of the pharmacophore. 
They include the trifluoromethyl group and piperazine ring (H, Blue), the aromatic ring 
(HAr, Cyan) and the amide carbonyl functionality (HBA, Green). No inactive 
compounds were able to be mapped to the pharmacophore as the max. omit feature was 
set at zero. 
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Results of the glucose uptake assay have identified the pharmacophore features 
necessary for activity. As a result the pharmacophore, Entry G with a ROC score of 
0.877, has been constructed and can be used to predict the ability of future compounds 
to act on the protein target. 
 
5.4 Conclusion 
A SAR study was subsequently performed on compound 4 to determine the key 
functional groups responsible for evoking such a biological response. A number of 
conclusions were drawn from this study: 
 changes to the trifluoromethyl phenyl group are not tolerated 
 a piperazine ring is essential 
 an amide carbonyl is required 
 the thiophene ring is not necessary for activity 
 the length of the molecule may play a vital role in ligand/protein interactions. 
It was possible to optimise 4 and generate compounds with greater potency with the 
knowledge that it was the length of the molecule and not the presence of a terminal 
heterocycle that was critical for biological activity. The heterocycle was therefore 
replaced with different functional groups which led to the discovery of a number of 
compounds, such as compounds 64 (terminal phenyl), 79 (terminal carboxylic acid) and 
82 (terminal ester), which proved to be more active than compound 4.  
Compound 4 was as active as its predecessor, compound 1, in an animal model. More 
importantly however were the results obtained with the use of compound 4 in an 
intervention study. Here we saw that the use of compound 4 restored both glucose and 
insulin sensitivity to normal levels 
The information obtained from the SAR study allowed for the development of a 
pharmacophore model. The developed model best represents the key functional groups 
required for a molecule to act on the protein target and stimulate glucose uptake. The 
final pharmacophore model had a ROC score of 0.877.Future work 
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A number of compounds have been subsequently synthesised, which will allow us to 
further investigate what functional groups in compound 4 are required to evoke a 
biological response. For example, the derivatives of compound 4, 48 and 49, contain 
para CH3 and tert-butyl groups respectively, as opposed to the CF3 group found in 4 
(Figure 5.20). Results for these compounds from the glucose uptake assay may indicate 
whether it is the steric bulk of the CF3 alone that is important for biological activity. The 
synthesis of these compounds and subsequent derivatives of compound 4 were 
discussed in Chapter 3. The structures of the compounds from this section, and 
subsequent sections, awaiting testing are highlighted (†) in the experimental section. 
 
     Figure 5.20. Structures of 48 and 49. 
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6. Biological evaluation of 
compound 2 and its derivatives, 
92 and 104-122. 
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6.1 Biological testing of pyrimidinone 2 and the derivatives of 2 
The pyrimidone containing 2 displayed similarities to 1 in that it was also inactive in the 
glucose uptake assay, suggesting a single mechanism of action (Figure 6.1). Compound 
2 may have evoked its biological response by disrupting the RBP4-TTR interaction. It 
was unlike compound 4 in that it was not able to stimulate glucose uptake by acting 
through the unknown protein target. 
 
Figure 6.1. Glucose uptake assay results and structure for compound 2. C2C12 muscle 
cells incubated overnight at 37 ºC in the presence 10 µM of each compound. Cells then 
exposed to 3H deoxy-2-glucose for 10 mins and a scintillation count of the C2C12 
muscle cells performed. 
Although initial results from the glucose uptake assay were discouraging, a SAR study 
of 2 was still performed. The SAR study of compound 1, which was also inactive in the 
glucose uptake assay, led to the highly active 4 and 79. It was therefore hoped that a 
SAR study of compound 2 would lead to useful compounds.  
A number of compounds were initially synthesised that probed the significance of the 
tert-butyl and phenyl functionalities (Figure 6.2), with 105 and 115 the first compounds 
tested in the glucose uptake assay.  
The results from the assay showed that by replacing the tert-butyl group with an iso-
propyl substituent, a compound (115) with similar activity to 79 was generated (Figure 
6.2). This suggested that the sterically bulky tert-butyl group may have been responsible 
for the observed inactivity of 2 in the glucose uptake assay. This is in agreement with 
the Charton values, which are used to describe the steric effects of substituent.176 A tert-
Chapter 6                                    Biological evaluation of compound 2 and its derivatives 
160 
 
butyl group has a Charton value of 1.24 which is greater than the Charton value of an 
iso-propyl group (Charton value = 0.76).156 This indicates that a tert-butyl is more 
sterically demanding than an iso-propyl group and can impose a greater steric effect on 
a protein target.176 
The size of the alkyl substituent may have prevented the compound from interacting 
with the protein target that is responsible for the glucose uptake effect. The presence of 
this less bulky iso-propyl substituent may have allowed the substituent to fit into a 
hydrophobic pocket that is too small for a tert-butyl group. Such a hydrophobic 
interaction could have stabilised the drug-protein interaction.63  
Like compound 2, compound 105 also proved to be inactive. This may be due to the 
presence of the tert-butyl group as opposed to changing the bis(trifluoromethylphenyl) 
group. Therefore, the importance of the bis(trifluoromethylphenyl) group required 
further investigation. 
 
Figure 6.2. Glucose uptake assay results for 105 and 115. Compound 115 shows similar 
activity to compound 79 while compound 105 is inactive in the glucose uptake assay. 
C2C12 muscle cells incubated overnight at 37 ºC in the presence 10 µM of each 
compound. Cells then exposed to 3H deoxy-2-glucose for 10 mins and a scintillation 
count of the C2C12 muscle cells performed. 
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To do this, a number of derivatives of 2 were synthesised, where structural alterations 
were made at the bis(trifluoromethylphenyl) substituted, C5 position Table 6.1. This 
family of compounds are awaiting biological testing.  
 
 
  
 
 
Table 6.1: Structures of derivatives of compound 2. 
 
6.2 Derivatives of compound 115. 
As compound 115 had a biological activity similar to 79 and 4, a family of derivatives 
of 115 were prepared which could be used to identify the functional groups responsible 
for inducing the biological response. This family focused on investigating the 
importance and type of substituent present at the C2 and the C5 position (Figure 6.3).  
 
      Figure 6.3. Structure of compound 115. 
6.2.1 Effect of the substituent at C2 for the derivatives of compound 115. 
The significance of the substituent at the C2 position was evident when the activities of 
2 and 115 were compared. For this reason, a number of derivatives were synthesised 
that further explored the effect of the substituent at this position. A number of 115 
Compound R 
101 H 
104 Me 
105 Et 
106 iPr 
107 tBu 
108 Ph 
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derivatives were synthesised with the aim of assessing their ability to stimulate glucose 
uptake. Table 6.2 shows the series of compound 115 derivatives synthesised. This 
family of compounds are awaiting biological testing 
 
 
Table 6.2: Structures of derivatives of compound 115. 
6.2.2 Effect of the substituent at C5 for the derivatives of compound 115. 
The glucose uptake assay results for the derivative 105 could not provide a conclusion 
on the biological significance of the bis(trifluoromethylphenyl) functional group. This 
was due to the presence of the tert-butyl group which was previously identified as 
inhibiting a compound’s ability to stimulate glucose uptake. For this reason, a series of 
115 derivatives that probed the relevance of the substituent at C5 were synthesised, with 
the aim of testing their activity in the glucose uptake assay (Table 6.3). This family of 
compounds are awaiting testing. 
 
 
 
 
 
 
 
 
 
Compound R 
117 Me 
118 Et 
119 Ph 
120 2-thienyl 
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Table 6.3: Structures of derivatives of compound 115. 
 
6.3 Conclusion. 
Biological evaluation of compound 2 and the derivatives of this compound led to the 
identification of compound 115 which proved to be highly active in the glucose uptake 
assay.  The presence of the iso-propyl group in the C2 position in compound 115 as 
opposed to the tert-butyl group in the C2 position in compound 2 may have allowed the 
substituent to fit into a hydrophobic pocket that is too small for a tert-butyl group. As a 
result of this improved activity, a number of derivatives of compound 115 were 
designed and synthesised and are currently awaiting biological evaluation.  
Chapter 4 saw the synthesis of a number of derivatives of compound 3. These 
compounds are also awaiting biological evaluation. 
 
 
 
 
 
Compound R 
98 H 
109 Me 
110 Et 
111 nPr 
112 iPr 
113 tBu 
114 Ph 
121 4-trifluoromethylphenyl 
122 3-trifluoromethylphenyl 
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7.  Identification of secondary protein 
target. 
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The initial aim of this project was to treat T2D by reducing serum levels of RBP4. 
Compound 1 and its derivatives were designed and synthesised to dock within the 
protein cavity of RBP4, causing disruption to the RBP4-TTR complex. It was expected 
that this would result in renal excretion of RBP4 and lower the serum levels of this 
protein. A compounds ability to induce RBP4-TTR disruption was assessed using the 
SPR assay, with 1 and 4 proving to be highly effective. The high throughput glucose 
uptake assay was then employed to test the ability of subsequent derivatives to induce 
glucose uptake in muscle cells. Compound 4, and several other compounds, were 
capable of inducing this uptake and this led to the identification of the highly active, 79. 
The glucose uptake assay however was an RBP4 independent assay. RBP4 was not 
necessary for compound 4 and the other active derivatives to stimulate the uptake of 
glucose. When cells were stimulated with and without RBP4, no difference in activity 
was observed (Figure 7.1). This indicated that the biological activity of the 1 
derivatives was not derived from their inhibition of the RBP4-TTR interaction alone 
and that they were also working through a secondary protein target. 
 
Figure 7.1. RBP4 independent glucose uptake. Compound 4 stimulated glucose uptake 
by C2C12 muscle cells is independent of an RBP4 supported mechanism. C2C12 
muscle cells incubated overnight at 37 ºC in the presence 10 µM of each compound. 
Cells then exposed to 3H deoxy-2-glucose for 10 mins and a scintillation count of the 
C2C12 muscle cells performed. 
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7.1 Immobilisation of active compounds on an affinity column 
Kosaka et al. described a method for the identification of an unknown small molecule 
protein target a using affinity purification and mass spectrometry.177 This molecule, 
Figure 7.2, was found to increase glucose uptake in myocytes through the activation of 
AMPK.  
The identification of the protein target involved immobilising the active molecule 145 
on an affinity column, via an organic linker, where the affinity column was made up of 
agarose beads. Compound 145 was immobilised on to the agarose bead via the 
carboxylic acid group. Kosaka et al. had previously performed a SAR study of this 
compound and found that the pharmacological activity was not affected when the 
furancarboxylic acid moiety was substituted. As a result the molecule was covalently 
bound to the agarose bead via the carboxylic acid group. Binding proteins, which were 
isolated from target cell lysate, were then passed through the affinity column. Trypsin 
was used to remove the bound proteins which were then analysed using mass 
spectrometry.177 
 
     Figure 7.2. Structure of compound 145.177 
Using the Kosaka method, both 4 and 79 were immobilized onto an agarose bead, 
commercially known as sepharose. As the affinity purification step was to be performed 
in an aqueous environment, we chose to use a linker that had adequate hydrophilic 
properties. For this reason, we chose to attach compounds 4 and 79 to the sepharose 
bead via a polyethylene glycol (PEG) linker. A PEG6 linker, which would create 
enough space between the active derivatives and the bead, was chosen so as not to 
hinder the active molecule’s ability to bind to the target protein.  
7.1.1 Immobilisation of 4 and 79 onto the affinity column 
The alcohol group present in the alkyl chain of 66 presented a viable option for 
attaching the chain to 4. Attaching at this position would leave both the arylpiperazine 
end and the thiophene ring free to interact with the protein target (Figure 7.3). This 
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approach was attempted but was not successful. An alternative approach was also 
explored for attaching linker/bead to compound 4. 
 
Figure 7.3. Proposed structure for the immobilization of compound 4 derivative onto a 
sepharose bead. 
The SAR study revealed that changes to the thiophene ring were tolerated, but changes 
to the arylpiperazine and/or carbonyl functionality resulted in a loss of activity. 
Therefore, 4 was functionalised at the thiophene end so as to allow the attachment of the 
PEG linker at the heteroaroamtic ring. Once the amino PEG linker was attached, the 4-
PEG construct was immobilised onto the sepharose bead (Figure 7.4).  
 
Figure 7.4. Immobilisation of 4 onto a sepharose bead. 
The SAR study also revealed that the biological activity of 79 remained if the 
carboxylic acid moiety was substituted with a methyl ester (81). We also chose to assess 
the effect attaching a PEG linker would have on the biological activity of 79. For this 
reason 79 was coupled to 2-methoxyethanamine to give compound 146 (Figure 7.5). 
The activity of this derivative was then investigated in the glucose uptake assay, with 
excellent results being obtained. 
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Figure 7.5. Structure and glucose uptake assay results and structure of 146. Compound 
55 increases the uptake of 3H deoxy-2-glucose by C2C12 muscle cells, compared to 
compound 4 and is as active as compound 79. C2C12 incubated overnight at 37 ºC in 
the presence 10 µM of each compound. Cells then exposed to 3H deoxy-2-glucose for 
10 mins and a scintillation count of the C2C12 muscle cells performed. 
From Figure 7.5, it is clear that 146 is more active than 4 and as active as 79. Therefore, 
as substituting 79 with a small PEG linker did not affect the biological activity of the 
molecule, we decided to proceed with attaching a longer PEG linker via the carboxylic 
acid. As 79 contained a carboxylic acid functionality, the PEG linker could be attached 
using amide bond formation. The 79-PEG construct could then be attached to the 
sepharose bead (Figure 7.6). 
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Figure 7.6. Immobilisation of 79 onto a sepharose bead. 
7.1.2 Synthesis of PEG constructs of 4 and 79. 
The alcohol group found in the alkyl chain of 66 allowed for the possible attachment of 
the PEG linker at this position. Functionalising 66 with a PEG linker first required the 
activation of the alcohol. The secondary alcohol was reacted with tosyl chloride with the 
aim of introducing a leaving group at this position (Scheme 7.1). However, only 
starting materials were recovered.  
 
Scheme 7.1: Synthetic route for the attempted tosylation of 66, (i) NEt3, DMAP, DCM, 
0 °C-rt, overnight. 
Mesylation of the alcohol was also attempted but again only starting materials were 
recovered. The lack of reactivity of the alcohol at this position maybe due to it being a 
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sterically hindered secondary alcohol. As a result an alternative strategy for attaching 
the PEG linker to compound 4 was employed. 
As previously mentioned, the glucose uptake assay revealed a tolerance for changes to 
the thiophene ring, As such; it was decided to attach the PEG linker to the thiophene 
ring. Thiophene rings readily undergo electrophilic aromatic substitutions, as observed 
previously and hence it is possible to substitute a thiophene at the C2 position.100 The 
synthetic approach that was chosen was to formylate the thiophene ring, using 
tin(IV)chloride and dichloromethyl methyl ether, as the methylating agent. This Rieche 
type formylation gave compound 147. This would then allow the amino PEG linker be 
attached to 147 via a reductive amination (Scheme 7.2). 
   
Scheme 7.2: Synthetic route to the 4-PEG construct. 
The formylated derivative of 4, 147, was isolated in a 62% yield. The presence of the 
product was clear from the characteristic aldehydic peak at 9.82 ppm in the 1H NMR 
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spectrum while the quartet resonating at 123.5 ppm in the 13C NMR spectrum, with a 
coupling constant of 270.0 MHz, indicated the presence of the trifluoromethyl phenyl 
group. Also, the aldehydic carbonyl stretch at 1661 cm-1 is indicative of the presence of 
an aldehyde moiety.  
Reductive aminations involve the formation of an imine, followed by its reduction, to 
give the aminated product. In this instance, NaBH4 was used as the reducing agent. To 
facilitate the attachment of the PEG linker to 147 and its subsequent attachment to the 
sepharose bead, a diamino PEG linker was required (Scheme 7.3). 
 
Scheme 7.3: Synthesis of diamino PEG6 linker 90, (i) NEt3, DMAP, DCM, 0 °C-rt, 
overnight, 94% (ii) CH3CN, reflux, 48 hrs, 54% (iii) PtO2, H2, MeOH, 48 hrs, 82%. 
Tosylation of hexaethylene glycol (148) followed by nucleophilic substitution of the 
resulting product allowed for the formation of the diazido PEG6 linker (149). The 
presence of compound 149 was determined from the IR spectrum with the presence of 
the characteristic azide peak at 2106 cm-1. The azide was then reduced to the primary 
amine, using Adams catalyst, affording the diamino PEG6 linker (150) in an 82% yield. 
With the linker now prepared, it was possible to attempt the reductive amination with 
147. 
Dou et al. reported the substitution of an aldehyde, by means of reductive amination, 
using a diamino PEG linker.178 This method was attempted but a complex mixture was 
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obtained. As a result, the diamino PEG6 linker was then reacted with di-tert-butyl 
dicarbonate (Boc), to give the mono protected PEG6 linker. The reductive amination 
with 147 was subsequently attempted. Again, the desired aminated product was not 
formed. Instead, what was observed was the reduction of the aldehyde to the primary 
alcohol 151 (Figure 7.7). 
 
Figure 7.7. Reduction of 147 to 151. 
Figure 7.8 shows the 1H NMR spectra for 147 and 151. The absence of the aldehyde 
peak at 9.82 ppm and the presence of a methylene peak at 4.66 ppm are indicative of a 
reduction having occurred. The presence of the alcohol was also determined by mass 
spectrometry. An ionized product of mass 413.1505 m/z was detected which is 
indicative of the protonated alcohol product. From the 13C NMR spectrum it was clear 
that the aldehyde functional group was no longer present with the absence of the peak at 
181.1 ppm which is characteristic for the aldehyde carbon. Also HSQC experiments 
showed a correlation between the methylene 1H signal at 4.66 ppm and the 13C signal at 
58.7 ppm. The chemical shift of this peak indicates the presence of a methylene group 
beside an electron withdrawing oxygen atom. 
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         Figure 7.8. The 1H NMR spectra of 147 (blue) and 151 (red). 
In order to determine whether the problem lay with the aldehyde (147) or the diamino 
PEG6 linker (150) a reductive amination was attempted using 147 and a simpler amine, 
propan-1-amine. This reaction successfully led to the aminated product 152, in a 56% 
yield (Scheme 7.4), and suggested that the problem lay with compound 150. 
   
Scheme 7.4: Synthesis of compound 152, (i) NaBH4, MeOH, 3 hrs, 56%. 
An alternative synthetic approach was taken involving the use of a shorter PEG linker, 
PEG3. In addition, a different protection strategy was employed. Hence, only one of the 
azide moieties of the diazido PEG3 linker, which was synthesised as for compound 149, 
was selectively transformed into an amine (154) using a Staudinger reduction (Scheme 
7.5).179 The reaction mechanism for this transformation is shown below (Scheme 7.6) 
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Scheme 7.5: Staudinger reduction, (i) NaN3, CH3CN, reflux, 48 hrs, 80% (ii) 1 M HCl, 
Et2O, EtOAc, 99%. 
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Scheme 7.6: The reaction mechanism for the Staudinger reduction of compound 153 to 
give compound 154. 
The presence of the mono amino PEG3 was confirmed by both HR-MS and IR, where 
the characteristic azide peak was observed at 2109 cm-1 in the IR spectrum.  
With 154 successfully synthesised, linking this compound to 147 was then performed 
via a reductive amination using the same conditions as before. This resulted in the 
successful isolation and characterisation of the desired aminated product, 155, in a 76% 
yield (Scheme 7.7). The IR spectrum indicated the presence of 155 with peaks at 2111 
and 1607 cm-1, characteristic for an azide and an amide respectively. Also, 13C NMR 
spectroscopy highlighted the presence of the CF3 group with a quartet having a coupling 
constant value of 268 Hz found at 124.6 ppm. From the 1H NMR it was clear that the 
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formation of 155 had occurred with the presence of the singlet at 3.94 ppm indicating 
the presence of the methylene group adjacent to the electron withdrawing secondary 
amine. 
  Scheme 7.7: Synthesis of 155, (i) NaBH4, MeOH, 3 hrs, 76%. 
The presence of the azide moiety not only allowed for the effective linkage of 154 to 
147, it also upon reduction, gave access to the free amine required to attach 155 to the 
sepharose bead. A Staudinger reduction was again utilised to convert the terminal azide 
into the primary amine (Scheme 7.8). This gave 156 in a 43% yield. The absence of the 
azide peak in the IR spectrum, as well as the presence of the N-H stretch at 3420 cm-1 
and the N-H bend at 1640 cm-1 verified the reduction of the azide to the amine was 
successful. 13C NMR spectroscopy indicated the presence of the trifluoromethyl phenyl 
group with the quartets at 125.4 (J = 3.0 Hz), 123.5 (J = 268.7 Hz) and 120.1 (J = 32.3 
Hz). 
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Scheme 7.8: Synthesis of 156, (i) 1 M HCl, Et2O, EtOAc, 1h 0 ºC then rt, overnight 
43%. 
Due to the presence of the terminal carboxylic acid, 79 did not require additional 
functionalization, prior to the attachment of the PEG3 linker. Compound 154 was 
attached to 79 using HOBt and TBTU. This gave 157 in a 96% yield. The azide was 
then converted to the free amine, using the Staudinger reduction as before, to yield 
compound 158 (Scheme 7.9). 
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Scheme 7.9: Synthesis of 157 and 158, (i) HOBt, TBTU, NEt3, DMF, rt, overnight, 
96% (ii) 1 M HCl, Et2O, EtOAc, 0 ºC then rt, overnight, 25%. 
Again the absence of the azide peak in the IR spectrum and the presence of the N-H 
stretch at 3373 cm-1 and the N-H bend at 1643 cm-1 indicated the reduction of the azide 
to the amide was successful. The presence of the trifluoromethyl phenyl group was 
supported by the presence of the quartets at 126.4 ppm (J = 3.3 Hz), 124.6 ppm (J = 
270.0 Hz) and 11.0 ppm (J = 32.5 Hz) in the 13C NMR spectrum. 
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7.1.3 Immobilization of 156 and 158 onto the sepharose beads 
With the PEG3 linker attached to the active compounds, they were next immobilized 
onto the sepharose bead. The bead in question was a cyanogen activated sepharose and 
was commercially available as the activated derivative from Sigma Aldrich. 
Compounds 156 and 158 were then attached to the sepharose bead as shown in 
(Scheme 7.10). 
Scheme 7.10: Immobilisation of 156 and 158 onto the sepharose bead. 
The aqueous washes, obtained by flushing the affinity column with three column 
volumes of distilled water, were extracted with DCM. This was to determine the 
amounts of unbound 156 and 158 and thus the amount of 156 and 158 immobilised on 
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the bead. The organic DCM layer was dried, concentrated and analysed by NMR 
spectroscopy for the presence of 156 or 158. The affinity column was also washed with 
MeOH to ensure the removal of any excess unbound 156 and 158. The MeOH wash 
was also concentrated and analysed by NMR spectroscopy. The resultant residues, from 
the extracted aqueous washes and the MeOH washes, contained both 156 and 158 
respectively, albeit in small amounts. Table 7.1 highlights the amount of recovered 
unbound compound found in the aqueous and organic washes and the percentage of 
compound immobilized on the bead. 
Compound Starting 
amount (mg) 
aqueous 
washes 
(mg) 
MeOH 
wash (mg) 
amount 
immobilized 
(mg) 
% 
compound 
immobilized 
156 23 4 1 18 78 
158 20 1 3 16 80 
Table 7.1: Percentage of compounds 156 and 158 immobilized on Sepharose bead. 
Analysis of the various washes indicated that immobilization had occurred. Although a 
number of publications do not report a method for verifying immobilization, other 
reports alluded to the use of certain tests for verification.180,181 In any case, we wanted to 
further test the immobilization process. 
Sepharose beads are commonly used for the immobilization of peptides.182 The process 
of attaching peptides to the bead is similar to the one described above. However, to 
verify that the peptides have been immobilized, amino acid analysis is performed.183 
This involves cleaving the bound molecule by means of hydrolysis and analysing the 
remaining residue. As this would be destructive to the ligand a different strategy was 
chosen. 
McMahon et al. reported that the immobilization of a substance onto the sepharose bead 
was verified by means of an observed colour change.184 As 156 and 158 were both 
colourless oils, no such colour change was expected and the beads remained white.  
To counteract this problem, a coloured derivative was synthesised to test the efficiency 
of the immobilization process. The glucose uptake assay uncovered a derivative, 42, 
which was active, but less active than 4. Compound 42, which contains a para nitro 
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group instead of the para CF3 found in 4, was an orange solid and it was hypothesised 
that its attachment to the sepharose bead would result in a colour change. 
Immobilization of 42 would leave the beads orange allowing verification of the 
immobilization protocol.184 
7.1.4 Synthesis of a coloured derivative of 158. 
The previous synthetic approaches used to attach 154 to the active derivatives, 4 and 79, 
could not be used for the functionalization of 42. As nitro groups are readily reduced to 
the corresponding amines, formylation of 42 followed by a reductive amination could 
result in the reduction of the nitro group. Therefore, an alternative route was needed.  
The attempted synthesis of the 42-bead conjugate is shown in Scheme 7.11. This 
involved the formylation of 74 using the conditions previously described. The PEG 
linker was then attached to the formylated ester derivative (159) via a reductive 
amination to give compound 160. This was then deprotected using base catalysed ester 
hydrolysis revealing the carboxylic acid (161), which was verified by 1H NMR 
spectroscopy due to the absence of the methyl ester peak and by IR spectroscopy where 
the peak at 2111 cm-1 is indicative of the presence of an azide. Due to the presence of 
the secondary amine however, the acidic work up resulted in the formation of a salt, 
which was evident as the product was not found in the various organic washes but was 
recovered from the aqueous layer. The product was carried forward to the next reaction 
and an attempted coupling to 33 using HOBt and TBTU was performed. A complex 
mixture was obtained however, and 162 was not isolated. This approach was therefore 
abandoned. 
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Scheme 7.11: Synthesis of 42-PEG3 linker 162 (i) Tin(IV)chloride, DCM, N2, rt, 1 hrs, 
56% (ii) NaBH4, MeOH, rt, 3 hrs, 58% (iii) KOH, EtOH, reflux, 2 hrs, quant. (iv) 
HOBt, TBTU, NEt3, DMF, N2, rt, overnight, product not isolated. 
As it was hoped to verify the immobilization of the compounds to the bead using a 
coloured compound with a similar structure to 4 or 79, the nitro derivative of 79 was 
synthesised. It was hoped that the nitro derivative of 79 would allow easy coupling to 
the PEG linker. The synthetic route for this approach is outlined in Scheme 7.12. 1-(4-
Nitrophenyl)piperazine was coupled to mono methylazelate using HOBt and TBTU to 
give 163. The ester was then hydrolysed to the acid using base catalysed ester 
hydrolysis. This gave 164 in a 79% yield. The Staudinger product, 164, was then 
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attached via an amide bond to give 165. The amide product was then transformed to the 
azide as before using the Staudinger reduction. This afforded the orange amino 
compound 166 (Scheme 7.12). This method did not require the use of a reducing agent 
and as a result the para nitro group remained intact. The synthesis of 166 was 
confirmed by IR spectroscopy firstly by the absence of the azide peak but also due to 
the presence of the N-H stretch at 3389 cm-1 and the N-H bend at 1631 cm-1. The 
presence of the para nitro group was also evident form the IR spectrum due to the bands 
at 1597 cm-1 and 1321 cm-1. 1H NMR spectroscopy confirmed the presence of the 
phenyl group with the two doublets at 8.14 and 7.02 ppm, which are indicative of the 
protons ortho and meta to the piperazine ring. 
Scheme 7.12: Synthesis of 166 (i) HOBt, TBTU, NEt3, DMF, rt, overnight, 81% (ii) 
KOH, EtOH, reflux, 4 hrs, 79% (iii) 154, HOBt, TBTU, NEt3, DMF, rt, overnight, 94% 
(iv) 1 M HCl, Et2O, EtOAc, rt, overnight, 13%. 
With a coloured PEG linked derivative now obtained, the next step was to attach the 
166-PEG3 construct to the sepharose bead as before. As with the previous examples, the 
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various organic and aqueous washes contained only small amounts of the ligand. Table 
7.2 shows the percentage of ligand immobilized onto the sepharose bead. 
Compound Starting 
amount 
(mg) 
aqueous 
wash (mg) 
MeOH 
wash (mg) 
amount 
immobilized 
(mg) 
% 
compound 
immobilized 
166 20 2 4 14 70 
Table 7.2: Percentage of compound 166 immobilized on the sepharose bead. 
A notable observation when 166 was immobilized on the bead was the distinct orange 
colour of the bead. After several aqueous and organic washes, the orange colour 
remained. This indicated that 166 was immobilized on the sepharose bead (Figure 7.9). 
As a result we were satisfied that the protocol for the immobilization of active 
compounds was successful and that the 4 and 79 affinity columns were ready for use. 
The identification of the unknown protein target using the immobilized compounds and 
the procedure described by Kosaka et al. is currently on-going.177 
 
Figure 7.9. Colour comparison of compounds 158 and 166 immobilized onto the 
Sepharose beads. 
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7.2 Conclusion 
The glucose uptake assay allowed for the identification of the functional groups 
required to evoke a biological response. The glucose uptake assay also allowed for the 
emergence of a secondary protein target as the glucose uptake assay activity was 
independent of RBP4. To work towards identifying this unknown target, the method 
described by Kosaka et al. was employed. This involved attaching the active 
compounds 4 and 79 to an affinity column where the subsequently bound proteins could 
be analysed using mass spectrometry.  
To attach 4 and 79 to the sepharose bead, it was first necessary to attach a PEG linker to 
both compounds. Compound 4 was functionalised at the C2 position of the thiophene 
ring as the glucose uptake assay revealed that changes to the thiophene were tolerated. 
A formyl group was introduced (147) so that the amino PEG linker could be attached 
via a reductive amination. A Staudinger reduction was performed on a diazido PEG3 
linker (153) generating the mono amino-product 154 which was attached to 147 via a 
reductive amination. This gave 155 in a 76% yield. A Staudinger reduction was again 
used to convert the remaining azide into the primary amine with 156 isolated in a 43% 
yield. A similar synthetic approach was applied when attaching the PEG3 linker to 79, 
however as 79 contained a carboxylic acid the mono amino PEG linker 154 was 
attached via amide bond formation and was followed by a Staudinger reduction to give 
158 in a 25% yield. Both compounds were covalently attached to the sepharose bead. 
The methodology for immobilising the ligand-PEG conjugates on the sepharose bead 
was verified by the attachment of the coloured derivative 166.  The use of the beads in 
the identification of the secondary protein target is currently on-going. 
 
 
 
 
 
 
 
Chapter 8                                                                                             Cyclodextrin studies 
186 
 
 
 
 
 
 
 
8. Use of cyclodextrin in the aqueous 
dissolution of compound 4. 
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8.1 Introduction 
Modern methods for identifying biologically active compounds, such as high 
throughput screening and combinatorial chemistry, can be effective at uncovering 
pharmacologically active molecules.66 However, these molecules can have poor drug-
like properties such as poor water solubility, inadequate membrane permeability etc. 
These inadequacies can prevent an active molecule from reaching its target in vivo in 
which case methods that aid in the delivery of a drug molecule to its target are needed. 
Drug delivery is defined as the administration of a pharmaceutical compound in humans 
or animals to achieve a therapeutic effect.185 Many systems exist which can be 
employed to deliver a drug to the necessary target, ranging from chemical modifications 
(e.g. prodrugs, attachment of PEG linkers) to the encapsulation of drugs within a 
suitable vehicle (e.g. liposomes, cyclodextrins).63 These systems work by improving 
certain lacklustre properties of a drug, such as premature metabolic degradation or poor 
water solubility, allowing the drug to reach its target and evoke a pharmacological 
response.63,67  
8.1.1 Prodrugs 
Prodrugs are derivatives of drug molecules that are enzymatically and/or chemically 
modified within the body resulting in the release of the active drug molecule, which can 
then cause the necessary biological effect.66 They can be used to improve membrane 
permeability, water solubility and associated toxicity, amongst other properties.63 For 
example, administering the steroid Oestrone as the lysine ester containing prodrug 
improves its water solubility. Hydrolysis of the prodrug then produces the active form 
of the drug while the metabolite is the non-toxic essential amino acid lysine (Scheme 
8.1).63 
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     Scheme 8.1: Hydrolysis of the Oestrone prodrug to give Oestrone and lysine.63 
An alternative drug delivery system which improves water solubility is that using 
cyclodextrins.  
8.1.2 Cyclodextrins 
Cyclodextrins (CD) improve the solubility, stability and bioavailability of drug 
molecules through their ability to form a non-covalent inclusion complex. This is 
simply the complex formed when the “guest” molecule (e.g. the drug) is present within 
the “host” molecule (e.g. CD).67,186 
Cyclodextrins are chemically formed by glucopyranose molecules being bound together 
through α-(1-4) bonds. They are most commonly composed of 6 (α-CD), 7 (β-CD) or 8 
(γ-CD) glucose units (Figure 8.1).67 
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Figure 8.1. (A) Structure of α-, β-, and γ-CD (B) Approximate geometric dimensions of 
the three CD.187 
Molecular polarity and the capability of the drug to fit within the hydrophobic cavity 
determines the binding observed within an inclusion complex.67 β-CD is the CD of 
choice for many pharmaceutical applications due to its ready availability and the 
appropriate size of its cavity, allowing for the inclusion of the widest range of drugs.186 
However its low aqueous solubility and associated nephrotoxicity limits its use, 
particularly when drugs are delivered parenterally.186 For this reason, modified CDs 
have been produced (Table 8.1).  
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Cyclodextrin R = H or 
β-Cyclodextrin -H 
2-Hydroxypropyl-β-cyclodextrin -CH2CHOHCH3 
Sulfobutylether β-cyclodextrin sodium salt -(CH2)4SO3-Na+ 
Randomly methylated β-cyclodextrin (RAMEB) -CH3 
Branched β-cyclodextrin Glucosyl or maltosyl group 
Table 8.1. Structures of modified CD.188 
Hydroxylpropyl-β-cyclodextrin (HPBCD) is one such modified CD that is used for the 
encapsulation of drug molecules.189 It has been used in parenteral, oral, transdermal, and 
ocular drug delivery systems due to its high water solubility and lack of toxicity in 
vivo.189,190 For example, the antidiabetic drug glimepiride, which has poor aqueous 
solubility, was complexed with HPBCD (Figure 8.2).31  
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Figure 8.2. Structures of glimepiride and HPBCD.32,191 
The addition of HPBCD to an aqueous mixture of glimepiride greatly improved its 
aqueous solubility due to the formation of an inclusion complex which allowed the drug 
to reach its biological target.  
It is the hydrophobic cavity and the hydrophilic exterior that enables these cyclic 
oligosaccharides to accommodate a vast array of drugs allowing for an efficient delivery 
system.67,192 The driving force behind the formation of an inclusion complex is the 
release of water molecules from the CD cavity. Electrostatic and hydrophobic 
interactions, van der Waals forces and H-bonding all contribute to the inclusion of a 
drug molecule within the CD cavity.188 The delivery of a drug molecule, such as 
glimepiride, to the appropriate target can occur as these interactions are relatively weak 
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which makes it possible for the free drug molecule and uncomplexed cyclodextrin to be 
in equilibrium with the inclusion complex when in solution.188 
8.1.2.1 Characterisation of an inclusion complex 
Formation of an inclusion complex can result in a change in physical and chemical 
properties of the guest molecule. These changes can be monitored using a number of 
techniques such as UV-visible and NMR spectroscopy, to confirm complexation. These 
changes can then be used to evaluate certain characteristics of the complex, such as 
improvements to water solubility and the stoichiometry of the complex. 
For example, a shift in the λmax in the UV-visible spectrum of the guest molecule within 
the host molecule generally indicates the formation of an inclusion complex. This shift 
can then be used to determine the aqueous solubility and stoichiometry of the complex 
using the phase-solubility diagram method of Higuchi and Connors.193 
8.1.2.1.1 Phase solubility method 
The phase solubility method, proposed by Higuichi and Connors in 1972, is the most 
commonly used method for studying inclusion complexation.192,193 This method probes 
the effect that a “host” molecule, e.g. CD, has on the solubility of the “guest” molecule, 
e.g. drug.  It involves the addition of an excess of the “guest” molecule to solutions 
containing increasing concentrations of the “host” molecule, with analytical techniques 
such as UV visible and fluorescence spectroscopy used to analyse the solutions.193 
Results of the analysis gives information regarding the concentration of the “guest” 
molecule present in the phase solution. A phase solubility diagram is generated by 
plotting the molar concentration of the “host” molecule used, on the horizontal axis, 
against the total molar concentration of the “guest” molecule, dissolved in the aqueous 
phase due to the formation of the inclusion complex, on the vertical axis.193 There are 
two main types of phase solubility diagrams, type A and type B, with subtypes found 
within both (Figure 8.3).  
β-CD generally gives rise to B type diagrams, due to their poor water solubility, 
whereas AL type curves are seen for HPBCD containing complexes due to the soluble 
nature of the complex.192 
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Figure 8.3. Types of phase solubility diagrams.192 
8.1.2.1.2 Type A phase solubility diagrams 
Type A phase solubility diagrams are commonly found when soluble inclusion 
complexes are formed.192 Three subtypes exist with AL type curves being associated 
with a linear increase in host solubility with increasing guest concentration.192 
AP type diagrams, which show positive deviation from linearity at higher 
concentrations, indicate the presence of higher order complexes such as 1:2 drug:CD 
type complexes.192,194 Curves which negatively deviate from linearity are known as AN 
type curves.192 Felton reports that the meaning of these types of curves are uncertain but 
that one plausible explanation may be that at high concentrations of the host molecule, 
self-association between the molecules occurs, preventing the formation of inclusion 
complexes.193,195 
8.1.2.1.3 Type B phase solubility diagrams 
From Figure 8.3, the presence of B type curves is associated with the formation of 
insoluble complexes. There are two subtypes, with BI type curves denoting the presence 
of insoluble complexes while BS curves are associated with the formation of complexes 
with limited solubility.  
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BS type curves first involve the formation of soluble complexes but at a certain point, A 
(Figure 8.3), the solubility limit of this complex is reached. This is the sum of the 
intrinsic solubility of the guest molecule and any guest molecule solubilized by the 
formation of a host guest complex. As more host molecule is added, the formation of 
additional complex occurs and precipitation of this complex ensues.193 As long as solid 
and undissolved guest molecule is present however, dissolution and complexation can 
occur to keep the concentration of the guest molecule constant. This is evident from the 
plateau observed in the BS type diagram (Figure 8.3). At point B, all of the guest 
molecule has been consumed by the host and has been removed from the system by 
precipitation of the insoluble complex (Figure 8.3).193 This results in the observed 
decrease in guest molecule concentration.195 
A recent publication by de Araujo et al. described the use of a phase solubility diagram 
to determine the effect that HPBCD had on the aqueous solubility of the compound 
pyrimethamine (PYR) (Figure 8.4).189 The CD was found to linearly increase the 
aqueous solubility of PYR with increasing concentration of CD (Figure 8.4). From this, 
de Araujo was able to determine that the type of complex formed was an AL type 
complex.189 
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Figure 8.4. Structure of PYR and phase solubility diagram of an AL type complex.
189 
8.1.2.1.4 Differential Scanning Calorimetry (DSC) 
Calorimetry is a technique used for measuring the thermal properties of a substance. It 
is used to identify the relationship between temperature and specific properties of a 
material.196 DSC is a common calorimetric technique used and measures the difference 
in the amount of heat needed to increase the temperature of a reference and sample as a 
function of temperature. The reference and sample are maintained at the same 
temperature, using a controlled temperature program, while the difference in the heat 
flow needed to keep both at the same temperature is measured as a function of 
temperature or time.197 The change in the heat flow is attributed to the sample 
undergoing a physical transformation.196 For example, when a sample undergoes a 
phase transition more or less heat will need to be applied to the sample to maintain both 
the sample and reference at the same temperature.196 
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DSC has a number of applications including the analysis of proteins, lipids and 
carbohydrates. The folding thermodynamics of nucleic acids can also be investigated 
using this thermoanalytical technique.196 DSC can also be used to study and characterise 
“host-guest” interactions such as the inclusion of a molecule within the hydrophobic 
cavity of a suitable CD.67 One such example is the inclusion of the anthelmintic drug, 6-
chloro-5-(1-naphthyloxy)-2-(trifluoromethyl)-1H-benzimidazole (RCB20), within 
HPBCD. The below DSC curves highlight the differences in heat flow observed for 
RCB20 and its associated inclusion complex (Figure 8.5).67 
  
Figure 8.5. Structure of RCB20 and DSC curves for (a) RCB20 (b) HPBCD and (c) 
RCB20:HPBCD inclusion complex.67 
From the above diagram, the DSC curve for RCB20 has two characteristic endothermic 
peaks at 107 °C and 184 °C which correspond to the melting and decomposition of the 
compound, respectively. The broad peak at 60 °C is due to the loss of water from the 
CD molecule while the sharp peak observed at 218 °C represents the decomposition of 
HPBCD. When the DSC curves for RCB20 and HPBCD are compared to that of the 
inclusion complex, it is evident that the endothermic peaks corresponding to the melting 
and decomposition of RCB20 are not present. This is a strong indication for the 
formation of an inclusion complex. 
Chapter 8                                                                                             Cyclodextrin studies 
197 
 
8.1.2.1.5 Scanning Electron Microscopy (SEM) 
Primary electrons are generated from the extraction of electrons from a source and are 
driven by an electron potential through a column under vacuum.198 These electrons can 
be manipulated into finely focused beams and scanned across a sample in a systematic 
fashion.198 A number of useful and interesting interactions arise when a beam of 
primary electrons strike a sample surface. 
Secondary electrons and backscattered electrons are the main signals used in SEM. The 
composition of a sample, as well as its surface topography, affect the emission of these 
signals which can be used to create an image.198 This technique can be used to 
characterise the topography and morphology of CD inclusion complexes as many 
inclusion complexes are morphologically distinct from the parent guest and host 
molecules. This was the case as seen with the inclusion complex formed by Rojas-
Aguirre et al..67 There was an obvious difference in the morphologies between the (a) 
“guest” molecule, (b) the “host” molecule (i.e. HPBCD), (c) the physical mixture (i.e. a 
mixture prepared by grinding the guest molecule and the host molecule together in the 
absence of water) and (d) the inclusion complex (Figure 8.6). As the morphology of the 
inclusion complex is distinct from that of the other three, it is supportive of a new, 
independent complex is formed.67 
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Figure 8.6. SEM analysis of an inclusion complexes (20 kv) at 500 magnifications (a) 
“guest” molecule, (b) “host” molecule i.e. HPBCD (c) Physical mixture (d) inclusion 
complex.67 
 
8.2 Improving the aqueous solubility of compound 4 with the use of CDs 
The role of compound 4 as a possible antidiabetic drug was evident from its ability to 
evoke a pharmacological response in the glucose uptake assay and in mice. Further 
animal experiments were considered involving 4; however these required aqueous 
solutions of the compound. As 4 had previously proven to be highly insoluble in water 
it therefore would not have been possible to administer 4 as an aqueous solution. 
Aqueous solubility was not only desirable for the considered animal experiments but it 
is also an important ADME property for many drugs (i.e. logP). The calculated logP 
value for 4 is 4.79 and is very close to the upper limit of 5, ideal logP value for an orally 
administered drug, as was suggested by Lipinski.63 The high logP value for 4 may 
explain its low aqueous solubility. As a result, a method for improving the aqueous 
solubility of 4 was sought. 
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The literature directed the investigation towards the use of CD as a way to improve 
aqueous solubility. This was a viable approach as numerous drugs, including 
antidiabetic drugs, were complexed with various CDs to improve several properties, 
such as aqueous solubility. A number of different CDs were available whose use may 
have improved the aqueous solubility of compound 4.  
α-CD is generally not used in the complexation of drug molecules due to the small size 
of its cavity, which has been found to be of insufficient size for many drugs.192 While 
the size of the cavity of the α-CD deterred us from its use, it was the low aqueous 
solubility and associated nephrotoxicity, reported by Challa et al., which excluded β-CD 
from our choices of CD. The modified CD, hydroxylpropyl-β-CD (HPBCD) was 
therefore chosen due to its low toxicity, excellent water solubility and ability to 
complex a variety of drugs.189,67 
The aim of this section of work was to prepare an aqueous 0.02 M solution of 
compound 4. Our first attempt involved the use of 20 eq of HPBCD however; this did 
not result in the dissolution of 4. The use of DMSO as a co-solvent was then considered 
and an aqueous solvent system containing 50% DMSO was used with 1, 2, 5, 10 or 12 
eq of HPBCD. DMSO was chosen due to its low toxicity, but also experimental studies 
in the formation of inclusion complexes have suggested that stable inclusion complexes 
can be formed in the presence of DMSO.199  
The 50% aqueous DMSO solution containing 12 eq of HPBCD was the only one that 
resulted in dissolution of the compound. The level of DMSO was considered too high 
and hence our next aim was to reduce the volume of DMSO required. An aqueous 
solvent system containing 10% DMSO and 12 eq of HPBCD was first prepared to 
which was added 4. Unfortunately, precipitation of 4 occurred. Subsequently, the 
number of HPBCD equivalents was increased from 12 to 18. Initial results were 
promising however after one hour precipitation of a white solid occurred. The number 
of equivalents was then increased to 20. This resulted in the complete dissolution of 4 
with a clear homogenous solution present after twenty four hours (Entry 9, Table 8.2). 
We then further reduced the level of DMSO and an aqueous solution containing 5% 
DMSO with 20 eq of HPBCD was prepared which resulted in the complete dissolution 
of 4. From Figure 8.7, it is clear that the improved aqueous solubility is due to the 
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presence of HPBCD. Compound 4 could not be dissolved in an aqueous solution 
containing 5% DMSO without the use of HPBCD (Figure 8.7 (b)). 
 The percentage of DMSO used was further decreased from 5% to 2%. This also gave 
rise to an aqueous solution of 4; however; after 18 days the formation of a white 
precipitate occurred. The combination of 5% DMSO with twenty equivalents of 
HPBCD was considered optimal (Entry 10, Table 8.2). 
 
Figure 8.7. (a) Compound 4 in 5% DMSO/H2O solution without HPBCD (b) 
Compound 4 in 5% DMSO/H2O solution with HPBCD. 
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Entry % DMSO HPBCD (eq) Solubility 
1 0 20 Insoluble 
2 50 1 Insoluble 
3 50 2 Insoluble 
4 50 5 Insoluble 
5 50 10 Insoluble 
6 50 12 Soluble 
7 10 12 Insoluble 
8 10 18 Insoluble 
9 10 20 Soluble 
10 5 20 Soluble 
11 2 20 Insoluble* 
Table 8.2: Conditions needed for the preparation of an aqueous 0.02 M solution of 4. 
*Initially appeared soluble but precipitate appeared after eighteen days. 
We believe that the preparation of an aqueous solution of 4 was due, in part, to the 
formation of an inclusion complex. To characterise this inclusion complex, a number of 
analytical techniques were employed, namely a phase solubility diagram, NMR 
spectroscopy, DSC and SEM. 
8.2.1 Phase Solubility Diagram  
The previously described method by Higuichi and Connors, section 8.1.2.1.1, was used 
to elucidate the effect of HPBCD on the aqueous solubility of 4. This is a widely 
accepted method for investigating the effects of CD on drug solubility, with an AL type 
complex being the most common complex formed.193 
To produce the phase-solubility diagram, a standard curve of 4 was required and this 
was generated using UV-visible spectroscopy. A series of solutions of compound 4 in 
MeOH were prepared and the UV absorption spectrum of each sample was obtained and 
the data analysed at 264 nm (λmax of 4). The absorbance values were then plotted against 
the varying concentrations of 4 (Figure 5.8). 
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Figure 8.8. Standard curve of 4 generated in MeOH using UV-vis spectroscopy. 
To produce the phase solubility diagram, a fivefold molar excess of 4 (i.e. 5.0 mM), 
relative to the highest concentration of HPBCD, was added to aqueous solutions 
containing increasing concentrations of HPBCD (0.2 mM, 0.4 mM, 0.6 mM, 0.8 mM, 
1.0 mM). These mixtures were stirred for 72 hours at room temperature before 
analysis.189 
After this time, the excess, uncomplexed, insoluble, 4 was removed by filtration and the 
different solutions were analysed using UV-visible spectroscopy. The below UV spectra 
(Figure 8.9) show an increase in the absorbance at 264 nm with increasing 
concentrations of HPBCD. This indicates an increase in the concentration of 4 in the 
aqueous solutions with increasing concentrations of HPBCD, which we believe is due to 
the formation of an inclusion complex. 
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Figure 8.9. Absorbances of compound 4, measured at 264 nm, in aqueous soulutions 
containing varying concentrations of HPBCD. 
The above spectrum shows that 1.0 mM HPBCD exhibits only minimal absorption at 
264 nm. As a result, the bands at 264 nm for the 4:HPBCD complex would be expected 
to result significantly from the absorption of 4 within the inclusion complex. All 
measurements made at 264 nm for the 4:HPBCD complex were corrected by 
subtracting the corresponding absorption resulting from HPBCD.  
The standard curve was then used to calculate the concentration of 4 present in each 
aqueous solution. The calculated concentrations of 4 were plotted against the 
concentrations of HPBCD used and a phase solubility diagram was generated (Figure 
8.10). 
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Figure 8.10. Phase solubility diagram. The conc. of 4 (x-axis) dissolved in aqueous 
solutions, due to the presence of HPBCD and calculated using the standard curve 
(Figure 8.9), are plotted against the various concentrations of HPBCD used in each 
solution (y-axis). 
From the above diagram, it is clear that the solubility of 4 increases linearly with 
increasing concentrations of HPBCD. This is a feature of an AL type complex, which 
indicates the presence of a water soluble complex. This is the most common complex 
observed for drug:CD interactions.189 The slope, of value 0.012 in this case is less than 
one and can indicate the presence of a complex with a 1:1 stoichiometry.193 
8.2.1.1 Calculation of the Stability Constant, K 
The previously described weak molecular interactions, such as van der Waals forces, 
which are involved in the formation of the inclusion complex allow free drug molecules 
in solution to be in rapid equilibrium with drug molecules bound in the CD cavity 
(Equation 8.1).188  
 
Equation 8.1. 
Equation 8.1 shows the observed equilibrium between unbound drug (D) and 
cyclodextrin (CD) and the inclusion complex (D/CD Complex), with K1:1 the stability 
constant of an inclusion complex with a 1:1 stoichiometry.188 The size of K1:1 is an 
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indication of the strength of the interaction between drug and CD. The larger the K1:1 
value, the stronger the interaction between the drug and CD in the inclusion complex. A 
large K1:1 value indicates the equilibrium lies in favour of the inclusion complex. 
Conversely, a small K1:1 value indicates a weak interaction between drug and CD, with 
equilibrium lying in favour of the free drug.190  
K1:1 can be calculated according to Equation 8.2, where So is the intrinsic water 
solubility of the drug and the slope is the slope of the line generated from the phase-
solubility diagram.189  
 
Equation 8.2 
The intrinsic water solubility was calculated by stirring 4 in water for seventy two 
hours. The excess 4 was removed and the UV absorption spectrum of the sample was 
obtained and the data analysed at 264 nm (λmax of 4). This gave an intrinsic water 
solubility of 0.32 μM. Using Equation 8.2, K1:1 was calculated to be 34755 M-1. 
Upadhye et al. reported a binding constant of 21137 M-1, which indicated a strong 
bonding interaction between the drug molecule THC and a CD (Figure 8.11).190 
Upadhye also gave an example of a drug molecule which formed weak, unstable 
interactions within a CD molecule. In this case the molecule, THC-HS, a prodrug 
derivative of the previously mentioned THC, was found to have a K1:1 value was 562.48 
M-1.190 The large stability constant value obtained for 4 indicates a strong interaction 
between the molecule and HPBCD, with the equilibrium lying in favour of the inclusion 
complex.  
 
Figure 8.11. Structure of the drug THC and the ester derivative THC-HS.190 
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8.2.2 Non-inclusion complex 
The formation of a complex with a 1:1 stoichiometry may appear somewhat 
contradictory to the previously prepared aqueous solutions of 4 that required twenty 
equivalents and not one equivalent of HPBCD. Rojas-Aguirre et al. explained that 
although a phase solubility diagram can indicate the presence of a complex with a 1:1 
stoichiometry, the level of complexation can sometimes be low and excess CD is 
needed to fully dissolve the required concentration of drug.67 In addition, the use of 
excess amounts of CD can achieve solubilisation of drug molecules by the formation of 
non-inclusion complexes.200  
Gabelica et al. reported that CD can form both inclusion and non-inclusion complexes 
with certain molecules and that both complexes can exist simultaneously in aqueous 
solutions.201 These non-inclusion complexes arise due to the formation of aggregates 
consisting of two or more CD molecules and drug/CD complexes. The water soluble 
aggregates can then function to further solubilise lipophilic drugs through the formation 
of a non-inclusion complex by creating a hydrophobic environment in which to 
accommodate the drug. Alternatively, Loftsson et al. suggested that solubilisation may 
also occur through the formation of a micelle like structure.200 
The formation of these non-inclusion complexes may apply to the preparation of the 
0.02 M 4 5% aqueous DMSO solution. As was reported by Loftsson, these non-
inclusion complexes occur when a high concentration of drug is present. Therefore, the 
preparation of a 0.02 M solution of 4 may have required 20 eq of HPBCD to allow the 
formation of, not only the 1:1 inclusion complex but also, the non-inclusion complex 
formed by the presence of a CD:inclusion complex aggregate.200  
8.2.3 NMR analysis 
1H NMR analysis was used to investigate the binding mode of 4 within HPBCD.  The 
encapsulation of 4, either by one molecule of HPBCD or by the formed aggregates, can 
be seen by changes in the 1D 1H NMR spectra of 4 for the inclusion complex.  
Full characterisation of the 4/HPBCD complex in D2O was not possible, as 4 could not 
be solubilised in this solvent. Therefore, a 5% D2O/CD3OD solution was prepared in 
which both 4 and the complex were soluble. This gave the spectra below where the 
characteristic peaks of 4 were observed within the CD complex (Figure 8.12 (b)), blue 
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spectrum). A shift in the resonance of a number of peaks of 4 was observed and the 
difference in chemical shift is shown in (Table 8.3). This indicates that 4 is in a 
different environment when it is present in the CD inclusion or non-inclusion 
complexes. These small changes in chemical shifts are common, with Rojas-Aguirre et 
al. reporting changes in chemical shifts ranging from 0.001 ppm to 0.012 ppm for the 
previously mentioned RCB20 molecule.67 
The information on the spatial proximity of 4 in the CD complexes was determined by 
means of two-dimensional rotating frame NOE spectroscopy (ROESY), which were 
performed by Dr. Paidraig McLoughlin. The 2D ROESY spectrum was also obtained in 
the 5% D2O/CD3OD solution with the contour plot revealing an interaction between H1, 
H2, H3, H4, H5 and H12 of 4 with the internal protons Ha and Hb of HPBCD, which 
were assigned by Rojas-Aguirre et al. (Figure 8.13).67 This gives strong evidence 
towards the presence of 4 within the cavity of HPBCD, further supporting the formation 
of an inclusion complex. 
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Figure 8.12.  1H NMR spectra (300 MHz) in 5% D2O/CD3OD of (a) 4 (red) and the 
inclusion complex (blue) and (b) a magnified view of the spectrum. 
Assignment (4) δ* (Free 4) δ* (Complex) ∆δ 
H2, H4 7.0904 7.0784 0.0120 
H6 2.5184 2.5078 0.0106 
H8 2.9384 2.9289 0.0095 
H10 6.8687 6.8621 0.0066 
H11 6.9540 6.9465 0.0075 
 Table 5.2: Chemical shifts for free 4 and complexed 4.*δ, ppm  
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Figure 8.13. (a) ROESY spectrum of inclusion complex between 4 and HPBCD (b) 
ROESY spectrum expansion showing the crosspeaks between the aromatic signals of 
the inclusion complex between 4 and HPBCD protons. 
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8.2.4 Differential Scanning Calorimetry (DSC) analysis 
The thermoanalytical technique, DSC, was used to determine the presence of the 
inclusion complex. The thermal behaviour of the inclusion complex was compared to 
that of 4, HPBCD and a physical mixture of 4 and HPBCD. A physical mixture simply 
contained 4 and HPBCD in the same ratios as the inclusion complex and was prepared 
by grinding the two in the absence of solvent. An inclusion complex would not form 
under these conditions. 
The DSC curve, Figure 8.14 (a), for 4 shows a sharp endothermic peak at 94 °C, which 
is characteristic of the melting point of 4. Figure 8.14 (b), the curve for HPBCD, is in 
accordance with the literature and shows two broad endotherms ranging from 25-103 
°C, due to the loss of water, and 280-340 °C, due to decomposition of the CD.189,67 The 
physical mixture shows the characteristic peaks of both 4 and HPBCD, with the sharp 
peak at 94 °C due to the melting of 4 and the broad endotherm ranging from 25-103 °C 
showing the loss of water from the HPBCD cavity (Figure 8.14 (c)). This indicates the 
absence of any interaction between 4 and HPBCD.67  
The inclusion complex, Figure 8.14 (d), has a broad endotherm at 25-103 °C due to the 
loss of water. Work by Rojas-Aguirre has suggested that this is the loss of water 
molecules which are bound to the -OH groups on the exterior of the CD and not the loss 
of water from the cavity.67 The sharp, endothermic peak observed at 94 °C, in the DSC 
curve of 4 and the physical mixture is notably absent from the DSC curve of the 
inclusion complex. This is a strong indication of the presence of a complex, whether it 
is an inclusion or non-inclusion complex, as the presence of 4 within either of these 
complexes would cause a change to its physicochemical properties.200 
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Figure 8.14. DSC curves: (a) 4 (b) HPBCD (c) Physical mixture (d) Inclusion complex. 
8.2.5 Scanning Electron Microscopy (SEM) 
SEM analysis was used to investigate and compare the shape and surface morphologies 
of HPBCD, 4, the physical mixture and the inclusion complex. Figure 8.15 shows the 
SEM images for HPBCD, 4, the physical mixture and the inclusion complex at 500 
magnifications. HPBCD and 4 show distinct morphologies, with 4 appearing to adopt a 
cluster like arrangement in the micrograph. The SEM image of the physical mixture 
(Figure 8.15 (c)) has a morphology comparable to that of both 4 and HPBCD. The 
characteristic clusters observed in the micrograph of 4 and the smooth morphology of 
HPBCD can be seen. This can be indicative of a lack of “host-guest” interactions.67 The 
morphology of the inclusion complex is clearly different from that of the physical 
mixture and 4. Figure 8.15 (d), the inclusion complex, shows a smooth amorphous 
solid, without the cluster like structures observed in the SEM image of 4. This change in 
morphology could be due to the formation of an inclusion complex (or the non-
inclusion complex previously described). These changes in morphologies are similar to 
that observed by Rojas-Aguirre et al., described in Figure 8.6, Section 8.1.2.1.5.67 
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Figure 8.15. SEM images (20 kV) of (a) HPBCD (b) 4 (c) Physical mixture of 4 and 
HPBCD (d) Inclusion complex between 4 and HPBCD at 500 x magnification. 
8.2.6 Glucose uptake assay 
The activity of the 4/HPBCD complex was investigated in the glucose uptake assay. 
This was to elucidate whether the complexation of 4 would hinder its ability to evoke a 
biological response. As the stability constant was large (K1:1 = 34755 M
-1), it was 
possible that the concentration of free drug would be too low to evoke a response.  
The assay was performed as before, using 10 μM of compound 4.  The results, shown in 
Figure 8.16, indicate that the binding of 4 in the HPBCD did not affect the compounds 
ability to stimulate glucose uptake. Although the stability constant was large, indicating 
the presence of strong interactions within the inclusion complex, it is still plausible for 4 
to become disassociated from the CD and reach the target protein. Also, the K1:1 value is 
only applicable for 4 within the inclusion complex and cannot be applied to describe the 
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interactions of 4 within the non-inclusion complex. It is therefore possible that 4 
encapsulated by the solubilizing aggregates was able to act on the target protein. 
 
Figure 8.16. Glucose uptake assay results for 4/HPBCD complex. 10 µM 4 used with 
20 eq of HPBCD. C2C12 muscle cells incubated overnight at 37 ºC. Cells then exposed 
to 3H deoxy-2-glucose for 10 mins and a scintillation count of the C2C12 muscle cells 
performed. 
 
8.3 Conclusion 
An efficient and convenient method for improving the aqueous solubility of 4 was 
identified with the use of the excipient HPBCD. The formation of 4/HPBCD 
complexes, such as a 1:1 inclusion complex, was determined by means of a phase 
solubility diagram. The presence of non-inclusion complexes was also suggested as a 
means to account for the large excess of HPBCD needed to solubilise 4.  
These complexes were characterised using analytical techniques such as SEM and DSC, 
while NMR spectroscopy allowed for the interaction to be investigated at an atomic 
level. Encouragingly each method pointed to the same conclusion; compound 4 was 
present in an aqueous solution due to the formation of a CD complex. 
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9.1 Conclusion 
The initial aim of this project was to identify an RBP4-TTR inhibitor that also acted as 
an antidiabetic agent. Compounds 1, 2 and 3 proved to be highly active in the SPR 
assay confirming their ability to inhibit the formation of the RBP4-TTR complex. 
Animal studies proved that these compounds were successful in controlling both 
glucose and insulin levels in diabetic mice. An additional important result was the 
reduced weight gain observed with the use of compound 1 in these mice. As many 
current antidiabetic drugs have the unwanted side effect of weight gain, a compound 
that can act as an insulin substitute while reducing weight gain would be highly 
beneficial to the diabetic patient.  
Due to the encouraging results obtain from the SPR assay and the animal studies, an 
initial SAR study was performed on compound 1 which led to the design and synthesis 
of eight compounds, 4-11, which were tested in a number of assays such as the 
fluorometric binding assay and the glucose uptake assay. The amide 4 proved to be 
more active than both compound 1 and the retinoid derivative Fen at inhibiting the 
formation of the RBP4-TTR complex in the SPR assay.  
Amide bond formation was the key final step in the synthesis of compound 1 and the 
derivatives of this compound. The coupling reagents HOBt and TBTU were used in 
most cases with the amide product generally isolated in acceptable yields.  
The synthesis of a number of arylpiperazines, required to investigate the importance of 
this functional group, involved the use of a number of different methods. Metal 
catalysed reactions were used in some cases but MW assisted SNAr gave access to the 
same arylpiperazines in an improved yield and reduced reaction time. MW assisted 
synthesis was not useful in the synthesis of arylpiperazines which did not contain an 
electron withdrawing group (e.g. 35 and 36, p-CH3 and p-tBu respectively). The 
cyclocondensation of substituted anilines and bis(2-chloroethyl)amine.HCl was used to 
access these arylpiperazines. From the synthesis of arylpiperazines, it was clear that: 
 
 
 
Chapter 9                                           Conclusion 
216 
 
 MW synthesis was useful to access arylpiperazines containing electron 
withdrawing groups and improved yields and reduced reaction times 
 the cyclocondensation approach was useful to access arylpiperazines that did not 
contain an electron withdrawing group 
The synthesis of compounds 2 and 3 and the derivatives of these compounds involved 
the synthesis of a number of substituted pyrazoles. Substituted β-ketonitriles and 
hydrazines were used in the synthesis of the substituted pyrazoles required for the 
synthesis of the derivatives of compound 2. β-Ketoesters and substituted hydrazines 
were used in the synthesis of the substituted pyrazoles necessary for the synthesis of the 
derivatives of compound 3. MW irradiation again proved to be useful, with a novel 
method for the synthesis of the pyrazoles, compounds 91 and 96, formed in good yields 
and short reaction times. 
Compounds 1, 2 and 3 and the derivatives of these compound were fully characterised 
using methods such as NMR spectroscopy, mass spectrometry, IR spectroscopy and in 
some cases CHN micro analysis. 
A SAR study was subsequently performed on compound 4 to determine the key 
functional groups responsible for evoking such a biological response. A number of 
conclusions were drawn from this study:  
 changes to the 1-(4-trifluoromethyl)phenyl group are not tolerated 
 a piperazine ring is essential 
 an amide carbonyl is required 
 the thiophene ring is not necessary for activity 
 the length of the molecule may play a vital role in ligand/protein interactions. 
A loss or reduction of activity was the overall trend when changes were made to the 
trifluoromethyl phenyl group, as was seen with compounds 1, 40, 47, or 67. This is 
exemplified in the loss of activity observed for compound 1 compared to the activity 
observed for compound 10 when the Cl and N are removed from the aryl group. This 
may indicate that there is a very specific and sensitive binding occurring. Changes to the 
trifluoromethyl group, either changing its position on the aromatic ring or replacing it 
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with alternative functional groups, led to a loss of activity. This implies that the CF3 
group may act in a multi-purpose fashion:  
 The steric bulk of this group may impact on the compounds conformation when 
in the protein active site resulting in an improved binding interaction. 
 The lipophilicity of a molecule is affected by the presence of a CF3. 
Lipophilicity is a key property for permeating cell membranes and hence a CF3 
may increase the amount of compound reaching the target protein.  
 The electronic properties of the fluorine atoms can affect the electron density of 
the aromatic ring which in turn can affect the binding interaction. Changing the 
electron density of the aromatic ring may have reduced the biological activity as 
seen with 42 and 73 for example where a CF3 group is replaced with a p-NO2 
and a p-NH2 respectively.  
Similarly, the role of the piperazine ring also proved important as no changes to this 
saturated heterocycle were tolerated. The piperazine carbonyl skeleton may serve to 
position the molecule in a suitable orientation for binding, while the aryl nitrogen may 
become involved in ionic interactions.  
A loss of activity was observed when the carbonyl group was removed, implying that it 
may function as an important hydrogen bond acceptor. This was seen with the 
derivative 70. 
The role of the thiophene ring was found to be unimportant and it is suggested that it is 
the length of the molecule and not the presence of a terminal heterocycle that was 
important for activity as was seen with compounds 57, 62 and 63. Increasing the length 
of the molecule did not inhibit activity with compound 55 (an extra CH2 in the alkyl 
chain) proving to be as active as 4 with 56 (two extra CH2’s in the alkyl chain) also 
demonstrating a high level of activity. Significantly, a drastic reduction in the length of 
the molecule did inhibit glucose uptake as was the case with compounds 58 and 67. 
When the length of the molecule from the amide carbonyl was reduced to 7.710 Ǻ, 
compound 59, we did not observe glucose uptake. The exception to this however, is 
compound 61, which remained active even though the length of the molecule from the 
amide carbonyl was reduced to 7.187 Ǻ.  This suggests the presence of a specific and 
sensitive binding interaction. 
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It was possible to optimise compound 4 and generate compounds with greater potency 
with the knowledge that it was the length of the molecule and not the presence of a 
terminal heterocycle that was critical for biological activity. The heterocycle was 
therefore replaced with different functional groups which led to the discovery of a 
number of compounds, such as 64 (terminal phenyl ring) and compound 81 (terminal 
ester), which proved to be more active than compounds 1 and 4. The most prominent 
discovery was the identification of compound 79, where the terminal carboxylic acid 
has the ability to operate as a hydrogen bond donor and acceptor or as a source of ionic 
interactions. This derivative proved to be the most active compound identified to date. 
Compound 4 was as active as its predecessor, compound 1, in an animal model. More 
importantly however were the results obtained with the use of compound 4 in an 
intervention study. Here we saw that the use of compound 4 restored both glucose and 
insulin sensitivity to normal levels 
The information obtained from the SAR study allowed for the development of a 
pharmacophore model. The developed model best represents the key functional groups 
required for a molecule to act on the protein target and stimulate glucose uptake. The 
final pharmacophore model had a ROC score of 0.877. 
The glucose uptake assay allowed for the identification of the functional groups 
required to evoke a biological response. It also allowed for the emergence of a 
secondary protein target as the glucose uptake activity was independent of RBP4. To 
work towards identifying this unknown target, the method described by Kosaka et al. 
was employed. This involved attaching the active compounds 4 and 79 to an affinity 
column where the subsequent bound proteins could be analysed using mass 
spectrometry. As compounds 4 and 79 are colourless, a coloured derivative, compound 
166, with structural similarities to compound 79, was synthesised and attached to the 
sepharose bead. The resultant colour change of the bead indicated the successful 
attachment of compound 166. 
To attach 4 and 79 to the sepharose bead, it was first necessary to attach a PEG linker to 
both compounds. A hydrophilic linker was chosen as the bead conjugate was to be used 
in an aqueous environment. Compound 4 was functionalised at the C2 position of the 
thiophene ring as the glucose uptake assay revealed that changes to the thiophene ring 
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were tolerated. A formyl group was introduced (147) so that the amino PEG linker 
could be attached via a reductive amination. A Staudinger reduction was performed on a 
diazido PEG3 linker (153) generating the mono amino-product 154 which was attached 
to 147 via a reductive amination. This gave compound 155 in a 76% yield. A Staudinger 
reduction was again used to convert the remaining azide into the primary amine with 
compound 156 isolated in a 43% yield. A similar synthetic approach was applied when 
attaching the PEG3 linker to 79, however as 79 contained a carboxylic acid, the mono 
amino PEG linker, compound 154, was attached by forming an amide bond and was 
followed by a Staudinger reduction to give compound 158 in a 25% yield. Immobilising 
the ligand-PEG conjugate on the sepharose bead was verified by the attachment of the 
coloured derivative, compound 166. The use of the beads in the identification of the 
secondary protein target is currently on-going. 
Compound 4 has recently shown, by a colleague on our research team, to stimulate the 
activity of the enzyme AMPK. The activation of AMPK has been proposed as a 
possible mechanism of action for the antidiabetic drug metformin. Activation of this 
enzyme has been shown to stimulate glucose uptake and decrease hepatic 
gluconeogenesis.38,39 Metformin is thought to activate AMPK through the inhibition of 
mitochondrial respiration by acting at Complex I. It is therefore possible that compound 
4, and other compounds active in the glucose uptake assay, are stimulating the uptake of 
glucose in muscles cells by acting on the mitochondrial enzyme Complex I. Further 
experiments are required to confirm this as the secondary protein target. 
A SAR study was subsequently performed on these two compounds with the compound 
2 derivative, compound 115, proving to be highly active in the glucose uptake assay. A 
number of derivatives were synthesised and are awaiting biological testing. 
The synthesis of these two structurally distinct compounds and their derivatives 
involved the synthesis of a number of substituted pyrazoles. Substituted β-ketonitriles 
and hydrazines were used in the synthesis of the substituted pyrazoles required for the 
synthesis of the compound 2 derivatives. β-Ketoesters and substituted hydrazines were 
used in the synthesis of the substituted pyrazoles necessary for the synthesis of the 
compound 3 derivatives. MW irradiation again proved to be useful, with a novel method 
for the synthesis of the pyrazoles, compounds 91 and 96, formed in good yields and 
short reaction times.  
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Compound 4 proved to be highly insoluble in aqueous solutions. Further animal studies, 
which required aqueous solutions of compound 4, were planned. As a result, a method 
for solubilising compound 4 in aqueous solutions was needed. The functionalised CD, 
HPBCD, was used and it was found that with twenty equivalents of the excipient, a 0.02 
M 5% aqueous DMSO solution of compound 4 could be prepared. Compound 4 was 
solubilised due to the formation an inclusion complex and non-inclusion complexes. 
The stoichiometry of the inclusion complex was found to be 1:1, compound 4:HPBCD. 
This was determined by means of a phase solubility diagram which demonstrated that 
the solubility of compound 4 increased linearly with increasing concentrations of 
HPBCD and indicated that the complex formed was an AL type complex. The phase 
solubility diagram was also used to calculate the binding constant K1:1 which was 
determined to be 34755 M-1. This indicated that a strong interaction was formed 
between compound 4 and the CD. Other analytical techniques, such as DSC, SEM and 
NMR were all used in the analysis of the inclusion complex. Results from these all 
confirmed the presence of a novel complex. 
In conclusion, this project has seen the identification, synthesis and testing of a number 
of novel and highly active compounds with the potential to act as antidiabetic agents.  
 
9.2 Future work 
This project has identified several compounds with the potential to act as antidiabetic 
agents. Future work will include the continuation of the SAR study of the active 
compounds and the biological evaluation of the compounds yet to be tested. This will 
allow the generation of even more accurate pharmacophore models and improved lead 
compounds. The optimization of compounds so as to improve their drug-likeness may 
also be necessary. 
Confirming the identity of the secondary protein target is required. This may involve the 
use of the Kosaka method where active compounds have been immobilized on an 
affinity column. The affinity column is then used to bind and identify the secondary 
protein target. Subsequent assay work, including possible assay development, will be 
needed to confirm the identity of the secondary protein target. 
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10.1 Instrumentation 
Reagents and reactants were purchased from Aldrich or Alfa Aesar and used as received 
unless otherwise stated. DCM was distilled over CaH2 and THF over Na wire and 
benzophenone. Anhydrous DMF was purchased from Sigma Aldrich  
All NMR spectra were recorded on a Bruker Avance spectrometer at a probe 
temperature of 25 °C, unless otherwise stated, operating at 300 MHz for the 1H nucleus 
and 75 MHz for the 13C nucleus. Proton and carbon signals were assigned with the aid 
of 2D NMR experiments (COSY, HSQC) and DEPT experiments for novel compounds. 
2D ROESY experiments were carried out in D2O on a Bruker Advance 500 
spectrometer at 500 MHz (Teagasc). High temperature NMR spectroscopy experiments 
were carried out by heating the probe. Spectra were recorded in CDCl3 unless otherwise 
stated, with Me4Si used as internal standard. Chemical shifts are given in ppm 
downfield form the internal standard and coupling constants are given in Hz. 13C NMR 
spectra were recorded with complete proton decoupling.  
Melting point analyses were carried out using a Stewart Scientific SMP11 melting point 
apparatus and are uncorrected.  
High resolution mass spectra (HR-MS) were performed on an Agilent-L 1200  Series 
coupled to a 6210 Agilent Time-of-Flight (TOF) mass spectrometer equipped with an 
both a positive and negative electronspray source. Infrared spectra were obtained in the 
region 4000-400 cm-1 on a Nicolet Impact 400D spectrophotometer or using a Perkin 
Elmer 2000 FTIR spectrometer. SEM was performed using a Hitachi S-3200-N with a 
tungsten filament and the sample was coated in gold. Differential Scanning Calorimetry 
was carried out on a Perkin Elmer Pyris 6.0. Scintillation counts were obtained using a 
Wallac MicroBeta scintillation counter (Perkin Elmer). 
Flash column chromatography was performed using silica gel 60 (Merck, 0.040-0.063 
mm). Analytical thin layer chromatography was carried out on aluminium sheets pre-
coated with Merck TLC Silica gel 60 F254. Developed sheets were visualised using a 
portable UVltec CV-006 lamp (λ = 254, 365 nm) or the appropriate stain. 
† = Compounds synthesised that are awaiting biological evaluation. 
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10.2 General procedure for amide bond formation using HOBt and TBTU. 
Carboxylic acid, HOBt, TBTU, anhydrous NEt3 and anhydrous DMF were placed in an 
oven-dried Schlenk tube under a N2 atmosphere. The resulting solution was stirred at rt 
for 15 mins. A second Schlenk tube was prepared containing amine and anhydrous 
DMF under a N2 atmosphere. The resulting solution was transferred, via a cannula, to 
the first Schlenk tube containing the carboxylic acid. The solution was stirred under N2 
and the reaction progress monitored by TLC. The DMF was removed under reduced 
pressure and the resulting oil was acidified (pH = 3) using a 0.1 M aqueous HCl 
solution. The aqueous mixture was extracted with DCM (20 mL, followed by 4 x 10 
mL). The organic combined layers were washed with a saturated aqueous solution of 
Na2CO3 (3 x 20 mL) and brine (3 x 20 mL) and dried over MgSO4 and the residue was 
purified using flash chromatography.  
10.3 Synthesis of 1-(4-(3-chloro-5-(trifluoromethyl)pyridin-2-yl)piperazin-1-yl)-3-
(thiophen-2-ylthio)propan-1-one (RTB70) (1) 
 
Prepare from 1-(3-chloro-5-(trifluoromethyl)pyridin-2-yl)piperazine (698 mg, 2.63 
mmol) and compound 30 (450 mg, 2.39 mmol) using HOBt (698 mg, 2.63 mmol), 
TBTU (767 mg, 2.63 mmol), anhydrous NEt3 (532 µL, 3.82 mmol) and anhydrous 
DMF (10 mL) and following the general procedure described in section 10.2. The 
reaction mixture was stirred overnight at room temperature under a N2 atmosphere. 
Purified using flash chromatography (3:2 EtOAc:n-hexane). The obtained product was 
dissolved in a minimal amount of DCM and Pet. Ether was added until precipitation 
began. The solution and the precipitate was stored at -20 °C overnight, and the resultant 
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crystals collected by vacuum filtration and washed with cold Pet. Ether (~ 20 mL) to 
give white needles, 2.1 g (71%).  
1H NMR: (300 MHz, CDCl3) δ 8.41-8.40 (m, 1H, H3), 7.79-7.78 (m, 1H, H1), 7.35 
(dd, J = 5.3 Hz, J = 1.2 Hz, 1H, H9), 7.45 (m, 1H, H7), 7.00-6.97 (m, 1H, H8), 3.78-
7.75 (m, 2H*), 3.58-3.55 (m, 2H*), 3.50-3.46 (m, 4H*), 3.11  (t, J = 7.1 Hz, 2H,  H5), 
2.68 (t, J = 7.1 Hz, 2H, H4) *Piperazine. 13C NMR: (75 MHz, CDCl3) δ 170.1 (C=O), 
160.1 (C2), 143.6 (q, J = 4.1 Hz, C3), 136.7 (q, J = 3.3 Hz, C1), 134.6 (C6, C9), 130.2 
(C7), 128.3 (C8), 123.8 (q, J = 270.0 Hz, CF3), 121.7 (CCl), 121.2 (q, J =  33.0 Hz, C-
CF3), 49.1 (C*), 45.7 (C*), 42.0 (C*), 34.8 (C5), 33.9 (C4) *Piperazine. Rf: 0.5 (3:2, 
EtOAc:n-hexane). HR-MS: calcd for C17H18ClF3N3OS2 m/z: [M + H]
+, 436.0526; 
found: 436.0531 [Diff (ppm) = 1.14]. IR (KBr): 2840 (C-H), 1636 (C=O), 1603 (C=C), 
1452 (C=C), 1323 (C-F), 1248 (C-N), 706 (C-Cl) cm-1. m.p.: 70-72 °C. Anal. calcd for 
C17H17ClF3N3OS2; C, 46.84; H, 3.93; N, 9.64% found: C, 46.51; H, 3.84; N, 9.30%. 
10.4 General procedure for the formation of a pyrimidinone ring using AcOH. 
Substituted amino pyrazole was dissolved in AcOH and a substituted β-ketoester was 
added. The reaction mixture was heated at reflux. After cooling to rt, the AcOH was 
removed under reduced pressure. The resulting residue was triturated using EtOAc to 
give a white solid. 
10.5 Synthesis of 5-(3,5-bis(trifluoromethyl)phenyl)-2-(tert-butyl)pyrazolo[1,5-
a]pyrimidin-7(4H)-one (RTB69) (2) 
 
Prepared from 5-amino-3-(tert-butyl)-1H-pyrazole (124 mg, 0.89 mmol) and ethyl 3-
(3,5-bis(trifluoromethyl)phenyl)-3-oxopropanoate (321 mg, 0.97 mmol) using HOAc (8 
mL) and following the procedure described in section 10.4. The reaction mixture was 
heated at reflux for 4 hrs and the residue triturated using EtOAc (2 mL) to give a white 
solid, 65 mg (18%). 
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1H NMR: (300 MHz, d6-DMSO) δ 12.59 (bs, 1H, NH), 8.52 (s, 2H, H6, H8), 8.34 (s, 
1H, H7), 6.30 (s, 1H, H2), 6.14 (s, 1H, H5), 1.34 (s, 9H, (CH3)3). 13C NMR: (75 MHz, 
d6-DMSO) δ 165.0 (C=O), 156.1 (C4), 146.2 (C3), 142.0 (C1), 134.9 (C9), 130.8 (q, J = 
32.7 Hz), C-CF3), 128.3 (C6, C8), 124.2 (C7), 123.2 (q, J = 269.8 Hz, CF3), 95.4 (C2), 
86.2 (C5), 2.4 (C(CH3)3), 29.9 ((CH3)3). Rf: 0.6 (1:9, MeOH:DCM). HR-MS: calcd for 
C18H16F6N3O m/z: [M + H]
+, 404.1192; found 404.1178 [Diff(ppm) = -3.46]. IR (KBr): 
3390 (N-H), 2969 (C-H), 1667 (C=O), 1616 (C=C), 1577 (N-H), 1488 (C=C), 1280 (C-
F), 1139 (C-N) cm-1 m.p.:  Above 300 °C. 
10.6 Synthesis of 4-(thiophen-3-yl)-1-(4-(4-(trifluoromethyl)phenyl)piperazin-1-
yl)butan-1-one (RTB86) (3) 
 
Compound 131 (54 mg, 0.24 mmol), HOBt (333 mg, 0.27 mmol), TBTU (79 mg, 0.27 
mmol), anhydrous NEt3 (53 µL, 0.38 mmol) and anhydrous DMF (5 mL) were placed in 
an oven-dried Schlenk tube under a N2 atmosphere. The resulting solution was stirred at 
rt for 15 mins. A second Schlenk tube, containing 137 (52 mg, 0.27 mmol) and 
anhydrous NEt3 (36 µL, 0.26 mmol) in anhydrous DMF (2 mL) under a N2 atmosphere, 
was stirred at rt. After 15 mins, the resulting solution was transferred, via a cannula, to 
the first Schlenk tube containing the carboxylic acid. The solution was stirred under N2 
and the reaction progress monitored by TLC. After 24 hrs, the DMF was removed under 
reduced pressure and the resulting oil was acidified (pH = 3) using a 0.1 M aqueous HCl 
solution. The aqueous mixture was extracted with DCM (20 mL, followed by 4 x 10 
mL). The organic combined layers were washed with a saturated aqueous solution of 
Na2CO3 (3 x 20 mL) and brine (3 x 20 mL) and dried over MgSO4 and the residue was 
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purified using flash chromatography (3:2 EtOAc:n-hexane) to give  a white solid, 74 mg 
(77%). 
1H NMR: (300 MHz, CD3CN, T = 60 °C) δ 7.67 (s, 1H, N=CH), 7.55-7.51 (m, 2H, H5, 
H6), 7.31-7.20 (m, 4H, H4, H7, Ar), 7.00-6.93 (m 2H, Ar), 4.57-4.36 (m, 2H*), 3.86 (s, 
3H, OCH3), 3.32-3.21 (m, 1H, Ar-CH), 3.11-3.03 (m, 2H*), 2.37 (s, 3H, CH3), 1.89-
1.85 (m, 2H*), 1.77-1.63 (m, 2H*).*Piperidine. 13C NMR: (75 MHz, CD3CN, T = 60 
°C) δ 164.0 (C=O), 162.3 (d, J = 245.7 Hz, C-F), 157.0 (C-OCH3), 139.7 (C1), 138.6 
(N=CH), 135.8 (d, J = 3.0 Hz, C8), 133.7 (C3), 127.3 (d, J = 8.8 Hz, C4, C7), 127.1 
(Ar), 126.5 (Ar), 120.6 (Ar), 116.6 (C2), 115.8 (d, J = 22.9 Hz, C5, C6), 111.1 (Ar), 
55.2 (OCH3), 45.3 (C*), 35.7 (Ar-C), 31.9 (C*), 10.5 (CH3).*Piperidine. Rf: 0.4 (3:2, 
EtOAc:n-hexane). HR-MS: calcd for C23H25FN3O2 m/z: [M + H]
+, 394.1925; found: 
394.1944 [Diff(ppm) = 4.76]. IR (KBr): 2940 (CH), 1612 (C=O), 1392 (C-F), 1236 (C-
N), 1220 (O-CH3) cm
-1. m.p.: 140-141 °C. 
10.7 Synthesis of 4-(thiophen-2-yl)-1-(4-(4-(trifluoromethyl)phenyl)piperazin-1-
yl)butan-1-one (RTC1) (4) 
 
Prepared from compound 33 (100 mg, 0.43 mmol) and 4-(2-thienyl)butyric acid (50 µL, 
0.34 mmol), using HOBt (58 mg, 0.43 mmol), TBTU (140 mg, 0.43 mmol), anhydrous 
NEt3 (100 µL, 0.69 mmol) and anhydrous DMF (3 mL) and following the general 
procedure described in section 10.2. The reaction mixture was stirred at rt overnight 
under a N2 atmosphere. Purified using flash chromatography (3:2 EtOAc:n-hexane). 
The obtained product was dissolved in minimal DCM (~ 1 mL) and Pet. Ether was 
added until precipitation began. The solution was stored at -20 °C overnight, and the 
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resultant crystals collected by vacuum filtration and washed with cold Pet. Ether (~ 20 
mL) to give white needles, 104 mg (80%).  
1H NMR: (300 MHz, CDCl3) δ 7.49 (d, J = 8.7 Hz, 2H, H1, H5), 7.12 (dd, J = 5.1 Hz, 
1.2 Hz, 1H, H12), 6.94-6.90 (m, 3H, H2, H4, H11), 6.82-6.80 (m, 1H, H10), 3.76 (m, 
2H*), 3.56 (m, 2H*), 3.24 (m, 4H*), 2.91 (t, J = 7 Hz,  2H, H8), 2.38 (t, J = 7 Hz, 2H, 
H6), 2.11-2.0 (m, 2H, H7). *Piperazine. 13C NMR: (75 MHz, CDCl3) δ 171.0 (C=O), 
152.9 (C3), 144.3 (C9), 126.8 (C10), 126.5 (q, J = 3.6 Hz, C1, C5), 124.61 (q,  J = 
270.0 Hz, CF3) 124.60 (C12), 123.2 (C11), 121.2 (q, J = 33.0 Hz, C-CF3), 115.0 (C2, 
C4), 48.3 (C*), 48.1 (C*), 45.0 (C*), 41.1 (C*), 31.9 (C6), 29.2 (C8), 26.9 (C7). 
*Piperazine. Rf: 0.5 (3:2, EtOAc:n-hexane). HR-MS: calcd for C19H22F3N2OS m/z: [M 
+ H]+, 383.1399; found: 383.1402 [Diff(ppm) = 0.61]. IR (KBr): 2924 (C-H), 1653 
(C=O), 1612 (C=C), 1438(C=C), 1331 (C-F), 1233 (C-N) cm-1. m.p.: 90-94 °C. Anal. 
calcd for C19H22F3N2OS; C, 59.67; H, 5.54; N, 7.33% found: C, 59.71; H, 5.14; N, 
7.17%. 
10.8 Synthesis of 1-(thiophen-2-yl)-4-(4-(4-(trifluoromethyl)phenyl)piperazin-1-
yl)butane-1,4-dione (RTC2) (5) 
 
Prepared from compound 33 (100 mg, 0.43 mmol) and 4-oxo-4-(thiophen-2-yl)butanoic 
acid (63 mg, 0.34 mmol), using HOBt (58 mg, 0.43 mmol), TBTU (140 mg, 0.43 
mmol), anhydrous NEt3 (100 µL, 0.69 mmol) and anhydrous DMF (3 mL) and 
following the general procedure described in section 10.2. The reaction mixture was 
stirred at rt overnight under an N2 atmosphere. Purified using flash chromatography (3:2 
EtOAc:n-hexane) to give an off white solid, 109 mg (81%). 
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1H NMR: (300 MHz, CDCl3) δ 7.81 (dd, J = 4.8 Hz, J = 1.0 Hz, 1H, H10), 7.63 (dd, J 
= 4.8 Hz, J = 1.0 Hz, 1H, H12), 7.50 (d, J = 8.7 Hz, 2H, H1, H5), 7.15-7.12 (m, 1H, 
H11), 6.92 (d, J = 8.7 Hz, 2H, H2, H4), 3.80-3.71 (m, 4H*), 3.54-3.31 (m, 4H*), 3.27-
3.24 (m, 2H, H7), 2.82 (t, J = 6.6 Hz, 2H, H6).*Piperazine. 13C NMR: (75 MHz, 
CDCl3) 191.9 (C=O), 170.1 (N-C=O), 152.9 (C3), 143.8 (C9), 133.6 (C12), 128.1 
(C11), 132.1 (C10), 126.5 (q, J = 3.7 Hz, C1, C5), 126.1 (q, J = 33.0 Hz, C-CF3), 124.6 
(q, J = 266.7 Hz, CF3), 114.9 (C2, C4), 48.2 (C*), 48.0 (C*), 45.0 (C*), 41.3 (C*), 34.1 
(C6), 27.0 (C7).*Piperazine. Rf: 0.5 (3:2, EtOAc:n-hexane). HR-MS: calcd for 
C38H38F6N4O4S2Na m/z: [2M + Na]
+, 815.2131; found: 815.2127 [Diff(ppm) = -0.51]. 
IR (KBr): 2954 (C-H), 1647 (C=O), 1612 (N-C=O), 1325 (C-F), 1230 (C-N) cm-1. 
m.p.: 172-176 °C. Anal. calcd for C19H19F3N2O2S; C, 57.56; H, 4.83; N, 7.07% found: 
C, 57.34; H, 4.62; N, 6.89%. 
10.9 Synthesis of 1-(thiophen-2-yl)-4-(4-(5-(trifluoromethyl)pyridin-2-
yl)piperazin-1-yl)butane-1,4-dione (RTC3) (6) 
  
Prepared from 1-(5-(trifluoromethyl)pyridin-2-yl)piperazine (99 mg, 0.43 mmol) and 4-
oxo-4-(thiophen-2-yl)butanoic acid (63 mg, 0.34 mmol), using HOBt (58 mg, 0.43 
mmol), TBTU (140 mg, 0.43 mmol), anhydrous NEt3 (100 µL, 0.69 mmol) and 
anhydrous DMF (3 mL) and following the general procedure described in section 10.2. 
The reaction mixture was stirred overnight at room temperature under a N2 atmosphere. 
Purified using flash chromatography (3:2 EtOAc:n-hexane) to give an off white solid, 
85 mg, (63%). 
1H NMR: (300 MHz, CDCl3) δ 8.41 (s, 1H, H4), 7.81-7.80 (m, 1H, H10), 7.68-7.63 (m, 
2H, H1, H8), 7.15-7.12 (m, 1H, H9), 6.65 (d, J = 9.1 Hz, 1H, H2), 3.79-3.61 (m, 8H*), 
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3.34 (t, J = 6.9 Hz, 2H, H6), 2.82 (t, J = 6.9 Hz, 2H, H5). *Piperazine. 13C NMR: (75 
MHz, CDCl3) δ 191.9 (C=O), 170.3 (N-C=O), 160.0 (C3), 147.7 (q, J = 4.1 Hz, C4), 
143.8 (C7), 134.7 (q, J = 3.3 Hz, C1), 133.5 (C8), 132.1 (C10), 128.1 (C9), 124.4 (q, J = 
268.5 Hz, CF3), 15.8 (q, J  = 32.0 Hz, C-CF3), 105.6 (C2), 44.9 (C*), 44.6 (C*), 44.2 
(C*), 41.9 (C*), 34.1 (C6), 27.1 (C5). *Piperazine. Rf: 0.5 (3:2, EtOAc:n-hexane). HR-
MS: calcd for C36H37F6N6O4S2 m/z: [2M + H]
+, 795.2216; found: 795.2223 [Diff (ppm) 
= 0.78]. IR (KBr):  1655 (C=O), 1638 (N-C=O), 1329 (C-F), 1102 (C-N) cm-1. m.p.: 
204-206 °C. Anal. calcd for C18H18F3N3O2S1; C, 54.40; H, 4.57; N, 10.58 found; C, 
54.39; H, 4.27; N, 10.59. 
10.10 Synthesis of 1-(4-(3-chloro-5-(trifluoromethyl)pyridin-2-yl)piperazin-1-yl)-4-
(thiophen-2-yl)butane-1,4-dione (RTC4) (7) 
 
Prepared from 1-(3-chloro-5-(trifluoromethyl)pyridin-2-yl)piperazine (114 mg, 0.43 
mmol) and 4-oxo-4-(thiophen-2-yl)butanoic acid (63 mg, 0.34 mmol), using HOBt (58 
mg, 0.43 mmol), TBTU (140 mg, 0.43 mmol), anhydrous NEt3 (100 µL, 0.69 mmol) 
and anhydrous DMF (3 mL) and following the general procedure described in section 
10.2. The reaction mixture was stirred overnight at room temperature under a N2 
atmosphere. Purified using flash chromatography (3:2 EtOAc:n-hexane) to give an off 
white solid, 102 mg (70%). 
1H NMR: (300 MHz, CDCl3) δ 8.41-8.40 (m, 1H, H3), 7.82-7.79 (m, 2H, H1, H7), 7.64 
(dd, J = 4.0 Hz, J = 1.0 Hz, 1H, H9), 7.15-7.12 (m, 1H, H8), 3.80-3.72 (m, 4H*), 3.57-
3.54 (m, 2H*), 3.50-3.47 (m, 2H*), 3.33 (t, J = 9.0 Hz, 2H, H5), 2.84 (t, J = 9.0 Hz, 2H, 
H4).*Piperazine. 13C NMR: (75 MHz, CDCl3) 191.9 (C=O), 170.2 (N-C=O), 159.5 
(C2), 143.9 (C6), 143.1 (q, J = 3.7 Hz, C3), 136.1 (q , J = 3.3 Hz, C1), 133.5 (C9), 
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132.1 (C7), 128.6 (q, J = 270.1 Hz, CF3), 128.1 (C8), 121.1 (q, J = 33.2 Hz, C-CF3), 
121.0 (C-Cl), 48.5 (C*), 45.1 (C*), 41.5 (C*), 34.2 (C5), 27.1 (C4). *Piperazine. Rf: 0.5 
(3:2, EtOAc:n-hexane). HR-MS: calcd for C18H18F3N3O2SCl m/z: [M + H]
+, 432.0755; 
found: 432.0765 [Diff(ppm) = 2.31]. IR (KBr): 2915 (C-H), 1647 (C=O), 1604 (N-
C=O), 1416(C=C), 1319 (CF), 1231 (C-N), 844 (C-Cl) cm-1. m.p.: 102-104 °C. Anal. 
calcd for C18H17F3N3O2SCl ; C, 50.06; H, 3.97; N, 9.73% found: C, 50.14; H, 3.77; N, 
9.47%. 
10.11 Synthesis of 4-(thiophen-3-yl)-1-(4-(5-(trifluoromethyl)pyridin-2-
yl)piperazin-1-yl)butan-1-one (RTC5) (8) 
 
Prepared from 1-(5-(trifluoromethyl)pyridin-2-yl)piperazine (99 mg, 0.43 mmol) and 4-
(2-thienyl)butyric acid (50 µL, 0.34 mmol) using HOBt (58 mg, 0.43 mmol), TBTU 
(140 mg, 0.43 mmol), anhydrous NEt3 (100 µL, 0.69 mmol) and anhydrous DMF (3 
mL) and following the general procedure described in section 10.2. The reaction 
mixture was stirred overnight at room temperature under a N2 atmosphere. Purified 
using flash chromatography (3:2 EtOAc:n-hexane) to give an off white solid, 104 mg 
(80%). 
1H NMR: (300 MHz, CDCl3) δ 8.41-8.40 (m, 1H, H4), 7.66 (dd, J = 9.0 Hz, J = 2.0 Hz, 
1H, H1), 7.13 (dd, J = 5.1 Hz, J = 1.2 Hz, 1H, H11), 6.94-6.91 (m, 1H, H10), 6.82-6.80 
(m, 1H, H9), 6.64 (d, J = 8.7 Hz, 1H, H2), 3.75-3.69 (m, 4H*), 3.61-3.58 (m, 2H*), 
3.54-3.51 (m, 2H*), 2.93 (t, J = 7.2 Hz, 2H, H7), 2.41 (t, J = 7.2, 2H, H5), 2.11-2.03 (m, 
2H, H6).*Piperazine. 13C NMR: (75 MHz, CDCl3) 171.2 (C=O), 160.4 (C3), 145.6 (q, 
J = 4.0 Hz, C4), 144.3 (C8), 134.6 (q, J = 4.0 Hz, C1), 126.8 (C10), 124.56 (C9), 124.52 
(q, J = 268.5 Hz, CF3),  123.2 (C11), 115.6 (q, J = 33.0 Hz, C-CF3), 105.6 (C2), 44.9 
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(C*), 44.6 (C*), 44.3 (C*), 40.9 (C*), 31.9 (C7), 29.2 (C5), 26.9 (C6).*Piperazine. Rf: 
0.5 (3:2, EtOAc:n-hexane). HR-MS: calcd for C18H21F3N3OS m/z: [M + H]
+, 384.1352; 
found: 384.1365 [Diff(ppm) = 3.38]. IR (KBr): 2953 (C-H), 1646 (C=O), 1611 (C=C), 
1417 (C=C), 1325 (C-F), 1231 (C-N) cm-1. m.p.: 107-109 °C. Anal. calcd for 
C18H20F3N3OS; C, 56.38; H, 5.26; N, 10.96% found: C, 56.64; H,4.95 ; N, 10.89%. 
10.12 Synthesis of 1-(4-(3-chloro-5-(trifluoromethyl)pyridin-2-yl)piperazin-1-yl)-4-
(thiophen-2-yl)butan-1-one (RTC6) (9) 
 
Prepared from 1-(3-chloro-5-(trifluoromethyl)pyridin-2-yl)piperazine (114 mg, 0.43 
mol) and 4-(2-thienyl)butyric acid (50 µL, 0.34 mmol) using HOBt (58 mg, 0.43 
mmol), TBTU (140 mg, 0.43 mmol), anhydrous NEt3 (100 µL, 0.69 mmol) and 
anhydrous DMF (3 mL) and following the general procedure described in section 10.2. 
The reaction mixture was stirred overnight at room temperature under a N2 atmosphere.  
The reaction mixture was stirred at rt overnight. Purified using flash chromatography 
(3:2 EtOAc:n-hexane) to give a grey solid, 90 mg (64%). 
1H NMR: (300 MHz, CDCl3) δ 8.40-8.39 (m, 1H, H3), 7.79 (d, J = 1.8 Hz, 1H, H1), 
7.13 (dd, J = 5.1 Hz, J = 1.2 Hz, 1H, H10), 6.94-6.91 (m, 1H, H9), 6.82-6.80 (m, 1H, 
H8), 3.37-3.375 (m, 2H*), 3.58-3.55 (m, 2H*), 3.49-3.45 (m, 4H*), 2.93 (t, J = 7.2 Hz, 
2H, H6), 2.41 (t, J = 7.2 H, 2H, H4), 2.11-2.01 (m, 2H, H5).*Piperazine. 13C NMR: (75 
MHz, CDCl3) 171.2 (C=O), 159.5 (C2), 144.3 (C7), 143.1 (q, J = 3.7 Hz, C3), 136.1 (q, 
J = 3.7 Hz, C1), 126.8 (C9), 124.5 (C8), 123.23 (C10), 123.21 (q, J = 270.0 Hz, CF3), 
121.1 (C-Cl), 120.59 (q, J = 33.0 Hz, C-CF3), 48.6 (C*), 45.2 (C*), 41.3 (C*), 32.0 
(C4), 29.2 (C6), 26.9 (C5).*Piperazine. Rf: 0.5 (3:2, EtOAc:n-hexane). HR-MS: calcd 
for C18H20F3N3OSCl m/z: [M + H]
+, 418.0971; found 418.0962 [Diff(ppm) = 3.12]. IR 
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(KBr):  2913 (C-H), 1650 (C=O), 1604 (C=C), 1438 (C=C), 1319 (C-F), 1251 (C-N), 
845 (C-Cl) cm-1. m.p.: 52-54 °C. Anal. calcd for C18H19F3N3OSCl; C, 51.73; H, 4.58; 
N, 10.06% found; C, 52.17; H, 4.66 ; N, 9.89%.  
10.13 Synthesis of 3-(thiophen-2-ylthio)-1-(4-(4-(trifluoromethyl)phenyl)piperazin-
1-yl)propan-1-one (RTC7) (10)  
 
Prepared from 1-(4-trifluoromethyl phenyl)piperazine (50 mg, 0.22 mmol) and 
compound 30 (37 mg, 0.19 mmol) using HOBt (30 mg, 0.22 mmol), TBTU (70 mg, 
0.22 mmol), anhydrous NEt3 (44 µL, 0.32 mmol) and anhydrous DMF (2 mL) and 
following the general procedure described in section 10.2. The reaction mixture was 
stirred overnight at room temperature under a N2 atmosphere. Purified using flash 
chromatography (3:2 EtOAc:n-hexane) to give a brown solid, 47 mg (63%).  
1H NMR: (300 MHz, CDCl3) δ 7.48 (d, J = 8.7 Hz, 2H, H1, H5), 7.34 (dd, J = 5.4 Hz, J 
= 1.2 Hz, 1H, H11), 7.13 (dd, J = 3.6 Hz, J = 1.2 Hz, 1H, H9), 6.99-6.96 (m, 1H, H10), 
6.89 (d, J = 8.7 Hz, 2H, H2, H4), 3.77-3.74 (m, 2H*), 3.57-3.53 (m, 2H*), 3.27-3.22 
(m, 2H*), 3.11 (t, J = 7.2 Hz, 2H, H7), 2.67 (t, J = 7.2 Hz, 2H, H6).*Piperazine. 13C 
NMR: (75 MHz, CDCl3) δ 169.4 (C=O), 152.8 (C3), 133.97 (C9), 133.95 (C8), 129.5 
(C11), 127.7 (C10), 126.5 (q, J = 3.3 Hz, C1, C5), 124.5 (q, J = 270.0 Hz, CF3), 121.3 
(q, J = 33.0 Hz, C-CF3), 115.0 (C2, C4), 48.3 (C*), 48.0 (C*), 44.9 (C*), 41.2 (C*), 
34.1 (C6), 33.2 (C7). *Piperazine. Rf: 0.5 (3:2, EtOAc:n-hexane). HR-MS: calcd for 
C18H20F3N2OS2 m/z: [M + H]
+, 401.0964; found: 401.0969 [Diff (ppm) = 1.22]. IR 
(KBr): 2923 (C-H), 1643 (C=O), 1616 (C=C), 1465 (C=C), 1339 (C-F), 1231 (C-N) 
cm-1. m.p.: 86-90 °C. 
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10.14 Synthesis of 1-(4-(2-chloro-4-(trifluoromethyl)phenyl)piperazin-1-yl)-4-
(thiophen-2-yl)butan-1-one (RTC8) (11)  
 
Prepared from compound 31 (90 mg, 0.34 mmol) and 4-(2-thienyl)butyric acid (46 µL, 
0.32 mmol) using HOBt (47 mg, 0.34 mmol), TBTU (111 mg, 0.34 mmol), anhydrous 
NEt3 (47 µL, 0.51 mmol) and anhydrous DMF (3 mL) and following the general 
procedure described in section 10.2. The reaction mixture was stirred overnight at room 
temperature under a N2 atmosphere. Purified using flash chromatography (3:2 
EtOAc:Pet. Ether) to give an orange solid, 106 mg (80%). 
1H NMR: (300 MHz, CDCl3) δ 7.63-7.62 (m, 1H, H1), 7.47 (dd, J = 8.7 Hz, J = 1.2 Hz, 
1H, H4), 7.12 (dd, J = 5.1 Hz, J = 1.0 Hz, 1H, H11), 7.05 (d, J = 8.7 Hz, 1H, H3), 6.93-
6.90 (m, 1H, H10), 6.81-6.80 (m, 1H, H9), 3.82-3.79 (m, 2H*), 3.61-3.57 (m, 2H*), 
3.07-3.04 (m, 4H*), 2.93 (t, J = 7.2 Hz, 2H, H7), 2.41 (t, J = 7.2 Hz, 2H, H5), 2.10-2.01 
(m, 2H, H6).*Piperazine. 13C NMR: (75 MHz, CDCl3) δ 171.1 (C=O), 151.6 (C2), 
144.3 (C8), 128.8 (C-Cl), 127.9 (q, J = 3.3 Hz, C1) 126.8 (C14), 125.9 (q, J = 33.0 Hz, 
C-CF3), 124.8 (q, J = 3.5 Hz, C4), 124.5 (C13), 123.5 (q, J = 270.0 Hz, CF3), 123.2 
(C15), 120.3 (C3), 51.2 (C*), 50.7 (C*),45.5 (C*), 41.6 (C*), 32.0 (C5), 29.2 (C7), 27.0 
(C6).*Piperazine. HR-MS: calcd for C19H21F3N2OSCl m/z: [M + H]
+, 417.101; found: 
401.1017 [Diff (ppm) = 1.74]. IR (KBr): 2888 (C-H), 1633 (C=O), 1612 (C=C), 1436 
(C=C), 1334 (C-F), 1231 (C-N), 700 (C-Cl) cm-1. Rf : 0.7 (3:2, EtOAc:Pet. Ether). m.p.: 
84-86 °C. Anal. calcd for C19H20F3N2OSCl; C, 54.74; H, 4.84; N, 6.72% found; C, 
54.73; H, 4.60 ; N, 6.58%. 
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10.15 Synthesis of 3-(thiophen-2-ylthio)propanoic acid (RD23) (30)115 
 
Thienyl-2-thiol (48 µl, 0.52 mmol), 3-bromopropanoic acid (80 mg, 0.52 mmol) and 
NaHCO3 (130 mg, 1.56 mmol) were heated at reflux in EtOH (2 mL) and reaction 
progress monitored by TLC. After, 5 hrs the reaction mixture was allowed to cool to rt 
and the EtOH was removed under reduced pressure. The residue was dissolved in H2O 
(2 mL) and washed with Et2O (10 mL, followed by 3 x 10 mL). The aqueous layer was 
acidified to pH = 6 with 0.1 M aqueous HCl and extracted with Et2O (10 mL, followed 
by 3 x 10 mL). The combined organic layers were concentrated under reduced pressure 
and the residue was purified using flash chromatography (1:9, MeOH:DCM) to give a 
clear oil,  83 mg (85%). 
1H NMR: (300 MHz, CDCl3) δ 10.86 (br s, 1H, OH), 7.37 (dd, J = 5.1 Hz, J = 1.2 Hz, 
1H, H7), 7.16 (dd, J = 2.4 Hz, J = 1.2 Hz, 1H, H6), 6.97-6.99 (m, 1H, H5), 2.97 (t, J = 
7.2 Hz, 2H, H2), 2.64 (t, J = 7.2 Hz, 2H, H1). 1H NMR data matches literature data.115 
HR-MS: calcd for C7H9O2S2 m/z: [M + H]
+, 189.0038; found: 189.0040 [Diff (ppm) = 
1.05]. Rf: 0.3 (1:9, MeOH:DCM). 
10.16 Synthesis of 1-(2-chloro-4-(trifluoromethyl)phenyl)piperazine (RD20) (31) 
 
3-Chloro-4-fluorobenzotrifluoride (100 µL, 0.75 mmol) and piperazine (129 mg, 1.5 
mmol) were dissolved in NMP (3 mL) and heated at 200 º C for 30 mins in a microwave 
reactor. The reaction mixture was purified using flash chromatography (1:9, 
MeOH:DCM) to give a clear oil, 120 mg (61%). 
1H NMR: (300 MHz, CDCl3) δ 7.61-7.60 (m, 1H, H1), 7.45 (dd, J = 8.4, J = 1.5 Hz, 
1H, H4), 7.07 (d, J = 8.4 Hz, 1H, H3), 3.09 (bs, 8H*), 2.68 (bs, 1H, NH).*Piperazine. 
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1H NMR data matches literature data.84 HR-MS: calcd for C11H13ClF3N2 m/z: [M + 
H]+, 264.06; found: 265.0711 [Diff (ppm) = -1.13]. Rf: 0.2 (1:9, MeOH:DCM). 
10.17 Synthesis of 1-(4-(trifluoromethyl)phenyl)piperazine (RD269) (33) 
 
1-chloro-4-(trifluoromethyl)benzene (1.59 mL, 11.91 mmol) and piperazine (2.00 g, 
23.82 mmol) were dissolved in NMP (5 mL) and heated at 200 º C for 30 mins in a 
microwave reactor. The reaction mixture was purified using flash chromatography (1:9, 
MeOH:DCM) to give a white solid, 1.42 g (50%). 
1H NMR: (300 MHz, CDCl3) δ 7.47 (d, J = 8.4 Hz, 2H, H1, H4), 6.91 (d, J = 8.4 Hz, 
2H, H2, H3), 3.24-3.20 (m, 4H*), 3.03-3.00 (m, 2H*), 1.68 (bs, 1H, NH).*Piperazine. 
1H NMR data matches literature data.205 HR-MS: calcd for C11H14F3N2 m/z: [M + H]
+, 
231.1104; found:  231.1105 [Diff (ppm) = 0.69]. Rf: 0.2 (1:9, MeOH:DCM). 
10.18 Synthesis of 1-(2-bromo-4-(trifluoromethyl)phenyl)piperazine (RD71) (34) 
 
3-Bromo-4-chlorobenzotrifluoride (200 µL, 1.33 mmol) and piperazine (229 mg, 2.66 
mmol) were dissolved in NMP (2 mL) and heated at 200 º C for 30 mins in a microwave 
reactor. Compound 34 was used without further purification. Clear oil, 95 mg (23%, 
crude yield).  
1H NMR: (300 MHz, CDCl3) δ 7.46 (d, J = 7.8 Hz, 1H, H3), 7.25-7.20 (m, 2H, H1, 
H2), 3.10 (m, 8H*), 2.95 (bs, 1H, NH).*Piperazine. Rf: 0.2 (1:9, MeOH:DCM). 
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10.19 Synthesis of 1-(p-tolyl)piperazine (RD115) (35)85 
 
p-Toluidine (1.00 g, 9.34 mmol) and bis(2-chloroethyl)amine.HCl (1.66 g, 9.34 mmol) 
were dissolved in bis(2-methoxyethyl)ether (20 mL) and heated at reflux for 16 hrs after 
which the reaction mixture was allowed to cool to rt. Et2O was added until the 
precipitation of a brown solid was complete. The precipitate was collected via vacuum 
filtration and washed with Et2O (3 x 20 mL) to give the HCl salt of compound 35, 
which was then dissolved in a 5% aqueous NaOH solution (10 mL) and stirred at rt for 
4 hrs. The aqueous layer was extracted with DCM (10 mL, followed be 3 x 10 mL) and 
and the combined organic layers were dried over MgSO4. The solvent was removed 
under reduced pressure and the residue was purified using flash chromatography to give 
a brown solid, 221 mg (13%). 
1H NMR: (300 MHz, CDCl3) δ 7.07 (d, J = 8.4 Hz, 2H, H1, H5), 6.83 (d, J = 8.4 Hz, 
2H, H2, H4), 3.14-3.13 (m, 4H*), 3.08-3.05 (m, 4H*), 2.26 (s, 3H, CH3).*Piperazine. 
1H NMR data matches literature data.85 HR-MS: calcd for C11H17N2 m/z: [M + H]
+, 
177.1385 found: 177.1394 [Diff (ppm) = 4.5]. Rf: 0.2 (1:9, MeOH:DCM). 
10.20 Synthesis of 1-(4-(tert-butyl)phenyl)piperazine (RD268) (36)85 
 
4-(tert-Butyl)aniline (500 µL, 3.1 mmol) and bis(2-chloroethyl)amine.HCl were 
dissolved in bis(2-methoxyethyl)ether (750 µL) and heated at reflux for 16 hrs after 
which the reaction mixture was allowed to cool to rt. Et2O was added until the 
precipitation of a brown solid occurred. The precipitate was collected via vacuum 
filtration and washed with Et2O (3 x 10 mL) to give the HCl salt of compound 36. The 
HCl salt (470 mg, 1.84 mmol) was dissolved in 5% aqueous NaOH solution (10 mL) 
and stirred at rt for 4 hrs. The aqueous layer was extracted with DCM (10 mL, followed 
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be 3 x 10 mL) and dried over MgSO4.The solvent was removed under reduced pressure 
to give a brown solid, 352 mg (87%), which was used without any further purification.  
1H NMR: (300 MHz, CDCl3) δ 7.33 (d, J = 8.0 Hz, 2H, H1, H4), 6.91 (d, J = 8.0 Hz, 
2H, H2, H3), 3.15-3.12 (m, 4H*), 3.05-3.02 (m, 4H*), 1.33 (s, 9H, (CH3)3).*Piperazine. 
1H NMR data matches literature data.206 HR-MS: calcd for C12H18NO m/z: [M + H]
+, 
192.1383; found: 192.1388 [Diff (ppm) = 2.60].Rf: 0.2 (1:9, MeOH:DCM). 
10.21 Synthesis of piperazin-1-yl(4-(trifluoromethyl)phenyl)methanone (RD212) 
(37) 
 
4-(Trifluoromethyl)benzoyl chloride (2.5 mL, 16.82 mmol) in DCM (15 mL) was added 
dropwise to a solution of piperazine (2.89g, 33.64 mmol) in DCM (15 mL) at 0 °C. The 
temperature of the reaction mixture was adjusted gradually to rt and stirred overnight at 
rt. The solvent was removed under reduced pressure and the residue was purified using 
flash chromatography (1:9; MeOH:DCM) to give an off white solid, 110 mg (3%). Bis-
substituted product main species isolated. 
1H NMR: (300 MHz, CDCl3, T = 45 °C) δ 7.62 (d, J = 8.7 Hz, 2H, H1, H4), 7.44 (d, J 
= 8.7 Hz, 2H, H2, H3), 3.49 (bs 4H*), 2.80 (bs, 4H*).*Piperazine. Rf: 0.2 (1:9, 
MeOH:DCM). HR-MS: calcd for C12H14F3N2O m/z: [M + H]
+, 259.1053; found: 
259.1065 [Diff(ppm) = 4.60]. 
10.22 Synthesis of 1-(4-(trifluoromethyl)benzyl)piperazine (RD265) (38)117 
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To a solution of  1-(bromomethyl)-4-(trifluoromethyl)benzene (500 mg, 0.21 mmol) in 
toluene (10 mL) was added piperazine (723 mg, 0.84 mmol) and the solution was 
heated at 85 °C. After 2 hrs the solution was cooled to rt, filtered and the filtrate was 
concentrated under reduced pressure. The residue was dissolved in 2 M aqueous HCl 
(10 mL) and the aqueous layer was washed with DCM (10 mL, followed by 2 x 10 mL). 
The pH of the aqueous layer was adjusted to pH = 14 with solid NaOH and extracted 
with DCM (10 mL, followed by 2 x 10 mL). The combined organic layers were dried 
over MgSO4 and concentrate under reduced pressure. The residue was purified using 
flash chromatography (1:9 MeOH:DCM) to give a clear oil, 293 mg (57%). 
1H NMR: (300 MHz, CD3OD) δ 7.57 (d, J = 8.1 Hz, 2H, H1, H5), 7.48 (d, J = 8.1 Hz, 
2H, H2, H4), 3.59 (s, 2H, ArCH2), 2.85-2.82 (m, 4H*), 2.42 (bs, 4H*).*Piperazine. 
Rf: 0.2 (1:9, MeOH:DCM). HR-MS: calcd for C12H16F3N2 m/z: [M + H]
+, 245.1260; 
found: 245.1260 [Diff(ppm) = 0.00]. 
10.23 Synthesis of 1-(4-(4-fluorophenyl)piperazin-1-yl)-4-(thiophen-2-yl)butan-1-
one (RTC11) (40) 
 
Prepared from 1-(4-fluorophenyl)piperazine (100 mg, 0.55 mmol) and 4-(2-
thienyl)butyric acid (73 µL, 0.50 mmol) using HOBt (74 mg, 0.55 mmol), TBTU (177 
mg, 0.55 mmol), anhydrous NEt3 (123 µL, 0.80 mmol) and anhydrous DMF (5 mL) and 
following the general procedure described in section 10.2. The reaction mixture was 
stirred overnight at room temperature under a N2 atmosphere. Purified using flash 
chromatography (3:2 EtOAc:n-hexane) to give an off white solid, 119 mg (71%). 
1H NMR: (300 MHz, CDCl3) δ 7.12-7.10 (m, 1H, H12), 6.99-6.80 (m, 5H, H1, H2, H4, 
H5, H11), 6.80-6.79 (m, 1H, H10), 3.78-3.74 (m, 2H*), 3.56-3.50 (m, 2H*), 3.05-3.02 
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(m, 4H*), 2.91 (t, J = 7.2 Hz, 2H, H8), 2.39 (t, J = 7.2 Hz, 2H, H6), 2.09-1.99 (m, 2H, 
H7).*Piperazine. 13C NMR: (75 MHz, CDCl3) 170.9 (C=O), 157.5 (d, J = 238.2 Hz, C-
F), 147.6 (d, J = 2.2 Hz, C3), 144.1 (C9), 126.8 (C12), 124.5 (C10), 123.2 (C11), 118.6 
(d, J = 7.3 Hz, C2, C4), 115.6 (d, J = 22.5 Hz, C1, C5), 50.7 (C*), 50.4 (C*), 45.4 (C*), 
41.5 (C*), 32.0 (C6), 29.2 (C8), 27.0 (C7).*Piperazine. HR-MS: calcd for 
C18H22FN2OS m/z: [M + H]
+, 333.1431; found 333.1431 [Diff (ppm) = 0.00]. IR 
(KBr): 2824 (C-H), 1651 (C=O), 1511 (C=C), 1437 (C=C) 1334 (C-F), 1203 (C-N) cm-
1. Rf: 0.6 (3:2, EtOAc:n-hexane). m.p.: 84-86 °C. Anal. calcd for C18H21FN2OS; C, 
54.74; H, 4.84; N, 6.72% found; C, 54.73; H, 4.60 ; N, 6.58%. 
10.24 Synthesis of 4-(thiophen-2-yl)-1-(4-(2-(trifluoromethyl)phenyl)piperazin-1-
yl)butan-1-one (RTC20) (41) 
 
Prepared from 1-(2-(trifluoromethyl)phenyl)piperazine (83 µL, 0.43 mmol) and 4-(2-
thienyl)butyric acid (57 µL, 0.39 mmol) using HOBt (58 mg, 0.43 mmol), TBTU (139 
mg, 0.43 mmol), anhydrous anhydrous NEt3 (60 µL, 0.62 mmol) and DMF (4 mL) and 
following the general procedure described in section 10.2. The reaction mixture was 
stirred overnight at room temperature under a N2 atmosphere. Purified using flash 
chromatography (3:2 EtOAc:n-hexane) to give an light yellow oil, 74 mg (63%). 
1H NMR: (300 MHz, CDCl3) δ 7.65-7.62 (m, 1H, H1), 7.55-7.50 (m, 1H, H4), 7.33-
7.23 (m, 2H, H2, H3), 7.12 (dd, J = 5.1 Hz, J = 1.2 Hz, 1H, H12), 6.94 (m, 1H, H11), 
6.82-6.81 (m, 1H, H10), 3.81-3.72 (m, 2H*), 3.55-3.52 (m, 2H*), 2.95-2.81 (m, 2H, H6, 
4H*), 2.41 (t, J = 7.2 Hz, 2H, H8), 2.10-2.02 (m, 2H, H7).*Piperazine. 13C NMR: (75 
MHz, CDCl3) δ 171.1 (C=O), 151.7 (C2), 144.4 (C9), 132.8 (C5), 127.4 (q, J = 28.3 Hz, 
C-CF3), 127.2 (q, J = 3.3 Hz, C1), 126.8 (C11), 125.4 (C12), 124.5 (C10), 124.0 (C4), 
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123.9 (q, J = 271.1 Hz, CF3), 123.1 (C3) 53.7 (C*), 53.0 (C*), 46.0 (C*), 42.0 (C*), 
32.1 (C8), 29.3 (C6), 27.0 (C7).*Piperazine. Rf: 0.5 (3:2, EtOAc:n-hexane). HR-MS: 
calcd for C19H22F3N2OS m/z: [M + H]
+, 383.1399; found: 383.1412 [Diff (ppm) = 
3.39]. IR (neat): 2919 (C-H), 1646 (C=O), 1587 (C=C), 1453 (C=C), 1315 (C-F), 1144 
(C-N) cm-1 
10.25 Synthesis of 1-(4-(4-nitrophenyl)piperazin-1-yl)-4-(thiophen-2-yl)butan-1-one 
(RTC22) (42) 
 
Prepared from 1-(4-nitrophenyl)piperazine (150 mg, 0.72 mmol) and 4-(2-
thienyl)butyric acid (95 µL, 0.66 mmol) using HOBt (97 mg, 0.72 mmol), TBTU (232 
mg, 0.72 mmol), anhydrous NEt3 (146 µL, 1.05 mmol) and anhydrous DMF (6 mL) and 
following the general procedure described in section 10.2. The reaction mixture was 
stirred overnight at room temperature under a N2 atmosphere. Purified using flash 
chromatography (7:3 EtOAc:DCM) to give an orange solid, 178 mg (75%). 
1H NMR: (300 MHz, CDCl3) δ 8.08 (d, J = 9.1 Hz, 2H, H1, H5), 7.11 (dd, J = 5.1 Hz, J 
= 1.2 Hz, 1H, H16), 6.93-6.90 (m, 2H, H15), 6.81-6.769 (m, 3H, H2, H4, H14), 3.81-
3.77 (m, 2H*), 3.71-3.68 (m, 2H*), 3.46-3.41 (m, 4H*), 2.92 (t, J = 7.2 Hz, 2H, H12), 
2.41 (t, J = 7.2 Hz, 2H, H10), 2.10-2.00 (m, 2H, H11).*Piperazine. 13C NMR: (75 
MHz, CDCl3) δ 171.2 (C=O), 154.3 (C3), 144.3 (C13), 138.6 (C-NO2), 126.8 (C14), 
125.9 (C1, C5), 124.5 (C15), 123.2 (C16), 112.7 (C2, C4), 46.7 (C*), 46.6 (C*), 44.5 
(C*), 40.7 (C*).*Piperazine. Rf: 0.7 (7:3, EtOAc:DCM). HR-MS: calcd for 
C18H22N3O3S m/z: [M + H]
+, 360.1376; found: 360.1387 [Diff (ppm) = 3.05]. IR 
(KBr): 2856 (C-H), 1650 (C=O), 1600 (C=C), 1584 (NO), 1479 (C=C), 1324 (NO) cm-
1. m.p.:  120-121 °C. 
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10.26 Synthesis of 1-(4-(3,5-bis(trifluoromethyl)phenyl)piperazin-1-yl)-4-(thiophen-
2-yl)butan-1-one (RTC26) (43)  
 
Prepared from 1-(3,5-bis(trifluoromethyl)phenyl)piperazine (192 mg, 0.65 mmol) and 
4-(2-thienyl)butyric acid (85 µL, 0.58 mmol) using HOBt (87 mg, 0.65 mmol), TBTU 
(207 mg, 0.65 mmol), anhydrous NEt3 (129 µL, 0.92 mmol) and anhydrous DMF (5 
mL) and following the general procedure described in section 10.2. The reaction 
mixture was stirred overnight at room temperature under a N2 atmosphere. Purified 
using flash chromatography (3:2 EtOAc:n-hexane) to give an off white solid, 103 mg 
(39%). 
1H NMR: (300 MHz, CDCl3) δ 7.33 (s, 1H, H1), 7.26 (s, 2H, H2), 7.13 (dd, J = 5.1 Hz, 
J = 1.2 Hz, H10), 6.96-6.91 (m, 1H, H9), 6.82-6.80 (m, 1H, H8), 3.82-3.79 (m, 2H*), 
3.61-3.58 (m, 2H*), 3.29-3.25 (m, 4H*), 2.93 (t, J = 7.2 Hz, 2H, H6), 2.41 (t, J = 7.2 
Hz, 2H, H4), 2.11-2.01 (m, 2H, H5).*Piperazine. 13C NMR: (75 MHz, CDCl3) δ 170.0 
(C=O), 150.2 (C3), 143.2 (C7), 131.4 (q, J = 33.2 Hz,   C-CF3), 125.8 (C9), 123.5 (C8), 
122.4 (q, J = 271.4 Hz, CF3), 122.2 (C10), 114.1 (m, C2), 117.0 (m, C1), 47.3 (C*), 
47.2 (C*), 43.8 (C*), 40.0 (C*), 30.8 (C6), 28.1 (C4), 25.8 (C5).*Piperazine. Rf: 0.5 
(1:1, EtOAc:n-hexane). HR-MS: calcd for C20H21F6N2OS m/z: [M + H]
+, 451.1273; 
found: 451.1288 [Diff (ppm) = 3.25]. IR (KBr): 2950 (C-H), 1657 (C=O), 1621 (C=C), 
1440 (C=C), 1315 (C-F), 1275 (C-N) cm-1. m.p.:  46-49 °C. Anal. calcd for 
C20H20F6N2OS; C, 53.33; H, 4.48; N, 6.22% found: C, 53.41; H, 4.25; N, 6.27%. 
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10.27 Synthesis of 1-(4-methylpiperazin-1-yl)-4-(thiophen-2-yl)butan-1-one (RTC 
32) (44) 
 
Prepared from 1-methylpiperazine (71 µL, 0.65 mmol) and 4-(2-thienyl)butyric acid (85 
µL, 0.59 mmol) using HOBt (87 mg, 0.65 mmol), TBTU (207 mg, 0.65 mmol), 
anhydrous NEt3 (90 µL, 0.94 mmol) and anhydrous DMF (4 mL) and following the 
general procedure described in section 10.2. The reaction mixture was stirred overnight 
at room temperature under a N2 atmosphere. Purified using flash chromatography (3:2, 
EtOAc:n-hexane) to give a yellow oil, 15 mg (10%).  
1H NMR: (300 MHz, CDCl3) δ 7.12 (dd, J = 5.1 Hz, J = 1.2 Hz, 1H, H7), 6.93-6.90 (m, 
1H, H6), 6.80-6.79 (m, 1H, H5), 3.64-3.61 (m, 2H*), 3.43-3.40 (m, 2H*), 2.90 (t, J = 
7.2 Hz, 2H, H3), 2.38-2.33 (m, 4H*, 2H, H1), 2.29 (s, 3H, CH3), 2.07-1.97 (m, 2H, 
H2).*Piperazine. 13C NMR: (75 MHz, CDCl3) δ 170.9 (C=O), 144.4 (C4), 126.7 (C6), 
124.4 (C5), 123.1 (C7), 55.1 (C*), 54.7 (C*), 46.0 (CH3), 45.3 (C*), 41.4 (C*), 32.0 
(C1), 29.3 (C3), 27.0 (C2).*Piperazine. Rf: 0.5 (3:2, EtOAc:n-hexane). HR-MS: calcd 
for C13H21N2OS m/z: [M + H]
+, 253.1369; found: 253.1375 [Diff (ppm) = 2.37]. IR 
(neat): 1630 (C=O), 1290 (C-N) cm-1. 
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10.28 Synthesis of 1-(4-(6-chloro-5-(trifluoromethyl)pyridin-2-yl)piperazin-1-yl)-4-
(thiophen-2-yl)butan-1-one (RTC44) (45)  
 
Prepared from 1-(6-chloro-5-(trifluoromethyl)pyridin-2-yl)piperazine (218 mg, 0.816 
mmol) and 4-(2-thienyl)butyric acid (100 µL, 0.68 mmol) using HOBt (110 mg, 0.82 
mmol), TBTU (262 mg, 0.82 mmol), anhydrous NEt3 (152 µL, 1.08 mmol) and 
anhydrous DMF (5 mL) and following the general procedure described in section 10.2. 
The reaction mixture was stirred overnight at room temperature under a N2 atmosphere. 
Purified using flash chromatography (3:2 EtOAc:Pet. Ether) to give a beige solid, 192 
mg (68%). 
1H NMR: (300 MHz, CDCl3) δ 7.67 (d, J = 9.0 Hz, 1H, H1), 7.11 (dd, J = 5.1 Hz, J = 
1.2 Hz, 1H, H10), 6.92-6.89 (m, 1H, H9), 6.80-6.79 (m, 1H, H8), 6.47 (d, J = 9.0 Hz, 
1H, H2), 3.72-3.67 (m, 4H*), 3.59-3.57 (m, 2H*), 3.52-3.49 (m, 2H*), 2.91 (t, J = 8.1 
Hz, 2H, H4), 2.39 (t, J = 7.2 Hz, 2H, H6), 2.09-1.99 (m, 2H, H5). *Piperazine. 13C 
NMR: (75 MHz, CDCl3) δ 171.2 (C=O), 158.9 (C7), 147.5 (C-Cl), 144.2 (C7), 137.7 
(q, J = 3.3 Hz, C1), 126.8 (C9), 124.5 (C8), 123.2 (q, J = 268.8 Hz, CF3), 123.2 (C10), 
112.7 (q, J = 33.0 Hz, C-CF3), 103.2 (C2), 43.7 (C*), 43.4 (C*), 43.1 (C*), 39.7 (C*), 
30.9 (C6), 28.1 (C4), 25.6 (C7). *Piperazine. Rf: 0.5 (3:2, EtOAc:n-hexane). HR-MS: 
calcd for C18H20ClF3N3OSCl m/z: [M + H]
+, 418.0962; found: 418.0953 [Diff (ppm) = -
2.23]. IR (KBr): 2904 (C-H), 1678 (C=O), 1641 (C=C), 1416 (C=C), 1321 (C-F), 1120 
(C-N), 698 (C-Cl) cm-1. m.p.: 62-64 °C. 
Chapter 10                                           Experimental 
244 
 
10.29 Synthesis of 1-(4-(2-bromo-4-(trifluoromethyl)phenyl)piperazin-1-yl)-4-
(thiophen-2-yl)butan-1-one (RTC62) (46) 
 
Prepared from compound 34 (95 mg, 0.30 mmol) and 4-(2-thienyl)butyric acid (41 µL, 
0.28 mmol) using HOBt (41 mg, 0.30 mmol), TBTU (98 mg, 0.30 mmol), anhydrous 
NEt3 (62 µL, 0.44 mmol) and anhydrous DMF (2 mL) and following the general 
procedure described in section 10.2. The reaction mixture was stirred overnight at room 
temperature under a N2 atmosphere. Purified using flash chromatography (1:1 
EtOAc:Pet. Ether to give a clear oil, 60 mg (50%).  
1H NMR: (300 MHz, CDCl3) δ 7.82 (s, 1H, H1), 7.53 (d, J = 8.7 Hz, 1H, H4), 7.12 (dd, 
J = 5.1 Hz, J = 1.2 Hz, 1H, H11), 7.05 (d, J = 8.7 Hz, 1H, H3), 6.94-6.91 (m, 1H, H10), 
6.82-6.80 (m, 1H, H9), 3.83-3.80 (m, 2H*), 3.61-3.58 (m, 2H*), 3.06-3.03 (m, 4H*), 
2.93 (t, J = 7.2 Hz, 2H, H7), 2.41 (t, J = 7.2 Hz, 2H, H5), 2.11-2.01 (m, 2H, H6). 
*Piperazine. 13C NMR: (75 MHz, CDCl3) 171.1 (C=O), 153.0 (C2), 144.3 (C8), 131. 
(q, J = 3.3 Hz, C1), 126.8 (C10), 126.3 (q, J = 33.0 Hz, C-CF3), 125.5 (q, J = 3.3 Hz, 
C4), 124.5 (C9), 123.3 (q, J = 270.0 Hz, CF3), 123.2 (C11), 120.8 (C3), 119.4 (C-Br), 
51.6 (C*), 51.1 (C*), 45.6 (C*), 41.6 (C*), 32.0 (C7), 29.3 (C5), 27.0 (C6). *Piperazine. 
Rf: 0.8 (1:1 EtOAc:Pet. Ether). HR-MS: calcd for C19H20BrF3N2OSK m/z: [M + K]
+, 
499.0063; found: 499.0079 [Diff (ppm) = 3.1]. IR (neat): 2914 (C-H), 1645 (C=O), 
1605 (C=C), 1432 (C=C), 1324 (C-F), 1122 (C-N), 680 (C-Br) cm-1. 
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10.30 Synthesis of 1-(4-phenylpiperazin-1-yl)-4-(thiophen-2-yl)butan-1-one 
(RTC162) (47) 
 
Prepared from 1-phenylpiperazine (100 µL, 0.64 mmol) and 4-(2-thienyl)butyric acid 
(84 µL, 0.58 mmol) using HOBt (86 mg, 0.64 mmol), TBTU (205 mg, 0.64 mmol), 
anhydrous NEt3 (129 µL, 0.93 mmol) and anhydrous DMF (5 mL) and following the 
general procedure described in section 10.2. The reaction mixture was stirred overnight 
at room temperature under a N2 atmosphere. Purified using flash chromatography (3:2 
EtOAc:n-hexane) to give a dark red oil, 109 mg (59%). 
1H NMR: (300 MHz, CDCl3) δ 7.34-7.28 (m, 2H, Ar), 7.15 (dd, J = 5.1 Hz, J = 1.2 Hz, 
1H, H8), 6.97-6.93 (m, 4H, Ar, H7), 6.85-6.84 (m, 1H, H6), 3.82-3.78 (m, 2H*), 3.58-
3.55 (m, 2H*), 3.17-3.14 (m, 4H*), 2.96 (t, J = 7.2 Hz, 2H, H4), 2.43 (t, J = 7.2 Hz, 2H, 
H2), 2.14-2.04 (m, 2H, H3).*Piperazine. 13C NMR: (75 MHz, CDCl3) δ 171.0 (C=O), 
151.0 (C1), 144.5 (C5), 129.2 (Ar), 126.8 (C6), 124.5 (C8), 123.2 (C7), 120.5 (Ar), 
116.6 (Ar), 49.7 (C*), 49.3 (C*), 45.4 (C*), 41.5 (C*), 32.0 (C6), 29.3 (C8), 27.0 (C7). 
Rf: 0.6 (3:2, EtOAc:n-hexane). HR-MS: calcd for C18H23N2OS m/z: [M + H]
+, 
315.1526; found: 315.1527 [Diff (ppm) = 0.45]. IR (KBr): 2915 (C-H), 1669 (C=O), 
1643 (C=C), 1439 (C=C), 1230 (C-N) cm-1. 
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10.31 Synthesis of 4-(thiophen-2-yl)-1-(4-(p-tolyl)piperazin-1-yl)butan-1-one 
(RTC33) (48)† 
 
Prepared from compound 35 (221 mg, 1.25 mmol) and 4-(2-thienyl)butyric acid (166 
µL,  1.13 mmol) using HOBt (168 mg, 1.25 mmol), TBTU (401 mg, 1.25 mmol), 
anhydrous NEt3 (253 µL, 1.82 mmol) and anhydrous DMF (5mL) and following the 
general procedure described in section 10.2. The reaction mixture was stirred overnight 
at room temperature under a N2 atmosphere. Purified using flash chromatography (1:1 
EtOAc:n-hexane) to give an orange oil, 102 mg (24%). 
1H NMR: (300 MHz, CDCl3) δ 7.16-7.11 (m, 3H, H1, H5, H12), 6.97-6.94 (m, 1H, 
H11), 6.88-6.83 (m, 3H, H2, H4, H10), 3.81-3.78 (m, 2H*), 3.59-3.55 (m, 2H*), 3.12-
3.08 (m, 4H*), 2.95 (t, J = 7.2 Hz, 2H, H8), 2.43 (t, J = 7.2 Hz, 2H, H6), 2.31 (s, 3H, 
CH3), 2.13-2.04 (m, 2H, H7).*Piperazine. 13C NMR: (75 MHz, CDCl3) δ 170.9 (C=O), 
148.8 (C3), 144.4 (C9), 130.1 (C-CH3), 129.7 (C1, C5), 126.8 (C10), 124.5 (C12), 
123.2 (C11), 117.0 (C2, C4), 50.3 (C*), 49.9 (C*), 45.5 (C*), 41.5 (C*), 32.0 (C6), 29.3 
(C8), 27.0 (C7), 20.5 (CH3).*Piperazine. Rf: 0.3 (1:1, EtOAc:n-hexane). HR-MS: calcd 
for C19H25N2OS m/z: [M + H]
+, 329.1682; found: 329.1687 [Diff (ppm) = 1.56]. IR 
(neat): 2917 (C-H), 1642 (C=O), 1439 (C=C), 1232 (C-N) cm-1. 
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10.32 Synthesis of 1-(4-(4-(tert-butyl)phenyl)piperazin-1-yl)-4-(thiophen-2-
yl)butan-1-one (RTC72) (49)† 
 
Prepared from compound 36 (200 mg, 0.92 mmol) and 4-(2-thienyl)butyric acid (121 
µL, 0.83 mmol) using HOBt (123 mg, 0.92 mmol), TBTU (294 mg, 0.92 mmol), 
anhydrous NEt3 (185 µL, 1.33 mmol) and anhydrous DMF (6 mL) and following the 
general procedure described in section 10.2. The reaction mixture was stirred overnight 
at room temperature under a N2 atmosphere. Purified using flash chromatography (3:2 
EtOAc:n-hexane) to give a deep red oil, 292 mg (86%). 
1H NMR: (300 MHz, CDCl3) δ 7.35 (d, J = 8.1 Hz, 2H, H3, H5), 7.16 (dd, J = 5.1 Hz, J 
= 1.2 Hz, H13), 6.97-6.95 (m, 1H, H12), 6.91 (d, J = 8.1 Hz, H2, H6), 6.86-6.84 (m, 
1H, H11), 3.83-3.79 (m, 2H*), 3.60-3.57 (m, 2H*), 3.16-3.13 (m, 4H*), 2.96 (t, J = 7.2 
Hz, 2H, H9), 2.45 (t, J = 7.2 Hz, 2H, H7), 2.14-2.03 (m, 2H, H8), 1.34 (s, 9H, (CH3)3). 
*Piperazine. 13C NMR: (75 MHz, CDCl3) δ 171.1 (C=O), 148.5 (C4), 144.4 (C10), 
143.4 (C1), 126.8 (C12), 126.4 (C5, C3), 124.5 (C11), 123.3 (C13), 116.0 (C6, C2), 
50.0 (C*), 49.7 (C*), 45.5 (C*), 41.6 (C*), 34.0 (C(CH3)3), 32.0 (C7), 31.4 ((CH3)3), 
29.3 (C9), 27.0 (C8). *Piperazine. Rf: 0.5 (3:2, EtOAc:Pet. Ether). HR-MS: calcd for 
C22H31F3N2OS m/z: [M + H]
+, 371.2152; found 371.2170 [Diff (ppm) = 4.84]. IR 
(neat): 2961 (C-H), 1643 (C=O), 1610 (C=C), 1450 (C=C), 1229 (C-N) cm-1. 
Chapter 10                                           Experimental 
248 
 
10.33 Synthesis of 4-(thiophen-2-yl)-1-(4-(4-(trifluoromethyl)benzoyl)piperazin-1-
yl)butan-1-one (RTC86) (50)† 
 
Prepared from compound 37 (50 mg, 0.19 mmol) and 4-(2-thienyl)butyric acid (34 µL, 
0.17 mmol) using HOBt (27 mg, 0.19 mmol), TBTU (61 mg, 0.19 mmol), anhydrous 
NEt3 (38 µL, 0.28 mmol) and anhydrous DMF (3 mL) and following the general 
procedure described in section 10.2. The reaction mixture was stirred overnight at room 
temperature under a N2 atmosphere. Purified using flash chromatography (1:1 
EtOAc:Pet. Ether) to give a clear oil, 36 mg (50%). 
1H NMR: (300 MHz, CDCl3) δ 7.70 (d, J = 8.4 Hz, 2H, H1, H5), 7.52 (d, J = 8.4 Hz, 
2H, H2, H4), 7.13-7.11 (m, 1H, H14), 6.93-6.90 (m, 1H, H13), 6.82-6.76 (m, 1H, H12), 
3.74-3.39 (m, 8H*), 2.91 (t, J = 7.1 Hz, 2H, H10), 2.38 (bs, 2H, H8), 2.08-1.98 (m, 2H, 
H9).*Piperazine. 13C NMR: (75 MHz, CDCl3) δ 171.2 (C6), 169.1 (C7), 144.1 (C3), 
138.6 (C11), 132.0 (q, J = 32.7 Hz, C-CF3), 127.4 (C2, C4), 126.8 (C13), 125.7 (q, J = 
3.3 Hz, C1, C5), 124.5 (C12), 123.6 (q, J = 270.0 Hz, CF3), 123.3 (C14), 47.4 (C*), 
45.1 (C*), 42.2 (C*), 41.6 (C*), 31.9 (C8), 29.1 (C10), 26.8 (C9).*Piperazine. Rf: 0.5 
(1:1, EtOAc:Pet. Ether). HR-MS: calcd for C20H22F3N2O2S m/z: [M + H]
+,411.1349; 
found: 411.1355 [Diff (ppm) = 1.52]. IR (neat): 2952 (C-H), 1650 (C=O), 1631 (C=C), 
1433 (C=C), 1324 (C-F), 1161 (C-N) cm-1. 
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10.34 Synthesis of 4-(thiophen-2-yl)-1-(4-(4-(trifluoromethyl)benzyl)piperazin-1-
yl)butan-1-one (RTC95) (51)† 
 
Prepared from compound 38 (293 mg, 1.19 mmol) and 4-(2-thienyl)butyric acid (158 
µL, 1.08 mmol) using HOBt (162 mg, 1.19 mmol) TBTU (385 mg, 1.19 mmol), 
anhydrous NEt3 (167 µL, 1.73 mmol) and anhydrous DMF (8 mL) and following the 
general procedure described in section 10.2. The reaction mixture was stirred overnight 
at room temperature under a N2 atmosphere. Purified using flash chromatography (1:1 
EtOAc:Pet. Ether) to give an orange oil, 302 mg (73%). 
1H NMR: (300 MHz, CDCl3) δ 7.57 (d, J = 8.1 Hz, 2H, H1, H5), 7.4 (d, J = 8.1 Hz, 2H, 
H2, H4), 7.09 (dd, J = 5.1 Hz, J = 1.0 Hz, 1H, H13), 6.79-6.78 (m, 1H, H12), 6.79-6.78 
(m, 1H, H11), 3.64-3.61 (m, 2H*), 3.54 (s, 2H, H6), 3.42-3.38 (m, 2H*), 2.89 (t, J =7.9 
Hz, 2H, H9), 2.42-2.37 (m, 4H*), 2.34 (t, J = 7.5 Hz, 2H, H7), 2.06-1.96 (m, 2H, 
H8).*Piperazine. 13C NMR: (75 MHz, CDCl3) δ 171.0 (C=O), 144.4 (C3), 141.8 (C10), 
129.4 (q, J = 31.0 Hz, C-CF3), 129.2 (C11), 126.7 (C13), 125.2 (q, J = 3.3 Hz, C1, C5), 
124.5 (C12), 124.2 (q, J = 270.0 Hz, CF3), 123.1 (C2, C4), 62.1 (C6), 53.0 (C*), 52.7 
(C*), 45.3 (C*), 41.4 (C*), 41.4 (C*), 32.0 (C7), 29.2 (C9), 27.0 (C8).*Piperazine. Rf: 
0.5 (1:1, EtOAc:Pet. Ether). HR-MS: calcd for C20H24F3N2OS m/z: [M + H]
+, 
398.1587; found: 98.1604 [Diff (ppm) = 4.50]. IR (neat): 2940 (C-H), 1638 (C=O), 
1616 (C=C), 1439 (C=C), 1326 (C-F), 1164 (C-N) cm-1. 
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10.35 Synthesis of 1-(4-cyclohexylpiperazin-1-yl)-4-(thiophen-2-yl)butan-1-one 
(RTC13) (52) 
 
Prepared from 1-cyclohexylpiperazine (150 mg, 0.89 mmol) and 4-(2-thienyl)butyric 
acid (118 µL, 0.81 mmol) using HOBt (120 mg, 0.89 mmol), TBTU (285 mg, 0.89 
mmol), anhydrous NEt3 (180 µL, 1.29 mmol) and anhydrous DMF (6 mL) and 
following the general procedure described in section 10.2. The reaction mixture was 
stirred overnight at room temperature under a N2 atmosphere. Purified using flash 
chromatography (3:2 EtOAc:n-hexane) to give an orange solid, 76 mg (70%). 
1H NMR: (300 MHz, CDCl3) δ 7.10 (d, J = 4.8 Hz, 1H, H7), 6.92-6.89 (m, 1H, H6), 
6.79-6.78 (m, 1H, H5), 3.63-3.60 (m, 2H*), 3.42-3.39 (m, 2H*), 2.89 (t, J = 7.5 Hz, 2H, 
H3), 2.54-2.51 (m, 4H*), 2.37-2.26 (m, 3H, H1, N-CH), 2.06-1.98 (m, 2H, H2), 1.84-
1.78 (m, 4H, Cy), 1.26-1.11 (m, 6H, Cy).*Piperazine.  13C NMR: (75 MHz, CDCl3) δ 
170.7 (C=O), 144.4 (C4), 126.7 (C6), 124.4 (C5), 123.1 (C7), 63.6 (N-CH), 49.2 (C*), 
48.6 (C*), 45.8 (C*), 41.8 (C*), 32.0 (C3), 29.3 (C1), 28.7 (Cy), 27.0 (C2), 26.1 (Cy), 
25.7 (Cy).*Piperazine. Rf: 0.5 (3:2, EtOAc:n-hexane). HR-MS: calcd for C18H29N2OS 
m/z: [M + H]+, 321.1995; found: 321.005 [Diff (ppm) = 3.10]. IR (KBr): 2928 (C-H), 
1634 (C=O), 1233 (C-N) cm-1 m.p.: 33-35 °C. 
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10.36 Synthesis of 4-(thiophen-2-yl)-N'-(4-(trifluoromethyl)phenyl)butane 
hydrazide (RTC21) (53) 
 
Prepared from (4-(trifluoromethyl)phenyl)hydrazine (195 mg, 1.11 mmol) and 4-(2-
thienyl)butyric acid (149 µL, 1.03 mmol) using HOBt (149 mg, 1.11 mmol), TBTU 
(356 mg, 1.11 mmol), anhydrous NEt3 (231 µL, 1.66 mmol) and anhydrous DMF (8 
mL) and following the general procedure described in section 10.2. The reaction 
mixture was stirred overnight at room temperature under a N2 atmosphere. Purified 
using flash chromatography (elution gradient 1:1 EtOAc:n-hexane to 3:2 EtOAc:n-
hexane) to give an off white solid, 235 mg (69%). 
1H NMR: (300 MHz, CDCl3) δ 7.44 (d, J = 8.7 Hz, 2H, H1, H5), 7.36 (bs, 1H, Ar-NH), 
7.15-7.14 (m, 1H, H12), 6.95-6.92 (m, 1H, H11), 6.83-6.78 (m, 3H, H2, H4, H10), 6.38 
(bs, 1H, HN-C=O), 2.91 (t, J = 7.2 Hz, 2H, H8), 2.31 (t, J = 7.2 Hz, 2H, H6), 2.11-2.02 
(m, 2H, H7). 13C NMR: (75 MHz, CDCl3) δ 172.7 (C=O), 150.7 (C3), 143.6 (C9), 
128.7 (q, J = 288.4 Hz, CF3), 126.9 (C11), 126.6 (q, J = 3.3 Hz, C1, C5), 124.7 (C10), 
123.4 (C12), 123.0 (q, J = 34.2 Hz, C-CF3), 112.7 (C2, C4), 32.9 (C8), 29.0 (C6), 26.9 
(C7). Rf: 0.3 (1:1, EtOAc:n-hexane). HR-MS: calcd for C15H16F3N2OS m/z: [M + H]
+, 
330.0975; found: 330.096 [Diff (ppm) = 4.83]. IR (KBr): 3309 (N-H), 2963 (C-H), 
1639 (C=O), 1614 (N-H), 1333 (C-F), 1104 (C-N) cm-1. m.p.:  110-112 °C. Anal. calcd 
for C15H15F3N2OS; C, 54.87; H, 4.60; N, 8.53% found: C, 54.44; H, 4.39; N, 8.09%. 
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10.37 Synthesis of 4-(thiophen-2-yl)-1-(4-(4-(trifluoromethyl)phenyl)piperidin-1-
yl)butan-1-one (RTC196) (54)  
 
4-(2-Thienyl)butyric acid (50 µL, 0.34 mmol), HOBt (51 mg, 0.38 mmol), TBTU (122 
mg, 0.38 mmol), anhydrous NEt3 (55 µL, 0.54 mmol) and anhydrous DMF (2 mL) were 
placed in an oven-dried Schlenk tube under a N2 atmosphere. The resulting solution was 
stirred at rt for 20 mins. A second Schlenk tube, containing 4-(4-
(trifluoromethyl)phenyl)piperidine.HCl (100 mg ,0.38 mmol) and anhydrous NEt3 (55 
µL, 0.54 mmol) in anhydrous DMF (2 mL) was stirred for 15 mins under a N2 
atmosphere before transfer, via a cannula, to the first Schlenk tube containing the 
carboxylic acid. The solution was stirred under N2 at rt. After 24 hrs, the DMF was 
removed under reduced pressure and the resulting oil was acidified (pH = 3) using a 0.1 
M aqueous HCl solution. The aqueous mixture was extracted with DCM (20 mL, 
followed by 4 x 10 mL). The organic combined layers were washed with a saturated 
aqueous solution of Na2CO3 (3 x 20 mL) and brine (3 x 20 mL) and dried over MgSO4 
and the residue was purified using flash chromatography (3:2 EtOAc:n-hexane) to give 
an off white solid, 63 mg (48%). 
1H NMR: (300 MHz, CDCl3) δ 7.56 (d, J = 8.7 Hz, 2H, H1, H5), 7.29 (d, J = 8.7 Hz, 
2H, H2, H4), 7.12 (dd, J = 5.1 Hz, J = 1.2 Hz, 1H, H12), 6.93-6.90 (m, 1H, H11), 6.82-
6.80 (m, 1H, H10), 4.84-4.80 (m ,1H, NCH), 3.94-3.90 (m, 1H, NCH), 3.14-3.06 (m, 
1H, NCH), 3.14-3.05 (m, 1H, NCH), 2.93 (t, J = 7.2 Hz, 2H, H8), 2.84-2.74 (m, 1H, 
ArCH), 2.67-2.58 (m, 1H, NCH), 2.41 (t, J = 7.2 Hz, 2H, H6),2.10-2.00 (m, 2H, H7), 
1.91-1.86 (m, 2H, CHCH2), 1.68-1.51 (m, 2H, CHCH2). 13C NMR: (75 MHz, CDCl3) δ 
170.8 (C=O), 149.1 (C3), 144.5 (C9), 128.8 (q, J = 32.2 Hz, C-CF3), 127.1 (C2, C4), 
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126.7 (C11), 125.5 (q, J = 3.3 Hz, C1, C5), 124.4 (C10), 124.1 (q, J = 270.4 Hz, CF3), 
123.1(C12), 46.0 (NCH2), 42.7 (ArCH), 42.1 (NCH2), 33.6 (CHCH2), 32.6 (CHCH2), 
32.2 (C6), 29.3 (C8), 27.1 (C7). HR-MS: calcd for C20H23F3NOS m/z: [M + H]
+, 
382.1447; found 382.1434 [Diff (ppm) = -3.39]. IR (KBr): 2947 (C-H), 1635 (C=O), 
1619 (C=C), 1437 (C=C), 1336 (C-F), 1119 (C-N) cm-1. m.p.: 48-49 °C. 
10.38 Synthesis of 5-(thiophen-2-yl)-1-(4-(4-(trifluoromethyl)phenyl)piperazin-1-
yl)pentan-1-one (RTC195) (55) 
 
Prepared from compound 33 (100 mg, 0.43 mmol) and 5-(thiophen-2-yl)pentanoic acid 
(72 mg, 0.39 mmol) using HOBt (58 mg, 0.43 mmol), TBTU (138 mg, 0.43 mmol), 
anhydrous NEt3 (86 µL, 0.62 mmol) and anhydrous DMF (4 mL) and following the 
general procedure described in section 10.2. The reaction mixture was stirred overnight 
at room temperature under a N2 atmosphere. Purified using flash chromatography (3:2 
EtOAc:n-hexane) to give an orange solid, 41 mg (25%).  
1H NMR: (300 MHz, CDCl3) δ 7.50 (d, J = 8.7 Hz, 2H, H1, H5), 7.09 (dd, J = 5.1 Hz, J 
= 1.2 Hz, 1H, H13), 6.92-6.88 (m, 3H, H2, H4, H12), 6.79-6.78 (m, 1H, H11), 3.79-
3.75 (m, 2H*), 3.61-3.58 (m, 2H*), 3.26-3.22 (m, 4H*), 2.89-2.85 (m, 2H, H9), 2.41-
2.63 (m, 2H, H6), 1.80-1.73 (m ,4H, H7, H8).*Piperazine. 13C NMR: (75 MHz, CDCl3) 
δ 171.3 (C=O), 152.9 (C3), 144.9 (C10), 126.7 (C12), 126.4 (q, J = 3.3 Hz, C1, C5), 
124.6 (q, J = 269.8 Hz, CF3), 124.2 (C11), 122.9 (C13), 121.3 (q, J = 32.0 Hz, C-CF3), 
115.0 (C2, C4), 48.3 (C*), 48.1 (C*), 45.1 (C*), 41.1 (C*), 32.9 (C6), 31.4 (C8), 29.6 
(C9), 24.6 (C7). *Piperazine. Rf: 0.6 (3:2, EtOAc:n-hexane). HR-MS: calcd for 
C20H24F3N2OS m/z: [M + H]
+, 397.1556; found: 397.1541 [Diff (ppm) = -3.75]. IR 
Chapter 10                                           Experimental 
254 
 
(KBr): 2930 (C-H), 1637 (C=O), 1614 (C=C), 1439 (C=C), 1331 (C-F), 1230 (C-N) 
cm-1. m.p.: 46-48 °C. 
10.39 Synthesis of 5-(thiophen-2-yl)-1-(4-(4-(trifluoromethyl)phenyl)piperazin-1-yl) 
pentan-1-one (RTC537) (56) 
  
Prepared from compound 33 (100 mg, 0.43 mmol) and 5-(thiophen-2-yl)pentanoic acid 
(77 mg, 0.34 mmol) using HOBt (58 mg, 0.43 mmol), TBTU (138 mg, 0.43 mmol), 
anhydrous NEt3 (87 µL, 0.63 mmol) and anhydrous DMF (4 mL) and following the 
general procedure described in section 10.2. The reaction mixture was stirred overnight 
at room temperature under a N2 atmosphere. Purified using flash chromatography (4:1 
EtOAc:n-hexane) to give a brown solid, 120 mg (75%). 
1H NMR: (300 MHz, CDCl3) δ 7.49 (d, J = 9.1 Hz, 2H, H1 H5), 7.08 (dd, J = 5.1 Hz, J 
= 1.2 Hz, 1H, H14), 6.92-6.88 (m, 3H, H2, H4, H13), 6.77-6.76 (m, 1H, H12), 3.78-
3.75 (m, 2H*), 3.62-3.59 (m, 2H*), 3.27-3.22 (m, 4H*), 2.83 (t, J = 7.2 Hz, 2H, H10), 
2.36 (t, J = 7.2 Hz, 2H, H6), 1.76-1.64 (m, 4H, H7, H9), 1.48-1.44 (m, 2H, 
H8).*Piperazine. 13C NMR: (75 MHz, CDCl3) δ 171.5 (C=O), 152.9 (C3), 145.3 (C11), 
126.7 (C13), 126.5 (q, J = 3.3 Hz, C1, C5), 124.1 (C12), 122.8 (C14), 124.6 (q, J = 
270.0 Hz, CF3), 121.7 (q,  J = 32.0 Hz, C-CF3), 114.9 (C2, C4), 48.3 (C*), 48.0 (C*), 
45.1 (C*), 41.1 (C*), 33.0 (C6), 31.5 (C7), 29.7 (C10), 28.8 (C9), 24.9 
(C8).*Piperazine. Rf: 0.5 (3:2, EtOAc:n-hexane). HR-MS: calcd for 
C42H50F6N4O2S2Na m/z: [2M + Na]
+, 843.3172; found: 843.3152  [Diff (ppm) = -2.27]. 
IR (KBr): 2926 (C-H), 1641 (C=O), 1613 (C=C), 1438 (C=C), 1332 (C-F), 1240 (C-N) 
cm-1. m.p.: 50-52 °C. 
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10.40 Synthesis of 1-(4-(4-(trifluoromethyl)phenyl)piperazin-1-yl)octan-1-one 
(RTC533) (57) 
 
Prepared from compound 33 (100 mg, 0.43 mmol) and octanoic acid (62 µL, 0.39 
mmol) using HOBt (58 mg, 0.43 mmol), TBTU (138 mg, 0.43 mmol), anhydrous NEt3 
(87 µL, 0.63 mmol) and anhydrous DMF (4 mL) and following the general procedure 
described in section 10.2. The reaction mixture was stirred overnight at room 
temperature under a N2 atmosphere. Purified using flash chromatography (3:2 EtOAc:n-
hexane) to give a cloudy white oil, 88 mg (63%). 
1H NMR: (300 MHz, CDCl3) δ 7.49 (d, J = 8.7 Hz, 2H, H1, H5), 6.92 (d, J = 8.7 Hz, 
2H, H2, H4), 3.80-7.67 (m, 2H*), 3.57-3.62 (m, 2H*), 3.30-3.23 (m, 4H*), 2.36 (t, J = 
7.2 Hz, 2H, H6), 1.70-1.60 (m, 2H, H7), 1.33-1.28 (m, 8H, CH2 x 4), 0.88 (t, J = 6.0 Hz, 
3H, CH3).*Piperazine. 13C NMR: (75 MHz, CDCl3) δ 171.8 (C=O), 152.9 (C3), 126.4 
(q, J = 3.3 Hz, C1, C5), 124.6 (q, J = 269.5 Hz, CF3), 121.2 (q, J = 32.7 Hz, C-CF3), 
114.9 (C2, C4), 48.3 (C*), 48.1 (C*), 45.1 (C*), 41.0 (C*), 33.2 (C6), 31.7 (CH2), 29.4 
(CH2), 29.0 (CH2), 25.3 (C7), 22.6 (CH2), 14.0 (CH3).*Piperazine. Rf: 0.7 (3:2, 
EtOAc:n-hexane). HR-MS: calcd for C19H28F3N2O m/z: [M + H]
+, 357.2148; found: 
357.2136 [Diff (ppm) = -3.36]. IR (neat): 2927 (C-H), 1641 (C=O), 1616 (C=C), 1436 
(C=C), 1331 (C-F), 1116 (C-N) cm-1.  
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10.41 Synthesis of 1-(4-(4-(trifluoromethyl)phenyl)piperazin-1-yl)ethanone 
(RTC12) (58) 
 
Prepared from compound 33 (150 mg, 0.65 mmol) and acetic acid (33 µL, 0.59 mmol) 
using HOBt (87 mg, 0.65 mmol), TBTU (208 mg, 0.65 mmol), anhydrous NEt3 (131 
µL, 0.94 mmol) and anhydrous DMF (3 mL) and following the general procedure 
described in section 10.2. The reaction mixture was stirred overnight at room 
temperature under a N2 atmosphere. Purified using flash chromatography (4:1 EtOAc:n-
hexane) to give an off white solid, 91 mg (57%). 
1H NMR: (300 MHz, CDCl3) δ 7.50 (d, J = 8.7 Hz, 2H, H1, H5), 6.92 (d, J = 8.7 Hz, 
2H, H2, H4), 3.79-3.76 (m, 4H*), 3.65-3.61 (m, 2H*), 3.31-3.24 (m, 2H*), 2.14 (s, 3H, 
CH3). *Piperazine. 13C NMR: (75 MHz, CDCl3) δ 168.0 (C=O), 151.9 (C3), 125.5 (q, J 
= 3.3 Hz, C1, C5), 123.5 (q, J = 269.4 Hz, CF3), 120.3 (q, J = 32.2 Hz, C-CF3), 114.0 
(C2, C4), 47.3 (C*), 47.0 (C*), 44.8 (C*), 40.0 (C*),  20.2 (C10).*Piperazine. Rf: 0.5 
(4:1, EtOAc:n-hexane). HR-MS: calcd for C13H16F3N2O m/z: [M + H]
+, 273.1209; 
found: 273.1222 [Diff (ppm) = 4.80]. IR (KBr): 2847 (C-H), 1647 (C=O), 1615 (C=C), 
1441 (C=C), 1336 (C-F), 1238 (C-N) cm-1. m.p.: 76-80 °C. Anal. calcd for 
C13H15F3N2O; C, 57.34; H, 5.55; N, 10.29% found: C, 57.16; H, 5.40; N, 9.87%. 
10.42 Synthesis of 3-(thiophen-2-yl)-1-(4-(4-(trifluoromethyl)phenyl)piperazin-1-
yl)propan-1-one (RTC532) (59) 
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Prepared from compound 33 (81 mg, 0.35 mmol) and 3-(thiophen-2-yl)propanoic acid 
(50 mg, 0.32 mmol) using HOBt (47 mg, 0.35 mmol), TBTU (113 mg, 0.35 mmol), 
anhydrous NEt3 (71 µL, 0.51 mmol) and anhydrous DMF (5 mL) and following the 
general procedure described in section 10.2. The reaction mixture was stirred overnight 
at room temperature under a N2 atmosphere. Purified using flash chromatography (3:2 
EtOAc:n-hexane) to give an orange solid, 52 mg (44%). 
1H NMR: (300 MHz, CDCl3) δ 7.49 (d, J = 8.7 Hz, 2H, H1, H5), 7.12 (dd, J = 5.1 Hz, J 
= 1.2 Hz, H11), 6.92-6.88 (m, 3H, H2, H4, H10), 6.85-6.83 (m, 1H, H9), 3.80-3.77 (m, 
2H*), 3.59-3.56 (m, 2H*), 3.25-3.17 (m, 2H, H7, 4H*), 2.72 (t, J = 7.2 Hz, 2H, 
H6).*Piperazine. 13C NMR: (75 MHz, CDCl3) δ 170.2 (C=O), 152.8 (C3), 143.6 (C8), 
126.9 (C9), 126.5 (q, J = 3.3 Hz, C1, C5), 124.8 (C11), 124.5 (q, J = 269.7 Hz, CF3), 
123.5 (C10), 121.3 (q, J = 32.4 Hz, C-CF3), 115.0 (C2, C4), 48.2 (C*), 48.0 (C*), 45.0 
(C*), 41.2 (C*), 35.1 (C6), 25.5 (C7). Rf: 0.5 (3:2, EtOAc:n-hexane). HR-MS: calcd 
for C18H20F3N2OS m/z: [M + H]
+, 369.1243; found: 369.1238 [Diff (ppm) = -1.25]. IR 
(KBr): 2826 (C-H), 1632 (C=O), 1615 (C=C), 1441(C=C), 1338 (C-F), 1229 (C-N) cm-
1. m.p.: 50-54 °C. 
10.43 Synthesis of 1-(4-(4-(trifluoromethyl)phenyl)piperazin-1-yl)pentan-1-one 
(RTC194) (60) 
 
Prepared from compound 33 (246 mg, 1.07 mmol) and pentanoic acid (106 µL, 0.98 
mmol) using HOBt (144 mg, 0.98 mmol), TBTU (343 mg, 0.98 mmol), anhydrous NEt3 
(216 µL, 1.56 mmol) and anhydrous DMF (6 mL) and following the general procedure 
described in section 10.2. The reaction mixture was stirred overnight at room 
temperature under a N2 atmosphere. Purified using flash chromatography (3:2 EtOAc:n-
hexane) to give an off white solid, 178 mg (57%). 
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1H NMR: (300 MHz, CDCl3) δ 7.49 (d, J = 8.7 Hz, 2H, H1, H5), 6.92 (d, J = 8.7 Hz, 
2H, H2, H4), 3.79-3.76 (m, 2H*), 3.66-3.62 (m, 2H*), 3.30-3.23 (m, 4H*), 2.37 (t, J = 
7.2 Hz, 2H, H6), 1.69-1.59 (m, 2H, H7), 1.45-1.32 (m, 2H, H8), 0.94 (t, J = 7.5 Hz, 2H, 
CH3).*Piperazine. 13C NMR: (75 MHz, CDCl3) δ 171.7 (C=O), 152.9 (C3), 126.4 (q, J 
= 3.3 Hz, C1, C5), 124.6 (q, J = 268.8 Hz, CF3), 121.0 (q, J = 32.7 Hz, C-CF3), 114.9 
(C2, C4), 48.3 (C*), 48.0 (C*), 45.1 (C*), 41.0 (C*), 32.9 (C6), 27.4 (C7), 22.5 (C8), 
13.8 (CH3).*Piperazine. Rf: 0.6 (3:2, EtOAc:n-hexane). HR-MS: calcd for 
C16H22F3N2O m/z: [M + H]
+, 315.1679; found: 315.1688 [Diff (ppm) = 2.9]. IR (KBr): 
2935 (C-H), 1650 (C=O), 1631 (C=C), 1450 (C=C), 1337 (C-F), 1228 (C-N) cm-1. 
m.p.: 46-48 °C. 
10.44 Synthesis of 2-(thiophen-2-yl)-1-(4-(4-(trifluoromethyl)phenyl)piperazin-1-
yl)ethanone (RTC536) (61) 
 
Prepared from compound 33 (100 mg, 0.43 mmol) and 2-(thiophen-2-yl)acetic acid (54 
mg, 0.34 mmol) using HOBt (58 mg, 0.43 mmol), TBTU (138 mg, 0.43 mmol), 
anhydrous NEt3 (87 µL, 0.63 mmol) and anhydrous DMF (4 mL) and following the 
general procedure described in section 10.2. The reaction mixture was stirred overnight 
at room temperature under a N2 atmosphere. Purified using flash chromatography (3:2 
EtOAc:n-hexane) to give an orange solid, 27 mg (20%). 
1H NMR: (300 MHz, CDCl3) δ 7.48 (d, J = 8.7 Hz, 2H, H1, H5), 7.20 (dd, J = 5.1 Hz, J 
= 1.2 Hz, 1H, H10), 6.97-6.87 (m, 4H, H2, H4, H8, H9), 3.95 (s, 2H, H6), 3.82-3.79 (m, 
2H*), 3.69-3.65 (m, 2H*), 3.27-3.23 (m, 2H*), 3.18-3.15 (m, 2H*). *Piperazine. 13C 
NMR: (75 MHz, CDCl3) δ 168.5 (C=O), 152.8 (C3), 136.1 (C7), 126.9 (C8), 126.5 (q, 
J = 3.3 Hz, C1, C5), 126.1 (C9), 124.8 (C10), 124.5 (q, J = 268.4 Hz, CF3), 121.4 (q, J 
= 32.7 Hz, C-CF3), 115.0 (C2, C4), 48.2 (C*), 47.9 (C*), 45.8 (C*), 41.5 (C*), 35.2 
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(C6). *Piperazine. Rf: 0.5 (3:2, EtOAc:n-hexane). HR-MS: calcd for C17H18F3N2O2S 
m/z: [M + H]+, 355.1086; found: 355.1084 [Diff (ppm) = -0.56]. IR (KBr): 2910 (C-
H), 1644 (C=O), 1616 (C=C), 1409 (C=C), 1337 (C-F), 1230 (C-N) cm-1. 
10.45 Synthesis of 3-(furan-2-yl)-1-(4-(4-(trifluoromethyl)phenyl)piperazin-1-
yl)propan-1-one (RTC535) (62) 
 
Prepared from compound 33 (100 mg, 0.43 mmol) and 3-(furan-2-yl)propanoic acid 
(54mg, 0.39 mmol) using HOBt (58 mg, 0.43 mmol), TBTU (138 mg, 0.43 mmol), 
anhydrous NEt3 (87 µL, 0.63 mmol) and anhydrous DMF (4 mL) and following the 
general procedure described in section 10.2. The reaction mixture was stirred overnight 
at room temperature under a N2 atmosphere. Purified using flash chromatography (3:2 
EtOAc:n-hexane) to give an orange solid, 43 mg (31%). 
1H NMR: (300 MHz, CDCl3) δ 7.52 (d, J = 8.7 Hz, 2H, H1, H5), 7.31-7.30 (m, 1H, 
H11), 6.91 (d, J = 8.7 Hz, 2H, H2, H4), 6.29-6.27 (m, 1H, H10), 6.05-6.04 (m, 1H, H9), 
3.80-3.79 (m, 2H*), 3.61-3.58 (m, 2H*), 3.26-3.21 (m, 4H*), 3.02 (t, J = 7.2 Hz, 2H, 
H7), 2.71 (t, J = 7.2 Hz, 2H, H6). *Piperazine. 13C NMR: (75 MHz, CDCl3) δ 170.3 
(C=O), 154.5 (C8), 152.8 (C3), 141.1 (C11), 126.5 (q, J = 3.3 Hz, C1, C5), 124.5 (q, J = 
269.4 Hz, CF3), 123.0 (q, J = 32.7 Hz, C-CF3), 15.0 (C2, C4), 110.3 (C10), 105.5 (C9), 
48.2 (C*), 48.0 (C*), 45.0 (C*), 41.2 (C*), 31.6 (C6), 23.8 (C7).*Piperaine. Rf: 0.6 (3:2, 
EtOAc:n-hexane). HR-MS: calcd for C18H20F3N2O2 m/z: [M + H]
+, 353.1471; found: 
353.1461 [Diff (ppm) = -2.83]. IR (KBr): 2921 (C-H), 1625 (C=O), 1616 (C=C), 1443 
(C=C), 1334 (C-F), 1227 (C-N) cm-1. m.p.: 77-81 °C. 
Chapter 10                                           Experimental 
260 
 
10.46 4-(1H-Pyrazol-4-yl)-1-(4-(4-(trifluoromethyl)phenyl)piperazin-1-yl)butan-1-
one (RTC193) (63) 
 
Prepared from compound 33 (100 mg, 0.71 mmol) and 4-(1H-pyrazol-4-yl)butanoic 
acid (100 mg, 0.65 mmol), using HOBt (96 mg, 0.71 mmol), TBTU (228 mg, 0.71 
mmol), anhydrous NEt3 (144 µL, 1.04 mmol) and anhydrous DMF (4 mL) and 
following the general procedure described in section 10.2. The reaction mixture was 
stirred overnight at room temperature under a N2 atmosphere. Purified using flash 
chromatography (3:2 EtOAc:n-hexane) to give an off white solid,  20 mg (10%). 
1H NMR: (300 MHz, CDCl3) δ 7.52-7.47 (m, 2H, H1, H5, H10, H11)), 7.06 (d, J = 9.0 
Hz, 2H, H2, H4), 3.76-3.62 (m, 4H*), 3.62-3.24 (m, 4H*), 2.60 (t, J = 7.5 Hz, 2H, H8), 
2.48 (t, J = 7.5 Hz, 2H, H6), 1.97-1.85 (m, 2H, H7).*Piperazine. Rf: 0.5 (3:2, EtOAc:n-
hexane). HR-MS: calcd for C18H22F3N4O m/z: [M + H]
+, 367.1740; found: 367.1750 
[Diff (ppm) = 2.74].IR (KBr): 2954 (C-H), 1647 (N-C=O), 1612 (C=O), 1325 (C-N-
C), 1230 (C-F) cm-1. 
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10.47 Synthesis of 5-phenyl-1-(4-(4-(trifluoromethyl)phenyl)piperazin-1-yl)pentan-
1-one (RTC16) (64) 
 
Prepared from compound 33 (150 mg, 0.65 mmol) and 5-phenylpentanoic acid (105 mg, 
0.59 mmol) using HOBt (87 mg, 0.65 mmol), TBTU (208 mg, 0.65 mmol), anhydrous 
NEt3 (131 µL, 0.94 mmol) and anhydrous DMF (5mL) and following the general 
procedure described in section 10.2. The reaction mixture was stirred overnight at room 
temperature under a N2 atmosphere. Purified using flash chromatography (4:1 EtOAc:n-
hexane) to give an off white solid, 101mg (44%). 
1H NMR: (300 MHz, CDCl3) δ 7.49 (d, J = 8.7 Hz, 2H, H1, H5), 7.28-7.24 (m, 2H, 
Ar), 7.18-7.16 (m, 3H, Ar), 6.98 (d, J = 8.7 Hz, 2H, H2, H4), 3.75-3.74 (m, 2H*), 3.57-
3.55 (m, 2H*), 3.22-3.20 (m, 4H*), 2.67-2.63 (m, 2H, H7), 2.39-2.34 (m, 2H, H6), 1.7-
1.68 (m, 4H, CH2 x 2).*Piperazine. 13C NMR: (75 MHz, CDCl3) δ 171.5 (C=O), 152.9 
(C3), 142.1 (C8), 128.4 (Ar), 128.3 (Ar), 126.5 (q, J = 3.3 Hz, C1, C5), 125.8 (Ar), 
124.7 (q, J = 271.1 Hz, CF3), 121.2 (q, J = 33.0 Hz, C-CF3), 114.9 (C2, C4), 48.35 (C*), 
48.1 (C*), 45.1 (C*), 41.1 (C*), 35.7 (C7), 33.1 (C6), 31.10 (CH2), 24.86 
(CH2).*Piperazine. Rf: 0.5 (4:1, EtOAc:n-hexane). HR-MS: calcd for C22H26F3N2O 
m/z: [M + H]+, 391.1992; found: 391.1992  [Diff (ppm) = -5.0]. IR (KBr): 2857 (C-H), 
1640 (C=O), 1612 (C=C), 1438(C=C), 1331 (C-F), 1201 (C-N) cm-1 m.p.: 72-76 °C. 
Anal. calcd for C22H25F3N2O; C, 67.67; H, 6.45; N, 7.18% found: C, 67.61; H, 6.51; N, 
7.18%. 
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10.48 Synthesis of thiophen-2-yl (4-(4-(trifluoromethyl)phenyl)piperazin-1-yl) 
methanone (RTC93) (65) 
 
Prepared from compound 33 (154 mg, 0.66 mmol) and thiophene-2-carboxylic acid (77 
mg, 0.61 mmol) using HOBt (90 mg, 0.66 mol), TBTU (214 mg, 0.66 mmol), 
anhydrous NEt3 (150 µL, 0.97 mmol) and anhydrous DMF (6 mL) and following the 
general procedure described in section 10.2. The reaction mixture was stirred overnight 
at room temperature under a N2 atmosphere. Purified using flash chromatography (1:1 
EtOAc:Pet. Ether) to give a green solid, 149 mg (73%). 
1H NMR: (300 MHz, CDCl3) δ 7.51-7.46 (m, 3H, H1, H5, H7), 7.3 (dd, J = 3.2 Hz, J = 
1.1 Hz, 1H, H9), 7.08-7.05 (m, 1H, H8), 6.92 (d, J = 8.7 Hz, 2H, H2, H4), 3.93-3.89 (m, 
4H*), 3.35-3.31 (m, 4H*). *Piperazine. 13C NMR: (75 MHz, CDCl3) δ 163.7 (C=O), 
152.8 (C3), 136.6 (C6), 129.1 (C9), 129.0 (C7), 126.8 (C8), 126.5 (q, J = 3.3 Hz, C1, 
C5), 124.6 (q, J = 269.7 Hz, CF3), 121.2 (q, J = 32.5 Hz, C-CF3), 114.9 (C2, C4), 48.2 
(C*). *Piperazine. Rf: 0.6 (1:1, EtOAc:Pet.Ether). HR-MS: calcd for C16H16F3N2OS 
m/z: [M + H]+, 342.0960; found: 342.0974 [Diff (ppm) = 4.07]. IR (KBr): 2836 (C-H), 
1609 (C=O), 1523 (C=C), 1442 (C=C), 1338 (C-F), 1072 (C-N) cm-1. m.p.: 126-130 
°C. Anal. calcd for C16H15F3N2OS; C, 56.46; H, 4.44; N, 8.23% found: C, 56.72; H, 
4.62; N, 8.42%. 
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10.49 Synthesis of 4-hydroxy-4-(thiophen-2-yl)-1-(4-(4-
(trifluoromethyl)phenyl)piperazin-1-yl)butan-1-one (RTC29) (66)  
 
To a solution of compound 5 (350 mg, 0.88 mmol) in MeOH (3 mL) was added NaBH4 
(66 mg, 1.76 mmol) and the suspension was heated at 50 °C for 12 hrs. The reaction 
mixture was concentrated under reduced pressure and the resulting solid dissolved in 
EtOAc (15 mL). The organic layer was washed with H2O (10 mL) and extracted with 
EtOAc (3 x 10 mL). The combined organic layers were dried over MgSO4. The residue 
was purified using flash chromatography (elution gradient 1:1 MeOH:DCM to 1:9, 
MeOH:DCM) to give an off white solid, 350 mg (81%). 
1H NMR: (300 MHz, CDCl3) δ 7.49 (d, J = 8.7 Hz, 2H, H1, H5), 7.23-7.21 (m, 1H, 
H15), 6.98-6.90 (m, 4H, H2, H4, H13, H14), 5.08-5.04 (m, 1H, CHOH), 3.80-3.77 (m, 
2H*), 3.63-3.60 (m, 2H*), 3.23-3.18 (m, 4H*), 2.57-2.53 (m, 2H, H10), 2.30-2.15 (m, 
2H, H11).*Piperazine. 13C NMR: (75 MHz, CDCl3) δ 170.0 (C=O), 151.7 (C3), 147.8 
(C12), 125.7 (C14), 125.5 (q, J = 3.7 Hz, C1, C5), 123.5 (q, J = 270.0 Hz, CF3), 123.2 
(C15), 122.2 (C13), 120.13 (q, J = 32.0 Hz, C-CF3), 113.9 (C2, C4), 68.6 (CHOH), 47.2 
(C*), 46.9 (C*), 44.1 (C*), 40.3 (C*), 32.9 (C11), 28.3 (C10). *Piperazine. Rf: 0.17 
(1:1, EtOAc:n-hexane). HR-MS: calcd for C19 H22 F3 N2 O2 S m/z: [M + H]
+, 399.1349; 
found 399.1339 [Diff(ppm) = -2.32]. IR (KBr): 3383, (OH), 2965 (C-H), 1635 (C=O), 
1335 (C-N), 1100 (C-F) cm-1. m.p.:  120-124 °C. 
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10.50 Synthesis of 1-methyl-4-(4-(trifluoromethyl)phenyl)piperazine (RTC31) 
(67)202 
 
Compound 33 (283 mg, 1.22 mmol) was dissolved in absolute EtOH (5 mL) before 
formic acid (795 µL, 20.90 mmol) and formaldehyde (585 µL, 6.14 mmol) were 
consecutively added. The solution was heated at reflux for 3 hrs after which the EtOH 
was removed under reduced pressure and the residue dissolved in minimal H2O. The 
aqueous solution was neutralised to pH ~ 13 using saturated aqueous NaHCO3 and 
extracted with CHCl3 (10 mL, followed by 3 x 10 mL). The organic layers were dried 
over MgSO4 and concentrated in vacuo. The residue was purified using flash 
chromatograpy (1:1 EtOAc: Pet. Ether) to give an off white solid, 216 mg (72%). 
1H NMR: (300 MHz, CDCl3) δ 7.46 (d, J = 9.0 Hz, 2H, H1, H5), 6.89 (d, J = 9.0 Hz, 
2H, H2, H4), 3.27-3.24 (m, 4H*), 2.54-2.50 (m, 4H*), 2.32 (s, 3H, CH3).*Piperazine. 
1H NMR data matches literature data.203 HR-MS: calcd for C12H16F3N2 m/z: [M + H]
+, 
245.1260; found: 245.1272 [Diff (ppm) = 4.89] 
10.51 Synthesis of 4-(thiophen-2-yl)butan-1-ol (RD28) (68)119  
 
To a suspension of LiAlH4 (130 mg, 3.43 mmol) in THF (2.5 mL) was added a solution 
of 4-(2-thienyl)butyric acid (500 µL, 3.43 mmol) in THF (2.5 mL). The suspension was 
stirred for 6 hrs at rt. The reaction mixture was quenched with MeOH (2 mL) and 10% 
aqueous NaOH (2 mL). The solution was neutralised with 10% aqueous HCl (2 mL) 
and the aqueous layer extracted with EtOAc (10 mL, followed by 3 x 10 mL). The 
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combined organic layers were dried over MgSO4 and the residue purified using flash 
chromatography (DCM) to give a colourless oil, 481 mg (90%).  
1H NMR: (300 MHz, CDCl3) δ 7.10 (dd, J = 5.1 Hz, J = 1.0 Hz, 1H, H6), 6.92-6.89 (m, 
1H, H5) 6.79-6.77 (m, 1H, H4), 3.65 (t, J = 6.0 Hz, 2H, CH2OH), 2.83 (t, J = 7.8 Hz, 
2H, H3), 1.78-1.62 (m, 4H, H1, H2), 1.60 (bs, 1H, OH). 1H NMR data matches 
literature data.207 HR-MS: calcd for C8H13OS m/z: [M + H]
+, 157.0682; found: 
157.0685 [Diff(ppm) = 1.99]. Rf: 0.25 (DCM). 
10.52 Synthesis of 4-(thiophen-2-yl)butyl methanesulfonate (RD31) (69) 
 
To a solution of compound 68 (135 mg, 0.86 mmol) and NEt3 (142 µl, 1.01 mmol) in 
anhydrous DCM (3 mL) kept at 0 ºC, was added methanesulfonyl chloride (71 µl, 0.91 
mmol). The reaction mixture was maintained at 0 °C for 1 hr, followed by warming to 
rt, where it was kept under vigorous stirring and a N2 atmosphere for 3 hrs. The solvent 
was removed under reduced pressure and purified using flash chromatogrphy (3:2 
EtOAc:Pet. Ether) to give a colourless oil, 152 mg (75%). 
1H NMR: (300 MHz, CDCl3) δ 7.12 (dd, J = 5.1 Hz, J = 1.2 Hz, 1H, H6), 6.93-6.90 (m, 
1H, H5) 6.80-6.78 (m, 1H, H4), 4.25-4.21 (m, 2H, H1), 2.98 (s, 3H, CH3), 2.88-2.86 (m, 
2H, H2), 1.83-1.78 (m, 4H, CH2 x 2). 13C NMR: (75MHz, CDCl3) δ 143.2 (C3), 125.8 
(C5), 123.4 (C4), 122.2 (C6), 68.7 (C1), 36.3 (CH3), 28.1 (C2), 27.4 (CH2), 26.5 (CH2). 
HR-MS: calcd for C9H14O3S2Na m/z: [M + Na]
+, 257.0277; found: 257.0273 
[Diff(ppm) = -1.6]. Rf: 0.6 (3:2, EtOAc:n-hexane). IR (neat): 2924 (C-H), 1352 (S=O), 
1173 (S=O) cm-1. 
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10.53 Synthesis of 1-(4-(thiophen-2-yl)butyl)-4-(4-
(trifluoromethyl)phenyl)piperazine (RTC46) (70)  
 
To a suspension of compound 69 (29 mg, 0.12 mmol) and Na2CO3 (26 mg, 0.24 mmol) 
in acetonitrile (5 mL), was added compound 33 (110 mg, 0.48 mmol). The mixture was 
heated at reflux for 24 hrs under vigorous agitation and a N2 atmosphere. The solvent 
was removed under reduced pressure and the residue was purified using flash 
chromatography (3:2, EtOAc:n-hexane) to give a white solid, 40 mg (91%).  
1H NMR: (300 MHz, CDCl3) δ 7.47 (d, J = 8.7 Hz, 2H, H1, H5), 7.12-7.10 (m, 1H, 
H13), 6.92-6.90 (m, 3H, H2, H4, H12), 6.79-6.78 (m, 1H, H11), 3.30-3.26 (m, 4H*), 
2.86 (t, J = 7.2 Hz, 2H, H6), 2.60-2.56 (m, 4H*), 2.42 (t, J = 7.2 Hz, 2H, H9), 1.78-1.68 
(m, 2H, H7), 1.65-1.60 (m, 2H, H8).*Piperazine. 13C NMR: (75MHz, CDCl3) δ 153.3 
(C3), 145.2 (C10), 126.7 (C12), 126.3 (q, J = 3.3 Hz, C1, C5), 124.7 (q, J = 269.4 Hz, 
CF3), 124.1 (C11), 120.4 (q, J = 32.4 Hz, C-CF3), 122.9 (C13), 114.4 (C2, C4), 58.2 
(C9), 52.9 (C*), 47.9 (C*), 29.7 (C6), 29.6 (C7), 26.2 (C8).*Piperazine. HR-MS: calcd 
C19H24F3N2S m/z: [M + H]
+, 369.1067; found 369.1603 [Diff(ppm) = -1.1].  IR (KBr): 
2932 (C-H), 1615 (C=C), 1469 (C=C), 1330 (C-F), 1292 (C-N) cm-1. m.p.: 78-80 °C. 
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10.54 Synthesis of 1-(4-(4-aminophenyl)piperazin-1-yl)-4-(thiophen-2-yl)butan-1-
one (RTC23) (73) 
 
Compound 42 (143 mg, 0.39 mmol) was dissolved in MeOH (10 mL) in a round bottom 
flask and PtO2 (20 mg, 0.08 mmol) was added. The resulting mixture was degassed and 
purged with H2 (x3), stirred vigorously overnight at rt under an atmosphere of H2 gas 
and monitored by TLC (7:1, EtOAc:DCM). The reaction mixture was passed through a 
bed of Celite and the filtrate was concentrated under reduced pressure. The residue was 
purified using flash chromatography (7:1, EtOAc:DCM) to give a brown oil, 75 mg 
(57%). 
1H NMR: (300 MHz, CDCl3) δ 7.11 (dd, J = 5.1 Hz, J = 1.2 Hz, 1H, H12), 6.92-6.90 
(m, 1H, H11), 6.80-6.77 (m, 3H, H1, H5, H10), 6.94-6.20 (m, 2H, H2, H4), 3.76-3.72 
(m, 2H*), 3.58-3.50 (m, 2H*, 2H, NH2), 2.97-2.88 (m, 4H*, 2H, H6), 2.38 (t, J = 7.2 
Hz, 2H, H8), 2.08-1.99 (m, 2H, H7).*Piperazine. 13C NMR: (75 MHz, CDCl3) δ 169.9 
(C=O), 143.4 (C3), 142.8 (CNH2), 139.9 (C9), 125.7 (C11), 123.4 (C10), 122.1 (C12), 
118.2 (C1, C5), 115.4 (C2, C4), 50.5 (C*), 50.1 (C*), 44.6 (C*), 40.6 (C*), 31.0 (C8), 
28.2 (C6), 26.0 (C7).*Piperazine. Rf: 0.5 (1:9, MeOH:DCM). HR-MS: calcd for 
C18H24N3OS m/z: [M + H]
+, 331.1664; found: 331.1669 [Diff (ppm) = 1.51]. IR (KBr): 
3426 (N-H), 3343 (N-H), 2914 (C-H), 1635 (C=O), 1514 (N-H), 825 (N-H) cm-1. 
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10.55 Synthesis of methyl 4-(thiophen-2-yl)butanoate (RTC19) (74)204 
 
4-(2-Thienyl)butyric acid (1 mL, 6.86 mmol) was dissolved in MeOH (10 mL) and 
concentrated H2SO4 (1.15 mL, 21.95 mmol) was added was added dropwise. The 
reaction mixture was stirred overnight at rt. The MeOH was removed under reduced 
pressure and the residue dissolved in minimal H2O. The pH was adjusted to ~7 using 2 
M HCl and the aqueous layer was extracted with DCM (15 mL x 3). The combined 
organic layers were dried over MgSO4 and the solvent removed under reduced pressure. 
The residue was purified using flash chromatography to give a clear oil, 1.03 g (81%) 
1H NMR: (300 MHz, CDCl3) δ 7.09 (dd, J = 5.1 Hz, J = 1.2 Hz,  1H, H6), 6.90-6.78 
(m, 1H, H5), 6.78-6.77 (m, 1H, H4), 2.85 (t, J = 7.0 Hz, H1), 3.65 (s, 3H, OCH3), 2.35 
(t, J = 7.0 Hz, H3), 2.04-1.94 (m, 2H, H2). 1H NMR data matches literature data.204 Rf: 
0.7 (9:1, Pet. Ether:EtOAc). HR-MS: calcd for C9H13O2S m/z: [M + H]
+, 207.0450; 
found: 207.0456 [Diff(ppm) = 2.90]. 
10.56 Synthesis of methyl 4-(5-bromothiophen-2-yl)butanoate (RD154) (75)  
 
To a solution of compound 74 (310 mg, 1.82 mmol) in THF (5 mL) at 0 °C was added 
NBS (323 mg, 1.82 mmol) in small portions. The mixture was allowed to equilibrate to 
rt gradually after which the reaction mixture was stirred for 4 hrs. The solvent was 
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removed under reduced pressure and the residue was purified using flash 
chromatography (9:1, Pet.Ether:EtOAc) to give a light yellow oil, 361 mg (80%). 
1H NMR: (300 MHz, CDCl3) δ 6.82 (d, J = 3.3 Hz, 1H, H6), 6.53 (d, J = 3.3 Hz, 1H, 
H5), 3.65 (s, 3H, OCH3), 2.78 (t, J = 7.2 Hz, 2H, H1), 2.34 (t, J = 7.2 Hz, 2H, H3), 
2.01-1.89 (m, 2H, H2). 1H NMR data matches literature data.208 HR-MS: calcd for 
C9H11BrO2SNa m/z: [M + Na]
+, 287.9566; found: 287.9576 [Diff(ppm) = 3.75]. Rf: 0.8 
(9:1, Pet. Ether:EtOAc). 
10.57 Synthesis of 4-(5-bromothiophen-2-yl)butanoic acid (RD157) (76) 
 
Compound 75 (457 mg, 1.74 mmol) was dissolved in EtOH (10 mL) and KOH (489 
mg, 8.72 mmol) was added. The suspension was heated at reflux and reaction progress 
monitored by TLC (3:2 EtOAc:Pet. Ether). After 3 hrs the reaction mixture was allowed 
to cool to rt and EtOH was removed under reduce pressure. The residue was dissolved 
in H2O (1 mL), the pH adjusted to pH = 6 with 2 M aqueous HCl and the aqueous layer 
extracted with DCM (20 mL, followed by 4 x 10 mL). The combined organic layers 
were washed with brine (3 x 20 mL), dried over MgSO4 and evaporated under reduced 
pressure. The residue was purified using flash chromatography (1:9, MeOH:DCM) and 
the obtained product was dissolved in minimal DCM and Pet. Ether was added until 
precipitation began. The solution and precipitate were stored at -20 °C overnight, and 
the resultant solid collected by vacuum filtration and washed with cold Pet. Ether (20 
mL) to give a beige solid, 151 mg (35%). 
1H NMR: (300 MHz, CDCl3) δ 11.48 (bs, 1H, OH), 6.83 (d, J = 3.3 Hz, 1H, H6), 6.54 
(d, J = 3.3 Hz, 1H, H5), 2.79 (t, J = 7.2 H, 2H, H1), 2.39 (t, J = 7.2 Hz, 2H, H3), 1.97-
1.90 (m, 2H, H2). 13C NMR: (75 MHz, CDCl3) 179.9 (C=O), 145.6 (C4), 129.6 (C6), 
125.1 (C5), 109.3 (C-Br), 33.0 (C3), 29.3 (C1), 26.2 (C2). Rf: 0.6 (1:9, MeOH:DCM). 
HR-MS: calcd for C8H10BrO2S m/z: [M + H]
+, 248.9579; found: 248.9579 [Diff(ppm) 
= 0]. IR (KBr): 2955 (C-H), 1708(C=O), 1211 (C-O), 797 (C-Br) cm-1. m.p.: 50-54 °C. 
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10.58 Synthesis of 4-(5-bromothiophen-2-yl)-1-(4-(4-
(trifluoromethyl)phenyl)piperazin-1-yl)butan-1-one (RTC30) (77)† 
 
Compound 76 (149 mg, 0.66 mmol), BOP (321 mg, 0.72 mmol), anhydrous NEt3 (147 
µL, 1.05 mmol) and anhydrous DCM (10 mL) were placed in an oven-dried three neck 
flask under a N2 atmosphere. The resulting solution was stirred at rt for 15 mins. 
Compound 33 (167 mg, 0.72 mmol) was added and the reaction mixture stirred under a 
N2 atmosphere and monitored by TLC. After 16 hrs, DCM was removed under reduced 
pressure and the resulting oil was acidified to pH = 3 using a 0.1 M aqueous HCl. The 
aqueous mixture was extracted with DCM (20 mL, followed by 4 x 10 mL) and the 
organic layer washed with a saturated aqueous solution of NaHCO3 (3 x 20 mL) and 
brine (3 x 20 mL). The organic layer was dried over MgSO4 and the solvent removed in 
vacuo and the residue was purified using flash chromatography (1:1 EtOAc:Pet. Ether) 
to give an light brown solid, 170 mg (55%).  
1H NMR: (300 MHz, CDCl3) δ 7.48 (d, J = 8.7 Hz, 2H, H1, H5), 6.90 (d, J = 8.7 Hz, 
2H, H2, H4), 6.84 (d, J = 3.3 Hz, 2H, H11), 6.56 (d, J = 3.3 Hz, 1H,  H10), 3.85-3.72 
(m, 2H*), 3.65-3.52 (m, 2H*), 3.31-3.19 (m, 4H*), 2.83 (t, J = 7.2 Hz, 2H, H8), 2.39 (t, 
J = 7.2 Hz, 2H, H6), 2.05-1.97 (m, 2H, H7).*Piperazine. 13C NMR: (75 MHz, CDCl3) 
170.7 (C=O), 152.8 (C3), 146.2 (C9), 129.6 (C11), 126.5 (q, J = 3.3 Hz, C1, C5), 125.0 
(C10), 124.6 (q, J = 269.7 Hz, CF3), 121.1 (q, J = 32.7 Hz, C-CF3), 114.9 (C2, C4), 
109.0 (C-Br), 48.2 (C*), 48.0 (C*), 44.9 (C*), 41.1 (C*), 31.7 (C6), 29.6 (C8), 26.5 
(C7). *Piperazine. Rf: 0.6 (1:1, EtOAc:Pet. Ether). HR-MS: calcd for C19H21BrF3N2OS 
m/z: [M + H]+, 461.0505; found: 461.0489 [Diff (ppm) = -3.46]. IR (KBr): 2957 (C-
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H), 1654 (C=O), 1616 (C=C), 149 (C=C), 1333 (C-F), 1114 (C-N), 652 (C-Br) cm-1. 
m.p.: 82-84 °C. 
10.59 Synthesis of 1-(4-(4-(trifluoromethyl)phenyl)piperazin-1-yl)-4-(5-(4-
(trifluoromethyl)phenyl) thiophen-2-yl)butan-1-one (RTC47) (78)† 
 
Trifluoromethylphenylboronic acid (15 mg, 0.07 mmol) and compound 77 (15 mg, 0.03 
mmol) were dissolved in anhydrous THF (1 mL). Pd(PPh3)4 (10 mg, 0.0075 mmol) and 
2 M aqueous Na2CO3 (535 µL) were added and the suspension was heated at reflux 
under a N2 atmosphere and reaction progress monitored by TLC. After 6 hrs the 
solution was cooled and poured onto ice-cold H2O and neutralised with 1 M aqueous 
HCl. The aqueous layer was extracted with EtOAc (10 mL, followed by 3 x 10 mL) and 
the combined organic layers were dried over MgSO4. The solvent was removed under 
reduced pressure and the residue was purified using flash chromatography (1:1 
EtOAc:Pet. Ether) to give an off white solid, 14 mg (82%). 
1H NMR: (300 MHz, CDCl3) δ 7.62 (d, J = 8.7 Hz, 2H, H14, H17), 7.57 (d, J = 8.7 Hz, 
2H, H15, H16), 7.48 (d, J = 8.7 Hz, 2H, H1, H5), 7.21 (d, J = 3.3 Hz, 1H, H11), 6.89 (d, 
J = 8.7 Hz, 2H, H2, H4), 6.81 (d, J = 3.3 Hz, 1H, H10), 3.80-3.76 (m, 2H*), 3.60-3.22 
(m, 2H*), 3.26-3.22 (m, 4H*), 2.93 (t, J = 7.2 Hz, 2H, H8), 2.44 (t, J = 7.2 Hz, 2H, H6), 
2.14-2.04 (m, 2H, H7).*Piperazine. 13C NMR: (75 MHz, CDCl3) δ 169.8 (C=O), 151.8 
(C3), 144.8 (C9), 139.2 (C13), 136.8 (C12), 127.7 (q, J = 33.1 Hz, C-CF3), 125.4 (q, J = 
3.3 Hz, C1, C5), 124.9 (C10), 124.8 (q, J = 3.3 Hz, C15, C16), 124.3 (C14, C17), 123.5 
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(q, J = 269.5 Hz, CF3), 123.2 (C11), 123.1 (q, J = 270.1 Hz, CF3), 120.2 (q, J = 32.5 Hz, 
C-CF3), 113.9 (C2, C4), 47.2 (C*), 47.0 (C*), 40.1 (C*), 43.9 (C*), 30.8 (C6), 28.5 
(C7), 25.6 (C8).*Piperazine. Rf: 0.7 (1:1, EtOAc:n-hexane). HR-MS: calcd for 
C26H25F6N2OS m/z: [M + H]
+, 527.1586; found 527.1599 [Diff(ppm) = 2.36]. IR 
(KBr): 2840 (C-H), 1652 (C=O), 1615 (C=C), 1443 (C=C), 1323 (C-F), 1110 (C-N) 
cm-1. m.p.: 150-152 °C 
10.60 Synthesis of 9-oxo-9-(4-(4-(trifluoromethyl)phenyl)piperazin-1-yl)nonanoic 
acid (RTC15) (79) 
 
Compound 81 (131 mg, 0.31 mmol) and KOH (88 mg, 1.55 mmol) in EtOH (5 mL) 
were heated at reflux and reaction progress monitored by TLC (3:2 EtOAc: Pet. Ether). 
After 3 hrs the solution was allowed to cool to rt and EtOH was removed under reduce 
pressure. The residue was dissolved in H2O (1 mL), the pH adjusted to pH = 6 with 2 M 
aqueous HCl and the aqueous layer extracted with DCM (20 mL, followed by 4 x 10 
mL). The organic layers were washed with brine (3 x 20 mL), dried over MgSO4 and 
evaporated under reduced pressure to give a white solid, 99 mg (80%). 
 1H NMR: (300 MHz, CDCl3) δ 10.30 (bs, 1H, OH), 7.50 (d, J = 8.7 Hz, 2H, H1, H5), 
6.92 (d, J = 8.7 Hz, 2H, H2, H4), 3.78-3.77 (m, 2H*), 3.64-3.62 (m, 2H*), 3.31-3.24 
(m, 4H*), 2.39-2.33 (m, 4H, (C=O)CH2 x 2), 1.68-1.60 (m, 4H, (C=O)CH2CH2 x 2), 
1.38-1.33 (m, 6H, CH2 x 3).*Piperazine. 13C NMR: (75 MHz, CDCl3) δ 174.2 (COOH), 
170.9 (C=O), 151.8 (C3), 125.4 (q, J = 3.7 Hz, C1, C5), 123.5 (q, J = 269.1 Hz, CF3), 
120.3 (q, J = 32.7 Hz, C-CF3), 114.0 (C2, C4), 47.4 (C*), 47.1 (C*), 44.2 (C*), 40.1 
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(C*), 32.9 ((C=O)CH2), 32.1 ((C=O)CH2), 28.1 (CH2), 27.9 (CH2), 27.8 (CH2), 24.1 
((C=O)CH2CH2), 23.6 ((C=O)CH2CH2).*Piperazine. Rf: 0.5 (1:19, MeOH:DCM) HR-
MS: calcd for C20H28F3N2O3 m/z: [M + H]
+, 401.2407; found: 401.2047  [Diff(ppm) = 
0]. IR (KBr): 2935 (C-H), 1706 (C=O), 1617 (N-C=O), 1333 (C-F), 1204 (C-N) cm-1 
m.p.:  90-92 °C Anal. calcd for C20H27F3N2O3; C, 59.99; H, 6.80; N, 7.00% found; C, 
60.40; H, 6.83; N, 6.85%. 
10.61 Synthesis of methyl 9-oxo-9-(4-(4-(trifluoromethyl)phenyl)piperazin-1-
yl)nonanoate (RTC56) (81) 
 
Methyl hydrogen azelate (479 mg, 2.30 mmol), BOP (1140 mg, 2.60 mmol), anhydrous 
NEt3 (512 µL, 3.60 mmol) and anhydrous DCM (20 mL) were placed in an oven-dried 
three neck flask under a N2 atmosphere. The resulting solution was stirred at rt for 15 
mins. Compound 33 (600 mg, 2.60 mmol) was added and the reaction mixture stirred 
under a N2 atmosphere and monitored by TLC. After 16 hrs, DCM was removed under 
reduced pressure and the resulting oil was acidified to pH = 3 using a 0.1 M aqueous 
HCl. The aqueous mixture was extracted with DCM (20 mL, followed by 4 x 10 mL) 
and the organic layer washed with a saturated aqueous solution of NaHCO3 (3 x 20 mL) 
and brine (3 x 20 mL). The organic layer was dried over MgSO4 and the solvent 
removed in vacuo and the residue was purified using flash chromatography (3:2, 
EtOAc:Pet.Ether) to give an off white solid, 952 mg (98%).  
1H NMR: (300 MHz, CDCl3) δ 7.42 (d, J = 8.7 Hz, 2H, H1, H5), 6.86 (d, J = 8.7 Hz, 
2H, H2, H4), 3.73-3.69 (m, 2H*), 3.63-3.53 (m, 2H*, 3H, OCH3), 3.27-3.14 (m, 4H*), 
Chapter 10                                           Experimental 
274 
 
2.33-2.21 (m, 4H, (C=O)CH2 x 2), 1.65-1.48 (m, 4H, (C=O)CH2CH2 x 2), 1.35-1.21 (m, 
6H, CH2 x 3).*Piperazine. 13C NMR: (75 MHz, CDCl3) 174.2 (COOCH3), 171.1 (N-
C=O), 152.9 (C3), 126.4 (q, J = 3.3 Hz, C1, C5), 124.5 (q, J = 269.7 Hz, CF3), 121.2 (q, 
J = 32.8 Hz, C-CF3), 114.9 (C2, C4), 54.4 (OCH3), 48.3 (C*), 48.0 (C*), 45.1 (C*), 41.0 
(C*), 34.0 ((C=O)CH2), 33.1 ((C=O)CH2), 29.2 (CH2), 29.0 (CH2), 28.9 (CH2), 25.1 
((C=O)CH2CH2), 24.8 ((C=O)CH2CH2). *Piperazine. Rf: 0.65 (3:2 EtOAc:Pet. Ether). 
HR-MS: calcd for C21H30F3N2O3 m/z: [M + H]
+, 415.2203; found: 415.219 [Diff (ppm) 
= -3.14]. IR: 2954 (C-H), 1739 ((C=O)OCH3), 1647 (N-C=O), 1613 (C=C), 1447 
(C=C), 1334 (C-F), 1160 (C-N) cm-1. m.p.: 81-85 °C. 
10.62 Synthesis of (E)-3-(dimethylamino)acrylonitrile (RD302) (90)211 
 
To a three-neck round bottom flask fitted with a reflux condenser and an addition funnel 
was added cyanoacetic acid (850 mg, 9.99 mmol) and anhydrous 1,4 dioxane (20 mL). 
The solution was heated at 80 °C and dimetylformamide dimethyl acetal (2 mL, 15.05 
mmol) was added over 1 hr. The solution was heated at 80 °C for 1 hr after which the 
reaction was cooled to rt. The solvent was removed under reduce pressure. The product 
was extracted from the residue using DCM and purified using flash chromatography 
(DCM) to give a yellow oil, 837 mg (87%).  
1H NMR: (300 MHz, CDCl3) δ 6.88 (d, J = 13.5 Hz, 1H, H1), 3.61 (d, J = 13.5 Hz, 1H, 
H2), 2.80 (bs, 6H, N(CH3)2). 
1H NMR data matches literature data.211 HR-MS: calcd 
for C5H9N2 m/z: [M + H]
+, 97.0760; found: 97.0763 [Diff (ppm) = 2.99]. Rf: 0.7 
(DCM). 
10.63 Synthesis of 1H-pyrazol-5-amine (RD305) (91) 
 
A solution of compound 92 (210 mg, 2.18 mmol) and hydrazine monohydrate (112 µL, 
2.23 mmol) in MeOH (1 mL) was irradiated in a sealed microwave tube at 120 °C for 
40 mins (100 W). MeOH was removed under reduced pressure and the residue was 
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triturated using Pet. Ether to give a brown solid. The product was used without further 
purification. Yellow oil, 164 mg (80%). 
1H NMR: (300 MHz, CD3OD) δ 7.36 (d, J = 2.4 Hz, 1H, N=CH), 5.64 (d, J = 2.4 Hz, 
1H, C=CH). Data matched literature data.212 HR-MS: calcd for C3H6N3 m/z: [M + H]
+, 
84.0556; found: 84.0558 [Diff(ppm) = 2.45]. Rf: 0.2 (1:10:89, NEt3:MeOH:DCM). 
10.64 Synthesis of 3-phenyl-1H-pyrazol-5-amine (RD226) (93)130 
 
A solution of benzoylnitrile (580 mg, 4.00 mmol) and hydrazine monohydrate (200 µL, 
4.10 mmol) in MeOH (2 mL) was irradiated in a sealed microwave tube at 120 °C for 
40 mins (100 W). MeOH was removed under reduced pressure and the residue was 
triturated using Pet. Ether to give a brown solid. The product was used without further 
purification. Brown solid, 480 mg (75%) 
1H NMR: (300 MHz, CD3OD) δ 7.65-7.62 (m, 2H, Ar), 7.42-7.28 (m, 3H, Ar), 5.94 (s, 
1H, C=CH). Data matched literature data.213 HR-MS: calcd for C9H10N3 m/z: [M + H]
+, 
160.0869; found: 1660.0877 [Diff (ppm) = 5.00]. m.p.: 114-118 °C. 
10.65 Synthesis of (1H-benzo[d][1,2,3]triazol-1-yl)(thiophen-2-yl)methanone 
(RD303) (94) 
 
Thiophene-2-carboxylic acid (500 mg, 3.9 mmol) was dissolved in EtOAc (10 mL) and 
benzotriazole (464 mg, 3.9 mmol) and 4-dimethylaminopyridine (47 mg, 0.39 mmol) 
were added. The solution was placed in an ice bath at 0 °C and N, N’-
dicyclohexylcarbodiimide (805 mg, 3.9 mmol) was added. The reaction temperature 
was adjusted to rt and the solution was stirred overnight. The white precipitate was 
removed via gravity filtration and was washed with EtOAc (3 x 10 mL). The filtrate 
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was concentrated under reduced pressure and the residue was purified using flash 
chromatography (DCM). The obtained product was dissolved in minimal DCM and Pet. 
Ether (~ 3 mL) was added until precipitation began. The solution was stored at -20 °C 
overnight, and the resultant crystals collected by vacuum filtration and washed with 
cold Pet. Ether (~ 20 mL) to give white needle, 890 mg (99%).  
1H NMR: (300 MHz, CDCl3) δ 8.58 (dd, J = 3.9 Hz, J = 1.2 Hz, 1H, H1), 8.42-8.39 (m, 
1H, Ar), 8.18-8.15 (m, 1H, Ar), 7.88 (dd, J = 4.9 Hz, J = 1.2 Hz, 1H, H3), 7.72-7.67 (m, 
1H, Ar), 7.57-7.52 (m, 1H, Ar), 7.30-7.27 (m, 1H, H2). 1H NMR data matches literature 
data.144 Rf: 0.9 (DCM). HR-MS: calcd for C11H8N3OS m/z: [M + H]
+, 230.0383; 
found: 230.0387 [Diff (ppm) = 1.77]. m.p.: 182-186 °C (DCM). 
10.66 Synthesis of 3-oxo-3-(thiophen-2-yl)propanenitrile (RD320) (95)144 
 
To a solution of acetonitrile (104 μL, 2 mmol) in anhydrous THF (10 mL) under an 
atmosphere of Ar at -78 °C, was slowly added n-BuLi (1.6 mL, 2.4mmol). The solution 
was stirred at -78 °C for 1 hr after which a solution of compound 94 (458 mg, 2 mmol) 
in THF (5 mL) was slowly added. The reaction mixture was stirred for 2 hrs at -78 °C. 
After this period, the reaction mixture was warmed to rt and poured in H2O (10 mL). 
The aqueous solution was acidified to pH = 3 using aqueous 1 M HCl (2 mL) and 
extracted with EtOAc. The combined organic layers were dried over MgSO4 and the 
solvent removed under reduced pressure. The residue was purified using flash 
chromatography (3:2, Pet. Ether: EtOAc) to give a yellow oil, 211 mg (70%). 
1H NMR: (300 MHz, CDCl3) δ 7.81-7.78 (m, 2H, H1, H3), 7.22-7.19 (m, 1H, H2), 4.04 
(s, 2H, CH2). 
1H NMR data matches literature data.144 Rf: 0.6 (3:2, Pet. ether: EtOAc). 
HR-MS: calcd for C7H6NOS m/z: [M + H]
+, 152.0165; found: 152.0161 [Diff(ppm) = -
2.5]. 
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10.67 Synthesis of 3-(thiophen-2-yl)-1H-pyrazol-5-amine (RD323) (96)214  
 
A solution of compound 95 (200 mg, 1.32 mmol) and hydrazine monohydrate (65, µL, 
1.35 mmol) in MeOH (1 mL) was irradiated in a sealed microwave tube at 120 °C for 
40 mins (100 W). MeOH was removed under reduced pressure and the residue was 
triturated using Pet. Ether. The product was used without further purification. Orange 
solid, 217 mg (55%) 
1H NMR: (300 MHz, CDCl3) δ 7.09-7.07 (m, 2H, H1, H3), 6.86-6.83 (m, 1H, H2), 5.61 
(s, 1H, H4). 1H NMR data matches literature data.214 Rf: 0.6 (3:2, Pet. ether: EtOAc). 
HR-MS: calcd for C7H8N3S m/z: [M + H]
+, 166.0433; found 166.0441 [Diff (ppm) = 
4.35]. m.p.: 50-53 °C (EtOH).  
10.68 Synthesis of 2-iso-propylpyrazolo[1,5-a]pyrimidin-7(4H)-one (RTC80) (98)† 
 
To a fine, stirred suspension of Na (575 mg, 0.25 x 10-2 g-atom) in toluene (10 mL) was 
added, in one portion, EtOAc (2.45 mL, 29.69 mmol).  Ethyl formate (2.01 mL, 22.89 
mmol) was added dropwise at 27 °C and the reaction mixture was stirred for 12 hrs at 
27 °C. 3-iso-Propyl-1H-pyrazol-5-amine (1.56 g, 12.5 mmol) in EtOH (10 mL) was 
added and the reaction mixture was heated at reflux for 5 hrs. The solvent was removed 
under reduced pressure and the residue re-dissolved in minimal H2O. The aqueous 
solution was acidified to pH = 2 using 6 M aqueous HCl (3 mL) which resulted in the 
precipitation of an orange/brown solid. The precipitate was recrystallized from EtOH to 
give an orange solid, 333 mg (15%). 
1H NMR: (300 MHz, d6-DMSO) δ 12.32 (bs, 1H, NH), 7.80 (d, J = 7.5 Hz, 1H, H4), 
6.02 (s, 1H, H2), 5.63 (d, J = 7.5 Hz, 1H, H5), 3.02-2.93 (m, 1H, CH(CH3)2), 1.24 (d, J 
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= 7.2 Hz, 6H, (CH3)2). 13C NMR: (75 MHz, d6-DMSO) δ 161.5 (C=O), 156.4 (C3), 
142.0 (C1), 138.9 (C4), 95.3 (C5), 85.9 (C2), 27.8 (CH(CH3)2), 22.7 ((CH3)2). HR-MS: 
calcd for C9H12N3O m/z: [M + H]
+, 178.0975; found: 178.0978 [Diff(ppm) = 1.81]. Rf: 
0.5 (1:9, MeOH:DCM). IR (KBr): 3165 (N-H), 1675 (C=O), 1632 (C=C), 1298 (C-N) 
cm-1. m.p.: 288-290 °C (EtOH). Anal. calcd for C9H11N3O; C, 61.00; H, 6.26; N, 
23.72% found; C, 61.06; H, 6.29; N, 23.54%. 
10.69 Synthesis of 2-(tert-butyl)pyrazolo[1,5-a]pyrimidin-7(4H)-one (RTC103) 
(101)153† 
 
 
To a fine, stirred suspension of Na (575 mg, 0.25 x 10 -2 g-atom) in toluene (10 mL) 
was added, in one portion, EtOAc (2.45 mL, 29.69 mmol).  Ethyl formate (2.01 mL, 
22.89 mmol) was added dropwise at 27 °C and the reaction mixture was stirred for 12 
hrs at 27 °C. 5-Amino-3-(tert-butyl)-1H-pyrazole (1.74 g, 12.5 mmol) in EtOH (10 mL) 
was added and the reaction mixture was heated at reflux for 5 hrs. The solvent was 
removed under reduced pressure and the residue re-dissolved in minimal H2O. The 
aqueous solution was acidified to pH = 2 using 6 M aqueous HCl (2 mL) which resulted 
in the precipitation of an orange/brown solid. The precipitate was recrystallized from 
EtOH to give a light brown solid, 318 mg (13%). 
1H NMR: (300 MHz, d6-DMSO) δ 12.24 (bs, 1H, NH), 7.81-7.77 (m, 1H, H4), 6.05 (s, 
1H, H2), 5.63-5.61 (d, J = 7.3 Hz, 1H, H5), 1.29 (s, 9H, (CH3)3). 13C NMR: (75 MHz, 
d6-DMSO) δ 161.2 (C=O), 156.5 (C3), 141.9 (C1), 138.8 (C4), 95.2 (C5), 85.4 (C2), 
32.3 (C(CH3)3), 30.03 ((CH3)3). HR-MS: calcd for C10H14N3O m/z: [M + H]
+, 
193.1160; found: 193.1167 [Diff (ppm) = 3.66]. Rf: 0.5 (1:9, MeOH:DCM). IR (KBr): 
3155 (N-H), 3085 (C=CH), 2966 (C-H), 1673 (C=O), 1616 (C=C) 1595 (N-H), 142 
(C=C), 1234 (C-N) cm-1. m.p.: Above 300 °C. 
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10.70 Synthesis  of ethyl 3-oxo-3-(4-(trifluoromethyl)phenyl)propanoate (RD74) 
(102)154 
 
1-(4-(Trifluoromethyl)phenyl)ethanone (500 mg, 2.65 mmol), diethyl carbonate (3.84 
mL, 31.90 mmol) and NaH (95 g, 3.98 mmol) were stirred at 80 °C for 1.5 hrs, after 
which H2O (5 mL) was added. The aqueous mixture was neutralised with 1 M aqueous 
HCl and extracted with EtOAc (10 mL, followed by 3 x 10 mL). The combined organic 
layers were dried over MgSO4 and concentrated under reduced pressure to give a 
colourless oil, 180 mg (crude yield). Compound 102 was used without further 
purification.  
1H NMR: (300 MHz, d6-DMSO) δ 8.06 (d, J = 8.0 Hz, 2H, H1, H4), 7.75 (d, J = 8.0 
Hz, 2H, H2, H3), 4.22 (q, J = 7.1 Hz, 2H, OCH2), 4.01 (s, 2H, CH2), 1.25 (t, J = 7.1 Hz, 
3H, OCH2CH3). 
1H NMR data matches literature data.154 Rf: 0.6 (9:1, Pet. 
Ether:EtOAc). 
10.71 Synthesis of ethyl 3-oxo-3-(thiophen-2-yl)propanoateacid (RD256) (103)155 
 
A solution of thiophene-2-carboxylic acid (370 mg, 2.88 mmol), 4-
dimethylaminopyridine (708 mg, 5.77 mmol) and Meldrums acid (500 mg, 3.45 mmol) 
in anhydrous DCM (5 mL) was cooled to 0 °C. N, N’-Dicyclohexylcarbodiimide (655 
mg, 3.16 mmol) was added and the reaction temperature was adjusted to rt. The reaction 
was stirred at rt for 2 hrs, after which the white precipitate was removed by gravity 
filtration. The filtrate was concentrated under reduced pressure and the residue was 
dissolved in absolute EtOH (16 mL). p-Toluene sulfonic acid monohydrate (1.30 g, 7.2 
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mmol) in EtOH (4 mL) was added and the solution was heated at reflux for 1 hr. The 
EtOH was removed under reduced pressure and the residue was dissolved in EtOAc and 
washed sequentially with H2O, saturated aqueous NaHCO3, and 1 M aqueous HCl and 
brine. The organic layer was dried over MgSO4 and evaporated under reduced pressure. 
The residue was purified using flash chromatography (3:2, Pet.Ether:EtOAc) to give a 
yellow oil, 225 mg (39%). 
1H NMR: (300 MHz, CDCl3) δ 7.66-7.65 (m, 1H, H3), 7.62-7.60 (m, 1H, H1), 7.07-
7.04 (m, 1H, H2), 4.10 (q, J = 7.5 Hz, 2H, OCH2), 3.83 (s, 2H, CH2), 1.16 (t, J = 7.5 Hz, 
3H, OCH2CH3). 
1H NMR data matches literature data.155 HR-MS: calcd for C9H11O3S 
m/z: [M + H]+, 199.0423; found 199.0418 [Diff(ppm) = -2.87]. Rf: 0.6 (2:3, Pet. Ether: 
EtOAc). 
10.72 Synthesis of 2-(tert-butyl)-5-methylpyrazolo[1,5-a]pyrimidin-7(4H)-one 
(RTC101) (104)† 
 
Prepared from 5-amino-3-(tert-butyl)-1H-pyrazole (400 mg, 2.87 mmol) and ethyl 3-
oxobutanoate (330 µL, 2.61 mmol) using AcOH (10 mL) and following the procedure 
described in section 10.4. The reaction mixture was heated at reflux for 4 hrs. 
Compound 104 was triturated from EtOAc (6 mL) to give an off white solid, 460 mg 
(78%). 
1H NMR: (300 MHz, d6-DMSO) δ 12.07 (bs, 1H, NH), 5.95 (s, 1H, H2), 5.50 (s, 1H, 
H5), 2.26 (s, 3H, CH3), 1.28 (s, 9H, (CH3)3). 13C NMR: (75 MHz, d6-DMSO) δ 164.2 
(C=O), 156.2 (C4), 149.5 (C3), 141.8 (C1), 94.8 (C5), 84.7 (C2), 32.3 (C(CH3)3), 30.0 
(C(CH3)3), 18.5 (CH3). Rf: 0.6 (1:9, MeOH:DCM). HR-MS: calcd for C11H16N3O m/z: 
[M + H]+, 206.1288; found: 206.1298 [Diff(ppm) = 4.69]. IR (KBr): 3158 (N-H), 1681 
(C=O), 1613 (C=C), 1579 (N-H) cm-1. m.p.:  Above 300 °C. Anal. calcd for 
C11H15N3O; C, 64.36; H, 7.37; N, 20.48% found; C, 64.21; H, 7.20; N, 19.96%. 
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10.73 Synthesis of 2-(tert-butyl)-5-ethylpyrazolo[1,5-a]pyrimidin-7(4H)-one 
(RTC54) (105) 
 
Prepared from 5-amino-3-(tert-butyl)-1H-pyrazole (100 mg, 0.71 mmol) and ethyl 3-
oxopentanoate (93 µL, 0.64 mmol) using AcOH (15 mL) and following the procedure 
following the procedure described in section 10.4. The reaction mixture was heated at 
reflux overnight. Compound 105 was triturated from EtOAc (4 mL) to give a white 
solid, 53 mg (33%) 
1H NMR: (300 MHz, d6-DMSO) δ 5.96 (s, 1H, H2), 5.67 (s, 1H, H5), 3.45 (bs, 1H, 
NH), 2.58-2.56 (q, J = 7.2 Hz, 2H, CH2), 1.28 (s, 9H, (CH3)3), 1.20 (t, J = 7.2 Hz, 3H, 
CH3). 13C NMR: (75 MHz, d6-DMSO) δ 164.3 (C=O), 156.5 (C4), 154.7 (C3), 141.9 
(C1), 93.3 (C2), 84.8 (C5), 32.3 (C(CH3)3), 30.0 ((CH3)3), 25.5 (CH2), 12.5 (CH3). Rf: 
0.6 (1:9, MeOH:DCM). HR-MS: calcd for C12H18N3O m/z: [M + H]
+, 220.1444; found: 
220.1453 [Diff (ppm) = 3.74]. IR (KBr): 3250 (N-H), 2963 (C=CH), 1678 (C=O), 
1619 (C=C), 1484 (C=C), 1217 (C-N) cm-1 m.p.: Above 300 °C. 
10.74 Synthesis of 2-(tert-butyl)-5-iso-propylpyrazolo [1,5-a] pyrimidin-7(4H)-one 
(RTC102) (106) 
 
 
Prepared from 5-amino-3-(tert-butyl)-1H-pyrazole (400 mg, 2.87 mmol) and ethyl 4-
methyl-3-oxopentanoate (421 µL, 2.61 mmol) using AcOH (10 mL) and following the 
procedure described in section 10.4. The reaction mixture was heated at reflux for 4 hrs. 
Compound 106 was triturated from EtOAc (8 mL) to give a white solid, 72 mg (65%) 
HR-MS: calcd for C26H38N6O2Na m/z: [2M + Na]
+; 489.2948; found: 489.2966 
[Diff(ppm) = 3.68]. Rf: 0.6 (1:9, MeOH:DCM). IR (KBr): 3174 (N-H), 2963 (C-H), 
Chapter 10                                           Experimental 
282 
 
1676 (C=O), 1630 (C=C), 1576 (N-H), 1238 (C-N) cm-1. m.p.:  Above 300 °C. Anal. 
calcd for C13H19N3O; C, 66.92; H, 8.21; N, 18.01% found; C, 66.53; H, 8.13; N, 
18.40%. 
10.75 Synthesis of 2,5-di-tert-butylpyrazolo[1,5-a]pyrimidin-7(4H)-one (RTC55) 
(107)† 
 
Prepared from 5-amino-3-(tert-butyl)-1H-pyrazole (100 mg, 0.71 mmol) and ethyl 4,4-
dimethyl-3-oxopentanoate (116 µL, 0.65 mmol) using AcOH (10 mL) and following the 
procedure described in section 10.4. The reaction mixture was heated at reflux 
overnight. Compound 107 was triturated from EtOAc (5 mL) to give a white solid, 42 
mg (23%). 
1H NMR: (300 MHz, CD3OD) δ 6.08 (s, 1H, H5), 5.74 (s, 1H, H2), 1.38 (s, 18H, 
(CH3)3 x 2).13C NMR: (75 MHz, CD3OD) δ 166.6 (C=O), 161.5 (C4), 158.5 (C1), 
142.1 (C3), 91.4 (C5), 85.4 (C2), 34.8 (C(CH3)3), 32.3 (C(CH3)3), 29.2 ((CH3)3), 27.6 
((CH3)3). Rf: 0.6 (1:9, MeOH:DCM). HR-MS: calcd for C14H22N3O m/z: [M + H]
+, 
248.1757; found: 248.1768 [Diff(ppm) = 4.45]. IR (KBr): 3090 (N-H), 2965 (C-H), 
1670 (C=O), 1614 (C=C), 1570 (NH), 1481 (C=C), 1240 (C-N) cm-1. m.p.:  Above 300 
°C. 
10.76 Synthesis of 2-(tert-butyl)-5-phenylpyrazolo[1,5-a]pyrimidin-7(4H)-one 
(RTC81) (108)† 
 
Prepared from 5-amino-3-(tert-butyl)-1H-pyrazole (400 mg, 2.87 mmol) and methyl 3-
oxo-3-phenylpropanoate (448 µL, 2.61 mmol) using AcOH (10 mL) and following the 
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procedure described in section 10.4. The reaction mixture was heated at reflux for 4 hrs. 
Compound 103 was triturated from EtOAc (5 mL) to give a white solid, 256 mg (40%). 
1H NMR: (300 MHz, d6-DMSO) δ 12.35 (s, 1H, NH), 7.86-7.77 (m, 2H, Ar), 7.63-7.53 
(m, 3H, Ar), 6.09 (s, 1H, H2), 6.00 (s, 1H, H5), 1.32 (s, 9H, (CH3)3). 13C NMR: (75 
MHz, d6-DMSO) δ 164.7 (C=O), 156.3 (C4), 149.3 (C3), 142.1 (C1), 132.4 (C6), 130.9 
(Ar), 129.0 (Ar), 127.1 (Ar), 93.6 (C2), 86.0 (C5), 32.4 (C(CH3)3), 30.0 ((CH3)3) HR-
MS: calcd for C16H17N3ONa m/z: [M + Na]
+, 290.1264; found: 290.1278 [Diff(ppm) = 
4.73]. IR (KBr): 3433 (N-H), 3127 (C-H), 1656 (C=O), 1611 (C=C), 1492 (C=C) cm-1. 
m.p.: Above 300 °C. Anal. calcd for C16H17N3O; C, 71.88; H, 6.41; N, 15.72% found: 
C, 71.71; H, 6.62; N, 15.79%. 
10.77 Synthesis of 2-iso-propyl-5-methylpyrazolo[1,5-a]pyrimidin-7(4H)-one 
(RTC60) (109)† 
 
Prepared from 3-iso-propyl-1H-pyrazol-5-amine (241 mg, 1.92 mmol) and ethyl 3-
oxobutanoate (222 µL, 1.75 mmol) using AcOH (10 mL) and following the procedure 
described in section 10.4. The reaction mixture was heated at reflux for 4 hrs. 
Compound 109 was triturated from EtOAc (6 mL) to give a beige solid, 232 mg (69%). 
1H NMR: (300 MHz, d6-DMSO) δ 12.13 (bs, 1H, NH), 5.62 (s, 1H, H2), 5.49 (s, 1H, 
H5), 3.02-2.88 (m, 1H, CH(CH3)2), 2.25 (s, 3H, CH3), 1.23 (d, J = 6.9 Hz, (CH3)2). 13C 
NMR: (75 MHz, d6-DMSO) δ 161.4 (C=O), 156.1 (C4), 149.5 (C3), 141.8 (C1), 94.8 
(C5), 58.1 (C2), 27.8 (CH(CH3)2), 22.2 ((CH3)2), 18.4 (CH3). HR-MS: calcd for 
C10H14N3O m/z: [M + H]
+, 193.1160; found: 193.1167 [Diff(ppm) = 3.88]. Rf: 0.5 (1:9, 
MeOH:DCM). IR (KBr): 342 (N-H), 2963 (C-H), 1679 (C=O), 1626 (N-H), 1578 
(C=C), 1409 (C=C), 1285 (C-N) cm-1. m.p.: 262-265 °C. 
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10.78 Synthesis of 5-ethyl-2-iso-propylpyrazolo[1,5-a]pyrimidin-7(4H)-one 
(RTC87) (110)† 
 
Prepared from 3-iso-propyl-1H-pyrazol-5-amine (100 mg, 0.79 mmol) and ethyl 3-
oxopentanoate (125 µL, 0.87 mmol) using AcOH (10 mL) and following the procedure 
described in section 10.4. The reaction mixture was heated at reflux for 5 hrs. 
Compound 110 was triturated from EtOAc (5mL) to give a brown solid, 100 mg (63%). 
1H NMR: (300 MHz, CD3OD) δ 5.99 (s, 1H, H2), 5.62 (s, 1H, H5), 5.07 (bs, 1H, NH), 
3.06-2.99 (m, 1H, CH(CH3)2), 2.63 (q, J = 7.2 Hz, 2H, CH2), 1.32-1.27 (m, 9H, CH3, 
(CH3)2). 13C NMR: (75 MHz, CD3OD) δ 161.6 (C=O), 158.2 (C4), 156.0 (C3), 142.1 
(C1), 93.0 (C5), 85.3 (C2), 28.3 (CH(CH3)2), 25.9 (CH2), 21.5 ((CH3)2), 11.5 (CH3).  
HR-MS: calcd for C11H16N3O m/z: [M + H]
+, 206.1288; found: 206.1298 [Diff(ppm) = 
4.90]. Rf: 0.5 (1:9 MeOH:DCM). IR (KBr): 3138 (N-H), 2965 (C-H), 1686 (C=O), 
1630 (C=C), 1577 (NH), 1478 (C=C), 1293 (C-N) cm-1. m.p.: 260-261 °C. 
10.79 Synthesis of 2-iso-propyl-5-propylpyrazolo[1,5-a]pyrimidin-7(4H)-one 
(RTC63) (111)† 
 
Prepared from 3-iso-propyl-1H-pyrazol-5-amine (219 mg, 1.75 mmol) and ethyl 3-
oxohexanoate (255 µL, 1.59 mmol) using AcOH (10 mL) and following the procedure 
described in section 10.4. The reaction mixture was heated at reflux for 4 hrs. 
Compound 111 was triturated from EtOAc (7 mL) to give a light brown solid, 253 mg 
(72%). 
1H NMR: (300 MHz, CD3OD) δ 6.06 (s, 1H, H2), 5.70 (s 1H, H5), 5.00 (bs, 1H, NH), 
3.11-2.97 (m, 1H, CH(CH3)2), 2.58 (t, J = 5.1 Hz, 2H, CH2CH2CH3), 179-.67 (m, 2H, 
CH2CH2CH3), 1.29 (d, J = 6.9 Hz, 6H, (CH3)2), 0.99 (t, J = 7.5, 3H, CH3).13C NMR: 
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(75 MHz, CD3OD) δ 163.6 (C=O), 158.1 (C4), 154.6 (C3), 142.0 (C1), 93.9 (C5), 85.4 
(C2), 34.5 (CH2CH2CH3), 28.3 (CH(CH3)2), 21.5 (CH2CH2CH3), (CH3)2), 12.4 (CH3). 
HR-MS: calcd for C12H18N3O m/z: [M + H]
+, 220.1444; found: 220.1455 [Diff (ppm) = 
5.00]. Rf: 0.5 (1:9 MeOH:DCM). IR (KBr): 3246 (N-H), 2965 (C-H), 1672 (C=O), 
1609 (C=C), 1477 (C=C), 1292 (C-N), 800 (N-H) cm-1. m.p.: 258-260 °C. Anal. calcd 
for C12H17N3O; C, 65.72; H, 7.81; N, 19.17% found; C, 66.08; H, 8.16; N, 19.44%. 
10.80 Synthesis of 2,5-di-iso-propylpyrazolo[1,5-a]pyrimidin-7(4H)-one (RTC58) 
(112)† 
 
Prepared from 3-iso-propyl-1H-pyrazol-5-amine (312 mg, 2.49 mmol) and ethyl 4-
methyl-3-oxopentanoate (365 µL, 2.27 mmol) using AcOH (10 mL) and following the 
procedure described in section 10.4.  The reaction mixture was heated at reflux for 4 
hrs. Compound 112 was triturated from EtOAc (5 mL) to give a beige solid, 326 mg 
(66%). 
1H NMR: (300 MHz, d6-DMSO) δ 11.97 (bs, 1H, NH), 5.94 (s, 1H, H2), 5.52 (s, 1H, 
H5), 3.03-2.89 (m, 1H, CH(CH3)2), 2.87-2.73 (m, 1H, CH(CH3)2), 1.24-1.22 (m, 12H, 
(CH3)2 x 2). 13C NMR: (75 MHz, d6-DMSO) δ 161.5 (C=O), 158.5 (C4), 156.5 (C3), 
141.9 (C1), 91.6 (C5), 85.4 (C2), 31.5 (CH(CH3)2), 27.9 (CH(CH3)2), 22.3 ((CH3)2), 
21.0 ((CH3)2). HR-MS: calcd for C12H18N3O m/z: [M + H]
+, 220.1444; found: 
220.1446 [Diff (ppm) = 0.90]. Rf: 0.5 (1:9 MeOH:DCM) IR (KBr): 3142 (N-H), 2964 
(C-H), 1674 (C=O), 1627 (C=C), 1480(C=C), 1291 (C-N) cm-1. m.p.: Above 300 °C. 
Anal. calcd for C12H17N3O; C, 65.72; H, 7.81; N, 19.17% found: C, 65.43; H, 7.98; N, 
19.17%. 
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10.81 Synthesis of 5-(tert-butyl)-2-iso-propylpyrazolo[1,5-a]pyrimidin-7(4H)-one 
(RTC57) (113)† 
 
Prepared from 3-iso-propyl-1H-pyrazol-5-amine (164 mg, 1.31 mmol) and ethyl 4,4-
dimethyl-3-oxopentanoate (213 µL, 1.19 mmol) using AcOH (10 mL) and following the 
procedure described in section 10.4. The reaction mixture was heated at reflux for 4 hrs. 
Compound 113 was triturated from EtOAc (5 mL) to give a white solid, 36 mg (13%). 
1H NMR: (300 MHz, d6-DMSO) δ 6.28 (s, 1H, H2), 6.05 (s, 1H, H5), 5.45 (bs, 1H, 
NH), 3.12-2.98 (m, 1H, CH(CH3)2), 1.35 (s, 9H, (CH3)3), 1.30 (d, J = 7.2 Hz, 6H, 
(CH3)2). 13C NMR: (75 MHz, d6-DMSO) δ 169.6 (C=O), 163.9 (C4), 161.5 (C3), 142.2 
(C1), 91.4 (C5), 85.6 (C2), 34.8 (C(CH3)3), 28.3 (CH(CH3)2), 27.6 ((CH3)3), 21.5 
((CH3)2). HR-MS: calcd for C13H20N3O m/z: [M + H]
+, 234.1600; found: 234.1061 
[Diff (ppm) = -0.40]. Rf: 0.5 (1:9, MeOH:DCM). IR (KBr): 3240 (N-H), 2964 (C-H), 
1681 (C=O), 1613 (C=C), 1482 (C=C), 1258 (C-N) cm-1. m.p.: Above 300 °C. 
10.82 Synthesis of 2-iso-propyl-5-phenylpyrazolo[1,5-a]pyrimidin-7(4H)-one 
(RTC61) (114)† 
 
Prepared from 3-iso-propyl-1H-pyrazol-5-amine (164 mg, 1.32 mmol) and methyl 3-
oxo-3-phenylpropanoate (208 µL, 1.19 mmol) using AcOH (10 mL) and following the 
procedure described in section 10.4. The reaction mixture was heated at reflux 
overnight. Compound 114 was triturated from EtOAc (5 mL) to give a white solid,  84 
mg (30%). 
1H NMR: (300 MHz, CD3OD) δ 12.38 (bs, 1H, NH), 7.83-7.80 (m, 2H, Ar), 7.59-7.56 
(m, 2H, Ar), 6.06 (s 1H, H2), 5.99 (s, 1H, H5), 3.06-2.97 (m, 1H, CH(CH3)2), 1.27 (d, J 
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= 6.9 Hz, 6H, (CH3)2). 13C NMR: (75 MHz, CD3OD) δ 163.9 (C=O), 157.9 (C4), 151.0 
(C3), 142.1 (C1), 132.4 (C6), 130.9 (Ar), 28.9 (Ar), 126.7 (Ar), 93.3 (C2), 86.4 (C5), 
28.3 (CH(CH3)2), 21.5 ((CH3)2). HR-MS: calcd for C15H16N3O m/z: [M + H]
+, 
254.1288; found: 254.1298 [Diff (ppm) = 3.90]. Rf: 0.5 (1:9, MeOH:DCM). IR (KBr): 
3239 (N-H), 2964 (C-H), 1662 (C=O), 1614 (C=C), 1490 (C=C), 1291 (C-N), 768 (N-
H) cm-1. m.p.: 248-251 °C. 
10.83 Synthesis of 5-(3,5-bis(trifluoromethyl)phenyl)-2-iso-propylpyrazolo[1,5-
a]pyrimidin-7(4H)-one (RTC53) (115) 
 
Prepared from 3-iso-propyl-1H-pyrazol-5-amine (70 mg, 0.55 mmol) and ethyl 3-(3,5-
bis(trifluoromethyl)phenyl)-3-oxopropanoate (201 mg, 0.61 mmol) using AcOH (15 
mL) and following the procedure outlined in section 10.4. The reaction mixture was 
heated at reflux overnight. Compound 115 was triturated from EtOAc (3 mL) to give a 
beige solid, 60 mg (27%). 
1H NMR: (300 MHz, d6-DMSO) δ 12.61 (bs, 1H, NH), 8.51 (s, 2H, H6, H8), 8.33 (s, 
1H, H7), 3.07-2.98 (m, 1H, CH(CH3)2), 1.27 (d, J = 6.9 Hz, 6H, (CH3)2). 13C NMR: (75 
MHz, d6-DMSO) δ 162.2 (C=O), 156.0 (C4), 146.3 (C3), 142.1 (C1), 134.9 (C9), 130.8 
(q, J = 33.0 Hz, C-CF3), 128.7 (C6, C8), 124.3 (C7), 123.0 (q, J = 270.0 Hz, CF3), 95.4 
(C2), 86.7 (C5), 27.9 (CH(CH3)2), 22.2 ((CH3)2). Rf: 0.5 (1:9, MeOH:DCM). HR-MS: 
calcd for C17H14F6N3O m/z: [M + H]
+, 390.1036; found: 390.1051 [Diff(ppm) = 2.79]. 
IR (KBr): 3423 (N-H), 2972 (C-H), 1670 (C=O), 1617 (C=C), 1577 (N-H), 1481 
(C=C), 1279 (C-F), 1139 (C-N) cm-1. m.p.: Above 300 °C. 
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10.84 Synthesis of 5-(3,5-bis(trifluoromethyl)phenyl)-2-methylpyrazolo[1,5-
a]pyrimidin-7(4H)-one (RTC83) (117)† 
 
Prepared from 3-methyl-1H-pyrazol-5-amine (68 mg, 0.70 mmol) and ethyl 3-(3,5-
bis(trifluoromethyl)phenyl)-3-oxopropanoate (208 mg, 0.64 mmol) using AcOH (10 
mL) and following the procedure described in section 10.4. The reaction mixture was 
heated at reflux for 4 hrs. Compound 117 was triturated from EtOAc (3 mL) to give an 
off white solid, 40 mg (49%). 
1H NMR: (300 MHz, d6-DMSO) δ 8.53 (s, 2H, H6, H8) 8.32 (s, 1H, H7), 6.29 (s, 1H, 
H2), 6.08 (s, 1H, H5), 2.32 (s, 3H, CH3). 13C NMR: (75 MHz, CD3OD) δ 164.2 (C=O), 
153.0 (C4), 148.8 (C3), 142.9 (C1), 135.5 (C9), 131.3 (q, J = 32.7 Hz, C-CF3), 128.8 
(C6, C8), 124.7 (C7), 123.6 (q, J = 272.2 Hz, CF3), 96.0 (C2), 90.2 (C5), 14.5 (CH3). 
Rf: 0.5 (1:9, MeOH:DCM). HR-MS: calcd for C15H10F6N3O m/z: [M + H]
+, 362.0723; 
found: 362.0738 [Diff(ppm) = 4.38]. IR (KBr): 3170 (N-H), 2986 (C-H), 1659 (C=O), 
1601 (C=C), 1532 (N-H), 1431 (C=C), 1275 (C-N), 1138 (C-F) cm-1. m.p.:  Above 300 
°C. 
10.85 Synthesis of 5-(3,5-bis(trifluoromethyl)phenyl)-2-ethylpyrazolo[1,5-
a]pyrimidin-7(4H)-one (RTC88) (118)† 
 
Prepared from 3-ethyl-1H-pyrazol-5-amine (81 µL, 0.73 mmol) and was 3,5-
bis(trifluoromethyl)phenyl)-3-oxopropanoate (200 mg, 0.61 mmol) using AcOH (10 
mL) and following the procedure described in section 10.4. The reaction mixture was 
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heated at reflux for 4 hrs. Compound 118 was triturated using EtOAc (4 mL) to give a 
beige solid, 66 mg (42%). 
1H NMR: (300 MHz, d6-DMSO) δ 12.64 (bs, 1H, NH), 8.51 (s, 2H, H6, H8), 8.33 (s, 
1H, H7), 6.30 (s, 1H, H2), 6.12 (s, 1H, H5), 2.70 (q, J = 7.5 Hz, 2H, CH2), 1.25 (t, J = 
7.5 Hz, 3H, 13C NMR: (75 MHz, d6-DMSO) δ 158.0 (C=O), 155.9 (C4), 146.3 (C3), 
142.2 (C1), 135.0 (C9), 130.8 (q, J = 33.3 Hz, C-CF3), 128.3 (C6, C8), 124.2 (C7), 
123.0 (q, J = 270.0 Hz, CF3), 95.3 (C2), 88.1 (C5), 21.5 (CH2), 13.2 (CH3). Rf: 0.5 (1:9, 
MeOH:DCM). HR-MS: calcd for C16H12F3N3O m/z: [M + H]
+, 376.0879; found: 
376.0897 [Diff (ppm) = 4.79]. IR (KBr): 3174 (N-H), 2980 (C-H), 1666 (C=O), 1604 
(C=C), 1524 (N-H), 1428 (C=C), 1277 (C-N), 1136 (C-F) cm-1. m.p.:  244-248 °C 
10.86 Synthesis of 5-(3,5-bis(trifluoromethyl)phenyl)-2-phenylpyrazolo[1,5-a] 
pyrimidin-7(4H)-one (RTC91) (119)† 
 
Prepared from compound 93 (88 mg, 0.55mmol) and ethyl 3-(3,5-
bis(trifluoromethyl)phenyl)-3-oxopropanoate (164 mg, 0.50 mmol) using AcOH (10 
mL) and following the procedure described in section 10.4. The reaction mixture was 
heated at reflux for 4 hrs. Compound 119 was triturated from EtOAc (4 mL) and 
purified using flash chromatography (1:9 MeOH:DCM) to give an off white solid, 44 
mg (21%) 
1H NMR: (300 MHz, d6-DMSO) δ 12.89 (bs, 1H, NH), 8.56 (s, 2H, H6, H8), 8.37 (s, 
1H, H7), 8.04-8.02 (m, 2H, Ar), 7.53-7.41 (m, 3H, Ar), 6.73 (s, 1H, H2), 6.41 (s, 1H, 
H5). 13C NMR: (75 MHz, d6-DMSO) δ 156.0 (C=O), 153.5 (C4), 146.7 (C1), 143.0 
(C3), 134.9 (C9), 132.1 (C10), 130.8 (q, J = 33.0 Hz, C-CF3), 129.0 (Ar), 128.7 (Ar), 
128.4 (C6, C8), 126.2 (Ar), 124.3 (C7), 123.0 (q, J = 270.0 Hz, CF3), 95.7 (C2), 86.7 
(C5). HR-MS: calcd for C20H12F6N3O m/z: [M + H]
+, 424.0879; found: 424.0893 [Diff 
(ppm) = 3.25]. Rf: 0.4 (1:9, MeOH:DCM). IR (KBr): 3429 (N-H), 3132 (C=C), 1661 
(C=O), 1527 (N-H), 1372 (C-F), 1278 (C-N), 808 (N-H) cm-1. m.p.: Above 300 °C. 
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10.87 5-(3,5-bis(trifluoromethyl)phenyl)-2-(thiophen-2-yl)pyrazolo[1,5-
a]pyrimidin-7(4H)-one (RTC97) (120)† 
 
 
Prepared from compound 96 (120 mg, 0.72 mmol) and ethyl 3-(3,5-
bis(trifluoromethyl)phenyl)-3-oxopropanoate (218 mg, 0.64 mmol) using AcOH (15 
mL) and following the procedure described in section 10.4. The reaction mixture was 
heated at reflux for 4 hrs. Compound 120 was precipitated using EtOAc (5 mL) to give 
a beige solid, 14 mg (30%). 
1H NMR: (300 MHz, d6-DMSO) δ 12.86 (bs, 1H, NH), 8.55 (s, 2H, H6, H8), 8.35 (s, 
1H, H7), 7.75-7.74 (m, 1H, H13), 7.65-7.62 (m, 1H, H11), 7.19-7.17 (m, 1H, H12), 
6.63 (s, 1H, H2), 6.39 (s, 1H, H5). 13C NMR: (75 MHz, d6-DMSO) 155.7 (C=O), 149.2 
(C4), 146.7 (C1), 142.9 (C3), 135.2 (C10), 134.7 (C9), 130.8 (q, J = 32.0 Hz, C-CF3), 
128.5 (C6, C8), 127.8 (C12), 127.2 (C13), 127.0 (C11), 124.4 (C7), 123.0 (q, J = 271.1 
Hz, CF3), 95.9 (C2), 86.5 (C5). Rf: 0.5 (1:9, MeOH:DCM). HR-MS: calcd for 
C18H10F6N3OS m/z: [M + H]
+, 430.0443; found: 430.0431 [Diff (ppm) = -2.75]. IR 
(KBr): 3424 (N-H), 3139 (C=C), 1618 (C=O), 1573 (N-H), 1370 (C-F), 1281 (C-N), 
822 (N-H) cm-1.m.p.: Above 300 °C. 
10.88 Synthesis of 2-iso-propyl-5-(4-(trifluoromethyl)phenyl)pyrazolo[1,5-
a]pyrimidin-7(4H)-one (RTC59) (121)† 
 
Prepared from compound 102 (164 mg, 0.63 mmol) and 3-iso-propyl-1H-pyrazol-5-
amine (91 mg, 0.73 mmol) using AcOH (5 mL) and following the procedure described 
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in section 10.4.  The reaction mixture was heated at reflux for 4 hrs. Compound 121 was 
triturated from EtOAc (4.5 mL) to give a beige solid, 40 mg (17%) 
1H NMR: (300 MHz, d6-DMSO) δ 8.04 (d, J = 8.3 Hz, 2H, H7, H8), 7.95 (d, J = 8.3 
Hz, 2H, H6, H9), 6.09 (s, 2H, H2, H5), 3.05-2.98 (m, 1H, CH(CH3)2), 1.28 (d, J = 6.9 
Hz, 6H, (CH3)2).13CNMR: (75 MHz, CD3OD) δ 164.2 (C=O), 157.1 (C4), 149.4 (C3), 
142.3 (C1), 136.5 (C10), 132.4 (q, J = 32.7 Hz, C-CF3), 127.7 (C6, C9), 125.7 (q, J = 
3.6 Hz, C7, C8), 123.8 (q, J = 270.0 Hz, CF3), 94.4 (C2), 86.5 (C5), 28.4 (CH(CH3)2), 
21.4 ((CH3)2). Rf: 0.6 (1:9, MeOH:DCM). HR-MS: calcd for C16H15F3N3O m/z: [M + 
H]+, 323.1192; found: 323.1205 [Diff (ppm) = 4.01]. IR (KBr): 3415 (N-H), 3972 (C-
H), 1655 (C=O), 1613 (C=C), 1589 (N-H), 1432 (C=C), 1324 (C-F), 1165 (C-N) cm-1. 
m.p.: Above 300 °C. 
10.89 Synthesis of 2-iso-propyl-5-(3-(trifluoromethyl)phenyl)pyrazolo[1,5-
a]pyrimidin-7(4H)-one (RTC84) (122)† 
 
Prepared from 3-iso-propyl-1H-pyrazol-5-amine (132 mg, 1.05 mmol) and ethyl 3-oxo-
3-(3-(trifluoromethyl)phenyl)propanoate (232 µL, 1.16 mmol) using AcOH (10 mL) 
and following the procedure described in section 10.4. The reaction mixture was heated 
at reflux for 4 hrs. Compound 122 was triturated from EtOAc (4 mL) to give an off 
white solid, 101 mg (30%). 
1H NMR: (300 MHz, CD3OD) δ 8.17 (s, 1H, H9), 8.14 (d, J = 8.1 Hz, 1H, H6), 7.93 (d, 
J = 7.5 Hz, 1H, H8), 7.82-7.77 (m, 1H, H7), 3.07-2.93(m, 1H, CH(CH3)2), 1.25 (d, J = 
7.1 Hz, 6H, (CH3)2). 13C NMR: (75 MHz, CD3OD) δ 162.1 (C=O), 156.1 (C4), 147.7 
(C3), 142.1 (C1), 133.4 (C10), 131.4 (C6), 130.1 (C7), 129.6 (q, J = 32.6 Hz, C-CF3), 
127.3 (q, J = 3.7 Hz, C8), 123.80 (q, J = 270.0 Hz, CF3), 123.84 (q, J = 3.7 Hz, C9), 
94.4 (C2), 86.6 (C5), 27.9 (CH(CH3)2), 22.1 (CH3)2). HR-MS: calcd for C16H15F3N3O 
m/z: [M + H]+, 322.1162; found: 322.1167 [Diff (ppm) = 1.6]. IR (KBr): 3183 (N-H), 
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2970 (C-H), 1671 (C=O), 1614 (C=C), 1593 (NH), 1437 (C=C), 1329 (C-F), 1249 (C-
N), 803 (N-H) cm-1. m.p.: Above 300 °C. 
10.90 Synthesis of 5-(3,5-bis(trifluoromethyl)phenyl)-4-ethyl-2-iso-
propylpyrazolo[1,5-a]pyrimidin-7(4H)-one (RTC64) (123)† 
  
K2CO3 (105 mg, 0.75 mmol) was added to a solution of compound 115 (100 mg, 0.25 
mmol) and iodoethane (31 µL, 0.37 mmol) dissolved in DMF (10 mL). The suspension 
was heated at reflux for 8 hrs after which the solvent was removed under reduced 
pressure. The residue was washed with 1 M aqueous HCl (10 mL) and the aqueous 
layer extracted with DCM (10 mL, followed by 3 x 10 mL). The combined organic 
layers were dried over MgSO4 and the solvent removed under reduced pressure. The 
residue was purified using flash chromatography (4:1 EtOAc:Pet. Ether) to give a white 
solid, 20 mg (18%). 
1H NMR: (300 MHz, CD3OD) δ 8.45 (s, 2H, H6, H8), 7.92 (s, 1H, H7), 6.49 (s, 1H, 
H2), 6.30 (s, 1H, H5), 4.89 (q, J = 7.5 Hz, 2H, CH2), 3.09-2.96 (m, 1H, CH(CH3)2), 
1.42 (d, J = 7.2 Hz, 6H, (CH3)2), 1.24 (t, J = 7.5 Hz, 3H, CH3). 13C NMR: (75 MHz, 
CD3OD) δ 159.6 (C=O), 158.2 (C4), 157.8 (C3), 153.6 (C1), 140.1 (C9), 131.9 (q, J = 
33.0 Hz, C-CF3), 127.2 (q, J = 3.3 Hz, C6, C8), 123.1 (q, J = 3.3 Hz, C7), 123.3 (q, J = 
270.0 Hz, CF3), 98.2 (C2), 96.5 (C5), 44.3 (CH2), 25.4 (CH(CH3)2), 22.0 ((CH3)2), 14.7 
(CH3). HR-MS: calcd for C19H18F6N3O m/z: [M + H]
+, 418.1349; found: 
418.1353[Diff(ppm) = 1.10]. Rf: 0.6 (4:1 EtOAc: Pet. Ether) IR (KBr): 2968 (C-H), 
1697 (C=O), 1653 (C=C), 1482 (C=C), 1369 (C-F), 1278 (C-N) cm-1. m.p.: 253-255 
°C. 
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10.91 Synthesis of ethyl 2-((dimethylamino)methylene)-3-oxobutanoate (RD159) 
(124)157 
 
Ethyl acetoacetate (194 µL, 1.53 mmol) was stirred at rt and N, N-dimethyl formamide 
dimethyl acetal (256 µL, 1.92 mmol) was added dropwise over 10 mins and stirred at rt 
overnight. The reaction mixture was concentrated under reduced pressure and 
azeotroped with toluene (3 x 5 mL) to give compound 124 as a yellow oil which 
became orange on standing, 238 mg (83%). 
1H NMR: (300 MHz, CDCl3) δ 7.66 (s, 1H, C=CH), 4.21 (q, J = 7.5 Hz, 2H, CH2CH3), 
3.05 (bs, 6H, N(CH3)2), 2.28 (s, 3H, (C=O)CH3), 1.31 (t, J = 7.5 Hz, 3H, CH2CH3). 
1H 
NMR data matches literature data.218 Rf: 0.2 (4:1, EtOAc:n-hexane). HR-MS: calcd for 
C9H16NO3 m/z: [M + H]
+, 186.1125; found: 186.1120 [Diff (ppm) = -2.69]. 
10.92 Synthesis of (Z)-ethyl 2-((dimethylamino)methylene)-3-oxopentanoate 
(RD347) (125)219 
 
Ethyl 3-oxopentanoate (303 µL, 2.13 mmol) was stirred at rt and N, N-dimethyl 
formamide dimethyl acetal (500 µL, 3.76 mmol) was added dropwise over 10 mins and 
stirred at rt overnight. The reaction mixture was concentrated under reduced pressure 
and azeotroped with toluene (3 x 5 mL) to give compound 125 as a red oil, 410 mg 
(crude yield), which was used without further purification.  
1H NMR: (300 MHz, CDCl3) δ 7.56 (s, 1H, C=CH), 4.13 (q, J = 7.14 Hz, 2H, OCH2), 
2.93 (bs, 6H, N(CH3)2), 2.63-2.55 (m, 2H, CH2), 1.23 (t, J = 7.14. 3H, OCH2CH3), 1.01 
(t, J = 7.38 Hz, 2H, CH2CH3). 
1H NMR data matches literature data.219 Rf: 0.2 (4:1, 
EtOAc:n-hexane). 
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10.93 Synthesis of ethyl 1-(4-fluorophenyl)-5-methyl-1H-pyrazole-4-carboxylate 
(RD161) (126)215 
 
Compound 124 (542 mg, 2.90 mmol) was dissolved in EtOH (5 mL) in a 20 mL round 
bottom flask. In a second flask, (4-fluorophenyl)hydrazine.HCl (476 mg, 2.90 mmol) 
and NEt3 (404 µL, 2.90 mmol) in EtOH (5 mL) were stirred for 10 mins at rt after 
which the solution was transferred to the round bottom containing compound 124. The 
reaction mixture was heated at reflux and the reaction progress monitored by TLC. 
After 2 hrs the EtOH was removed under reduced pressure and the residue dissolved in 
a saturated aqueous NaHCO3 solution (10 mL). The aqueous layer was extracted with 
EtOAc (10 mL, followed by 3 x 10 mL) and dried over MgSO4. The combined organic 
layers were concentrated under reduced pressure and the residue was purified using 
flash chromatography (1:9, EtOAc:Pet. Ether) to give a beige solid, 647 mg (90%). 
1H NMR: (300 MHz, CDCl3) δ 7.87 (s, 1H, N=CH), 7.32-7.25 (m, 2H, H2, H3), 7.08-
7.00 (m, 2H, H1, H4), 4.18 (q, J = 7.2 Hz, 2H, CH2CH3), 2.41 (s, 3H, CH3), 1.24 (t, J = 
7.2 Hz, 3H, CH2CH3). 
1H NMR data matches literature data.215 Rf: 0.5 (1:9, EtOAc:Pet. 
Ether). HR-MS: calcd for C13H14FN2O2 m/z: [M + H]
+, 250.1065; found: 250.1075 
[Diff (ppm) = 4.13]. m.p.: 30-32 °C. 
10.94 Synthesis of ethyl 5-methyl-1-phenyl-1H-pyrazole-4-carboxylate (RD1) 
(127)222 
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Compound 124 (596 mg, 3.22 mmol) was dissolved in EtOH (5 mL) in a 20 mL round 
bottom flask to which a solution of phenylhydrazine (317 µL, 3.22 mmol) in EtOH (5 
mL) was added. The reaction mixture waa heated at reflux and the reaction progress 
monitored by TLC. After 4 hrs the EtOH was removed under reduced pressure and the 
residue dissolved in a saturated aqueous NaHCO3 solution (10 mL). The aqueous layer 
was extracted with EtOAc (10 mL, followed by 3 x 10 mL) and dried over MgSO4. The 
combined organic layers were concentrated under reduced pressure and the residue was 
purified using flash chromatography (9:1 EtOAc:n-hexane) to give a dark red solid, 720 
mg (97%). 
1H NMR: (300 MHz, CDCl3) δ 8.03 (s, 1H, N=CH), 7.53-7.40 (m, 5H, Ar), 4.33 (q, J = 
7.2 Hz, 2H, CH2CH3), 2.56 (s, 3H, CH3), 1.37 (t, J = 7.2 Hz, 3H, CH2CH3). 
1H NMR 
data matches literature data.222 13C NMR: (75 MHz, CDCl3) δ 163.8 (C=O), 143.5 (C3), 
141.8 (N=CH), 138.8 (C2), 129.2 (Ar), 128.6 (Ar), 125.5 (Ar), 112.9 (C1), 59.9 
(CH2CH3), 14.4 (CH3), 11.9 (CH2CH3).  Rf: 0.8 (9:1 EtOAc:n-hexane). HR-MS: calcd 
for C13H15N2O2 m/z: [M + H]
+, 231.1128; found: 231.1134 [Diff(ppm) = 2.59]. m.p.: 
160-161 °C. 
10.95 Synthesis of ethyl 1-(4-chlorophenyl)-5-methyl-1H-pyrazole-4-carboxylate 
(RD2) (128) 
 
Compound 124 (677 mg, 3.66 mmol) was dissolved in EtOH (5 mL) in a 20 mL round 
bottom flask. In a second flask, (4-chlorophenyl)hydrazine.HCl (1.03 g, 3.66 mmol) 
using NEt3 (561 µL, 4.02 mmol) in EtOH (5 mL) were stirred for 10 mins at rt after 
which the solution was transferred to the round bottom containing compound 124. The 
reaction mixture was heated at reflux and the reaction progress monitored by TLC. 
After 2 hrs the EtOH was removed under reduced pressure and the residue dissolved in 
a saturated aqueous NaHCO3 solution (10 mL). The aqueous layer was extracted with 
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EtOAc (10 mL, followed by 3 x 10 mL) and dried over MgSO4. The combined organic 
layers were concentrated under reduced pressure. Compound 128 used without further 
purification. Red oil, 698 mg (72%, crude yield). 
1H NMR: (300 MHz, CDCl3) δ 8.01 (s, 1H, N=CH), 7.45 (d, J = 8.7 Hz, 2H, H1, H4), 
7.34 (d, J = 8.7 Hz, 2H, H2, H3), 4.31 (q, J = 7.1 Hz, 2H, CH2CH3), 2.54 (s, 3H, CH3), 
1.36 (t, J = 7.1 Hz, 3H, CH3). Rf: 0.7 (9:1 EtOAc:n-hexane). 
10.96 Synthesis of ethyl 1-(4-methoxyphenyl)-5-methyl-1H-pyrazole-4-carboxylate 
(RD3) (129) 
 
Compound 124 (544 mg, 2.9 mmol) was dissolved in EtOH (5 mL) in a 20 mL round 
bottom flask. In a second flask, (4-methoxyphenyl)hydrazine.HCl (513 mg, 2.9 mmol) 
using NEt3 (404 µL, 2.9 mmol) and EtOH (10 mL) were stirred for 10 mins at rt after 
which the solution was transferred to the round bottom containing compound 124. The 
reaction mixture was heated at reflux and the reaction progress monitored by TLC. 
After 2 hrs the EtOH was removed under reduced pressure and the residue dissolved in 
a saturated aqueous NaHCO3 solution (10 mL). The aqueous layer was extracted with 
EtOAc (10 mL, followed by 3 x 10 mL) and dried over MgSO4. The combined organic 
layers were concentrated under reduced pressure and compound 129 was used without 
further purification. Beige solid, 714 mg (crude yield). 
1H NMR: (300 MHz, CDCl3) δ 7.99 (s, 1H, N=CH), 7.31 (d, J = 9.1 Hz, 2H, H2, H3), 
6.97 (d, J = 9.1 Hz, 2H, H1, H4), 4.31 (q, J = 7.2 Hz, 2H, CH2CH3), 3.82 (s, 3H, OMe), 
2.51 (s, 3H, CH3), 1.36 (t, J = 7.2 Hz, 3H, CH2CH3). 
1H NMR data matches literature 
data.138 Rf: 0.7 (9:1, EtOAc:Pet. Ether). 
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10.97 Synthesis of ethyl 5-ethyl-1-(4-fluorophenyl)-1H-pyrazole-4-carboxylate 
(RD348) (130) 
 
Compound 125 (426 mg, 2.13 mmol) was dissolved in EtOH (5 mL) in a 20 mL round 
bottom flask. In a second flask, (4-fluorophenyl)hydrazine.HCl (347 mg, 2.13 mmol) 
and NEt3 (328 µL, 2.34 mmol) in EtOH (5 mL) were stirred for 10 mins at rt after 
which the solution was transferred to the round bottom containing compound 125. The 
reaction mixture was heated at reflux and the reaction progress monitored by TLC. 
After 2 hrs the EtOH was removed under reduced pressure and the residue dissolved in 
a saturated aqueous NaHCO3 solution (10 mL). The aqueous layer was extracted with 
EtOAc (10 mL, followed by 3 x 10 mL) and dried over MgSO4. The combined organic 
layers were concentrated under reduced pressure and the residue was purified using 
flash chromatography (1:9, EtOAc:Pet. Ether) to give a yellow oil, 483 mg (90%). 
1H NMR: (300 MHz, CDCl3) δ 7.88 (s, 1H, N=CH), 7.30-7.26 (m, 2H, H3, H6), 7.09-
7.04 (m 2H, H4, H5), 4.20 (q, J = 7.1 Hz, 2H, OCH2), 2.81 (q, J = 7.5 Hz, 2H, CH2), 
1.25 (t, J = 7.1 Hz, 3H, OCH2CH3), 1.04 (t, J = 7.5 Hz, 3H, CH2CH3). 13C NMR: (75 
MHz, CDCl3) 162.7 (C=O), 161.4 (d, J = 247.4 Hz, C-F), 148.5 (C22), 141.0 (N=CH), 
134.0 (d, J = 3.1 Hz, C7), 126.8 (d, J = 8.7 Hz, C3, C6), 115.2 (d, J = 22.1 Hz, C4, C5), 
111.0 (C1), 58.9 (OCH2), 17.5 (CH2), 13.3 (OCH2CH3), 12.5 (CH2CH3). Rf: 0.5 (1:9, 
EtOAc:Pet. Ether). HR-MS: calcd for C14H16FN2O2 m/z: [M + H]
+, 265.1247; found: 
265.1259 [Diff (ppm) = 4.43]. IR (KBr): 2981 (C-H), 1710 (C=O), 1605 (C=C), 1474 
(C=C), 1264 (C-F), 1220 (C-N) cm-1. 
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10.98 Synthesis of 1-(4-fluorophenyl)-5-methyl-1H-pyrazole-4-carboxylic acid 
(RD182) (131)215 
 
Compound 126 (424 mg, 1.71 mmol) and NaOH (341 mg, 8.55 mmol) in EtOH (10 
mL) were heated at reflux and reaction progress monitored by TLC (3:2 EtOAc: Pet. 
Ether). After 5 hrs the solution was allowed to cool to rt and EtOH was removed under 
reduced pressure. The residue was dissolved in H2O (3 mL), the pH adjusted to pH = 6 
with 2 M aqueous HCl and the aqueous layer extracted with DCM (20 mL, followed by 
4 x 10 mL). The organic layers were washed with brine (3 x 20 mL), dried over MgSO4 
and evaporated under reduced pressure. The residue was purified using flash 
chromatography (1:9, MeOH:DCM) to give a beige solid, 306 mg (81%). 
1H NMR: (300 MHz, CDCl3) δ 8.10 (s, 1H, N=CH), 7.45-7.39 (m, 2H, H2, H3), 7.24-
7.17 (m 2H, H1, H4), 2.57 (s, 3H, CH3). 
1H NMR data matches literature data.216 Rf: 
0.4 (1:9, MeOH:DCM). HR-MS: calcd for C11H10FN2O2 m/z: [M + H]
+, 221.0721; 
found: 221.0716 [Diff(ppm) = -2.26]. m.p.: 158-160 °C. 
10.99 Synthesis of 5-methyl-1-phenyl-1H-pyrazole-4-carboxylic acid (RD4) (132)215  
 
Compound 127 (494 mg, 2.15 mmol) and KOH (603 mg, 10.75 mmol) in EtOH (12 
mL) were heated at reflux and reaction progress monitored by TLC (3:2 EtOAc: Pet. 
Ether). After 5 hrs the solution was allowed to cool to rt and EtOH was removed under 
reduced pressure. The residue was dissolved in H2O (3 mL), the pH adjusted to pH = 6 
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with 2 M aqueous HCl and the aqueous layer extracted with DCM (20 mL, followed by 
4 x 10 mL). The organic layers were washed with brine (3 x 20 mL), dried over MgSO4 
and evaporated under reduced pressure. The residue was purified using flash 
chromatography (1:9, MeOH:DCM) to give a light brown solid, 405 mg (93%). 
1H NMR: (300 MHz, CDCl3) δ 12.04 (bs, 1H, OH), 8.13 (s, 1H, N=CH), 7.54-7.41 (m 
5H, Ph), 2.58 (s 3H, CH3). 
1H NMR data matches literature data.216 Rf: 0.5 (1:9, 
MeOH:DCM). HR-MS: calcd for C11H11N2O2 m/z: [M + H]
+, 203.0815; found: 
203.082 [Diff(ppm) = 2.55]. m.p.:  160-162 °C (DCM). Literature m.p.: 163-164 
(Pet.Ether/Benzene).223 
10.100 Synthesis of 1-(4-chlorophenyl)-5-methyl-1H-pyrazole-4-carboxylic acid 
(RD5) (133)215 
 
Compound 128 (703 mg, 2.66 mmol) and KOH (746 mg, 13.31 mmol) in EtOH (15 
mL) were heated at reflux and reaction progress monitored by TLC (3:2 EtOAc: Pet. 
Ether). After 5 hrs the solution was allowed to cool to rt and EtOH was removed under 
reduced pressure. The residue was dissolved in H2O (3 mL), the pH adjusted to pH = 6 
with 2 M aqueous HCl and the aqueous layer extracted with DCM (20 mL, followed by 
4 x 10 mL). The organic layers were washed with brine (3 x 20 mL), dried over MgSO4 
and evaporated under reduced pressure. The residue was purified using flash 
chromatography (1:9, MeOH:DCM) to give a brown solid, 365 mg (58 %). 
1H NMR: (300 MHz, d6-DMSO) δ 12.53 (bs, 1H, OH), 7.98 (s, 1H, N=CH), 7.63 (d, J 
= 9.1 Hz, 2H, H1, H4), 7.58 (d, J = 9.1 Hz, 2H, H2, H3), 2.51 (s, 3H, CH3). 
1H NMR 
data matches literature data.221 HR-MS: calcd for C11H9ClN2O2K m/z: [M + K]
+, 
274.9984; found 274.9972 [Diff(ppm) = -4.24]. m.p.: 182-184 °C. m.p. data matches 
literature data.221  
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10.101 Synthesis of 1-(4-methoxyphenyl)-5-methyl-1H-pyrazole-4-carboxylic acid 
(RD6) (134)215 
 
Compound 129 (714 mg, 2.7 mmol) and NaOH (486 mg, 12.15 mmol) in EtOH (10 
mL) were heated at reflux and reaction progress monitored by TLC (3:2 EtOAc: Pet. 
Ether). After 5 hrs the solution was allowed to cool to rt and EtOH was removed under 
reduced pressure. The residue was dissolved in H2O (3 mL), the pH adjusted to pH = 6 
with 2 M aqueous HCl and the aqueous layer extracted with DCM (20 mL, followed by 
4 x 10 mL). The organic layers were washed with brine (3 x 20 mL), dried over MgSO4 
and evaporated under reduced pressure. The residue was purified using flash 
chromatography (1:9, MeOH:DCM) to give a beige solid, 230 mg (33%). 
1H NMR: (300 MHz, CDCl3) δ 8.07 (s, 1H, N=CH), 7.33 (d, J = 9.0 Hz, 2H, H2, H3), 
7.00 (d, J = 9.0 Hz, 2H, H1, H4), 3.87 (s, 3H, OMe), 2.54 (s, 3H, CH3). 
1H NMR data 
matches literature data.220 Rf: 0.4 (1:9, MeOH:DCM). HR-MS: calcd for C12H13N2O3 
m/z: [M + H]+, 233.0921; found 233.0923 [Diff (ppm) = 1.15]. 
10.102 Synthesis of 5-ethyl-1-(4-fluorophenyl)-1H-pyrazole-4-carboxylic acid 
(RD349) (135)  
 
Compound 130 (335 mg, 1.27 mmol) and KOH (358 mg, 6.35 mmol) in EtOH (10 mL) 
were heated at reflux and reaction progress monitored by TLC (3:2 EtOAc: Pet. Ether). 
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After 5 hrs the solution was allowed to cool to rt and EtOH was removed under reduced 
pressure. The residue was dissolved in H2O (3 mL), the pH adjusted to pH = 6 with 2 M 
aqueous HCl and the aqueous layer extracted with DCM (20 mL, followed by 4 x 10 
mL). The organic layers were washed with brine (3 x 20 mL), dried over MgSO4 and 
evaporated under reduced pressure. The residue was purified using flash 
chromatography (1:9, MeOH:DCM) to give an off white solid, 290 mg (96%). 
1H NMR: (300 MHz, CDCl3) δ 12.08 (bs, 1H, OH), 8.10 (s, 1H, N=CH), 7.44-7.40 (m, 
2H, H3, H6), 7.24-7.18 (m, 2H, H4, H5), 2.95 (q, J = 7.4 Hz, 2H, CH2), 1.18 (t, J = 7.4 
Hz, 3H, CH3). 13C NMR: (75 MHz, CDCl3) δ 168.9 (C=O), 162.3 (d, J = 248.1 Hz, C-
F), 150.6 (C2), 142.8 (N=CH), 134.7 (d, J = 3.1 Hz, C7), 127.9 (d, J = 9.1 Hz, C3, C6), 
116.3 (d, J = 23.2 Hz, C4, C5), 111.3 (C1), 18.6 (CH2), 13.6 (CH3). Rf: 0.5 (1:19, 
MeOH:DCM). HR-MS: calcd for C12H12FN2O2 m/z: [M + H]
+, 237.0932; found: 
237.0942 [Diff (ppm) = 4.01]. IR (KBr): 3427 (OH), 1672 (C=O), 1477 (C=C), 1223 
(C-F) cm-1. m.p.: 140-143 °C. 
10.103 Synthesis of 4-(2-methoxyphenyl)pyridine.HCl (RD215) (136)159 
 
4-Bromopyridine.HCl (639 mg, 3.88 mmol) and (2-methoxyphenyl)boronic acid (500 
mg, 3.39 mmol) were dissolved in toluene (20 mL). Pd(PPh3)4 (760 mg, 0.65 mmol) and 
Cs2CO3 (3.21 g, 10.17 mmol) were added and the suspension was heated at reflux 
overnight. The reaction was cooled to rt and passed through a bed of Celite. The filtrate 
was concentrated under reduced pressure to give compound 136 as a yellow oil, which 
was used without any further purification. 330 mg (crude yield). 
1H NMR: (300 MHz, D2O) δ 8.76-8.46 (m, 2H, N=CH), 7.53-7.30 (m, 4H, Ar), 7.12-
6.93 (m, 2H, Ar), 3.88 (s, 3H, OCH3). 
10.104 Synthesis of 4-(2-methoxyphenyl)piperidine (RD216) (137)159 
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Compound 136 (330 mg, 1.48 mmol) was dissolved in MeOH (20 mL) and PtO2 (168 
mg, 0.74 mmol) was added. The flask was evacuated and purged with H2 (x 3) and the 
reaction was stirred overnight at rt. The reaction mixture was filtered through a pad of 
Celite and washed with MeOH (15 mL, x 3). The filtrate was concentrated under 
reduced pressure and residue was dissolved in saturated aqueous NaHCO3 (10 mL) and 
stirred for 2 hrs at rt. The aqueous layer was extracted with DCM (10 mL, x 3) and 
dried over MgSO4. The combined organic layers were concentrated under reduced 
pressure and the residue was purified using flash chromatography (2:98, NEt3:MeOH) 
to give a brown oil, 225 mg (18%). 
1H NMR: (300 MHz, CDCl3) δ 7.20-7.18 (m, 2H, Ar), 6.95-6.84 (m, 2H, Ar), 4.81-4.23 
(m, 1H, ArCH), 3.81 (s, 3H, OCH3), 3.40-3.02 (m, 2H*), 2.95-2.71 (m 2H*), 1.81-1.67 
(m, 4H*)*Piperidine. 1H NMR data matches literature data.217 Rf: 0.2 (2:98, 
NEt3:MeOH). HR-MS: calcd for C12H18NO m/z: [M + H]
+, 192.1383; found 192.1388 
[Diff(ppm) = 2.6]. 
10.105 Synthesis of (5-methyl-1-phenyl-1H-pyrazol-4-yl(4-(4-
(trifluoromethyl)phenyl)piperazin-1-yl) methanone (RTC206) (138)† 
 
Prepared from compound 33 (270 mg, 1.17 mmol) and compound 132 (215 g, 1.06 
mmol) using HOBt (158 mg, 1.17 mmol), TBTU (375 mg, 1.17 mmol), anhydrous NEt3 
(327 µL, 1.70 mmol) and anhydrous DMF (10 mL) and following the general procedure 
described in section 10.2. The reaction mixture was stirred overnight at room 
temperature under a N2 atmosphere. Purified using flash chromatography (3:2 
EtOAc:Pet. Ether) to give an off white solid, 149 mg (36%). 
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1H NMR: (300 MHz, CDCl3) δ 7.68 (s, 1H, N=CH), 7.52-7.42 (m, 7H, H1, H5, Ar x 5), 
6.95 (d, J = 8.7 Hz, 2H, H2, H4), 3.91 (m, 4H*), 3.36-3.32 (m, 4H*), 2.45 (s, 3H, 
CH3).*Piperazine. 13C NMR: (75 MHz, CDCl3) δ 164.7 (C=O), 152.9 (C3), 141.2 (C7), 
139.0 (C8), 138.8 (N=CH), 129.2 (Ar), 128.5 (Ar), 126.5 (q, J = 3.0 Hz, C1, C5), 125.3 
(Ar), 124.6 (q, J = 269.5 Hz, CF3), 121.3 (q, J = 33.1 Hz, C-CF3), 115.1 (C6), 115.0 
(C2, C4), 48.4 (C*), 11.7 (CH3).*Piperazine. Rf: 0.4 (3:2 EtOAc:Pet. Ether). HR-MS: 
calcd for C22H22F3N4O m/z: [M + H]
+, 416.1770; found: 416.1762 [Diff (ppm) = -1.95].  
IR(Br): 2893 (C-H), 1626 (C=O), 1617 (C=C), 1426 (C=C), 1332 (C-F), 1232 (C-N) 
cm-1. m.p.: 204-208 °C. Anal. calcd for C22H21F3N4O; C, 63.76; H, 5.11; N, 13.52% 
found: C, 63.53; H, 4.90; N, 13.20%. 
10.106 Synthesis of (4-(3-chloro-5-(trifluoromethyl)pyridin-2-yl)piperazin-1-yl(1-
(4-chlorophenyl)-5-methyl-1H-pyrazol-4-yl)methanone (RTC213) (139)† 
 
Prepared from 1-(3-chloro-5-(trifluoromethyl)pyridin-2-yl)piperazine (126 mg, 0.47 
mmol) and compound 133 (102 mg, 0.43 mmol) using HOBt (64 mg, 0.47 mmol) 
TBTU (152mg, 0.47 mmol), NEt3 (60 µL, 0.68 mmol) and DMF (6 mL) and following 
the general procedure described in section 10.2. The reaction mixture was stirred at rt 
overnight under a N2 atmosphere. Purified using flash chromatography (1:1 EtOAc:n-
hexane) to give an off white solid, 95 mg (46%). 
1H NMR: (300 MHz, CDCl3) δ 8.43-8.42 (m, 1H, H3), 7.82-7.81 (m, 1H, H1), 7.68 (s, 
1H, N=CH), 7.48 (d, J = 9.2 Hz, 2H, H7, H9), 7.40 (d, J = 9.2 Hz, 2H, H6, H10), 3.91-
3.86 (m, 4H*), 3.58-3.55 (m, 4H*), 2.46 (s, 3H, CH3).*Piperazine. 13C NMR: (75 MHz, 
CDCl3) δ 164.6 (C=O), 159.5 (C2), 143.0 (q, J = 4.1 Hz, C3), 141.0 (C5), 139.1 
(N=CH), 137.5 (C11), 136.1 (q, J = 3.3 Hz, C1), 134.3 (C8), 129.4 (C7, C9), 126.4 (C6, 
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C10), 123.1 (q, J = 270.0 Hz, CF3), 121.2 (C-Cl), 120.6 (q, J = 33.0 Hz, C-CF3), 115.6 
(C4), 48.8 (C*), 11.7 (CH3).*Piperazine. Rf: 0.3 (1:1 EtOAc:Pet. Ether). HR-MS: calcd 
for C21H19Cl2F3NO m/z: [M + H]
+, 484.0913; found: 484.0912 [Diff (ppm) = -0.25].  IR 
(KBr): 2863 (C-H), 1623 (C=O), 1604 (C=C), 1449 (C=C), 1314 (C-F), 1234 (C-N) 
cm-1. m.p.: 122-124 °C. Anal. calcd for C21H18Cl2F3N5O; C, 52.08; H, 3.75; N, 14.46% 
found: C, 51.76; H, 3.93; N, 14.56%. 
10.107 Synthesis of (1-(4-methoxyphenyl)-5-methyl-1H-pyrazol-4-yl)(4-(2-
methoxyphenyl)piperidin-1-yl)methanone (RTC218) (140)† 
 
Compound 137 (50 mg, 0.21 mmol), BOP (70 mg, 0.15 mmol), anhydrous NEt3 (30 µL, 
0.21 mmol) and anhydrous DCM (6 mL) were placed in an oven-dried three neck flask 
under a N2 atmosphere. The resulting solution was stirred at rt for 15 mins. In a second 
flask, compound 134 (28 mg, 0.12 mmol) and NEt3 (30 µL, 0.21 mmol) in DCM (3 mL) 
were stirred under a N2 atmosphere at rt for 15 mins after which the solution was 
transferred to the flask containing compound 137. The reaction mixture stirred under a 
N2 atmosphere and the reaction progress was monitored by TLC. After 12 hrs, DCM 
was removed under reduced pressure and the resulting oil was acidified to pH = 3 using 
a 0.1 M aqueous HCl. The aqueous mixture was extracted with DCM (20 mL, followed 
by 4 x 10 mL) and the organic layer washed with a saturated aqueous solution of 
NaHCO3 (3 x 20 mL) and brine (3 x 20 mL). The organic layer was dried over MgSO4 
and the solvent removed in vacuo and the residue was purified using flash 
chromatography (3:2 EtOAc:Pet. Ether) to give  an off white solid 68 mg (62%). 
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1H NMR: (300 MHz, CD3CN, T = 60 °C) δ 7.64 (s, 1H, N=CH), 7.43-7.38 (m, 2H, Ar), 
7.24-7.19 (m, 2H, Ar), 7.10-7.06 (m, 2H, Ar), 7.00-6.92 (m, 2H, Ar), 4.46-4.42 (m, 
2H*), 3.88 (s, 3H, OCH3), 3.86 (s, 3H, OCH3), 3.31-3.21 (m, 1H, Ar-CH), 3.10-3.02 
(m, 2H*), 1.88-1.84 (m, 2H*), 1.76-1.62 (m, 2H*).*Piperidine. 13C NMR: (75 MHz, 
CD3CN, T = 60 °C) δ 164.3 (C=O), 159.6 (C5), 157.0 (C2), 139.6 (C1), 138.2 (N=CH), 
133.7 (C6), 132.6 (C4), 127.2 (Ar), 126.7 (Ar), 126.5 (Ar), 120.7 (Ar), 116.1 (C3), 
114.3 (Ar), 111.1 (Ar), 55.3 (OCH3), 55.2 (OCH3), 45.3 (C*), 35.8 (Ar-CH), 32.0 (C*), 
10.6 (CH3).*Piperidine. Rf: 0.7 (3:2 EtOAc:Pet.Ether). HR-MS: calcd for C24H28N3O3 
m/z: [M + H]+, 406.2125; found: 406.2139 [Diff (ppm) = -3.4]. IR (KBr): 2935 (CH), 
1614 (C=O), 1236 (C-N), 1219 (O-CH3) cm
-1.m.p.: 176-178 °C. 
10.108 Synthesis of (5-ethyl-1-(4-fluorophenyl)-1H-pyrazol-4-yl)(4-(2-
methoxyphenyl)piperazin-1-yl)methanone (RTC217) (141)† 
 
Compound 137 (50 mg, 0.21 mmol), BOP (70 mg, 0.15 mmol), anhydrous NEt3 (30 µL, 
0.21 mmol) and anhydrous DCM (6 mL) were placed in an oven-dried three neck flask 
under a N2 atmosphere. The resulting solution was stirred at rt for 15 mins. Compound 
135 (55 mg, 0.23 mmol) was added and the reaction mixture stirred under a N2 
atmosphere and the reaction progress was monitored by TLC. After 12 hrs, DCM was 
removed under reduced pressure and the resulting oil was acidified to pH = 3 using a 
0.1 M aqueous HCl. The aqueous mixture was extracted with DCM (20 mL, followed 
by 4 x 10 mL) and the organic layer washed with a saturated aqueous solution of 
NaHCO3 (3 x 20 mL) and brine (3 x 20 mL). The organic layer was dried over MgSO4 
and the solvent removed in vacuo and the residue was purified using flash 
chromatography (3:2 EtOAc:Pet. Ether) to give  a colourless oil, 70 mg (67%). 
Chapter 10                                           Experimental 
306 
 
1H NMR: (300 MHz, CD3CN, T = 60 °C) δ 7.64 (s, 1H, N=CH), 7.52-7.46 (m, 2H, H5, 
H6), 7.32-7.19 (m, 4H, Ar), 6.99-6.92 (m, 2H, H4, H7), 4.47-4.43 (m, 2H*), 3.85 (s, 
3H, OCH3), 3.31-3.21 (m, 1H, Ar-CH), 3.10-3.01 (m, 2H*), 2.81 (q, J = 7.5 Hz, 2H, 
CH2CH3), 1.90-1.80 (m, 2H*), 1.76-1.62 (m, 2H*), 1.08 (t, J = 7.5 Hz, 3H, 
CH2CH3)*Piperidine. 13C NMR: (75 MHz, CD3CN, T = 60 °C) δ 164.1 (C=O), 162.2 
(d, J = 244.7 Hz, C-F), 157.0 (C-OCH3), 145.4 (C1), 138.2 (N=CH), 135.9 (d, J = 3.0 
Hz, C8), 133.6 (C3), 127.8 (d, J = 9.0 Hz, C4, C7), 127.1 (Ar), 126.5 (Ar), 120.6 (Ar), 
115.8 (d, J = 22.9 Hz, C5, C6), 115.7 (C2), 111.0 (Ar), 55.1 (OCH3), 45.2 (C*), 35.8 
(Ar-C), 31.9 (C*), 17.9 (CH2), 12.6 (CH3).*Piperidine. Rf: 0.7 (3:2, EtOAc:Pet. Ether). 
HR-MS: calcd for C24H27FN3O2 m/z: [M + H]
+, 408.2082; found: 408.2088 [Diff (ppm) 
= 1.51]. IR (KBr): 2937 (CH), 1621 (C=O), 1373 (C-F), 1238 (C-N), 1218 (O-CH3) 
cm-1. 
10.109 Synthesis of (1-(4-fluorophenyl)-5-methyl-1H-pyrazol-4-yl)(4-(2-
methoxyphenyl)piperazin-1-yl)methanone (RTC220) (142)† 
 
Compound 131 (200 mg, 0.90 mmol), BOP (401 mg, 0.90 mmol), anhydrous NEt3 (200 
µL, 1.44 mmol) and anhydrous DCM (20 mL) were placed in an oven-dried three neck 
flask under a N2 atmosphere. The resulting solution was stirred at rt for 15 mins. 1-(2-
Methoxyphenyl)piperazine (192 mg, 0.99 mmol) was added and the reaction mixture 
stirred under a N2 atmosphere and the reaction progress was monitored by TLC. After 
18 hrs, DCM was removed under reduced pressure and the resulting oil was acidified to 
pH = 3 using a 0.1 M aqueous HCl. The aqueous mixture was extracted with DCM (20 
mL, followed by 4 x 10 mL) and the organic layer washed with a saturated aqueous 
solution of NaHCO3 (3 x 20 mL) and brine (3 x 20 mL). The organic layer was dried 
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over MgSO4 and the solvent removed in vacuo and the residue was purified using flash 
chromatography (3:2, EtOAc:Pet.Ether) to give a give a white solid, 70 mg (71%). 
1H NMR: (300 MHz, CD3CN) δ 7.69 (s, 1H, N=CH), 7.54-7.49 (m, 2H, H5, H6), 7.31-
7.25 (m, 2H, Ar), 7.05-6.90 (m, 4H, H4, H7, Ar), 3.86 (s, 3H, OCH3), 3.86-3.77 (m, 
4H*), 3.09-3.06 (m, 4H*), 2.37 (s, 3H, CH3).*Piperazine. 13C NMR: (75 MHz, 
CD3CN) δ 164.1 (C=O), 161.9 (d, J = 244.5 Hz, C-F), 152.6 (C1), 141.4 (C3), 139.9 (C-
OCH3), 138.7 (N=CH), 135.7 (d, J = 2.9 Hz, C8), 127.2 (d, J = 8.8 Hz, C4, C7), 122.9 
(Ar), 121.0 (Ar), 118.5 (Ar), 116.1 (C2), 115.7 (J = 23.0 Hz, C5, C6), 112.4 (Ar), 55.1 
(OCH3), 50.6 (C*), 44.8 (C*), 10.6 (CH3).*Piperazine. Rf: 0.4 (3:2, EtOAc:Pet. Ether) 
HR-MS: calcd for C22H24FN4O2 m/z: [M + H]
+, 397.1936; found: 397.1954 [Diff (ppm) 
= 4.5]. IR (KBr): 2758 (CH), 1629 (C=O), 1385 (C-F), 1236 (C-N), 1219 (O-CH3) cm
-
1.m.p.: 138-140 °C. 
10.110 Synthesis of (1-(4-fluorophenyl)-5-methyl-1H-pyrazol-4-yl)(4-
phenylpiperazin-1-yl)methanone (RTC200) (143)† 
 
Prepared from 1-phenylpiperazine (65 mg, 0.42 mmol) and compound 131 (65 mg, 0.37 
mmol) using HOBt (56 mg, 0.42 mmol), TBTU (133 mg, 0.42 mmol), anhydrous NEt3 
(84 µL, 0.60 mmol) and anhydrous DMF (5 mL) and following the general procedure 
described in section 10.2. The reaction mixture was stirred overnight at room 
temperature under a N2 atmosphere. Purified using flash chromatography (1:1 EtOAc:n-
hexane) to give a beige solid, 112 mg (81%). 
1H NMR: (300 MHz, CDCl3) δ 7.66 (s, 1H, N=CH), 7.43-7.38 (m, 2H, H4, H7), 7.31-
7.26 (m, 2H, Ar), 7.20-7.15 (m, 2H, H5, H6), 6.96-6.88 (m, 3H, Ar), 3.89 (m, 4H*), 
3.24-3.21 (m, 4H*), 2.42 (s, 3H, CH3).*Piperazine. 13C NMR: (75 MHz, CDCl3) δ 
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164.5 (C=O), 162.2 (d, J = 247.3 Hz, C-F), 150.9 (C1), 141.1 (C3), 138.9 (N=CH), 
135.2 (d, J = 3.7 Hz, C8), 129.2 (Ar), 127.2 (d, J = 8.2 Hz, C4, C7), 120.5 (Ar), 116.6 
(Ar), 116.2 (d, J = 23 Hz, C5, C6), 115.4 (C2), 49.8 (C*), 11.6 (CH3).*Piperazine. Rf: 
0.4 (3:2 EtOAc:Pet. Ether). HR-MS: calcd for C21H22FN4O m/z: [M + H]
+, 365.1772; 
found: 365.1771 [Diff (ppm) = -0.24]. IR (KBr): 2824 (C-H), 1601 (C=O), 1390 (C-F), 
1222 (C-N) cm-1. m.p.: 144-146 °C. 
10.111 Synthesis of (1-(4-fluorophenyl)-5-methyl-1H-pyrazol-4-yl)(4-
phenylpiperidin-1-yl)methanone (RTC216) (144)† 
 
Compound 124 (100 mg, 0.45 mmol), BOP (221 mg, 0.49 mmol), anhydrous NEt3 (101 
µL, 0.72 mmol) and anhydrous DCM (10 mL) were placed in an oven-dried three neck 
flask under a N2 atmosphere. The resulting solution was stirred at rt for 15 mins. 4-
Phenylpiperidine (80 mg, 0.49 mmol) was added and the reaction mixture stirred under 
a N2 atmosphere and the reaction progress was monitored by TLC. After 18 hrs, DCM 
was removed under reduced pressure and the resulting oil was acidified to pH = 3 using 
a 0.1 M aqueous HCl. The aqueous mixture was extracted with DCM (20 mL, followed 
by 4 x 10 mL) and the organic layer washed with a saturated aqueous solution of 
NaHCO3 (3 x 20 mL) and brine (3 x 20 mL). The organic layer was dried over MgSO4 
and the solvent removed in vacuo and the residue was purified using flash 
chromatography (3:2, EtOAc:Pet.Ether) to give  a white solid, 72 mg (60%). 
 1H NMR: (300 MHz, d6-DMSO, T = 60 °C) δ 7.75 (s, 1H, N=CH), 7.61-7.57 (m, 2H, 
H5, H6), 7.39-7.71 (m, 7H, Ar x 5, H4, H7), 4.36-4.42 (m, 2H*), 3.09-3.01 (m, 2H*), 
2.88-2.80 (m, 1H, Ar-CH), 2.34 (s, 3H, CH3), 1.89-1.84 (m, 2H*), 1.68-1.56 (m, 
2H*).*Piperidine. 13C NMR: (75 MHz, d6-DMSO, T = 60 °C) δ 163.5 (C=O), 161.4 (d, 
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J = 244.5 Hz, C-F), 145.5 (C1), 139.6 (C3), 138.7 (N=CH), 135.4 (d, J = 3.0 Hz, C8), 
128.3 (Ar), 127.2 (d, J = 8.8 Hz, C4, C7), 126.6 (Ar), 126.1 (Ar), 116.1 (C2), 115.9 (d, 
J = 22.3 Hz, C5, C6), 45.9 (C*), 41.7 (Ar-CH), 33.1 (C*), 11.0 (CH3). Rf: 0.3 (3:2 
EtOAc: Pet. Ether).*Piperidine. HR-MS: calcd for C22H23FN3O m/z: [M + H]
+, 
365.1859; found: 365.1851 [Diff (ppm) = 2.21]. IR (KBr): 2938 (CH), 1614 (C=O), 
1216 (C-N) cm-1.m.p.: 158-159 °C. 
10.112 Synthesis of N-(2-methoxyethyl)-9-oxo-9-(4-(4-
(trifluoromethyl)phenyl)piperazin-1-yl)nonanamide (RTC18) (146) 
 
Prepared from compound 79 (137 mg, 0.34 mmol) and 2-methoxyethanamine (29 µL, 
0.43 mmol) using HOBt (58 mg, 0.43 mmol), TBTU (140 mg, 0.43 mmol), anhydrous 
NEt3 (100 µL, 0.69 mmol) and anhydrous DMF (2 mL) and following the general 
procedure described in section 10.2. The reaction mixture was stirred overnight at room 
temperature under a N2 atmosphere. Purified using flash chromatography (elution 
gradient 1:1 EtOAc:n-hexane to EtOAc:n-hexane 4:1) to give an white solid, 52 mg 
(34%). 
1H NMR: (300 MHz, CDCl3) δ 7.50 (d, J = 8.4 Hz, 2H, H1, H5), 6.92 (d, J = 8.4 Hz, 
2H, H2, H4), 5.81 (bs, 1H, NH), 3.79-3.76 (m, 2H*), 3.65-3.62 (m, 2H*), 3.49-3.41 (m, 
4H, H6, H7), 3.62 (s, 3H, OCH3), 3.32-3.22 (m, 4H*), 2.36 (t, J = 7.2 Hz, 2H, 
((C=O)CH2), 2.17 (t, J = 7.2 Hz, 2H, ((C=O)CH2), 1.73-1.57 (m, 4H, CH2), 1.41-1.299 
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(m, 6H, CH2).*Piperazine. 13C NMR: (75 MHz, CDCl3) δ 173.0 (HN-(C=O), 171.7 (N-
C=O), 152.9 (C3), 126.5 (q, J = 3.3 Hz, C1, C5), 124.6 (q, J = 278.1 Hz, CF3), 121.2 (q, 
J = 26.0 Hz, C-CF3), 115.0 (C2, C4), 71.2 (C7), 58.7 (OCH3), 48.4 (C*), 48.1 (C*), 45.1 
(C*), 41.1 (C*), 39.0 (C6), 36.6 ((C=O)CH2), 33.2 ((C=O)CH2), 28.1 (CH2), 27.9 
(CH2), 27.8 (CH2), 24.1 (CH2), 23.6 (CH2). *Piperazine. Rf: 0.2 (4:1, EtOAc:n-hexane). 
HR-MS: calcd for C23H35F3N3O3 m/z: [M + H]
+, 458.2625; found: 458.2631  [Diff 
(ppm) = 1.31]. IR (KBr): 2932 (C-H), 1676 (NH-C=O), 1636 (N-C=O), 1618 (C=C), 
1442 (C=C), 1344 (C-F), 1208 (C-N) cm-1. m.p.: 88-92 °C. 
10.113 Synthesis of 5-(4-oxo-4-(4-(4-(trifluoromethyl)phenyl)piperazin-1-
yl)butyl)thiophene-2-carbaldehyde (RTC82) (147)† 
 
To a solution of dichloromethyl methyl ether (158 µL, 1.75 mmol) in anhydrous DCM 
(10 mL) at 0 °C was added tin(IV)chloride (1.76 mL, 15.00 mmol) under a N2 
atmosphere. After 5 mins, a solution of compound 4 (500 mg, 1.30 mmol) in anhydrous 
DCM (5 mL) was added dropwise over a period of 20 mins. The reaction mixture was 
stirred for 1 hr at rt, after which it was poured onto ice-water and stirred for 30 mins. 
The organic layer was removed and washed with H2O (10 mL, followed by 2 x 10 mL), 
dried over MgSO4 and concentrated in vacuo. The residue was purified using flash 
chromatography (3:2 EtOAc: Pet. Ether) to give a white solid, 332 mg, (62%). 
1H NMR: (300 MHz, CDCl3) δ 9.82 (s, 1H, CHO), 7.62 (d, J = 3.3 Hz, 1H, H11), 7.50 
(d, J = 8.7 Hz, 2H, H1, H5), 6.95-6.90 (m, 3H, H2, H4, H10), 3.80-3.77 (m, 2H*), 3.61-
3.59 (m 2H*), 3.28-3.25 (m, 4H*), 2.98 (t, J = 7.2 Hz, 2H, H8), 2.42 (t, J = 7.2 Hz, 2H, 
H6), 2.15-2.04 (m, 2H, H7).*Piperazine. 13C NMR: (75 MHz, CDCl3) δ 181.1 (CHO), 
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169.4 (C=O), 155.1 (C3), 151.8 (C9), 140.9 (C12), 136.0 (C11), 125.5 (q, J = 3.0 Hz, 
C1, C5), 125.2 (C10), 123.5 (q, J = 269.2 Hz, CF3), 120.4 (q, J = 32.7 Hz, C-CF3), 
114.0 (C2, C4), 47.3 (C*), 47.1 (C*), 44.0 (C*), 40.1 (C*), 30.7 (C6), 29.1 (C8), 25.1 
(C7).*Piperazine. Rf: 0.3 (3:2, EtOAc:Pet. Ether). HR-MS: calcd for C20H22F3N2O2S 
m/z: [M + H]+, 411.1349; found: 411.1333 [Diff (ppm) = -3.75]. IR (KBr): 2907 
(H(C=O)), 2833(CHO), 1661 (CHO), 1643 (C=O), 1615 (C=C), 1437 (C=C), 1333 (C-
F), 1222 (C-N) cm-1. m.p.: 98-100 °C. 
10.114 Synthesis of 3,6,9,12,15-pentaoxaheptadecane-1,17-diyl-bis(4-
methylbenzenesulfonate) (RD190) (148)209 
 
Hexaethylene glycol (1.23 g, 4.35 mmol) and DMAP (97 mg, 0.87 mmol) were 
dissolved in NEt3 (1.22 mL, 9.58 mmol) and DCM (30 mL) and the solution cooled to 0 
°C. Tosyl chloride (1.67 g, 9.58 mmol) was added and the reaction stirred at 0 °C for 15 
mins. The reaction was allowed to warm to rt and was stirred for 24 hrs at rt and was 
monitored by TLC. The reaction mixture was diluted with DCM (50 mL) and washed 
with saturated aqueous NaHCO3 (3 x 20 mL). The combined organic layer was dried 
over MgSO4, filtered and the solvent removed under reduced pressure. The residue was 
purified using flash chromatography (3:2, EtOAc:Pet.Ether) to give a clear oil, 1.88 g 
(80%). 
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1H NMR: (300 MHz, CDCl3) δ 7.78 (d, J = 8.3 Hz, 4H, H2, H3), 7.34 (d, J = 8.3 Hz, 
4H, H1, H4), 4.16-4.13 (m, 4H, OCH2 x 2),  3.69-3.66 (m, 4H, OCH2 x 2), 3.61 (bs, 8H, 
OCH2 x 4), 3.57 (bs, 8H, OCH2), 2.44 (s, 6H, CH3 x 2). 
1H NMR data matches literature 
data.209  Rf: 0.3 (3:2, EtOAc:Pet.Ether). HR-MS: calcd for C26H39O11S2 m/z: [M + H]
+, 
591.1928; found: 591.1928 [Diff(ppm) = 0.00]. 
10.115 Synthesis of 1,17-diazido-3,6,9,12,15-pentaoxaheptadecane (RD191) (149)208 
 
Sodium azide (0.56 g, 8.55 mmol) was added to a solution of compound 148 (2.3 g, 
3.88 mmol) in acetonitrile (60 mL) and the mixture was heated at reflux. After 48 hrs, 
the white precipitate was removed by filtration and washed with Et2O. The filtrate was 
concentrated under reduced pressure and the residue was purified using flash 
chromatography (3:2 EtOAc:Pet. Ether) to give a clear oil, 1.00 g (78%). 
1H NMR: (300 MHz, CDCl3) δ 3.69-3.51 (m, 20H, OCH2 x 10), 3.39 (t, J = 5.4 Hz, 4H, 
N3CH2 x 2). 
1H NMR data matches literature data.209 Rf: 0.3 (3:2, EtOAc:Pet.Ether). IR 
(neat):  2106 (N=N=N), 1121 (C-O) cm-1. HR-MS: calcd for C12H25N6O5 m/z: [M + 
H]+, 333.1881; found: 333.1879 [Diff(ppm) = -0.54]. 
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10.116 Synthesis of 3,6,9,12,15-pentaoxaheptadecane-1,17-diamine (RD198) 
(150)209  
 
A solution of compound 149 (416 mg, 1.25 mmol) in MeOH (30 mL) was degassed 
three times and purged with H2 gas (x 3). Platinum oxide (50 mg) was added and the 
mixture was stirred overnight under an atmosphere of H2 gas. The platinum oxide was 
removed using a bed of Celite and the filtrate was reduced under reduced pressure to 
give an off white oil in a quantitative yield, which was used without any further 
purification. 
1H NMR: (300 MHz, CDCl3) δ 3.33-3.20 (m, 20H, OCH2 x 10), 2.43-2.39 (m, 4H, 
NH2CH2 x 2). 
1H NMR data matches literature data.209 13CNMR: (75 MHz, CDCl3) δ 
70.3 (OCH2), 70.2 (OCH2), 70.2 (OCH2), 70.08 (OCH2), 70.04 (OCH2), 69.9 (OCH2), 
48.9 (OCH2). Rf: 0.1 (3:2, EtOAc:Pet.Ether).  HR-MS: calcd for C12H28N2O5K m/z: [M 
+ K]+, 319.163; found 319.1619 [Diff(ppm) = -3.44]. 
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10.117 Synthesis of 4-(5-((propylamino)methyl)thiophen-2-yl)-1-(4-(4-
(trifluoromethyl)phenyl)piperazin-1-yl)butan-1-one (RD222) (152)  
 
To a solution of compound 147 (50 mg, 0.13 mmol) in MeOH (4 mL), was added a 
solution of propan-1-amine (15 μL, 0.19 mmol) in MeOH (2 mL) and the resulting 
solution was stirred at rt. After 2 hrs, NaBH4 (4 mg, 0.13 mmol) was added and the 
mixture stirred overnight at rt. MeOH was removed under reduced pressure and the 
residue was purified flash chromatography (1:9, MeOH:DCM) to give a colourless oil, 
31 mg (56%). 
1H NMR: (300 MHz, CDCl3) δ 7.50 (d, J = 8.7 Hz, 2H, H1, H5), 6.92 (d, J = 8.7 Hz, 
2H, H2, H4), 6.77 (d, J = 3.3 Hz, 1H, H11), 6.62 (d, J = 3.3 Hz, 1H, H10), 3.94 (s, 2H, 
H13), 3.80-3.76 (m, 2H*), 3.60-3.57 (m, 2H*), 3.27-3.24 (m, 4H*), 2.87 (t, J = 7.2 Hz, 
2H, H8), 2.64 (t, J = 7.2 Hz, 2H, H14), 2.52 (bs, 1H, NH), 2.41 (t, J = 7.2 Hz, 2H, H6), 
2.07-1.98 (m, 2H, H7), 1.62-1.50 (m, 2H, H15), 0.92 (t, J = 7.2 Hz, 3H, 
CH3).*Piperazine. 13C NMR: (75 MHz, CDCl3) δ 171.0 (C=O), 152.9 (C3), 143.8 (C9), 
140.4 (C12), 126.5 (q, J = 3.7 Hz, C1, C5), 125.3 (C11), 124.5 (q, J = 268.0 Hz, CF3), 
124.1 (C10), 121.2 (q, J = 32.0 Hz, C-CF3), 115.0 (C2, C4), 50.6 (C*), 48.3 (C*), 48.17 
(C13), 48.11 (C*), 45.0 (C*), 41.1 (C6), 32.0 (C8), 29.5 (C7), 22.6 (C15), 11.7 
(CH3).*Piperazine. Rf: 0.4 (1:9, MeOH:DCM). HR-MS: calcd for C23H31F3N3OS m/z: 
[M + H]+, 454.2134; found: 454.2135 [Diff(ppm) = 0.20]. IR (neat): 3436 (N-H), 2928 
(C-H), 1642 (C=O), 1616 (C=C), 1439 (C=C), 1331 (C-F), 1115(C-N) cm-1. 
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10.118 Synthesis of 1,2-bis(2-azidoethoxy)ethane (RD208) (153)209 
 
Prepared from (ethane-1,2-diylbis(oxy))bis(ethane-2,1-diyl)bis(4-
methylbenzenesulfonate) (1 g, 2.18 mmol) using sodium azide (312 mg, 4.79 mmol) 
and CH3CN (30 mL) and following the procedure described for the synthesis of 
compound 89. The reaction mixture was heated at reflux for 48 hrs. Purified using flash 
chromatography (3:2 EtOAc:Pet. Ether) to give a yellow oil, 353 mg (80%). 
1H NMR: (300 MHz, CDCl3) δ 3.58-3.55 (m, 8H, OCH2 x 4), 3.28-3.25 (m, 4H, 
(N3CH2) x 2). 
1H NMR data matches literature data.210 Rf: 0.7 (3:2, Pet. Ether:EtOAc). 
HR-MS: calcd for C6H12N6O2Na m/z: [M + Na]
+, 223.0914; found: 223.0918 
[Diff(ppm) = 1.70]. 
10.119 Synthesis of 2-(2-(2-azidoethoxy)ethoxy)ethanamine (RD225) (154)209 
 
Et2O (1.2 mL), 1 M aqueous HCl (3.52 mL) and EtOAc (1.2 mL) were added to 
compound 153 (353 mg, 1.76 mmol) in a round bottom flask and the resulting solution 
solution was cooled to 0 °C. Triphenylphosphine (461 mg, 1.76 mmol) was added, in 
four portions (4 x 115 mg), over 1 hr. The biphasic solution was warmed to rt and 
monitored by TLC. After 18 hrs, the aqueous layer was separated and washed with Et2O 
(2 x 5 mL) to remove triphenyl phosphine oxide. The pH was adjusted to pH~13, with 2 
M aqueous NaOH, before extraction with DCM (10 mL, followed by 3 x 10 mL). The 
combined organic layers were dried over MgSO4 and concentrated under reduced 
pressure to give a light yellow oil, 305 mg (99%). 
1H NMR: (300 MHz, CDCl3) δ 3.52-3.47(m, 2H, NH2CH2), 3.46-3.38 (m, 6H, OCH2 x 
3), 3.20-3.12 (m, 4H, OCH2, N3CH2). 
1H NMR data matches literature data.210. HR-
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MS: calcd for C6H13N4O2 m/z: [M + H]
+, 175.1190; found: 175.1191 [Diff (ppm) = 
0.60]. Rf: 0.2 (MeOH) 
10.120 Synthesis of 4-(5-(((2-(2-(2-
azidoethoxy)ethoxy)ethyl)amino)methyl)thiophen-2-yl)-1-(4-(4-
(trifluoromethyl)phenyl)piperazin-1-yl)butan-1-one (RD232) (155) 
 
To a solution of compound 147 (50 mg, 0.13 mmol) in MeOH (4 mL), was added a 
solution of compound 154 (124 mg, 0.71 mmol) in MeOH (4 mL) and the resulting 
solution was stirred at rt. After 2 hrs, NaBH4 (19 mg, 0.52 mmol) was added and the 
mixture stirred overnight at rt. MeOH was removed under reduced pressure and the 
residue was purified flash chromatography (1:24 MeOH:DCM) to give a yellow oil, 227 
mg (76%). 
1H NMR: (300 MHz, CDCl3) δ 7.49 (d, J = 8.7 Hz, 2H, H1, H5), 6.92 (d, J = 8.7 Hz, 
2H, H2, H4), 6.74 (d, J = 3.3 Hz, 1H, H11), 6.62 (d, J = 3.3 Hz, 1H, H10), 3.94 (s, 2H, 
H13), 3.79-3.76 (m, 2H*), 3.67-3.56 (m, 2H*, 8H, OCH2 x 4), 3.37 (t, J = 5.4 Hz, 2H, 
H14), 3.27-3.25 (m, 4H*), 2.88-2.82 (m, 4H, H8, H15), 2.67 (bs, 1H, NH), 2.41 (t, J = 
7.2 Hz, 2H, H6), 2.07-1.97 (m, 2H, H7). *Piperazine. 13C NMR: (75 MHz, CDCl3) δ 
171.0 (C=O), 152.8 (C3), 143.6 (C9), 141.3 (C12), 126.4 (q, J = 3.2 Hz, C1, C5), 124.9 
(C11), 124.6 (q, J = 268.5 Hz, CF3), 124.0 (C10), 121.0 (q, J = 32.9 Hz, C-CF3), 14.9 
(C2, C4), 70.5 (OCH2), 70.35 (OCH2), 70.30 (OCH2), 70.0 (OCH2), 50.5 (C14), 48.4 
Chapter 10                                           Experimental 
317 
 
(C13), 48.2 (C*, C15), 48.0 (C*), 45.0 (C*), 41.0 (C*), 32.0 (C6), 29.5 (C8), 26.8 
(C7).*Piperazine. Rf: 0.3 (1:24, MeOH:DCM). HR-MS: calcd for C26H36F3N6O3S m/z: 
[M + H]+, 569.2516; found: 569.2526 [Diff(ppm) = 1.8]. IR (neat): 3054 (N-H), 2924 
(C-H), 2111 (N3), 1643 (NH), 1617 (C=O), 1330 (C-F), 1265 (C-O), 1117 (C-N) cm
-1. 
10.121 Synthesis of 4-(5-(((2-(2-(2-
aminoethoxy)ethoxy)ethyl)amino)methyl)thiophen-2-yl)-1-(4-(4-
(trifluoromethyl)phenyl)piperazin-1-yl)butan-1-one (RD240) (156) 
 
Et2O (1 mL), 1 M aqueous HCl (3.03 mL) and EtOAc (2 mL) were added to compound 
155 (167 mg, 0.29 mmol) in a round bottom flask and the resulting solution solution 
was cooled to 0 °C. PPh3 (168 mg, 0.81 mmol) was added, in four portions (4 x 42 mg), 
over 1 hr. The biphasic solution was warmed to rt and monitored by TLC. After 18 hrs, 
the aqueous layer was separated and washed with Et2O (2 x 5 mL) to remove triphenyl 
phosphine oxide. The pH was adjusted to pH~13, with 2 M aqueous NaOH, before 
extraction with DCM (10 mL, followed by 3 x 10 mL). The combined organic layers 
were dried over MgSO4 and concentrated under reduced pressure. The residue was 
purified using flash chromatography (97:3, MeOH:NEt3) to give a yellow oil, 70 mg 
(43%).  
1H NMR: (300 MHz, CDCl3) δ 7.50 (d, J = 8.7 Hz, 2H, H1, H5), 6.92 (d, J = 8.7 Hz, 
2H, H2, H4), 6.73 (d, J = 3.3 Hz, 1H, H11), 6.62 (d, J = 3.3 Hz, 1H, H10), 3.94 (s, 2H, 
H13), 3.79-3.76 (m, 2H*), 3.67-3.48 (m, 2H*, 8H, OCH2 x 4), 3.29-3.22 (m, 4H*), 
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3.01-2.71 (m, 9H, H8, NH2, NH, NCH2 x 2), 2.41 (t, J = 7.2 Hz, 2H, H6), 2.07-1.96 (m, 
2H, H7).*Piperazine. 13C NMR: (75 MHz, CDCl3) δ 170.0 (C=O), 151.8 (C3), 142.5 
(C9), 140.4 (C12), 125.4 (q, J = 3.0 Hz, C1, C5), 123.8 (C11), 123.5 (q, J = 268.7 Hz, 
CF3), 123.0 (C10), 120.1 (q, J = 32.3 Hz, C-CF3), 113.9 (C2, C4), 71.7 (C*), 69.3 
(OCH2), 69.2 (OCH2), 69.1, (OCH2), 47.2 (C13, C*), 47.0 (C14, C15, C*), 44.0 
(OCH2), 40.0 (C*), 31.0 (C6), 28.5 (C8), 25.7 (C7).*Piperazine. Rf: 0.3 (1:24, 
MeOH:DCM). HR-MS: calcd for C26H37F3N4O3SNa m/z: [M + Na]
+, 565.2431; found: 
565.2445 [Diff(ppm) = 2.58]. IR (neat): 3420 (N-H), 2914 (C-H), 1640 (N-H), 1615 
(C=O), 1331 (C-F), 1233 (C-O), 1112 (C-N) cm-1. 
10.122 Synthesis of (2-(2-(2-azidoethoxy)ethoxy)ethyl)-9-oxo-9-(4-(4-
(trifluoromethyl)phenyl)piperazin-1-yl)nonanamide (RD295) (157) 
  
Prepared from compound 79 (60 mg, 0.15 mmol) and compound 154 (28 mg, 0.16 
mmol) using HOBt (22 mg, 0.16 mmol), TBTU (52 mg, 0.16 mmol), anhydrous NEt3 
(33 µL, 0.24 mmol) and anhydrous DMF (4 mL) and following the general procedure 
described in section 10.2. The reaction mixture was stirred overnight at room 
temperature under a N2 atmosphere. Purified using flash chromatography (1:9, 
MeOH:DCM) to give a brown oil, 80 mg (96%). 
1H NMR: (300 MHz, CDCl3) δ 7.50 (d, J = 8.7 Hz, 2H, H1, H5), 6.93 (d, J = 8.7 Hz, 
2H, H2, H4), 6.16 (bs, 1H, NH), 3.79-3.76 (m, 2H*), 3.71-3.62 (m, 2H*, 6H, OCH2 x 
3), 3.57-3.54 (m, 2H, OCH2), 3.47-3.44 (m, 2H, H6), 3.42-3.38 (m, 2H, H7), 3.31-3.24 
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(m, 4H*) , 2.36 (t, J = 7.5 Hz, 2H, (C=O)CH2), 2.17 (t, J = 7.5 Hz, 2H, (C=O)CH2), 
1.64-1.60 (m, 4H, ((C=O)CH2CH2 x 2), 1.34-1.33 (m, 6H, CH2 x 3).*Piperazine. 13C 
NMR: (75 MHz, CDCl3) δ 173.2 (HN-C=O), 171.7 (N-C=O), 152.9 (C3), 126.4 (q, J = 
3.3 Hz, C1, C5), 124.6 (q, J = 270.0 Hz, CF3), 121.0 (q, J = 32.0 Hz, C-CF3), 114.9 (C2, 
C4), 70.4 (OCH2), 70.1 (OCH2), 70.0 (OCH2), 69.9 (OCH2), 50.5 (C7), 48.3 (C*), 48.0 
(C*), 45.1 (C*), 41.0 (C*), 39.0 (C6), 36.5 ((C=O)CH2), 33.1 ((C=O)CH2), 29.2 (CH2), 
29.08 (CH2), 29.06 (CH2), 25.6 ((C=O)CH2CH2), 25.1 ((C=O)CH2CH2).*Piperazine Rf: 
0.5 (1:9, MeOH:DCM). HR-MS: calcd for C26H40F3N6O4 m/z: [M + H]
+, 557.3058; 
found: 557.3046 [Diff (ppm) = -2.08]. IR (neat): 2928 (C-H), 2107 (N=N=N), 1645 
(C=O), 1615 (C=O), 1331 (C-F), 1233 (C-N), 1114 (C-O) cm-1. 
10.123 Synthesis of N-(2-(2-(2-aminoethoxy)ethoxyethyl)-9-oxo-9-(4-(4-
(trifluoromethyl)phenyl)piperazin-1-yl)nonanamide (RD298) (158) 
 
Et2O (1000 µL), 1 M aqueous HCl (900 µL) and EtOAc (500 µL) were added to 
compound 157 (89 mg, 0.16 mmol) in a round bottom flask and the resulting solution 
solution was cooled to 0 °C. PPh3 (48 mg, 0.18 mmol) was added, in four portions (4 x 
12 mg), over 1 hr. The biphasic solution was warmed to rt and monitored by TLC. After 
18 hrs, the aqueous layer was separated and washed with Et2O (2 x 5 mL) to remove 
triphenyl phosphine oxide. The pH was adjusted to pH~13, with 2 M aqueous NaOH, 
before extraction with DCM (10 mL, followed by 3 x 10 mL). The combined organic 
layers were dried over MgSO4 and concentrated under reduced pressure. The residue 
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was purified using flash chromatography (89:10:1, DCM:MeOH:NEt3) to give a clear 
oil, 21 mg (25%). 
1H NMR: (300 MHz, CDCl3) δ 7.50 (d, J = 8.7 Hz, 2H, H1, H5), 6.93 (d, J = 8.7 Hz, 
2H, H2, H4), 6.36 (bs, 1H, (C=O)NH), 3.79-3.76 (m, 2H*), 3.65-3.63 (m, 6H, OCH2 x 
3), 3.58-3.54 (m, 2H*, 2H, OCH2), 3.47-3.42 (m, 2H, NCH2), 3.30-3.24 (m, 4H*), 2.92 
(bs, 2H, NH2), 2.36 (t, J = 8.4 Hz, 2H, (C=O)CH2), 2.20-1.93 (m, 4H, (C=O)CH2, 
NCH2), 1.64-1.63 (m, 4H, (C=O)CH2CH2 x 2), 1.34-1.33 (m, 6H, CH2 x 3).*Piperazine. 
13C NMR: (75 MHz, CDCl3) δ 173.2 (HN-C=O), 171.7 (N-C=O), 152.9 (C3), 126.4 (q, 
J = 3.3Hz, C1, C5), 124.6 (q, J = 270.0 Hz, CF3), 121.0 (q, J = 32.5 Hz, C-CF3), 114.9 
(C2, C4), 69.2 (OCH2), 69.0 (OCH2), 68.9 (OCH2), 47.3 (C*), 47.0 (C*), 44.1 (C*), 
40.0 (C*), 38.0 (OCH2), 35.5 (NCH2), 32.1 (NCH2), 29.2 (CH2), 29.08 (CH2), 29.06 
(CH2), 25.6 (C=O)CH2CH2), 25.1 (C=O)CH2CH2).*Piperazine. Rf: 0.5 (1:9, 
MeOH:DCM). HR-MS: calcd for C26H40F3N6O4 m/z: [M + H]
+, 557.3058; found: 
557.3046 [Diff(ppm) = -2.08]. IR (neat): 3373 (N-H), 2930 (C-H), 1643 (N-H), 1639 
(HN-C=O), 1616 (N-C=O), 1331 (C-F), 1233 (C-O), 1114 (C-N) cm-1. 
10.124 Synthesis of 4-(5-formylthiophen-2-yl)butanoic acid (RD283) (159) 
 
To a solution of dichloromethyl methyl ether (212 µL, 2.34 mmol) in anhydrous DCM 
(5 mL) at 0 °C was added tin(IV)chloride (610 µL, 2.07 mmol) under a N2 atmosphere. 
After 5 mins, a solution of compound 74 (320 mg, 1.73 mmol) in DCM (4 mL) was 
added dropwise over a period of 20 mins. The reaction mixture was stirred for 1 hr at rt, 
after which it was poured onto ice-water and stirred for 30 mins. The organic layer was 
removed and washed with H2O (10 mL followed by 2 x 10 mL), dried over MgSO4 and 
concentrate in vacuo to give compound  99 as a clear oil, 193 mg (52%, crude yield). 
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1H NMR: (300 MHz, CDCl3) δ 9.82 (s, 1H, CHO), 7.63 (d, J = 3 Hz, H5), 6.94 (d, J = 
3 Hz, H4), 3.68 (s, 3H, CH3), 2.94 (t, J = 7.5 Hz, 2H, H3), 2.39 (t, J = 7.5 Hz, 2H, H1), 
2.09-1.99 (m, 2H, H2). Rf: 0.6 (9:1, Pet.Ether:EtOAc).  
10.125 Synthesis of methyl 4-(5-(((2-(2-azidoethoxy)ethyl)amino)methyl)thiophen-
2-yl)butanoate (RD290) (160) 
 
To a solution of compound 159 (100 mg, 0.43 mmol) in MeOH (4 mL), was added a 
solution of compound 154 (114 mg, 0.64 mmol) in MeOH (2 mL) and the resulting 
solution was stirred at rt. After 2 hrs, NaBH4 (16 mg, 0.43 mmol) was added and the 
mixture stirred overnight at rt. MeOH was removed under reduced pressure and the 
residue was purified using flash chromatography (1:9, MeOH:DCM) to give an range 
oil, 94 mg (58%).  
1H NMR: (300 MHz, CDCl3) δ 6.72 (d, J = 3.3 Hz, 1H, H6), 6.60 (d, J = 3.3 Hz, 1H, 
H5), 3.92 (s, 2H, H8), 3.68-3.59 (m, 11H, CH3, OCH2 x 4), 3.39-3.35 (m, 2H, H9), 
2.84-2.78 (m, 4H, H3, H10), 2.39 (t, J = 7.3 Hz, 2H, H1), 2.02-1.92 (m, 2H, H2). 13C 
NMR: (75 MHz, CDCl3) δ 171.8 (C=O), 141.3 (C4), 139.7 (C7), 122.9 (C6), 122.1 
(C5), 68.6 (OCH2), 68.5 (OCH2), 68.4 (OCH2), 68.1 (OCH2), 49.6 (CH3), 48.7 (C9), 
46.6 (C8), 46.4 (C10), 31.2 (C1), 27.5 (C3), 24.7 (C2). Rf: 0.5 (1:9, MeOH:DCM). HR-
MS: calcd for C16H27N4O4S m/z: [M + H]
+, 374.1756; found: 374.1771 [Diff(ppm) = 
4.02]. IR (neat): 3325 (N-H), 2867 (C-H), 2109 (N=N=N), 1736 (C=O), 1123 (C-O), 
804 (N-H) cm-1. 
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10.126 Synthesis of 4-(5-(((2-(2-(2-
azidoethoxy)ethoxy)ethyl)amino)methyl)thiophen-2-yl)butanoic acid (RD296) 
(161) 
 
Compound 160 (94 mg, 0.25 mmol) and KOH (71 mg, 1.26 mmol) in EtOH (5 mL) 
were heated at reflux and reaction progress monitored by TLC (3:2 EtOAc: Pet. Ether). 
After 3 hrs the solution was allowed to cool to rt and EtOH was removed under reduce 
pressure. The residue was dissolved in H2O (1.5 mL), the pH adjusted to pH = 6 with 2 
M aqueous HCl and the aqueous layer extracted with DCM (20 mL, followed by 4 x 10 
mL). The organic layers were washed with brine (3 x 20 mL), dried over MgSO4 and 
evaporated under reduced pressure to give an orange solid, 90 mg, (98%). 
1H NMR: (300 MHz, D2O) δ 7.08-7.07 (m, 1H, H6), 6.86-6.85 (m, 1H, H5), 4.31 (s, 
2H, H8), 3.80-3.73 (m, 8H, OCH2 x 4), 3.54-3.51 (m, 2H, H9), 3.17-3.15 (m, 2H, H10), 
2.88-2.83 (m, 2H, H3), 2.27-2.22 (m, 2H, H1), 1.97-1.87 (m, 2H, H2). 13C NMR: (75 
MHz, D2O) δ 183.0 (C=O), 148.7 (C4), 131.1 (C7), 129.7 (C6), 125.3 (C5), 69.7 
(OCH2), 69.4 (OCH2), 65.8 (OCH2), 50.3 (C9), 45.9 (C10), 45.4 (C8), 37.0 (C1), 29.3 
(C3), 28.0 (C2). HR-MS: calcd for C15H25N4O4S m/z: [M + H]
+, 357.1591; found 
357.1587 [Diff(ppm) = -1.17]. IR (KBr): 2922 (C-H), 2110 (N=N=N), 1625 (C=O), 
1119 (C-O) cm-1. 
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10.127 Synthesis of methyl 9-(4-(4-nitrophenyl)piperazin-1-yl)-9-oxononanoate 
(RTC98) (163)† 
 
Prepared from 1-(4-nitrophenyl)piperazine (500 mg, 2.40 mmol) and 9-methoxy-9-
oxononanoic acid (424 µL, 2.18 mmol) using HOBt (325 mg, 2.40 mmol), TBTU (775 
mg, 2.40 mmol), anhydrous NEt3 (489 µL, 3.49 mmol) and anhydrous DMF (10 mL) 
and following the general procedure described in section 10.2. The reaction mixture was 
stirred overnight at room temperature under a N2 atmosphere. Purified using flash 
chromatography (1:9 MeOH:DCM) to give an orange solid, 682 mg (80%). 
1H NMR: (300 MHz, CDCl3) δ 8.01 (d, J = 9.1 Hz, 2H, H1, H5), 6.75 (d, J = 9.1 Hz, 
2H, H2, H4), 3.75-3.71 (m, 2H*), 3.64-3.61 (m, 2H*), 3.58 (s, 3H, OCH3), 3.45-3.36 
(m, 4H*), 2.30 (t, J = 7.2 Hz, 2H,  (C=O)CH2), 2.23 (t, J = 7.2 Hz, 2H, (C=O)CH2), 
1.60-1.52 (m, 4H, (C=O)CH2CH2 x 2), 1.28-1.26 (m, 6H, CH2 x 3).*Piperazine. 13C 
NMR: (75 MHz, CDCl3) δ 174.2 (COOCH3), 171.9 (C=O), 154.4 (C3), 139.0 (C-NO2), 
125.8 (C1, C5), 112.7 (C2, C4), 51.4 (OCH3), 46.8 (C*) 46.7 (C*), 44.6 (C*), 40.7 
(C*), 33.9 ((C=O)CH2), 33.1 ((C=O)CH2), 29.1 (CH2), 28.9 (CH2), 28.8 (CH2), 24.7 
((C=O)CH2CH2), 25.0 ((C=O)CH2CH2).*Piperazine. Rf: 0.7 (1:9, MeOH:DCM). HR-
MS: calcd for C20H30N3O5 m/z: [M + H]
+, 392.2180; found: 39.2198 [Diff (ppm) = 
4.60]. IR (KBr): 2911 (C-H), 1736 ((C=O)OCH3), 1649 (C=O), 1587 (NO), 1320 (NO) 
cm-1. m.p.: 97-100 °C. 
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10.128 Synthesis of 9-(4-(4-nitrophenyl)piperazin-1-yl)-9-oxononanoic acid 
(RTC99) (164)† 
 
Compound 163 (300 mg, 0.76 mmol) and KOH (172 mg, 3.06 mmol) in EtOH (5 mL) 
were heated at reflux and reaction progress monitored by TLC (3:2 EtOAc: Pet. Ether). 
After 5 hrs the solution was allowed to cool to rt and EtOH was removed under reduced 
pressure. The residue was dissolved in H2O (1.5 mL), the pH adjusted to pH = 6 with 2 
M aqueous HCl and the aqueous layer extracted with DCM (20 mL, followed by 4 x 10 
mL). The organic layers were washed with brine (3 x 20 mL), dried over MgSO4 and 
evaporated under reduced pressure. The residue was purified using flash 
chromatography (1:9, MeOH:DCM) to give an orange solid, 230 mg (79%). 
1H NMR: (300 MHz, CDCl3) δ 8.14 (d, J = 9.1 Hz, 2H, H1, H5), 6.82 (d, J = 9.1 Hz, 
2H, H2, H4), 3.82-3.79 (m, 2H*) 3.69-3.66 (m, 2H*), 3.49-3.42 (m, 4H*), 2.40-2.31 
(m, 4H, (C=O)CH2 x 2), 1.65-1.60 (m, 4H, (C=O)CH2CH2 x 2), 1.45-1.25 (m, 6H, CH2 
x 3).Piperazine.13C NMR: (75 MHz, CDCl3) δ 179.0 (C=O), 172.2 (N-C=O), 154.3 
(C3), 138.8 (C-NO2), 125.9 (C1, C5), 112.8 (C2, C4), 46.8 (C*) 46.7 (C*), 44.7 (C*), 
40.8 (C*), 34.1 ((C=O)CH2), 33.1 ((C=O)CH2), 29.1 (CH2), 28.9 (CH2), 28.8 (CH2), 
25.0 ((C=O)CH2CH2), 24.6 ((C=O)CH2CH2).Piperazine. Rf: 0.7 (1:9, MeOH:DCM). 
HR-MS: calcd for C19H28N3O5 m/z: [M + H]
+, 378.2023; found: 378.2040 [Diff(ppm) = 
4.50]. IR (KBr): 3430 (OH), 2920 (C-H), 1776 (C=O), 1598 (N-C=O), 1598 (NO), 
1320 (NO) cm-1. m.p.: 98-100 °C. 
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10.129 Synthesis of N-(2-(2-(2-azidoethoxy)ethoxy)ethyl)-9-(4-(4-
nitrophenyl)piperazin-1-yl)-9-oxononanamide (RD333) (165) 
  
Prepared from compound 164 (112 mg, 0.29 mmol) and compound 154 (57 mg, 0.33 
mmol) using HOBt (44 mg, 0.29 mmol), TBTU (105 mg, 0.29 mmol), anhydrous NEt3 
(157 µL, 0.47 mmol) and anhydrous DMF (4 mL) and following the general procedure 
described in section 10.2. The reaction mixture was stirred overnight at room 
temperature under a N2 atmosphere. Purified using flash chromatography (1:9, 
MeOH:DCM) to give an orange oil, 150 mg (94%).  
1H NMR: (300 MHz, CDCl3) δ 8.13 (d, J = 9.3 Hz, 2H, H1, H5), 6.83 (d, J = 9.3 Hz, 
2H, H2, H4), 3.82-3.78 (m, 2H*), 3.71-3.62 (m, 2H*, 6H, OCH2 x 3), 3.57-3.54 (m, 2H, 
OCH2) 3.50-3.38 (m, 4H*, 4H, H6, H7), 2.36 (t, J = 7.3 Hz, 2H, (C=O)CH2), 2.16 (t, J 
= 7.3 Hz, 2H, (C=O)CH2), 1.67-1.60 (m, 4H, (C=O)CH2CH2 x 2), 1.35-1.33 (m, 6H, 
CH2 x 3).*Piperazine. 13C NMR: (75 MHz, CDCl3) δ 173.1 (HN-C=O), 171.8 (N-
C=O), 154.4 (C3), 138.8 (C-NO2), 125.9 (C1, C5), 112.8 (C2, C4), 70.4 (OCH2), 70.1 
(OCH2), 70.0 (OCH2), 69.9 (OCH2), 50.5 (C7), 46.9 (C*), 46.8 (C*), 44.7 (C*), 40.7 
(C*), 39.0 (C6) 36.5 ((C=O)CH2), 33.1 ((C=O)CH2), 29.1 (CH2), 29.06 (CH2), 29.04 
(CH2), 25.5 ((C=O)CH2CH2), 25.0 ((C=O)CH2CH2).*Piperazine. Rf: 0.6 (1:9, 
MeOH:DCM). HR-MS: calcd for C25H40N7O6 m/z: [M + H]
+, 534.3035; found: 
534.3046 [Diff(ppm) = 2.17]. IR (neat): 2928 (C-H), 2106 (N=N+=N-), 1643 (C=O), 
1597 (NO), 1322 (NO) cm-1. 
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10.130 Synthesis of N-(2-(2-(2-aminoethoxy)ethoxy)ethyl)-9-(4-(4-
nitrophenyl)piperazin-1-yl)-9-oxononanamide (RD341) (166) 
  
Et2O (2 mL), 1 M aqueous HCl (2 mL) and EtOAc (2 mL) were added to compound 
165 (204 mg, 0.38 mmol) in a round bottom flask and the resulting solution solution 
was cooled to 0 °C. PPh3 (112 mg, 0.38 mmol) was added, in four portions (4 x 38 mg), 
over 1 hr. The biphasic solution was warmed to rt and monitored by TLC. After 18 hrs, 
the aqueous layer was separated and washed with Et2O (2 x 5 mL) to remove triphenyl 
phosphine oxide. The pH was adjusted to pH~13, with 2 M aqueous NaOH, before 
extraction with DCM (10 mL, followed by 3 x 10 mL). The combined organic layers 
were dried over MgSO4 and concentrated under reduced pressure. The residue was 
purified using flash chromatography (1:9, MeOH:DCM) to give an orange oil, 26 mg 
(13%).  
1H NMR: (300 MHz, CD3OD) δ 8.14 (d, J = 9.4 Hz, 2H, H1, H5), 7.02 (d, J = 9.4 Hz, 
2H, H2, H4), 3.75-3.48 (m, 8H*, 8H, OCH2 x 4), 3.39-3.35 (m, 2H, NCH2), 3.10-2.93 
(m, 2H, NCH2), 2.46 (t, J = 7.2 Hz, 2H, (C=O)CH2), 2.21 (t, J = 7.2 Hz, 2H, 
(C=O)CH2), 1.63-1.62 (m, 4H,(C=O)CH2CH2 x 2), 1.47-1.33 (m, 6H, CH2 x 3). 13C 
NMR: (75 MHz, CD3OD) δ 175.0 (HN-C=O), 172.9 (N-C=O), 154.7 (C3), 138.2 (C-
NO2), 125.3 (C1, C5), 112.5 (C2, C4), 69.8 (OCH2), 69.2 (OCH2), 69.1 (OCH2), 46.5 
(C*), 46.1 (C*), 44.6 (C*), 40.8(C*), 39.9 (C*), 38.7 (OCH2), 35.6 (C6), 32.5 (C7), 
28.87 (CH2), 28.80 (CH2), 28.7 (CH2), 25.5 ((C=O)CH2CH2), 24.9 ((C=O)CH2CH2).  
Rf: 0.6 (1:10:89, NEt3:MeOH:DCM). HR-MS: calcd for C25H42N5O6 m/z: [M + H]
+, 
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509.316; found: 509.3184 [Diff(ppm) = 4.77]. IR (neat): 3389 (N-H), 2923 (C-H), 
1645 (HN-C=O), 1638 (N-C=O), 1631 (N-H), 1597 (NO), 1321 (NO), 1237 (C-N) cm-1 
10.131 Fluorometric binding assay 
The binding of compounds to His-RBP4 was monitored by titration of the intrinsic 
fluorescence emission of the protein in the presence of increasing concentrations of 
compounds (0, 0.2, 0.4, 0.6, 1.0, 1.5, 2.0, 5.0, 10.0, 15.0 μM). The quenching of protein 
fluorescence due to the transfer of energy to the ligand was evaluated using excitation 
and emission wavelengths of 280 and 350 nm, respectively, in a Cary Eclipse 
fluorescence spectrophotometer (Varian). Purified His-RBP4 expressed with the P. 
pastoris system was diluted to a concentration of 1 μM in PBS buffer, and small 
increments of compound solutions in ethanol were added. The system was mixed and 
allowed to equilibrate for 5 mins before the fluorescence emission of the compound 
His-RBP complex was recorded. The final concentration of ethanol never exceeded 2%. 
A solution of N-acetyl-L-tryptophanamide was used as a blank. 
10.132 Glucose Uptake Assay 
C2C12 muscle cells were incubated with 10 μM of compound at 37 °C for ~12 hrs. 
Following treatment, the media was removed and the cells were washed in KRB ( x 3) 
and 3H deoxy-2-glucose (1μCi/mL; specific activity 8mCi/mmol) added for 10 mins at 
37 C. The cells were washed in ice-cold KRB (x 3) and solubilized in 0.1% SDS for 30 
mins. The cells were harvested and 500μl (~250 μg protein) added to 2 mL scintillation 
fluid (Ultima Gold, Perkin Elmer, UK). Counts were read, per minute, using a Wallac 
MicroBeta scintillation counter (Perkin Elmer) and results are expressed as counts per 
minute per mg protein (CPM/ mg).  
10.133 Immobilisation of compounds onto sepharose bead 
10.133.1 General procedure for the immobilisation of compounds onto 
sepharose bead 
The cyanogen activated sepharose beads were transferred to a column where they were 
soaked and swelled in 1 mM aqueous HCl. The beads were then washed with 0.1 M 
aqueous NaHCO3 containing NaCl (x 3). The compound to be immobilised was 
dissolved in DMF and added to a 0.1 M NaHCO3 solution containing and NaCl 
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solution. The solution was then mixed with the sepharose beads and gently agitated in a 
water bath at 25 °C for 20 hrs. A 0.2 M aqueous glycine solution (5 mL) containing 
NaHCO3 (43 mg, 0.5 mmol) was added and the bead solution was stirred for a further 2 
hrs to deactivate the remaining active groups. The bead solution was then washed with 
distilled H2O followed by washing with 0.15 M NaCl (5 mL), 1M NaCl (5 mL) and 
0.15 M NaCl (5 mL). This wash cycle was repeated five times and the aqueous washes 
were extracted with DCM (10 mL x 3) and the combined organic layers were dried over 
MgSO4. The organic layers were concentrated under reduced pressure and analysed 
using 1H NMR spectroscopy. The beads were washed with MeOH (5 mL x 3) and the 
organic layers were concentrated under reduced pressure. The residue was analysed 
using 1H NMR spectroscopy. The beads were then stored in a 1 M NaCl solution at 2-8 
°C.  
10.133.2 Immobilisation of compound 156 onto sepharose bead 
The cyanogen activated sepharose beads (100 mg) were swelled in 1mM HCl (10 mL) 
for 30 mins and washed with 0.1 M aqueous NaHCO3 containing NaCl (146 mg, 0.05 
mol) (5 mL) x 3). Compound 156 (23 mg, 0.04 mmol) was dissolved in DMF (400 µL) 
and added to a 0.1 M NaHCO3 solution containing and NaCl (146 mg, 0.05 mol) (1 
mL). The solution was then mixed with the sepharose beads and gently agitated in a 
water bath at 25 °C for 20 hrs. The series of washes describe in section 10.133.1 were 
then performed. Analysis revealed that 18 mg (78%) of compound 156 was immobilised 
on the sepharose bead. 
10.133.3 Immobilisation of compound 158 onto sepharose bead 
The cyanogen activated sepharose beads (100 mg) were swelled in 1mM HCl (10 mL) 
for 30 mins and washed with 0.1 M aqueous NaHCO3 containing NaCl (146 mg, 0.05 
mol) (5 mL) x 3). Compound 158 (20 mg, 0.04 mmol) was dissolved in DMF (400 µL) 
and added to a 0.1 M NaHCO3 solution containing and NaCl (146 mg, 0.05 mol) (1 
mL). The solution was then mixed with the sepharose beads and gently agitated in a 
water bath at 25 °C for 20 hrs. The series of washes describe in section 10.133.1 were 
then performed. Analysis revealed that 16 mg (80%) of compound 158 was immobilised 
on the sepharose bead. 
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10.133.4 Immobilisation of compound 166 onto sepharose bead 
The cyanogen activated sepharose beads (100 mg) were swelled in 1mM HCl (10 mL) 
for 30 mins and washed with 0.1 M aqueous NaHCO3 containing NaCl (146 mg, 0.05 
mol) (5 mL) x 3). Compound 166 (20 mg, 0.04 mmol) was dissolved in DMF (400 µL) 
and added to a 0.1 M NaHCO3 solution containing and NaCl (146 mg, 0.05 mol) (1 
mL). The solution was then mixed with the sepharose beads and gently agitated in a 
water bath at 25 °C for 20 hrs. The series of washes describe in section 10.133.1 were 
then performed. Analysis revealed that 14 mg (70%) of compound 166 was immobilised 
on the sepharose bead. 
10.134 Cyclodextrin studies 
10.134.1 Preparation of compound 4 and HPBCD inclusion complex 
The inclusion complex was prepared by dissolving compound 4 (1 eq) and HPBCD (20 
eq) in a DMSO-water solution (5:95). The solvent was removed under reduced pressure 
to give the solid inclusion complex as a white crystalline solid. 
10.134.2 Preparation of compound 4 and HPBCD physical mixture  
The physical mixture was prepared by thoroughly grinding compound 4 (1 eq) and 
HPBCD (20 eq) in a mortar and pestle for 5 mins. 
10.134.3 Standard curve 
A series of solutions of compound 4 (10, 20, 25, 30, 37.5, 40 and 50 μM) in MeOH 
were prepared and the UV absorption spectrum of each sample was obtained and the 
data analysed at 264 (λmax of compound 4). The absorbance values were then plotted 
against the varying concentrations of compound 4. This experiment was performed 
three times using new solutions of compound 4.  
10.134.4 Phase-solubility diagram193 
Compound 4 (47 mg, 0.125 mmol) was added to aqueous 25 mL HPBCD solutions of 
increasing concentrations (0.2, 0.4, 0.6, 0.8, and 1.0 mM) (fivefold molar excess of 
compound 4 used, relative to the highest conc. of HPBCD i.e. 5.0 mM compound 4 
solution required). The mixtures were stirred for 72 hrs at rt after which each solution 
was centrifuged and filtered through a 0.45 μm Millipore filter. The absorbance value of 
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each solution was determined using UV spectroscopy at 264 (λmax of compound 4). The 
final concentration was then determined using the standard curve. This experiment was 
repeated three times using new compound 4 and HPBCD solutions. New data ws 
recorded each time. 
10.134.5 Differential Scanning Calorimetry 
Work pans containing approximately 2 mg of samples were heated from 20 to 400 °C, 
at a constant rate of 10 °C/min, under a N2 atmosphere. The instrument used was a 
Perkin Elmer Pyris 6.0 apparatus and the result were recorded and analysed by means of 
Pyris Data Analysis software. 
10.134.6 Scanning Electron Microscopy 
SEM was used to examine the morphologies of the samples. SEM analysis was carried 
out using a Hitachi S-3200-N instrument. In all cases samples were mounted on 
aluminium stubs with carbon tabs. Prior to imaging, the samples were gold sputtered 
using an Agar automatic sputter coater B7341. An accelerating voltage of 20 kV was 
used in all cases. 
10.134.7 NMR spectroscopy 
1H NMR spectra were acquired on a Bruker Advance 300 spectrometer at 300 MHz; the 
samples were referenced relative to the residual peak of CD3OD at δ ppm. 2D ROESY 
spectra were acquired in D2O on a Bruker Advance 500 spectrometer at 500 MHz. 
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J.; Järvinen, T.; Rautio, J., Journal of Medicinal Chemistry 2009, 52 (14), 4142-4148. 
41. Donnelly, P. S.; Liddell, J. R.; Lim, S.; Paterson, B. M.; Cater, M. A.; Savva, M. S.; 
Mot, A. I.; James, J. L.; Trounce, I. A.; White, A. R.; Crouch, P. J., Proceedings of the 
National Academy of Sciences 2012, 109 (1), 47-52. 
42. Sazanov, L. A., Biochemistry 2007, 46 (9), 2275-2288. 
43. Chittiboyina, A. G.; Venkatraman, M. S.; Mizuno, C. S.; Desai, P. V.; Patny, A.; 
Benson, S. C.; Ho, C. I.; Kurtz, T. W.; Pershadsingh, H. A.; Avery, M. A., Journal of 
Medicinal Chemistry 2006, 49 (14), 4072-4084. 
44. Pirat, C.; Farce, A.; Lebègue, N.; Renault, N.; Furman, C.; Millet, R.; Yous, S.; Speca, 
S.; Berthelot, P.; Desreumaux, P.; Chavatte, P., Journal of Medicinal Chemistry 2012, 
55 (9), 4027-4061. 
45. Murphy, G. J.; Holder, J. C., Trends in Pharmacological Sciences 2000, 21 (12), 469-
474. 
46. Reddy, K. A.; Lohray, B. B.; Bhushan, V.; Reddy, A. S.; Mamidi, N. V. S. R.; Reddy, 
P. P.; Saibaba, V.; Reddy, N. J.; Suryaprakash, A.; Misra, P.; Vikramadithyan, R. K.; 
Rajagopalan, R., Journal of Medicinal Chemistry 1999, 42 (17), 3265-3278. 
47. Ferreira, S. B.; Sodero, A. C. R.; Cardoso, M. F. C.; Lima, E. S.; Kaiser, C. R.; Silva, F. 
P.; Ferreira, V. F., Journal of Medicinal Chemistry 2010, 53 (6), 2364-2375. 
  Bibliography 
 
 
48. Hanefeld, M.; Cagatay, M.; Petrowitsch, T.; Neuser, D.; Petzinna, D.; Rupp, M., 
European Heart Journal 2004, 25 (1), 10-16. 
49. Shimpukade, B.; Hudson, B. D.; Hovgaard, C. K.; Milligan, G.; Ulven, T., Journal of 
Medicinal Chemistry 2012, 55 (9), 4511-4515. 
50. Greene, R. J.; Tu, H.; Gibbs, J. P.; Slatter, J. G., Xenobiotica 2011, 41 (11), 945-957. 
51. Monami, M.; Iacomelli, I.; Marchionni, N.; Mannucci, E., Nutrition, Metabolism and 
Cardiovascular Diseases 2010, 20 (4), 224-235. 
52. Potashman, M. H.; Duggan, M. E., Journal of Medicinal Chemistry 2009, 52 (5), 1231-
1246. 
53. Ohtake, Y.; Sato, T.; Kobayashi, T.; Nishimoto, M.; Taka, N.; Takano, K.; Yamamoto, 
K.; Ohmori, M.; Yamaguchi, M.; Takami, K.; Yeu, S.-Y.; Ahn, K.-H.; Matsuoka, H.; 
Morikawa, K.; Suzuki, M.; Hagita, H.; Ozawa, K.; Yamaguchi, K.; Kato, M.; Ikeda, S., 
Journal of Medicinal Chemistry 2012, 55 (17), 7828-7840. 
54. Jurczak, M. J.; Lee, H.-Y.; Birkenfeld, A. L.; Jornayvaz, F. R.; Frederick, D. W.; 
Pongratz, R. L.; Zhao, X.; Moeckel, G. W.; Samuel, V. T.; Whaley, J. M.; Shulman, G. 
I.; Kibbey, R. G., Diabetes 2011, 60 (3), 890-898. 
55. Mascitti, V.; Thuma, B. A.; Smith, A. C.; Robinson, R. P.; Brandt, T.; Kalgutkar, A. S.; 
Maurer, T. S.; Samas, B.; Sharma, R., MedChemComm 2013, 4 (1), 101-111. 
56. Preitner, F.; Mody, N.; Graham, T. E.; Peroni, O. D.; Kahn, B. B., American Journal of 
Physiology - Endocrinology and Metabolism 2009, 297 (6), 1420-1429. 
57. Campos-Sandoval, J. A.; Redondo, C.; Kinsella, G. K.; Pal, A.; Jones, G.; Eyre, G. S.; 
Hirst, S. C.; Findlay, J. B. C., Journal of Medicinal Chemistry 2011, 54 (13), 4378-
4387. 
58. Yang, Q.; Graham, T. E.; Mody, N.; Preitner, F.; Peroni, O. D.; Zabolotny, J. M.; 
Kotani; Quadro, L.; Kahn, B. B., Nature 2005, 436 (7049), 356-362. 
59. Flower, D. R.; North, A. C. T.; Sansom, C. E., Biochimica et Biophysica Acta- Protein 
Structure and Molecular Enzymology 2000, 1482 (1–2), 9-24. 
60. Zanotti, G.; Folli, C.; Cendron, L.; Alfieri, B.; Nishida, S. K.; Gliubich, F.; Pasquato, 
N.; Negro, A.; Berni, R., FEBS Journal 2008, 275 (23), 5841-5854. 
61. Findlay, J. B. C.; Sivaprasadarao, A.; Sundaram, M.; Van Aalten, D. M. F., 
Biochemical Journal 2002, 362 (2), 265-271. 
  Bibliography 
 
 
62. Coward, P.; Conn, M.; Tang, J.; Xiong, F.; Menjares, A.; Reagan, J. D., Analytical 
Biochemistry 2009, 384 (2), 312-320. 
63. Patrick, G. L., An Introduction to Medicinal Chemistry, 4th ed, Oxford University Press 
Inc., 2009. 
64. Patrick, G. L., An Introduction to Medicinal Chemistry, 2nd ed, Oxford University Press 
Inc., 2001. 
65. Veber, D. F.; Johnson, S. R.; Cheng, H.-Y.; Smith, B. R.; Ward, K. W.; Kopple, K. D., 
Journal of Medicinal Chemistry 2002, 45 (12), 2615-2623. 
66. Rautio, J.; Kumpulainen, H.; Heimbach, T.; Oliyai, R.; Oh, D.; Järvinen, T.; 
Savolainen, J., Nature Reviews Drug Discovery 2008, 7 (3), 255-270. 
67. Rojas-Aguirre, Y.; Yépez-Mulia, L.; Castillo, I.; López-Vallejo, F.; Soria-Arteche, O.; 
Hernández-Campos, A.; Castillo, R.; Hernández-Luis, F., Bioorganic and Medicinal 
Chemistry 2011, 19 (2), 789-797. 
68. Pattnaik, P., Applied Biochemistry and Biotechnology 2005, 126 (2), 79-92. 
69. Stephens, J.; Kinsella, G.; Martin, D.; Devine, R.; Velasco-Torrijos, T.; Findlay, J. B. C. 
WO2013060860A1, 2013. 
70. Tovey, M. G., Detection and quantification of antibodies to biopharmaceuticals: 
practical and applied considerations, 1st ed, Hoboken, N.J. : Wiley, 2011. 
71. Motani, A.; Wang, Z.; Conn, M.; Siegler, K.; Zhang, Y.; Liu, Q.; Johnstone, S.; Xu, H.; 
Thibault, S.; Wang, Y.; Fan, P.; Connors, R.; Le, H.; Xu, G.; Walker, N.; Shan, B.; 
Coward, P., Journal of Biological Chemistry 2009, 284 (12), 7673-7680. 
72. Dobri, N.; Qin, Q.; Kong, J.; Yamamoto, K.; Liu, Z.; Moiseyev, G.; Ma, J.-x.; 
Allikmets, R.; Sparrow, J. R.; Petrukhin, K., Investigative Ophthalmology & Visual 
Science 2013, 54 (1), 85-95. 
73. Ford, E. S.; Williamson, D. F.; Liu, S., American Journal of Epidemiology 1997, 146 
(3), 214-222. 
74. Kim, Y. L.; Kim, T. K.; Cheong, E. S.; Shin, D. G.; Choi, G. S.; Jung, J.; Han, K.-A.; 
Min, K. W., Diabetes Metab J 2012, 36 (6), 415-421. 
75. Jang, D.-J.; van den Berg, R.; El-Sayed, M. A., FEBS Letters 1990, 261 (2), 279-282. 
  Bibliography 
 
 
76. Cline, G. W.; Petersen, K. F.; Krssak, M.; Shen, J.; Hundal, R. S.; Trajanoski, Z.; 
Inzucchi, S.; Dresner, A.; Rothman, D. L.; Shulman, G. I., New England Journal of 
Medicine 1999, 341 (4), 240-246. 
77. Ferré, P.; Leturque, A.; Burnol, A. F.; Penicaud, L.; Girard, J., The Biochemical journal 
1985, 228 (1), 103-110. 
78. De Savi, C.; Waterson, D.; Pape, A.; Lamont, S.; Hadley, E.; Mills, M.; Page, K. M.; 
Bowyer, J.; Maciewicz, R. A., Bioorganic and Medicinal Chemistry Letters 2013, 23 
(16), 4705-4712. 
79. Sıdır, Y. G.; Sıdır, İ., Journal of Molecular Structure 2013, 1045 (0), 131-138. 
80. Short, F. W.; Elslager, E. F., Journal of Medicinal and Pharmaceutical Chemistry 1962, 
5 (3), 642-646. 
81. Hayat, F.; Cho, S.; Rhim, H.; Indu Viswanath, A. N.; Pae, A. N.; Lee, J. Y.; Choo, D. 
J.; Choo, H.-Y. P., Bioorganic and Medicinal Chemistry 2013, 21 (17), 5573-5582. 
82. Liu, K. G.; Robichaud, A. J., Tetrahedron Letters 2005, 46 (46), 7921-7922. 
83. Scholz, U. US2005/250791, 2005. 
84. Pinard, E.; Alanine, A.; Alberati, D.; Bender, M.; Borroni, E.; Bourdeaux, P.; Brom, V.; 
Burner, S.; Fischer, H.; Hainzl, D.; Halm, R.; Hauser, N.; Jolidon, S.; Lengyel, J.; 
Marty, H.-P.; Meyer, T.; Moreau, J.-L.; Mory, R.; Narquizian, R.; Nettekoven, M.; 
Norcross, R. D.; Puellmann, B.; Schmid, P.; Schmitt, S.; Stalder, H.; Wermuth, R.; 
Wettstein, J. G.; Zimmerli, D., Journal of Medicinal Chemistry 2010, 53 (12), 4603-
4614. 
85. Anastasiadis, C.; Hogarth, G.; Wilton-Ely, J. D. E. T., Inorganica Chimica Acta 2010, 
363 (13), 3222-3228. 
86. Hassan, J.; Sévignon, M.; Gozzi, C.; Schulz, E.; Lemaire, M., Chemical Reviews 2002, 
102 (5), 1359-1470. 
87. Nelson, T. D.; Crouch, R. D., Cu, Ni, and Pd Mediated Homocoupling Reactions in 
Biaryl Syntheses: The Ullmann Reaction, 1st ed, John Wiley & Sons, Inc., 2004. 
88. Ma, D.; Xia, C., Organic Letters 2001, 3 (16), 2583-2586. 
89. Xi, M.; Bent, B. E., Journal of the American Chemical Society 1993, 115 (16), 7426-
7433. 
  Bibliography 
 
 
90. Nadri, S.; Azadi, E.; Ataei, A.; Joshaghani, M.; Rafiee, E., Journal of Organometallic 
Chemistry 2011, 696 (18), 2966-2970. 
91. Goodbrand, H. B.; Hu, N.-X., The Journal of Organic Chemistry 1998, 64 (2), 670-674. 
92. Hoffmann-la Roche, A. G. F.; Chen, L.; Feng, L.; Huang, M.; Liu, Y.; Wu, G.; Wu, J. 
Z.; Zhou, M. WO2011/128251, 2011. 
93. Sperotto, E.; van Klink, G. P. M.; van Koten, G.; de Vries, J. G., Dalton Transactions 
2010, 39 (43), 10338-10351. 
94. Urgaonkar, S.; Verkade, J. G., The Journal of Organic Chemistry 2004, 69 (26), 9135-
9142. 
95. Paul, F.; Patt, J.; Hartwig, J. F., Journal of the American Chemical Society 1994, 116 
(13), 5969-5970. 
96. Guram, A. S.; Buchwald, S. L., Journal of the American Chemical Society 1994, 116 
(17), 7901-7902. 
97. Guram, A. S.; Rennels, R. A.; Buchwald, S. L., Angewandte Chemie International 
Edition in English 1995, 34 (12), 1348-1350. 
98. Louie, J.; Hartwig, J. F., Tetrahedron Letters 1995, 36 (21), 3609-3612. 
99. Silverman, L. S.; Caldwell, J. P.; Greenlee, W. J.; Kiselgof, E.; Matasi, J. J.; Tulshian, 
D. B.; Arik, L.; Foster, C.; Bertorelli, R.; Monopoli, A.; Ongini, E., Bioorganic and 
Medicinal Chemistry Letters 2007, 17 (6), 1659-1662. 
100. Clayden, J.; Greeves, N.; Warren, S.; Wothers, P., Organic Chemistry, 1st ed, Oxford 
University Press Inc., 2001. 
101. Gianotti, M.; Tehan, B. G.; Seri, C.; Lovell, P. J. WO2008/152089, 2008. 
102. Kappe, C. O., Microwaves in organic and medicinal chemistry, 2nd ed, Weinheim : 
Wiley-VCH., 2005. 
103. Stuerga, D., Delmotte, M., Perreux, L., Loupy, A., Microwaves in Organic synthesis, 1st 
ed, WILEY-VCH GmbH& Co. KGaA., 2002. 
104. Hayes, B., Microwave Synthesis: Chemistry at the Speed of Light, 1st ed, CEM 
publishing, 2002. 
105. Meng, X.; Cai, Z.; Xiao, S.; Zhou, W., Journal of Fluorine Chemistry 2013, 146 (0), 
70-75. 
  Bibliography 
 
 
106. Akkani, A.; Paterlini, G.; Gleason, W. B.; Ojala, W. H.; Abul-Hajj, Y. J., Journal of 
Medicinal Chemistry 1997, 40 (20), 3263-3270. 
107. Neves, M. A. C.; Dinis, T. C. P.; Colombo, G.; Sá e Melo, M. L., Journal of Medicinal 
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